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ABSTRACT 
The aim of this thesis is to explore the role of common genetic variation, 
identified through genome-wide association (GWA) studies, in human traits and 
diseases, using height as a model polygenic trait, type 2 diabetes as a model 
common polygenic disease, and maturity onset diabetes of the young (MODY) as 
a model monogenic disease. 
The wave of the initial GWA studies, such as the Wellcome Trust Case-
Control Consortium (WTCCC) study of seven common diseases, substantially 
increased the number of common variants associated with a range of different 
multifactorial traits and diseases. The initial excitement, however, seems to have 
been followed by some disappointment that the identified variants explain a 
relatively small proportion of the genetic variance of the studied trait, and that only 
few large effect or causal variants have been identified. Inevitably, this has led to 
criticism of the GWA studies, mainly that the findings are of limited clinical, or 
indeed scientific, benefit. 
Using height as a model, Chapter 2 explores the utility of GWA studies in 
terms of identifying regions that contain relevant genes, and in answering some 
general questions about the genetic architecture of highly polygenic traits.  
Chapter 3 takes this further into a large collaborative study and the largest 
sample size in a GWA study to date, mainly focusing on demonstrating the 
biological relevance of the identified variants, even when a large number of 
associated regions throughout the genome is implicated by these associations. 
Furthermore, it shows examples of different features of the genetic architecture, 
such as allelic heterogeneity and pleiotropy.  
Chapter 4 looks at the predictive value and, therefore, clinical utility, of 
variants found to associate with type 2 diabetes, a common multifactorial disease 
that is increasing in prevalence despite known environmental risk factors. This is a 
disease where knowledge of the genetic risk has potentially substantial clinical 
relevance.  
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Finally, Chapter 5 approaches the monogenic-polygenic disease bridge in 
the direction opposite to that approached in the past: most studies have 
investigated genes mutated in monogenic diseases as candidates for harboring 
common variants predisposing to related polygenic diseases. This chapter looks at 
the common type 2 diabetes variants as modifiers of disease onset in patients with 
a monogenic but clinically heterogeneous disease, maturity onset diabetes of the 
young (MODY). 
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CHAPTER 1: INTRODUCTION 
 
Adapted from published review article: 
Hana Lango and Michael N Weedon: What will Whole Genome Searches for 
Susceptibility Genes for Common Complex Disease Offer to Clinical Practice? 
Journal of Internal Medicine (2008); 263: 16-27 
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Many human diseases have a genetic component. Some diseases are 
caused entirely by a genetic mutation, and much success has been had in 
identifying the genes that, when mutated, cause these monogenic disorders 1. 
Over 1500 genes for monogenic diseases such as cystic fibrosis and maturity 
onset diabetes of the young (MODY) have been identified 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM). Identifying these monogenic 
disease genes has led to deep insights into the biology of these and closely 
related diseases, and has led to the development of therapeutic measures 2. 
Monogenic diseases, however, are relatively rare within populations, explaining 
only a small percentage of the overall disease burden. 
In the developed world the majority of disease results from common, but 
complex disorders such as diabetes, obesity, and cancer. Environmental and 
lifestyle factors such as diet, exercise and smoking are important risk factors for 
the development of these diseases; however, twin, family, admixture and migration 
studies have also demonstrated a large genetic component to an individual‟s 
disease risk. Heritably estimates for some common diseases are given in Table 1. 
A heritability of 50% suggests that half of the variation in disease risk for an 
individual in a population can be explained by genetic variation. 
Success in identifying the genes and variants which explain the genetic 
component of common complex disease has been slow, but recent advances in 
the understanding of the genetic architecture of complex traits and diseases, 
together with advances in high-throughput genotyping technology, has led to a 
new era of genetic analyses – genome-wide association studies – which are 
providing novel and important insights into common polygenic disorders. These 
findings could be of substantial clinical importance in the relatively near future. 
Here, we first discuss the genetic architecture of common complex disease. 
We then describe how we go about finding polygenic disease genes using the 
genome-wide association study approach. We go on to present some recent, 
exciting findings in the genetics of complex disease, and introduce height as a 
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model polygenic trait. Finally, we discuss the potential clinical applications of 
finding common disease susceptibility variants and implicated genes. 
 
Table 1. Heritability of some common complex diseases. * males, ** females. 
Disease h2 (95% CI / SE / SD) References 
Age-related maculopathy  
Age-related macular degeneration 
0.45 (CI 0.35-0.53) 
0.46-0.71 
3 
4 
Crohn‟s disease 1.00 (CI 0.80-1.00 5 
Prostate cancer 0.42 (CI 0.29-0.50) 6 
Breast cancer 0.27 (CI 0.04-0.41) 6 
Type 2 diabetes 0.26 (CI 0.0-0.85) 7 
Body mass index 0.54 (SE 0.05) 
0.40 (SD 0.075) 
8 
9 
Coronary artery disease (CAD) 
Death from CAD 
0.49 (SE 0.12) 
0.57 (CI 0.45–0.69)* 
0.38 (0.26–0.50)** 
10 
11 
11 
Hypertension 0.80 (SE 0.19) 12 
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The genetic architecture of common complex disease 
In the search for genetic variants (see Box 1) that predispose to common 
disease, the most powerful strategies depend on the (often unknown) underlying 
genetic model. For monogenic disorders the genetic model can, most often, be 
defined as dominant (where a single mutated gene causes the disease) or 
recessive (where two copies of the disease genes are required). These models 
produce distinct inheritance patterns in families that allow, with sufficiently large 
families, the single highly-penetrant causal mutations to be identified through 
classical linkage studies. This is in contrast to polygenic diseases that strongly 
cluster in families and are highly heritable, but do not demonstrate simple 
inheritance patterns. Figure 1 compares monogenic and polygenic disease 
inheritance. One explanation for the polygenic inheritance pattern is that many 
(tens to hundreds) of common genetic variants (minor allele frequency >1% in the 
population), each with only a modest effect on disease risk (affecting relative risk 
by < 50%) are responsible for the heritability of polygenic disease. This is the 
common disease/common variant hypothesis (CDCV) 13. 
A number of people have argued against the CDCV hypothesis, suggesting 
that rare, modest-risk alleles may explain a large proportion of the variation in 
susceptibility to common disease 14-16, and it is likely that both common and rare 
alleles are important in polygenic disease. However, given the current near 
impossibility of reliably detecting effects of rare alleles (owing to sample size and 
sequencing constraints), studies have focused on finding common disease alleles.  
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Box 1. The nature of genetic variation  
Genetic variation can take the form of chromosomal rearrangements, 
large-scale deletions or insertions, small-scale deletions or insertions, or single 
base pair changes. A polymorphism is defined as a genetic variant that has at 
least two alleles in a population at a frequency of greater than 1%. Single-base 
pair substitution polymorphisms are referred to as single nucleotide 
polymorphisms (SNPs). SNPs account for most of the genetic variation of the 
human genome. There are thought to be 20-30 million SNPs across the human 
genome. Many of these are catalogued in online databases, and are publicly 
accessible. With the recent completion of the human genome project, the 
physical map position of these SNPs is precisely defined. Unlike insertions and 
deletions, SNPs are not thought to mutate very frequently. 
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Figure 1: (a) A typical monogenic pedigree (e.g. MODY). (b) A typical polygenic 
pedigree (e.g. type 2 diabetes).  = male without the disease;  = male with the 
disease;  = female without the disease;  = female with the disease. NN and 
NM are the normal and mutation (disease) genotypes, respectively. Age (age at 
diagnosis) and body mass index are indicated by the top and bottom numbers, 
respectively. 
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Finding susceptibility genes for common complex disease: past 
approaches 
Until very recently, the two major strategies that have been used to identify 
complex disease genes were positional cloning through genome-wide linkage 
scans, and candidate gene association studies. The linkage approach has been 
very successful in identifying genes responsible for monogenic diseases following 
Mendelian pattern of inheritance, but very few linkage studies of diseases with 
polygenic inheritance patterns have provided reproducible evidence for linkage, 
and only a small number of disease genes have been identified through this 
approach 17. 
In their 1996 paper, Risch and Merikangas 18 showed that genetic 
association studies are much more powerful than linkage studies in identifying 
common variants of modest effects. Since then genetic association studies have 
become the method of choice for identifying common gene variants predisposing 
to disease. At their core, genetic association studies of disease are 
straightforward. In its simplest form, when applied to unrelated individuals, the 
frequency of a variant (allele) of a SNP is determined in a sample of subjects with 
a particular disease, and a sample of subjects without the disease. A statistically 
significant higher frequency of a variant of a SNP (or other genetic variant) in the 
cases versus the controls suggests that it is associated with a particular disease. 
There are around 20-30 million SNPs in the human genome and, until 
recently, it was not possible to assay such a large number of variants. Instead, 
many studies used a candidate gene approach and analysed a small number of 
candidate SNPs in these genes. However, most of these studies used sample 
sizes that provided insufficient power to detect the association unless the allele 
had extremely high odds ratio 19. When an association was detected it was usually 
a false-positive or, in a few cases, a true-positive with a greatly overestimated risk 
effect 20, 21. In type 2 diabetes, for example, years of research had identified only 
two reproducibly associated susceptibility variants, in PPARG 22 and KCNJ11 23 
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genes. Lessons have been learned from the poor performance of the candidate 
gene studies (Box 2), and the power of the association approach is now being 
demonstrated with the advent of the large-scale genome-wide association study. 
The era of the genome-wide association study 
We are now in the era of the genome-wide association study, whereby 
using the phenomenon of linkage disequilibrium (LD; association between alleles 
in a population, due to their proximity on a chromosome such that recombination 
at meiosis has not had a chance to “separate” them) and DNA chips that allow the 
assaying of several hundred SNPs simultaneously, we are able to evaluate a large 
proportion of the 20-30 million common genetic variants across the human 
genome. The Affymetrix 500K chip (Affymetrix, Inc., Santa Clara, CA, USA) 
captures ~65% of common variation across the genome, and the Illumina 317K 
chip (Illumina, Inc., San Diego, CA, USA) captures ~75% 24, 25. Coverage of the 
genome for these chips can be substantially increased using the statistical 
technique of imputation, whereby information from a group of typed SNPs and LD 
information from the HapMap (http://www.hapmap.org) can be used to infer 
genotypes at untyped SNPs 26. We now discuss some of the recent exciting 
findings from genome-wide association studies. 
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Box 2. Lessons learned from past approaches 
Many lessons have been learned from past failing of complex trait genetic 
studies, the most important of which are: 
 A large sample size is crucial. Polygenic variants have small effects, which to 
detect reliably requires many thousands of subjects. Past studies used just tens 
to just a few hundred subjects, which will be powered to find nothing but the 
strongest polygenic effects. 
 Statistical significance levels need to be interpreted with much caution. A P-
value of 0.05 in a genome-wide association study cannot be considered 
significant; when genetic association studies test hundreds of thousands of 
variants against many traits a much more stringent threshold is required. P-
values of <5x10-7 and less are required for a SNP to be considered to have 
genome-wide evidence for association.  
 Replication of findings is essential. The multiple hypothesis testing problem 
makes replication of genome-wide association results (in suitably powered 
follow-up studies) essential. 
 An even more powerful approach than an initial GWA scan followed by 
replication is to put all available GWA studies together and perform one large 
meta-analysis of individual studies‟ summary statistics. Such approach 
inevitably requires collaboration between research groups that would otherwise 
compete with each other. The formation of several international consortia has 
already led to meta-analyses of tens of thousands of samples and to the 
identification of a number of novel genome-wide associations. 
 Comprehensive coverage of the common variation across the genome is 
required. By focusing on known biological candidates there is less chance of 
important novel insights into disease pathophysiology. Also, the lack of success 
of this approach in type 2 diabetes for example, bears testament to the lack of 
underlying knowledge of common disease pathophysiology. 
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Recent findings in genome-wide association studies 
One of the largest, most comprehensive GWA study to date was carried out 
by the Wellcome Trust Case-Control Consortium (WTCCC) 27. The WTCCC study 
used the Affymetrix 500K GeneChip and examined 3000 shared controls and 2000 
cases, all of UK Caucasian ancestry, for seven common complex diseases: bipolar 
disorder (BD), coronary artery disease (CAD), Crohn disease, hypertension, 
rheumatoid arthritis (RA), type 1 diabetes and type 2 diabetes 27. The study 
identified 25 independent association signals at a stringent level of significance 
(P<5x10-7). Association signals were identified for all diseases except 
hypertension, where the strongest signal had P=7.7x10-7. This initial analysis of 
the WTCCC study therefore doubled the number of known complex disease 
genes. However, the WTCCC was primarily a hypothesis generating study, with 
only the “low hanging fruit” being convincingly identified in this “first pass” analysis: 
many of the SNPs with P values greater than 5x10-7 will also be disease-causing 
variants. As will be described in the sections below, follow-up studies in sufficiently 
powered replication cohorts, and the combination of findings from several GWA 
scans have confirmed many other complex disease variants.  
Type 2 diabetes 
It is perhaps the results of the first type 2 diabetes genome-wide scans28-32 
that best illustrate the power of the GWA approach for identifying novel genes that 
are important in the etiology of complex disease. Following up the results from the 
initial WTCCC GWA scan 27, we worked closely with the DGI 28 and FUSION 32 
groups, who had performed similar studies. We used the combined information 
from these three studies to prioritise variants for follow-up. Including replication 
samples, these three studies provided data from 14586 cases and 17968 controls. 
The combined analyses identified three entirely novel type 2 diabetes susceptibility 
genes: CDKAL1 (cyclin-dependent kinase 5 [CDK5] regulatory subunit associated 
protein 1-like 1) (OR 1.12, combined P = 4.1x10-11), IGF2BP2 (insulin-like growth 
factor 2 binding protein 2) (OR 1.14, combined P=8.6x10-16), and 
CDKN2A/CDKN2B (cyclin-dependent kinase inhibitor 2 A/B) gene region (OR 
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1.20, combined P=7.8x10-15) and demonstrated that integrating the results from 
multiple genome-scans can aid the prioritisation of signals for replication, and 
allow confirmation of genes at appropriate levels of statistical confidence not 
possible with individual GWA studies. 
Other type 2 diabetes GWA studies have also been published. The 
deCODE study 31 of several European and a Chinese population replicates the 
association of the CDKAL1 variant (OR 1.20 in Europeans and 1.25 in Chinese). 
These four studies also confirm the association of variants near HHEX 
(homeobox, hematopoietically expressed) and SLC30A8 (solute carrier family 30 
[zinc transporter], member 8) genes, originally published by Sladek et al. 29. 
Importantly, as a positive control, associations for variants in PPARG 22, KCNJ11 
23 and TCF7L2 33, originally identified through candidate gene and positional 
cloning methods, were also seen in the GWA scans, with expected odds ratios.   
Of the variants identified through the GWA approach, the two in or near the 
CDKN2A/CDKN2B gene are particularly interesting. CDKN2A encodes P16INK4a, 
and is a known tumor-suppressor gene 34. Mutations of CDKN2A cause diverse 
neoplasias. CDKN2A is an inhibitor of cyclin dependent kinase 4 (CDK4), which is 
important for beta-cell replication 35. Overexpression of Cdkn2a in mice leads to 
decreased islet proliferation, while Cdkn2a knockout mice demonstrate enhanced 
islet proliferation and survival after beta-cell ablation 36. Overexpression of Cdkn2b 
causes islet hypoplasia and diabetes in murine models 37. Together with the 
CDKAL1 association, the CDKN2A/B finding implicates the cyclin-dependent 
kinase pathway in the pathophysiology of type 2 diabetes. 
Another interesting feature of the CDKN2A/B finding is that, as described 
below, variants of the CDKN2A/B gene have also recently been shown to 
predispose to myocardial infarction (MI). Determining why a gene predisposes to 
type 2 diabetes and heart disease may lead to an explanation for the link between 
these two disorders. 
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The CDKN2A/B finding also highlights the power of GWA studies to identify 
variants outside described genes: while one of the signals occurs in the 
CDKN2A/B region, the other (much stronger) association signal occurs >200kb 
from these genes, in a gene desert. This association would not have been picked 
up by a candidate gene approach. Identifying the mechanism by which this variant 
(presumably) affects CDKN2A/B expression will provide new insights into the 
regulation of this important gene(s). 
The other newly identified type 2 diabetes genes are generally involved in 
beta-cell development and function, and insulin secretion 28, 30, 32. For example, the 
HHEX gene is highly expressed in fetal and adult pancreas, and is implicated in 
pancreatic development 38, 39. It is a target of WNT signalling pathway, which has 
been shown to be critical for the development of the pancreas and islets during 
embryonic growth 40. Importantly, TCF7L2 also has an important role in WNT 
signaling, acting as a nuclear receptor for -catenin 41. Together, these findings 
highlight the importance of the WNT signaling pathway in glucose homeostasis. 
Obesity 
In addition to the newly identified type 2 diabetes genes described above, 
the WTCCC study found strong association with FTO (fat mass and obesity 
associated) gene region (OR 1.27, P=2.0x10-8) 30. This finding, which was the 
strongest susceptibility locus outside TCF7L2, showed strong replication in further 
3757 type 2 diabetes cases and 5346 controls from the UK (OR 1.22, P=5.4x10-7) 
30. However, the lack of such strong association in the DGI study 28, which 
matched cases and controls for BMI, and the FUSION study 32, where there was 
minimal BMI differences between cases and controls, suggested that the 
association with type 2 diabetes was caused by the primary effect on adiposity. 
Indeed, adjustment for BMI in the UK replication samples abolished the type 2 
diabetes association (OR 1.03, P=0.44).  
This exciting observation lead to the study of association of FTO gene 
variation with BMI and the risk of being overweight and obese in an additional 
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19424  adults and 10172 children, all of white European origin 42. In the combined 
dataset each additional copy of the rs9939609 risk allele is associated with a BMI 
increase of ~0.4kg/m2 (P=3x10-35). Individuals homozygous for the A allele (16% 
of the population) are at a substantially increased risk of being overweight (OR 
1.38, P=4x10-11) and obese (OR 1.67, P=1x10-14) compared to those homozygous 
for the low-risk T allele (37% of the population). This association was observed in 
children at ages 7-11, but not at birth, and reflects a specific increase in fat 
mass42.  
FTO is a gene of unknown function in an unknown pathway. It seems to be 
widely expressed in both fetal and adult tissues, with highest levels in the brain 42. 
One possibility therefore is that FTO is an important regulator of appetite. This 
would be consistent with the role of monogenic obesity genes, such a Leptin, but 
much work is needed to determine whether this is the case. It is clear though that 
understanding how variants of the FTO gene increase fat-mass will lead to the 
identification of a new obesity pathway, with implications for drug development and 
treatments. 
Age-related macular degeneration 
Age-related macular degeneration (AMD), the main cause of blindness in 
developed countries, is a chronic, common and complex disease characterised by 
progressive destruction of retina‟s central region and drusen formation behind the 
retina (reviewed in 43). Currently, there is no broadly effective therapy available. 
The major environmental risk factor for AMD is smoking (smokers have up to 2.5-
fold increased risk of AMD than non-smokers) 44, 45. One of the first published 
genome-wide case-control studies was by Klein and colleagues 46. Using the 
relatively sparse Affymetrix 100K chip they identified a common variant in the 
complement factor H gene (CFH) as the SNP most strongly associated with AMD 
46. Although this was a small study (96 cases and 50 controls), it increased its 
power by using enriched samples (severe AMD cases and older controls to 
increase the probability of them not developing AMD). A more recent case-control 
candidate gene study replicated the association of CFH gene, and confirmed that 
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individuals homozygous for the most strongly associated risk allele have over 7-
fold higher risk for AMD than those homozygous for the non-risk allele 47. Human 
CFH is a regulator of the innate complement system that responds to infection by 
normally attacking only the diseased cells. Observations of activated complement 
components within drusen of AMD patients, and of strong effects of smoking and 
age on CFH plasma levels, suggest that AMD may result from abnormal 
complement activation in an anomalous inflammatory response 46. Although the 
CFH polymorphisms are non-coding, they may alter the binding of CFH to heparin 
and C-reactive protein 46. Furthermore, since CFH is a member of the complement 
and coagulation cascade pathway, these findings highlight that several different 
complement and coagulation factors may be potential drug targets and justify 
further research. 
Crohn disease 
Crohn disease, most commonly affecting ileum and colon, is a common form of 
idiopathic inflammatory bowel disease (IBD) where genetic predisposition has 
been supported by twin studies showing concordance rate of 50% in monozygotic 
compared to 10% in dizygotic pairs. Previously, years of research effort involving 
linkage, candidate gene and targeted association studies, identified only two 
genuinely associated variants, in CARD15 gene and the IBD5 haplotype. A recent 
GWA study by Rioux and colleagues 48 identified and replicated several new 
susceptibility loci for ileal Crohn disease. The most associated SNP, independently 
identified by a smaller German study 49, was a non-synonymous amino acid 
change in ATG16 autophagy-related 16-like 1 (ATG16L1) gene. The risk allele is a 
major allele (it has a frequency of about 52% and 60% in controls and cases, 
respectively), and individuals carrying one copy are at a 35-45% higher risk of 
developing the disease than those carrying no ATG16L1 risk alleles 48, 49. This 
SNP is in strong LD (r2=0.97) with the strongest signal in the WTCCC scan for 
Crohn disease. Autophagy is a constitutive biological process involved in immune 
pathogen recognition, and the variants in ATG16L1 gene may alter innate immune 
control or antigen presentation in the adaptive immune pathways 48. The WTCCC 
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study identified four novel association signals, all of which have since been 
replicated. These map to IRGM (immunity-related guanosine triphosphatase), 
MST1 (macrophage stimulating 1), NKX2-3 (NK2 transcription factor related, locus 
3), and PTPN2 (protein tyrosine phosphatase, non-receptor type 2) gene regions. 
These novel findings highlight that defects in a number of components of innate 
and adaptive immune pathways, such as those in autophagy and the processing 
of phagocytosed bacteria, are a major cause of Crohn disease. 
Height as a model polygenic trait 
Adult human height is a classic, highly heritable polygenic trait, product of 
many different developmental processes. It is an easily and accurately measured 
phenotype, with data available in large numbers of individuals from virtually every 
disease or population cohort used in GWA studies. This makes height an ideal 
model trait that can be used to study the architecture of polygenic traits in general, 
as well as answer questions about the biological relevance and clinical usefulness 
of associated variants with modest effect sizes identified through GWA studies 
with large sample sizes. Furthermore, the implicated genes should provide 
important insights into the mechanisms of normal growth and development, and 
would be excellent candidate genes for mutations responsible for growth and 
skeletal disorders without known genetic causes. 
Two independent common variants have already been identified by GWA 
studies, in the HMGA2 50 and GDF5-UQCC 51 gene regions. Both studies used 
sample size of several thousand individuals, and it was clear that much larger 
studies would be needed for sufficient power to identify additional common 
variants for human height. 
What benefits can GWAS findings bring to clinical practice 
Identifying the genes and pathways involved in predisposing individuals to 
complex disease is giving us insights into the pathophysiology of these diseases, 
which may eventually lead to the development of novel treatments. These insights 
are the most valuable thing to come out of these genetic studies, and will, in time, 
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without doubt lead to better clinical management and treatment of these diseases. 
But is there any immediate clinical utility of knowing an individual‟s genotypes at 
these disease variants? 
Pharmacogenetics 
Pharmacogenetics is a study of how genetically determined variation affects 
an individual‟s response to drugs. It is well known that adverse side effects and 
therapeutic failure of drugs may both have a strong genetic component 52. If a 
patient‟s genotypes in the relevant genes are known, it may be possible to truly 
personalise medication and optimise treatment by selecting the most effective 
drug and its dose. It has been estimated that adverse drug reactions account for 
6.5% of hospital admissions, 4% of hospital bed capacity, and 0.15% fatalities in 
England, at a projected annual cost to the NHS of £466 million 53. Although a large 
portion of this figure can be attributed to prescription errors and accidental 
overdoses, pharmacogenetics could be used to identify individuals both at a 
highest and lowest risk of developing adverse effects to particular drugs or doses. 
Furthermore, clinical efficacy could be much improved if drugs are prescribed only 
to individuals likely to benefit from them, thus reducing the number of ineffective 
treatments. Pharmacogenetic testing will be particularly desirable in cases where it 
proves to be more effective than the current practice of just careful monitoring of a 
patient‟s response to a drug/dose.  
There are many examples of where this has already happened, such as for 
monogenic types of diabetes. The definition of six different genetic subtypes in 
MODY has led to recognition of different clinical phenotypes 54. Molecular genetics 
is now commonly used as a diagnostic test, and the diagnosis has a dramatic 
effect on the treatment decisions in MODY. Patients with glucokinase mutations 
have life-long mild but stable fasting hyperglycaemia from birth, and require no 
treatment because they essentially have a glucose sensing defect where glucose 
is regulated at a higher level 54. In contrast, patients with HNF1A mutation have a 
progressive hyperglycaemia but are very sensitive to hypoglycaemic effects of 
sulphonylureas 55. The correct diagnosis is very important in this case because 
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many of these patients are misdiagnosed as having type 2 diabetes, in which case 
the most common pharmacological treatment is metformin, but HNF1A patients 
have a four-fold greater response to sulphonylurea gliclazide than to metformin 55. 
The ability to analyse thousands of SNPs in a large number of individuals 
will be essential for defining genetic heterogeneity of diabetes, which could then 
be translated into clinical heterogeneity between the patients. Even if a gene does 
not cause or predispose to a disease, it can still interfere with the drug-targeted 
metabolic pathway and modify the toxicity (effectiveness and side effects) of the 
drug and the clinical response. For example, the putative role of TCF7L2 in beta-
cell function has lead to a hypothesis that TCF7L2 variation may have an effect on 
glycaemic response to sulphonylureas, but not to metformin 56. A study that tested 
this using 747 and 864 metformin users with type 2 diabetes found that, while the 
tested variant had no effect on metformin response, in the sulphonylurea treatment 
group only 40% of patients homozygous for the risk allele reached the target 
HbA1c < 7%, compared to 61% of patients with the other two genotypes (OR 0.46, 
P<0.001) 56. This study provides a strong example of pharmacogenetics in type 2 
diabetes, where a common variant predicts treatment response. If a patient‟s 
genotypes in several of the relevant genes are known, it may be possible to 
personalise medication and optimise treatment.  
Disease prediction 
In type 2 diabetes and other complex polygenic diseases the number of 
confirmed common risk variants is relatively small. This means that, for now, 
molecular genetics cannot be used as a diagnostic test because family history and 
environmental and lifestyle influences, such as BMI, smoking, physical activity and 
social class, have much higher predictive power. One way of assessing predictive 
power of polygenic variant information is to use the area under the ROC curve 
(AUC), which measures the discriminatory power of the test 57. The test is 100% 
accurate when the AUC is 1, and is no better than chance when AUC is 0.5. It has 
been estimated that for an AUC of ~0.8 it will be necessary to genotype 20-25 risk 
variants with allele frequencies greater than 10% and ORs of 1.5 58 . In 
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multifactorial diseases where preventative measures exist, coupled with the low 
cost of genotyping, it may be practically and economically justifiable to identify 
individuals with the highest risk of developing the disease if the preventative 
measures are still effective in such high-risk groups. This should certainly be the 
case in type 2 diabetes where lifestyle factors have a big impact on onset and 
severity of the disease. 
A recent type 2 diabetes case-control study demonstrated that, although 
individual susceptibility variants only moderately increase the risk of type 2 
diabetes and are of limited use in disease prediction, by combining the information 
from the three replicated risk variants (known at the time) it is possible to identify 
individuals at significantly greater risk of developing the disease than when a 
single polymorphism is used 59. Individuals with all six risk alleles had an OR of 
5.71 (95% CI 1.15 to 28.3) compared to those with no risk alleles, and the area 
under the ROC curve for the three polymorphisms was 0.58. This study, however, 
only included variants discovered prior to the availability of the GWA approaches, 
and now it would be interesting to look at the combined predictive value of the 
much increased number of variants identified through GWA studies. 
Conclusions 
Genome-wide association studies are a powerful new approach to 
identifying genes influencing predisposition to common, complex disease. 
Genome-wide studies are “hypothesis-free” and allow the identification of 
previously unsuspected genes and pathways in disease aetiology. One of the 
challenges now is to determine how relevant the new variants are for our 
understanding, and eventual treatment, of disease. Considering that little is still 
known about the exact roles of most of these new variants and implicated genes 
and regions, even about the higher-risk ones such as TCF7L2 in type 2 diabetes, 
at the moment they remain just potential targets for predictive testing and drug 
development.  
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In the short-term the greatest value of GWAS is likely to come from 
etiological insights - the effect of variants on disease onset, severity and 
progression, as well as an individual‟s response to treatment. In the long-term, 
there are two major clinical benefits. Firstly, there is a great opportunity to identify 
important new biological pathways, genes and gene interactions, providing us with 
more complete picture of disease aetiology and progression, and the best 
therapeutic targets. Excitingly, there may be cases where there are the same 
targets for more than one disease, such as the CDKN2A/B gene region in type 2 
diabetes and cardiovascular disease. Secondly, once enough variants are 
identified that together explain a clinically useful portion of a disease, it will be 
possible to identify individuals at most risk of developing the disease. Genetic 
testing will be particularly useful where effective prevention is available, and if 
studies show that this genetic knowledge will positively influence individuals‟ 
lifestyle choices. The initial success of many genome-wide association studies has 
certainly brought much excitement to the scientific community, but there will be 
several years before patients see real benefits in clinical practice. 
Aims of the Thesis 
The aim of this thesis is to explore the biological and clinical value of 
common variants identified through genome-wide association studies, by using 
height as a model polygenic trait, type 2 diabetes as a model common, 
multifactorial disease, and HNF1A-MODY as a model monogenic disease.  
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Abstract 
Adult height is a model polygenic trait, but there has been limited success in 
identifying the genes underlying its normal variation. To identify gene variants 
influencing adult height, we used genome-wide association data from 13,665 
individuals and genotyped 39 variants in an additional 16,482 samples. We 
identified 20 variants associated with adult height (P<5x10-7, with 10 reaching 
P<1x10-10). Combined, the 20 SNPs explain ~3% of height variation, with a ~5cm 
difference between the 6.2% of people with =<17 or fewer “tall” alleles compared 
to the 5.5% with >=27. The loci identified implicate genes in hedgehog signaling 
(IHH, HHIP, PTCH1), extracellular matrix (EFEMP1, ADAMTSL3, ACAN) and 
cancer (CDK6, HMGA2, DLEU7) pathways and provide novel insights into human 
growth and development processes. Finally, our results provide insights into the 
genetic architecture of a classic quantitative trait. 
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Introduction 
Adult height is a model polygenic trait. It is the ideal phenotype for genetic 
studies of quantitative traits in humans, as it is easily and accurately measured, 
and is highly heritable, with up to 90% of variation in adult height within a 
population being explained by genetic variation 1-5. Final adult height is the result 
of growth and development processes. Identifying genes for human height should 
therefore provide insights into mechanisms of growth and development, as well as 
into the genetic architecture of quantitative traits, and how best to dissect them. 
Despite its strong heritability, there has been little success in identifying the 
specific genetic variants that influence height in the general population 5, 6. Some 
mutations resulting in extreme stature have been identified, but these are rare and 
cannot explain normal variation of adult height 6. Linkage and candidate gene 
association studies have not identified any robustly associated loci. The advent of 
genome-wide association (GWA) studies, however, is providing new opportunities 
for identifying genetic variants influencing adult height. 
Recently, using GWA study data from 4,921 individuals we identified the 
most convincing example of a common variant associated with adult height 7. The 
variant was the only one to reach a level of significance suggestive of true 
association in the GWA study (P=4x10-8), and we confirmed the association in 
19,064 adults from four further studies (P=3x10-11). The variant associated with a 
0.4cm greater height per allele, explained ~0.3% of the population variation of 
height, and occurred in the HMGA2 oncogene. In this study, we extend our 
analyses to a two-staged design of 13,665 individuals with GWA study data and 
16,482 follow-up individuals. 
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Results 
Height loci identified 
We used GWA data from five studies that ranged in size from 1,437 to 
3,560 people of UK ancestry and a sixth study of 2,978 Scandinavian individuals 
for which summary height association statistics have been made publicly available 
(http://www.broad.mit.edu/diabetes/scandinavs/index.html; Supplementary Table 
1). All studies were genotyped using the Affymetrix 500K chip. We compared the 
additive model statistics of 402,951 SNPs that passed quality-control (QC) criteria 
in at least 4 of the 6 studies to those expected under the null distribution using 
quantile-quantile (QQ) plots. Figure 1 shows that the sequential addition of each 
of the six studies resulted in increased deviation of the observed statistics from the 
null distribution. The number of independent SNPs (using a cut-off of less than 0.2 
for the pairwise linkage disequilibrium statistic r2) reaching a P<1x10-5, was 4 
(N=1914), 6 (4892), 12 (6788), 13 (8668), 18 (12228), and 27 (13665) as each 
study was added in, against the expected <4 under the null distribution. 
In the meta-analysis of 13,665 individuals with GWA data, there were many 
more significant associations than expected by chance. For example, we observed 
8 independent signals with a P<5x10-7, where we would expect none under the 
null distribution, and 27 with a P<1x10-5, where we would expect < 4. 
Approximately 23 of these loci are therefore likely to represent true positives. The 
availability of dense genome-wide SNP data allows us to be confident that these 
results are not due to population stratification. First, any individuals of non-
European ancestry were removed. Second, adjusting for residual population 
structure using EIGENSTRAT8 did not affect the distribution of effect sizes 
(Supplementary Figure 1 gives individual study QQ plots before and after 
EIGENSTRAT adjustment). Third, the genomic control inflation factor lambda9 for 
the GWA study meta-analysis was only 1.12, despite the large size of the study 
(there is a strong relationship between sample size and lambda10) and the 
apparently highly polygenic nature of height. Fourth, 12 of the ancestry informative 
markers (AIMS) described by the WTCCC, which vary substantially in allele 
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frequency across the UK, did not associate with height (all P>0.01; the 13th AIM 
did not pass QC criteria in this study; Supplementary Table 2). 
We took forward 39 SNPs into the second stage of our study: the 
genotyping of an additional 16,482 individuals of European ancestry from four 
studies (Supplementary Table 1). Of these, 27 represented all the independent 
(r2<0.2) signals with a P<1x10-5. Eleven of the SNPs represented independent 
regions where there was a SNP with a P<1x10-4 and a gene within flanking 
recombination hotspots in which mutations affect length in mouse studies or cause 
monogenic human phenotypes of extreme stature.  GWA data from CoLaus (one 
of our stage 2 cohorts) became available during the course of our analyses, and 
we also took forward a SNP representing a region with the strongest association 
(P=4x10-8) from that study. Five of the AIMs with the largest differences in allele 
frequency across the UK11 were also genotyped in stage 2 samples.  
In the stage 2 analyses, 20 of the 39 SNPs reached a P<0.005 (with the 
same direction of effect as the GWA data), all of which reached a P<5x10-7 in a 
joint analysis across GWA and stage 2 samples. While this is an arbitrary 
statistical cut-off, we chose to focus on these SNPs for the reasons discussed in 
11, and we note that of the SNPs that reached a P<5x10-7 in 11 and that have been 
subjected to replication efforts, all have been confirmed. The majority of the 20 
SNPs had P-values substantially lower than 5x10-7: 17 of the SNPs reached a 
P<5x10-8 and 10 reached a P<1x10-10 in joint analyses. Of the 19 SNPs that did 
not reach P<5x10-7, 15 had the same direction of effect in stage 2 as in stage 1 
(P=0.02), suggesting that there are true positives amongst these. The details of 
the 20 SNPs are presented in Figure 2 and Table 1, and details of the SNPs that 
did not reach the statistical cut-off are presented in Supplementary Table 3. For 
the 20 SNPs, there was no evidence of heterogeneity across studies when taking 
into account the number of tests (all P>0.008). In both joint and stage 2 only 
analyses, none of the WTCCC AIMS was associated with height providing further 
evidence that population stratification is unlikely to have influenced the results (all 
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P>0.01 see Supplementary Table 2). This means the associations are likely to 
reflect true biological effects on height. 
Implicated genes and their function 
The correlation between SNPs due to linkage disequilibrium (LD) and the 
occurrence of many of the 20 SNPs in non-coding regions means we cannot be 
certain about which genes are involved, but they implicate genes of many different 
functions in several different pathways and processes. In 10 instances, genes 
within the region of interest have previously been implicated in the regulation of 
growth because of known effects from rodent knockouts and/or human 
syndromes. LD plots for each region are presented in Supplementary Figure 2, 
and Table 2 shows the genes most probably affected by the associated SNPs, 
along with the pathways the genes are known to be involved in, and where known, 
the monogenic syndromes caused by mutations in the associated genes and the 
phenotypes from knockout mouse models.  
In two instances, there is evidence that the SNPs we have identified (or 
those in LD with them) influence gene expression. We used data from the publicly 
available “mRNA by SNP Browser 1.0” program described recently 12 to determine 
if any of the SNPs were associated with mRNA expression levels in lymphocytes. 
Rs2282978, which associates with height at P=8x10-23, and occurs in the 4th intron 
of the cyclin-dependent kinase 6 (CDK6) gene associated with expression of 
CDK6 (P=1x10-6). Rs1863913, an r2 = 1 proxy for rs10935120 (height P=7x10-8), 
which occurs in intron 2 of anaphase promoting complex 13 (ANAPC13) and 4.4kb 
upstream of centrosomal protein 63 (CEP63) was associated with ANAPC13 
(P=9x10-18) and CEP63 (P=4x10-12) expression. There was no evidence for any of 
the other SNPs affecting any transcript levels in these lymphoblastoid cell lines. 
The genes implicate a number of biological pathways and processes in the 
normal determination of human height, including: hedgehog signaling (IHH, HHIP, 
PTCH1); basic cell cycle regulation (CDK6, one of the cyclin-dependent kinases 
implicated in cell cycle progression 13); extra-cellular matrix (ADAMTSL3 and 
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EFEMP1); chromatin rearrangement and polycomb proteins (HMGA2 and 
SCMH1). Several of the genes are also disrupted in cancers (e.g. HMGA2, CDK6, 
DLEU7) providing further evidence of a link between normal growth and 
unregulated cell differentiation. For other loci, no gene in the region is an obvious 
candidate for influencing height, and in one case (rs4549631) only a hypothetical 
gene, LOC387103, is within a 750Kb window of the SNP.  
One of the most interesting findings is that rs6060373 (P=2x10-17) is highly 
correlated (HapMap r2 = 0.89) with a functional SNP in the GDF5 gene that has 
recently been convincingly shown to alter the risk of osteoarthritis 14, 15. The allele 
that is associated with higher height associates with a decreased risk of hip and 
knee osteoarthritis. A plausible explanation of these associations is that the variant 
influences the “thickness” of a person‟s cartilage. 
Methodological issues 
We next performed a series of analyses to address additional important 
issues about the genetic architecture of human height. Although our results are 
limited to height, our findings may prove useful in guiding studies of other 
quantitative traits. 
We first tested whether the SNPs representing the 20 loci deviated from an 
additive model or had different effect sizes in males and females. There was 
suggestive evidence for deviation from an additive (per-allele) mode of inheritance 
for two of the variants: rs12735613 (P=0.009) and rs1390401 (P=0.007). There 
was also suggestive evidence that rs6440003, the most strongly associated SNP 
in our study, had a greater effect in females (0.12SD [0.09, 0.14]) than males 
(0.07SD [0.04, 0.09]), P=0.01 (Table 1).  
Adult height is the result of both growth throughout childhood and loss of 
height during the ageing process. We therefore assessed the influence of age on 
the 20 robust associations. We found no evidence that the effects on height were 
different in individuals under age 50 years compared to those aged >50 years (all 
P>0.01; similar results were obtained when we used a cut-off of 40 years of age), 
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or when adjusting for age decade (see Supplementary Table 4). This suggests 
the effects are predominantly on developmental and childhood growth rather than 
driven by processes involved in loss of height, although studies of more young 
adults and children are needed to confirm this. 
It has often been stated that gene-gene interactions may play a prominent 
role in complex traits but there are few, if any, empirical data to show this. We 
looked for any evidence of deviation from an additive model of the joint effects 
between all possible pairs of the 20 loci. When taking into account the number of 
tests, we find no strong evidence for deviation from additivity (all P>0.017; see 
Supplementary Table 5). 
To assess the combined impact of the 20 SNPs on adult height we 
analysed only the UK stage 2 samples. This removes the bias due to the effect of 
the “winners curse” 16, which we observed in our data with 17 of the 20 SNPs 
having a larger effect size in the GWA study compared to our follow-up study 
(P=0.003 in a test against a 50/50 distribution). Figure 3 shows the linear increase 
in the average height of individuals with increasing numbers of “tall” alleles, and 
the normal distribution of the frequency of “tall” alleles. Combined, these 20 SNPs 
explain ~2.9% of the variance in adult height in the UK stage 2 sample. There is a 
0.7SD (~5cm) difference in height between the 6.2% of people with 17 or fewer 
“tall” alleles compared to the 5.5% of people with 27 or more.  
Power and sample size issues are of major importance to the field of 
complex traits genetics. Our results indicate that many tens of thousands of 
individuals will be needed to reliably detect a large proportion of the variance in 
some quantitative traits. In this study, real signals only emerged after combining 
many individually underpowered GWA studies (Figure 1 and Supplementary 
Figure 3). We used the effect sizes observed in the stage 2 samples for each of 
the 20 SNPs to determine how much power we had to detect the associations in 
the GWA study; Figure 4 plots the results. We had low power to detect some of 
the SNPs. For example, for 4 of the SNPs we had less than 10% power to detect 
the associations at a P<1x10-5 in the GWA study. 
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Considerable effort and resources have been devoted to identifying regions 
of the genome that are shared between relatives of similar height more often than 
expected by chance – the linkage approach to gene identification. We analysed 
the overlap between linked regions (LOD >2.0, at 
http://www.genomeutwin.org/stature_gene_map.htm) and our association results 5. 
We assumed a linked region to be a 10Mb window around the peak marker for all 
regions with LOD >2.0. Given the proportion of the genome that these regions 
cover we would have expected 3.5 (5.3x108 base-pairs covered by linkage regions 
/ 3.0x109 base-pairs in the human genome) of the 20 SNPs to have occurred in 
linked regions by chance alone, and we observed 4 (P=0.73); for linked regions 
with LOD scores > 3, the corresponding statistics were: expected 0.80 and 
observed 1, P=0.81. We found no evidence of over-representation of significant 
associations in linked regions (227 SNPs of 79241 SNPs (0.29%) in LOD > 2 
linked regions had P values less than 0.001, compared to 892/323710 (0.28%) in 
non-linked regions, P=0.60. For LOD > 3 linked regions the corresponding figures 
are 48/22036 (0.22%) and 1071/380915 (0.28%), respectively, P=0.08).  
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Discussion 
Our results are consistent with Fisher‟s proposal from 1918 that many 
variants of individually small effect explain the heritability of height 17. The 20 
robustly associated variants alter height by between ~0.2 and 0.6cm per allele, 
based on the stage 2 samples, but explain only ~3% of the variation in height 
within the population.  
Some of the remaining heritability of height will be explained by additional 
SNPs, with small effect. Firstly, we have shown that some of the SNPs which we 
took forward into stage 2, but that did not reach a P<5x10-7 on joint analyses 
probably represent true associations (for example, an excess of SNPs showed the 
same direction of effect in stage 2 as in stage 1, P=0.02). Secondly, we observed 
a large effect of the winners curse 16 and, as such, we had low power to detect 
some of the SNPs in the GWA part of our study, strongly suggesting that there are 
many more common variants of a similar effect size to be found. As Figure 4 
shows, identifying these and variants of even smaller effect will require tens of 
thousands of individuals.  
To further investigate whether there are more height associated SNPs to be 
identified through larger sample size, we compared our results to those presented 
in the accompanying manuscript from Lettre et al. 18 They identify association for 
several of the loci reported in our study (ZBTB38, HMGA2, GDF5, HHIP, 
ADAMTSL3, CDK6), and find suggestive association with a SNP at the FUBP3 
locus (P=8x10-7), which we also followed up and found suggestive evidence for 
(P=2x10-5). FUBP3 therefore likely represents an additional height gene. We 
produced a QQ plot for the P-values observed in the Lettre et al.18 study for the 
most-associated 10,000 SNPs from our study, excluding known loci. The deviation 
of the observed statistics from the null distribution (see Figure 5) clearly 
demonstrates that there are many more height-associated SNPs that remain to be 
identified from GWA studies. While SNPs will explain some of the residual 
variation, it is possible that much of the heritability of height will be explained by 
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rare variants or copy number polymorphisms, which are not captured by the GWA 
approach. 
As we only tested an additive model, and did not perform sex specific 
analyses on a genome-wide level we were biased away from detecting sex-
specific and non-additive effects in this study. However, we did find some weak 
evidence that our most associated SNP had a stronger effect in females (0.12SD 
[0.09, 0.14]) than males (0.07SD [0.04, 0.09]), P=0.01, although this finding needs 
to be replicated. Given that final adult height is highly dichotomized by sex, growth 
trajectories show clear sex differences and sex hormones influence height, further 
studies are needed to investigate more thoroughly the presence of sex-specific 
effects. It will also be important to test for non-additive within and between loci 
effects, and to investigate the role of these and other loci in individuals of non-
European ancestry. 
We found no overlap between previously reported linkage peaks and the 
results from our GWA study. The variants we have identified have small effects, 
and as such it is not surprising that they do not, individually, explain previously 
observed linkage peaks. It may be that some of the linkage peaks are explained 
by low-frequency, relatively high penetrance alleles, which would not be captured 
using the GWA approach. However, our findings do not support the idea that 
genes with common variants associating with height also contain the type of 
variant that is readily identifiable through the linkage approach. 
A limitation of this study is that we have not fine-mapped the identified loci. 
However, ten of the loci we have identified contain genes previously known to be 
involved in growth from rare human syndromes or animal studies, and we have 
shown that common variation in or around these genes influences normal human 
growth. Additionally, two of the variants appear to alter expression of nearby 
genes (CDK6 and ANAPC13). Further fine mapping and functional studies of 
these and the remaining loci will likely provide completely novel insights into 
growth and development. Mutations in these regions may also explain some 
monogenic syndromes for which no genes have currently been identified. The 
 Chapter 2 44 
observation that half of the identified loci contained candidate genes suggests that 
combining genome-wide with candidate gene approaches may be a productive 
way for identifying more height loci. 
In conclusion, using 13,665 individuals with genome-wide scan data and 
16,482 follow-up subjects we have identified 20 regions of the genome, common 
variation of which influences adult height. The study highlights several important 
pathways and processes involved in normal growth, and provides insights into the 
genetic architecture of a classic quantitative trait. 
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Methods 
Study Descriptions 
Genome-wide association (Stage 1) samples 
Four of the six genome-wide scan studies were part of the UK Wellcome 
Trust Case Control Consortium (WTCCC) and have been described in detail 
previously11. Briefly, these four studies were the type 2 diabetes (WTCCC-T2D), 
hypertension (WTCCC-HT), and coronary artery (WTCCC-CAD) disease branches 
and the national blood service (WTCCC-UKBS) controls. A manuscript describing 
the cohorts used in the Diabetes Genetics Initiative (DGI) 500K genome-wide 
association study for type 2 diabetes has already been published 19 and a 
description of the sample is also available online 
(http://www.broad.mit.edu/diabetes/). The EPIC Obesity case-cohort study 
includes 3,847 participants and is nested within the EPIC-Norfolk Study, a 
population-based cohort study of 25,663 Europid men and women aged 39-79 
years recruited in Norfolk, UK between 1993 and 1997. The cases (N = 1,685) 
were randomly selected from the obese individuals within this cohort and are 
defined as those with a BMI >30 kg/m2. The control-cohort consists of 2,566 
individuals randomly selected from the EPIC-Norfolk study and thus by design, 
381 individuals are part of the control-cohort as well as the case group. 
Basic anthropometric data for all genome-wide studies are presented in 
Supplementary Table 1. Extensive quality control steps were taken to exclude 
poorly performing or non-European descent samples from analyses. For 5 of the 6 
GWA studies these are described in detail in 11, 19. For the EPIC-Obesity study, of 
the 3,847 participants, 277 were excluded (sample call rate <94%: N = 202, 
heterozygosity <23% or >30%: 36, >5.0% discordance in SNP pairs with r2 = 1 in 
HapMap: N = 25, ethnic outlier: N = 8, related individuals (concordance with 
another DNA is >70.0% and <99.0%, 1 selected based on sample call rate): N = 5, 
duplicate (concordance with another DNA is >99.0%, 1 selected based on sample 
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call rate): N = 1), and for 10 individuals no genotype data was available, such that 
3560 individuals were included in the analyses. 
The WTCCC-T2D, WTCCC-HT, DGI and EPIC-Obesity studies measured 
height using standard anthropometric techniques. For WTCCC-CAD and WTCCC-
UKBS height data was self reported from questionnaires. The lack of evidence of 
heterogeneity across all studies for the 20 confirmed loci indicates that the 
inclusion of self-report data has not affected the results appreciably. 
All subjects gave written informed consent and the project protocols were 
approved by the local research ethics committees in the UK. 
Stage 2 samples 
UKT2D GCC 
This study has been described previously 20. All subjects were of self-
reported white European descent, living in the Tayside region of Dundee, UK. 
Height measurements were made as for the WTCCC samples. This study was 
approved by the Tayside Medical Ethics Committee and informed consent was 
obtained from all subjects. 
EFSOCH  
EFSOCH (Exeter Family Study of Childhood Health) is a prospective study 
of parents and children from a consecutive birth cohort 21. Subjects were recruited 
from a postcode-defined region of Exeter, UK between 2000 and 2004 and were of 
self-reported white, European descent. Parental height was measured using a 
stadiometer by the research midwife at 28 weeks gestation. Ethical approval was 
given by the North and East Devon Local Research Ethics Committee and 
informed consent was obtained from the parents of the newborns. 
BRIGHT 
The MRC British Genetics of Hypertension (BRIGHT) study has been 
described previously 22. Briefly, severely hypertensive individuals were recruited 
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from the Medical Research Council General Practice Framework and other family-
physician practices in the UK. All subjects were of self-reported white European 
ancestry up to level of grandparents. Height was measured by using a Marsden 
ultrasonic height measure; the standard operating procedure for this is described 
at the MRC BRIGHT study webpage (www.brightstudy.ac.uk). 
CoLaus 
The CoLaus study has been described in detail previously 23. Briefly, it is a 
single-centre, cross-sectional study including a random sample of 6,188 
extensively phenotyped European descent subjects (3,251 women and 2,937 
men) aged 35 to 75 years living in Lausanne, Switzerland. Height was measured 
to the nearest 5mm using a Seca® height gauge (Hamburg, Germany). 
Statistical methods 
Stage 1 analyses 
All GWA studies were genotyped using the Affymetrix 500K chip. For the 
WTCCC studies we used the WTCCC-defined list of 459,446 QC-passed SNPs 11, 
with additional exclusion criteria of a MAF > 0.01, and a Hardy-Weinberg 
Equilibrium P<1x10-4 for each individual GWA study, in our analyses. For the 
EPIC-Obesity study, SNPs included in the analyses have passed the following 
quality control criteria: they (1) were polymorphic (7,532 excluded), (2) have a call 
rate ≥90% (31,067 excluded), (3) show Hardy-Weinberg Equilibrium with a P>10-6 
(25,907 excluded), and (4) have a minor allele frequency of ≥5%. The total number 
of SNPs analysed is 338,830. The DGI data SNP quality control and exclusion 
criteria are reported in detail elsewhere 19, and resulted in the use of 386,731 
SNPs. We note that there is a small familial component to the DGI data, which is 
not taken into account in the betas and standard errors provided in the publicly 
available data that was used in our analyses. The extent of the P-value inflation 
that is caused by this is small (genomic control lambda < 1.1), so will have 
marginal effects on the association results, but we have provided a DGI excluded 
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result in Table 1 to demonstrate the robustness of the associations. We report the 
402,951 SNPs which passed QC in at least 4 of the 6 GWA studies. 
Individual level genotype data were available from only one GWA study 
(WTCCC-T2D); only summary height association statistics were available for the 
other studies. For each GWA study, summary statistics, assuming an additive 
inheritance model, from linear regression using Z-scores (described below) were 
generated using PLINK 24 (WTCCC-T2D, WTCCC-UKBS, WTCCC-CAD, DGI), 
SAS/Genetics 9.1 (SAS Institute Inc., Cary, NC, USA; EPIC-Obesity Study) or 
using R (http://www.R-project.org; WTCCC-HT). 
Stage 2 analyses  
For each stage 2 study the associations between genotype and height z-
score were examined using linear regression (described below). Stage 2 analyses 
were performed in Stata/SE 9.1 for Windows (StataCorp LP, Texas, USA) for all 
studies, except for CoLaus, which were performed using PLINK 24. 
Z-score generation 
Height was normally distributed in all cohorts. For the WTCCC GWA 
studies, UKT2D GCC, BRIGHT and EFSOCH studies, sex-specific height Z-
scores were generated within each study. Details for the DGI are available at 
http://www.broad.mit.edu/diabetes/. For EPIC-Obesity, height z-scores were 
created by sex and age decades (<50, 50<60, 60<70, ≥70). For the CoLaus study, 
height was corrected using a linear model, regressing height simultaneously onto 
age, sex, ancestry principal components 8 and grandparental birthplaces. The 
residuals were rescaled to have variance 1, and then were used as a “corrected” 
phenotype.  
Meta-Analysis 
Meta-analysis statistics were generated using the inverse-variance meta-
analysis method assuming fixed effects. The Q test was used to test for between-
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study heterogeneity. We used Stata/SE 9.1 for Windows (StataCorp LP, Texas, 
USA) for all meta-analysis calculations.  
Eigenstrat Analyses 
For the GWA study, EIGENSTRAT 8 was run in each individual study on the 
full set of markers (~400,000 SNPs). Within each study, similar results were 
obtained when using the first three principal components or the first ten principal 
components. 
Individual level data analyses in Stage 2 samples 
All individual level data analyses were performed in Stata/SE 9.1 for 
Windows (StataCorp LP, Texas, USA). To test for a deviation from an additive 
mode of inheritance for each of the 39 SNPs that we took forward into stage 2, we 
performed a likelihood ratio test of the additive regression model against the full 
2df model.  
To test for a difference in effect size between sexes, we performed a 
likelihood ratio test of the additive model against a model that also included a sex 
by genotype interaction term. To test for an influence of age on the effect size of 
we compared a regression model including dichotomized age (<50 and >= 50) and 
genotype to a model that also included a dichotomized age by genotype 
interaction term. We also performed the same analysis, but using 40 years as a 
cut-off and age deciles rather than dichotomized age. 
For the gene-gene interaction analyses, we assumed additive effects within-
loci, and compared a joint effects model to a model containing an interaction term 
using likelihood ratio tests.  
Combined results plot 
For the combined effect analyses we used only Stage 2 UK subjects to 
reduce the effect of the “winners curse”25. We only used subjects that had been 
successfully genotyped at each of the 20 SNPs that reached a P<5x10-7, and 
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grouped subjects by the total number of “tall” alleles that they carried. The mean 
height (estimated by multiplying the Z-score effect size by 6.82cm, the average SD 
of adult height across the cohorts used in this study) and frequency were then 
plotted using SigmaPlot for Windows Version 10.0 (Systat Software, Germany). 
Quantile-quantile plots and power results 
Quantile-quantile plots were generated using Stata/SE 9.1 for Windows. 
The 95% concentration bands, which are the approximate 95% confidence 
intervals around the null distribution were generated as described by 26. 
Quanto was used for the power calculation 27. To assess the impact of the 
“winners curse” we performed a binomial distribution test of the number of times 
the stage 1 result was greater than the stage 2 result, compared to that expected 
under the null of 50%. 
Linkage analyses 
We used linkage data from the website provided by Perola et al.5 which 
describes all reports in the literature that achieved LOD scores > 2 for height. 
Where a peak marker (or markers) was reported we called a 10Mb window around 
the marker (or markers) a “linked region”. Where no peak marker was reported we 
used the reported DeCode cM coordinates to determine the linked region. To 
compare the observed number of occasions that one of the 20 “real” SNPs 
occurred in a linked region to that expected under the null distribution, we took the 
total number of base-pairs in non-overlapping linked regions and divided it by the 
number of base-pairs in the human genome (http://genome.ucsc.edu from NCBI 
build 36.1 statistics). The expected number of times that the 20 real SNPs 
occurred in linked regions is then 20 x (base-pairs in linked regions / total number 
of base-pairs in the human genome). We used a Poisson test to determine the 
significance of the difference in the number of confirmed SNPs observed under 
linkage peaks compared to the expected number. We did this for SNPs with LODs 
> 3 and those > 2. 
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To determine if there was any over-representation of all associations at 
P<0.001 in linked regions we compared the proportions of these SNPs occurring in 
linked regions to those not occurring in linked regions. Again we performed this for 
a LOD > 2 and a LOD > 3 cut-off. 
Stage 2 genotyping 
Genotyping of the UKT2D GCC, BRIGHT and EFOSCH samples was 
performed by KBiosciences (Hoddesdon, UK) using their own novel system of 
fluorescence-based competitive allele-specific PCR (KASPar). Details of assay 
design are available from the KBiosciences website 
(http://www.kbioscience.co.uk). The CoLaus study is a GWA study (for which 
GWA data were not available in time for this study to be involved in stage one) and 
is described in detail elsewhere (Firman et al. Submitted). 
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Figure 1. QQ plots for the 402,951 SNPs from the genome-wide association 
meta-analysis as more studies are added in. A: N = 1914 (WTCCC-T2D); B: N 
= 4892 (adding DGI); C: N=6788 (adding WTCCC-HT); D: N=8668 (adding 
WTCCC-CAD); E: N=12228 (adding EPIC-Obesity); F: N=13665 (adding WTCCC-
UKBS). Blue line is the observed P values. The black line is the expected line 
under the null distribution. The grey bands are 95% concentration bands which are 
an approximation to the 95% confidence intervals around the expected line. 
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Figure 2. Manhattan plot for the 402,951 SNPs from the stage 1 genome-wide 
association meta-analysis of the WTCCC-T2D, DGI, WTCCC-HT, WTCCC-
CAD, EPIC-Obesity and WTCCC-UKBS studies. The red dots are the SNPs that 
reached a P<5x10-7 in a joint analysis of stage 1 and stage 2 samples.  
 
 
22 
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Figure 3. The combined impact of the 20 SNPS with a P<5x10-7. Subjects have 
been classified according to the number of height increasing alleles at each of the 
20 SNPS, and the mean height for each group is plotted (blue dots). The black line 
is a linear regression line through these points. The grey bars represent the 
proportion of the sample, with increasing numbers of „tall‟ alleles. The approximate 
height difference in cm, was obtained by multiplying the mean Z-score height for 
each group, by 6.82cm (the approximate average SD of height across the samples 
used in this study).  
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Figure 4 (a) The power of the genome-wide study to identify the variants that 
had a P<5x10-7 in the joint analysis at P<1x10-5 using the effect size 
estimates from the follow-up samples only and, (b) the sample size required 
o identify these variants using the effect size estimates from the follow-up 
samples only at a P<5x10-7 with 80% power. Effect sizes ranged from 0.083SD 
with minor allele frequency ~0.44 for rs6440003 to 0.033SD with minor allele 
frequency of 0.35 for rs8099594. 
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Figure 5. QQ plot for the P-values from the accompanying Lettre et al.18 
study of the most associated 10,000 SNPs from our study (excluding the DGI 
component to make the observations independent), including (dark blue 
dots) and excluding known loci (light blue dots). The black line is the expected 
line under the null distribution. The grey band is the 95% concentration bands 
which are an approximation to the 95% confidence intervals around the expected 
line. 
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Table 1. Results for the 20 SNPs taken forward into stage 2 that reached P<5x10-7 in joint analyses. The results are 
ordered by the joint-analyses P value. Chromosome positions are based on NCBI build 125. The alleles all refer to the positive 
strand. Betas are per each additional copy of allele 1. Minor allele frequency (MAF) based on the minor allele (bold and 
underlined in the alleles column) in the WTCCC-T2D study. R2 (% variation explained) is for follow-up sample only, and does 
not include CoLaus. The additive model test and sex test P values do not include data from DGI or CoLaus. * r2 = 1 proxies 
used in the stage 2 studies because of assay design issues. Candidate gene is given when monogenic human and/or mouse 
phenotypes and/or expression results clearly implicate a gene. An overall P-value excluding DGI is given because of the small 
related component of DGI and to provide evidence independent from the accompanying manuscript by Lettre et al.18  
 
SNP 
Candidate 
Gene 
Chromosome 
(position) 
Alleles 
(1/2) 
MAF 
Additive 
model 
test P  
Sex test 
P 
Male SD difference 
(95% CI) 
Female SD 
Difference (95% CI) 
R
2
 
GWA 
Study P 
Follow-
up P 
Hetero-
geneity 
P 
Overall P 
excluding 
DGI 
Overall P 
rs6440003 ZBTB38 3 (142576907) A/G 0.44 0.80 0.01 0.07 (0.04, 0.09) 0.12 (0.09, 0.14)  0.32 1.3x10
-14
 8.7x10
-12
 0.52 2.7x10
-23
 1.8x10
-24
 
rs2282978 
/ rs42046 * 
CDK6 7 (91898623) C/T 0.33 0.14 0.69 0.09 (0.06, 0.12) 0.08 (0.05, 0.11)  0.28 5.0x10
-11
 5.1x10
-13
 0.98 3.1x10
-21
 7.8x10
-23
 
rs1042725 HMGA2 12 (64644614) C/T 0.49 0.70 0.34 0.05 (0.03, 0.08) 0.07 (0.05, 0.10)  0.25 5.9x10
-9
 8.6x10
-11
 0.50 1.1x10
-14
 2.5x10
-18
 
rs6060373 GDF5 20 (33377622) A/G 0.38 0.17 0.70 -0.08 (-0.11, -0.05) -0.07 (-0.10, -0.04)  0.21 2.2x10
-12
 1.6x10
-7
 0.27 2.0x10
-15
 1.7x10
-17
 
rs16896068 LCORL 4 (17621109) A/G 0.16 0.31 0.99 -0.07 (-0.11, -0.03) -0.07 (-0.11, -0.03) 0.12 1.0x10
-4
 2.5x10
-10
 0.06 2.0x10
-13
 2.4x10
-13
 
rs4549631 LOC387103 6 (127008001) C/T 0.50 0.62 0.85 0.06 (0.03, 0.08) 0.05 (0.03, 0.08)  0.11 1.2x10
-8
 4.6x10
-6
 0.47 2.9x10
-11
 4.7x10
-13
 
rs3791675 EFEMP1 2 (56022960) C/T 0.23 0.43 0.34 0.09 (0.05, 0.12) 0.06 (0.03, 0.10)  0.12 7.1x10
-8
 6.0x10
-6
 0.54 1.5x10
-12
 2.2x10
-12
 
rs2814993 C6orf106 6 (34726871) A/G 0.15 0.18 0.87 0.09 (0.05, 0.13) 0.10 (0.06, 0.14)  0.20 8.9x10
-9
 5.7x10
-5
 0.04 4.0x10
-11
 4.1x10
-12
 
rs10512248 PTCH1 9 (95339258) G/T 0.31 0.14 0.10 0.05 (0.02, 0.07) 0.08 (0.05, 0.11)  0.19 1.5x10
-6
 6.0x10
-6
 0.82 1.0x10
-9
 4.2x10
-11
 
rs12735613 SPAG17 1 (118596015) A/G 0.24 0.0090 0.02 -0.08 (-0.11, -0.05) -0.03 (-0.06, 0.00)  0.09 3.4x10
-8
 8.2x10
-5
 0.51 2.0x10
-9
 4.4x10
-11
 
rs11107116 SOCS2 12 (92480972) G/T 0.23 0.047 0.73 -0.04 (-0.07, -0.01) -0.05 (-0.08, -0.02)  0.06 2.5x10
-5
 5.6x10
-6
 0.41 2.3x10
-8
 5.6x10
-10
 
rs6854783 / 
rs2055059 * 
HHIP 4 (146000684) A/G 0.43 0.17 0.50 0.06 (0.03, 0.08) 0.04 (0.01, 0.017)  0.10 1.2x10
-5
 3.2x10
-5
 0.24 2.2x10
-8
 2.1x10
-9
 
rs1390401 ZNF678 1 (224104685) A/G 0.18 0.0067 0.34 0.04 (0.01, 0.08) 0.07 (0.03, 0.10) 0.09 4.3x10
-6
 2.0x10
-4
 0.58 1.4x10
-6
 5.4x10
-9
 
rs3116602 DLEU7 13 (50009356) G/T 0.21 0.88 0.02 -0.04 (-0.07, 0.00) -0.09 (-0.12, -0.06)  0.07 5.6x10
-6
 1.8x10
-4
 0.82 6.1x10
-9
 6.8x10
-9
 
rs6686842 SCMH1 1 (41199964) C/T 0.44 0.30 0.97 -0.05 (-0.08, -0.02) -0.05 (-0.08, -0.02)  0.14 8.6x10
-6
 3.3x10
-4
 0.57 4.9x10
-7
 1.7x10
-8
 
rs10906982 ADAMTSL3 15 (82371586) A/T 0.48 0.33 0.92 0.05 (0.02, 0.07) 0.04 (0.02, 0.07)  0.07 5.4x10
-7
 2.1x10
-3
 0.57 5.3x10
-7
 1.7x10
-8
 
rs6724465 IHH 2 (219769351) A/G 0.10 0.96 0.85 -0.06 (-0.10, -0.02) -0.05 (-0.10, -0.01)  0.04 3.1x10
-5
 2.8x10
-4
 0.52 2.2x10
-6
 2.1x10
-8
 
rs10935120 
ANAPC13 or 
CEP63 
3 (135715790) A/G 0.33 0.10 0.63 -0.06 (-0.09, -0.03) -0.05 (-0.08, -0.02)  0.10 2.2x10
-6
 3.1x10
-3
 0.57 8.7x10
-7
 7.3x10
-8
 
rs8041863 ACAN 15 (87160693) A/T 0.47 0.90 0.21 0.04 (0.01, 0.06) 0.06 (0.03, 0.09)  0.03 2.2x10
-5
 8.6x10
-4
 0.02 4.9x10
-9
 8.1x10
-8
 
rs8099594 DYM 18 (45245158) A/G 0.35 0.69 0.53 0.05 (0.02, 0.08) 0.04 (0.01, 0.07)  0.01 7.8x10
-6
 4.1x10
-3
 0.008 1.6x10
-8
 3.1x10
-7
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Table 2. Candidate genes in the 20 loci, together with monogenic syndromes and mouse models associated with the 
genes. Candidate gene is given when monogenic human and/or mouse phenotypes and/or expression results clearly implicate 
a gene, otherwise nearest gene is given, unless no gene within 500kb window around SNP. Information on each gene was 
obtained either from the OMIM (http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM) or Jackson lab (http://www.jax.org/) 
websites. * Details are from Uniprot summaries.  
 
SNP 
Candidate or 
nearest gene(s) 
Monogenic syndrome 
caused by mutation in 
gene 
Knockout mouse 
phenotype 
Details* 
rs6440003 
Zinc finger and BTB 
domain-containing 
protein 38 (ZBTB38) 
- - Transcription factor. 
rs2282978 
Cyclin-dependent 
Kinase-6 (CDK6) 
- 15% smaller embryos 
Involved in the control of the cell cycle. 
Interacts with D-type G1 cyclins. 
rs1042725 
High-mobility group 
A2  
(HMGA2) 
Disruption causes tall 
stature, extreme bone 
and dental overgrowth, 
and multiple lipomas. 
Pygmy mice 
Belongs to the non-histone 
chromosomal high mobility group 
(HMG) protein family. HMG proteins 
function as chromatin architectural 
factors. 
rs6060373 
Growth 
Differentiation Factor 
5 (GDF5) 
Chondrodysplasia 
(abnormally short and 
deformed limbs); 
brachydactyly (short 
digits) DuPan 
syndrome; multiple 
synostoses syndrome. 
Homozygous null 
mutants demonstrate 
skeleton defects, such as 
reduced or absent limb 
bones and joints. 
Involved in bone formation. Also 
known as Cartilage-derived 
morphogenetic protein 1. 
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rs16896068 
Ligand-dependent 
nuclear receptor 
corepressor-like 
protein (LCORL) 
- - May act as transcription activator. 
rs4549631 LOC387103 - - Not known 
rs3791675 
EGF-Containing 
Fibulin-like 
extracellular matrix 
protein 1 (EFEMP1) 
Doyne honeycomb 
retinal dystrophy; no 
obvious skeletal 
defects. 
Normal phenotype 
Extra-cellular matrix. Belongs to the 
fibulin family. 
rs2814993 C6orf106 - - Not known 
rs10512248 
Patched, drosophilia, 
homolog of, 1 
(PTCH1) 
Gorlin syndrome (basal 
cell carcinoma); 
holoprosencephaly. 
Homozygous null mice 
die during 
embryogenesis, 
heterozygotes larger 
than normal, with hind 
limb defects.  
Hedgehog signalling. Acts as a 
receptor for sonic hedgehog (SHH), 
Indian hedgehog (IHH) and desert 
hedgehog (DHH). 
rs12735613 
Sperm associated 
antigen 17 (SPAG17) 
- - Not known 
rs11107116 
Suppressor of 
cytokine signaling 2 
(SOCS2) 
- 
Homozygous null mice 
grow more rapidly. Males 
are 40% heavier than 
wild-type littermates; The 
increase in weight results 
from general increase in 
visceral organ weight 
and long bone length. 
SOCS family proteins form part of a 
classical negative feedback system 
that regulates cytokine signal 
transduction. SOCS2 appears to be a 
negative regulator in the growth 
hormone/IGF1 signaling pathway. 
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rs6854783 
Hedgehog interacting 
protein (HHIP) 
- 
Ectopic expression in 
transgenic mice results in 
severe skeletal defects 
similar to those observed 
in IHH mutants. 
Hedgehog signalling. Modulates 
hedgehog signaling through direct 
interaction with members of the 
hedgehog family including SHH, IHH 
and DHH. 
rs1390401 
Zinc finger protein 
678 (ZNF678) 
- - 
Transcription factor. Belongs to the 
Krueppel C2H2-type zinc-finger 
protein family by similarity. 
rs3116602 
Deleted in 
lymphocytic 
leukaemia, 7 
(DLEU7) 
- - Not known 
rs6686842 
Sex comb on midleg 
homolog 1 (SCMH1) 
- 
Homozygous null mice 
present with multiple 
defects including of 
skeleton.  
Polycomb protein. A constituent of the 
mammalian Polycomb repressive 
complexes 1 involved in chromatin 
modifications 
rs10906982 
ADAMTS-like protein 
3 (ADAMTSL3) 
- - 
Extra-cellular matrix. Strongly similar 
to members of the ADAMTS family but 
lacks metalloprotease and disintegrin-
like domains. 
rs6724465 
Indian hedgehog 
(IHH) 
Brachydactyly; 
acrocapitofemoral 
dysplasia (cone-shaped 
ends of hand and hip 
bones). 
Homozygous null mice 
display impaired 
chondrocyte proliferation 
and maturation, resulting 
in dwarfism and 
numerous skeletal 
abnormalities. 
Hedgehog signalling. Intercellular 
signal essential for a variety of 
patterning events during development. 
Binds to the patched (PTC) receptor. 
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rs10935120 
Anaphase promoting 
complex subunit 13 
(ANAPC13) 
- - 
Cell cycle. Component of the 
anaphase promoting 
complex/cyclosome (APC/C), a cell 
cycle-regulated E3 ubiquitin ligase that 
controls progression through mitosis 
and the G1 phase of the cell cycle. 
rs8041863 Aggrecan (ACAN) 
Autosomal dominant 
spondyloepiphyseal 
dysplasia type 
Kimberley, 
characterised by 
severe, premature 
osteoarthritis. 
Homozygous mutants 
are dwarfed at birth. 
Extra-cellular matrix. A member of the 
aggrecan/versican proteoglycan 
family. Part of the extra-cellular matrix 
in cartilaginous tissue. 
rs8099594 Dymeclin (DYM) 
Autosomal recessive 
disorder characterized 
by abnormal skeletal 
development and 
mental retardation. 
- 
May have a role in process of 
intracellular digestion of proteins or in 
proteoglycan metabolism. 
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Supplementary Table 1. Characteristics of samples used in this study. 
 
  N % Male 
Males: age 
at study 
(yrs; 
mean, SD) 
Females: age 
at study (yrs; 
mean, SD) 
Males: average 
height (cm; mean, 
SD) 
Females: average 
height (cm; mean, SD) 
a) GWAS WTCCC-T2D 1914 58.2 59.0 (9.9) 57.9 (10.4) 175.5 (7.0) 161.5 (6.6) 
 WTCCC-HT 1896 39.9 56.5 (10.9) 57.8 (11.1) 174.3 (7.4) 161.3 (6.4) 
 WTCCC-CAD 1880 79.4 60.0 (8.0) 60.3 (8.5) 173.8 (6.9) 159.8 (6.7) 
 
WTCCC-
UKBS 
1437 48.2 45.4 (11.8) 41.4 (12.6) 178.2 (6.7) 164.7 (6.5) 
 EPIC-Obesity 3560 45.7 59.8 (9.0) 58.8 (8.9) 173.7 (6.7) 160.9 (6.0) 
 DGI (T2D) 1511 50.6 63.1 (10.3) 65.4 (10.5) 174.3 (6.4) 161.1 (6.2) 
 DGI (Controls) 1467 48.6 58.4 (10.5) 59.2 (10.3) 175.6 (6.2) 162.4 (5.9) 
b) Replication 
samples 
UKT2D-GCC 6698 54.0 61.8 (10.7) 60.6 (11.7) 175.2 (6.9) 161.2 (6.7) 
 EFSOCH 1929 49.5 32.9 (6.0) 30.4 (5.2) 177.9 (6.6) 165.0 (6.3) 
 BRIGHT 2446 39.0 58.7 (9.7) 59.0 (9.1) 175.6 (7.0) 162.3 (6.6) 
 CoLaus 5409 47.1 52.9 (10.8) 53.9 (10.7) 175.0 (7.4) 162.6 (6.7) 
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Supplementary Table 2. Results for 12 UK ancestry informative markers described by the WTCCC. The beta refers to the 
effect of each additional copy of allele 1. Only five of the AIMS were taken into the replication cohorts. Chromosome positions 
are based on NCBI build 125. The alleles all refer to the positive strand. *rs6644913 is also described as an AIM by the 
WTCCC, but did not pass quality control criteria. 
 
SNP Chromosome 
Alleles 
(1/2) 
Stage 1  
beta 
Stage 
1 P  
Stage 2 
beta 
Stage 
2 
P 
Overall 
beta 
Overall 
P 
rs1042712 2q21 C/G -0.038 0.04 -0.002 0.89 -0.017 0.32 
rs7696175 4p14 C/T 0.010 0.43 0.009 0.40 0.009 0.81 
rs1460133 4q28 C/T 0.002 0.90 - - - - 
rs9378805 6p25 A/C -0.005 0.67 0.015 0.16 0.006 0.45 
rs3873375 6p21 C/T 0.016 0.21 - - - - 
rs11790408 9p24 G/T 0.012 0.35 - - - - 
rs12295525 11p15 C/T 0.020 0.33 - - - - 
rs12797951 11q13 G/T -0.004 0.79 - - - - 
rs10774241 12p13 A/G 0.007 0.64 -0.013 0.35 -0.004 0.90 
rs17449560 14q12 C/G 0.023 0.25 - - - - 
rs3760843 19q13 A/T 0.027 0.08 - - - - 
rs2143877 20q12 A/G 0.008 0.55 0.004 0.76 0.006 0.52 
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Supplementary Table 3. Results for the SNPs taken forward into stage 2 which did not reach a P<5x10-7 in joint 
analysis. The results are ordered by the joint-analyses P value. Chromosomes positions are based on NCBI build 125. The 
alleles all refer to the positive strand. Betas are per each additional copy of allele 1. Minor allele frequency (MAF) based on the 
minor allele (bold and underlined in the alleles column) in the WTCCC-T2D study. R2 is for follow-up sample only, and does not 
include CoLaus. The additive model test, and sex test P values do not include data from DGI or CoLaus. * Failed in Broad, 
EPIC-Obesity and CoLaus.  
 
SNP 
Chromosome 
(position) 
Alleles 
(1/2) 
MAF 
Additive 
model 
test P  
Sex 
test P 
Male SD  
difference  
(95% CI) 
Female SD 
Difference (95% 
CI) 
R2 
(%) 
GWA 
Study P 
Follow-
up P 
Overall 
P 
rs11049407* 12 (28225631) A/G 0.30 0.24 0.82 0.06 (0.02, 0.09)  0.05 (0.02, 0.08) 0.06 2.5x10-5 1.0x10-2 4.1x10-6 
rs508521 6 (116853934) A/G 0.28 0.12 0.63 -0.05 (-0.08, -0.02) -0.06 (-0.09, -0.03) 0.05 3.3x10-6 4.9x10-2 5.1x10-6 
rs509035 3 (173646151) A/G 0.31 0.20 0.92 0.04 (0.01, 0.07) 0.04 (0.01, 0.07) 0.02 9.4x10-6 4.8x10-2 8.5x10-6 
rs6598287 15 (98359299) C/T 0.40 0.68 0.79 0.05 (0.02, 0.07)  0.04 (0.01, 0.07) 0.03 4.0x10-6 0.08 1.1x10-5 
rs7030440 9 (130470174) A/G 0.33 0.86 0.83 -0.03 (-0.06, 0.00)  -0.03 (-0.06, 0.00) 0.01 4.8x10-6 0.11 2.0x10-5 
rs450902 12 (118723761) A/G 0.34 0.85 0.17 0.05 (0.02, 0.08)  0.02 (-0.01, 0.05) 0.03 2.6x10-5 0.12 5.3x10-5 
rs4934353 10 (89379558) A/G 0.24 0.76 0.48 -0.03 (-0.06, 0.00)  -0.05 (-0.08, -0.01) 0.02 8.3x10-5 7.0x10-2 6.3x10-5 
rs2096196 1 (200664650) C/T 0.44 0.78 0.05 0.02 (-0.01, 0.04)  0.05 (0.03, 0.08) 0.01 1.3x10-6 0.40 9.3x10-5 
rs2043314 19 (35805410) C/T 0.48 0.18 0.60 -0.04 (-0.07, -0.01) -0.03 (-0.06, 0.00) 0.01 2.6x10-6 0.28 9.4x10-5 
rs7567851 2 (178510227) C/G 0.08 0.33 0.91 0.06 (0.01, 0.11)  0.05 (0.00, 0.10) <0.01 5.8x10-6 0.15 1.1x10-4 
rs17001086 19 (10978436) C/T 0.11 0.41 0.40 -0.04 (-0.08, 0.00)  -0.07 (-0.11, -0.03) 0.04 7.8x10-5 0.13 1.8x10-4 
rs4527833 8 (130830826) C/T 0.48 0.71 0.91 0.03 (0.00, 0.06)  0.03 (0.00, 0.05) <0.01 7.8x10-6 0.40 3.8x10-4 
rs12625434 20 (18369779) C/T 0.50 0.05 0.89 -0.03 (-0.06, 0.00)  -0.03 (-0.06, 0.00) <0.01 8.5x10-6 0.39 5.6x10-4 
rs211389 10 (32334017) G/T 0.12 0.72 0.73 -0.03 (-0.07, 0.01)  -0.04 (-0.08, 0.01) <0.01 1.1x10-6 0.92 7.3x10-4 
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rs3806089 6 (71027464) C/T 0.10 0.98 0.66 -0.04 (-0.08, 0.00)  -0.05 (-0.10, -0.01) <0.01 3.3x10-5 0.69 1.4x10-3 
rs1556263 9 (113544161) C/T 0.47 0.007 0.13 0.04 (0.02, 0.07)  0.01 (-0.01, 0.04) <0.01 7.0x10-6 0.83 3.8x10-3 
rs12539316 7 (72422549) A/G 0.28 0.97 0.92 -0.03 (-0.06, 0.00)  -0.03 (-0.06, 0.00) <0.01 1.4x10-5 0.22 4.4x10-3 
rs17082799 5 (92344239) A/G 0.04 0.22 0.98 -0.03 (-0.11, 0.04)  -0.04 (-0.11, 0.04) <0.01 6.6x10-6 0.22 0.055 
rs4130172 2 (43028076) C/T 0.37 0.91 0.67 0.03 (0.00, 0.06)  0.04 (0.00, 0.07) <0.01 4.1x10-6 0.23 0.059 
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Supplementary Table 4. Effect of age on height associations for all 39 SNPs 
taken into stage 2. The results do not include data from DGI and CoLaus. Effect 
size estimates are given per additional height-increasing allele. Decade cut offs 
were <=30, 31 to 40, 41 to 50, 51 to 60, 61 to 70 and > 70 years of age.  
 
SNP 
SNP overall SD 
difference (95% CI) 
SNP + age 
(decade) SD 
difference (95% CI) 
Age test P 
(cut-off 
40yrs) 
Age test P 
(cut-off 
50yrs) 
rs6440003 0.090 (0.07, 0.11)  0.088 (0.07, 0.11)  0.34 0.71 
rs2282978 0.086 (0.06, 0.11)  0.084 (0.06, 0.10)  0.94 0.54 
rs1042725 0.063 (0.04, 0.08)  0.063 (0.04, 0.08)  0.39 0.43 
rs6060373 0.076 (0.06, 0.10)  0.076 (0.06, 0.10)  0.50 0.97 
rs16896068 0.071 (0.05, 0.10) 0.069 (0.04, 0.09)  0.08 0.05 
rs4549631 0.056 (0.04, 0.08)  0.054 (0.04, 0.07)  0.30 0.79 
rs3791675 0.075 (0.05, 0.10)  0.074 (0.05, 0.10)  0.48 0.47 
rs2814993 0.096 (0.07, 0.12)  0.096 (0.07, 0.12)  0.13 1.00 
rs10512248 0.063 (0.04, 0.08)  0.062 (0.04, 0.08)  0.44 0.38 
rs12735613 0.059 (0.04, 0.08)  0.059 (0.04, 0.08)  0.93 0.20 
rs11107116 0.045 (0.02, 0.07)  0.047 (0.02, 0.07)  0.88 0.41 
rs6854783 0.049 (0.03, 0.07)  0.050 (0.03, 0.07)  0.78 0.65 
rs1390401 0.053 (0.03, 0.08) 0.048 (0.02, 0.07) 0.32 0.89 
rs3116602 0.061 (0.04, 0.08)  0.061 (0.04, 0.08)  0.32 0.31 
rs6686842 0.051 (0.03, 0.07)  0.050 (0.03, 0.07)  0.64 0.68 
rs10906982 0.046 (0.03, 0.06)  0.045 (0.03, 0.06)  0.11 0.43 
rs6724465 0.058 (0.03, 0.09)  0.059 (0.03, 0.09)  0.86 0.07 
rs10935120 0.055 (0.03, 0.07)  0.052 (0.03, 0.07)  0.74 0.92 
rs8041863 0.048 (0.03, 0.07)  0.048 (0.03, 0.07)  0.48 0.29 
rs8099594 0.045 (0.02, 0.07)  0.047 (0.03, 0.07)  0.36 0.51 
rs11049407 0.054 (0.03, 0.08)  0.054 (0.03, 0.08)  0.22 0.06 
rs508521 0.055 (0.03, 0.08)  0.056 (0.04, 0.08)  0.23 0.87 
rs509035 0.039 (0.02, 0.06)  0.041 (0.02, 0.06)  0.62 0.99 
rs6598287 0.044 (0.03, 0.06)  0.047 (0.03, 0.07)  0.30 0.69 
rs7030440 0.031 (0.01, 0.05)  0.030 (0.01, 0.05)  0.45 0.28 
rs450902 0.036 (0.02, 0.06)  0.037 (0.02, 0.06)  0.12 0.17 
rs4934353 0.037 (0.02, 0.06)  0.037 (0.02, 0.06)  0.96 0.83 
rs2096196 0.034 (0.02, 0.05)  0.036 (0.02, 0.05)  0.10 0.24 
rs2043314 0.036 (0.02, 0.06)  0.037 (0.02, 0.06)  0.47 0.73 
rs7567851 0.057 (0.02, 0.09)  0.060 (0.03, 0.09)  0.24 0.75 
rs17001086 0.055 (0.03, 0.09)  0.056 (0.03, 0.09)  0.93 0.99 
rs4527833 0.027 (0.01, 0.05)  0.027 (0.01, 0.05)  0.39 0.36 
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rs12625434 0.031 (0.01, 0.05)  0.027 (0.01, 0.05)  0.48 0.93 
rs211389 0.031 (0.00, 0.06)  0.032 (0.00, 0.06)  0.39 0.64 
rs3806089 0.046 (0.01, 0.08)  0.052 (0.02, 0.08)  0.28 0.79 
rs1556263 0.030 (0.01, 0.05)  0.028 (0.01, 0.05)  1.00 0.53 
rs12539316 0.030 (0.01, 0.05)  0.033 (0.01, 0.05)  0.82 0.48 
rs17082799 0.035 (-0.02, 0.09)  0.026 (-0.03, 0.08)  0.71 0.85 
rs4130172 0.030 (0.01, 0.05)  0.031 (0.01, 0.05)  0.47 0.65 
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Supplementary Table 5. Interaction results for each of the 20 SNPs that 
reached P<5x10-7 in joint analyses. The beta refers to the multiplicative effect of 
each additional copy of the “tall” alleles at each of the pairs of SNPs. 
 
SNP1 SNP2 Interaction beta (95% CI) Interaction P 
rs4549631 rs16896068 -0.046 (-0.084, -0.008) 0.017 
rs1042725 rs10906982 0.032 (0.005, 0.059) 0.021 
rs2814993 rs6060373 0.048 (0.007, 0.09) 0.022 
rs2814993 rs4549631 0.045 (0.004, 0.085) 0.030 
rs6686842 rs16896068 0.041 (0.002, 0.079) 0.039 
rs12735613 rs4549631 0.033 (0.002, 0.065) 0.039 
rs6686842 rs2282978 -0.030 (-0.061, 0) 0.049 
rs3791675 rs1042725 -0.031 (-0.063, 0.001) 0.054 
rs6686842 rs1390401 0.034 (-0.001, 0.069) 0.058 
rs6854783 rs11107116 -0.031 (-0.064, 0.002) 0.067 
rs6440003 rs6854783 -0.025 (-0.052, 0.003) 0.077 
rs3791675 rs10906982 -0.029 (-0.06, 0.003) 0.078 
rs10935120 rs4549631 0.025 (-0.004, 0.055) 0.090 
rs3116602 rs16896068 0.039 (-0.007, 0.085) 0.093 
rs6060373 rs16896068 0.033 (-0.006, 0.071) 0.096 
rs12735613 rs3791675 0.031 (-0.006, 0.068) 0.097 
rs6854783 rs2282978 0.024 (-0.006, 0.054) 0.120 
rs3791675 rs2814993 0.036 (-0.01, 0.083) 0.124 
rs11107116 rs1390401 0.033 (-0.009, 0.074) 0.125 
rs10512248 rs10906982 -0.022 (-0.051, 0.006) 0.128 
rs6686842 rs6440003 -0.021 (-0.049, 0.006) 0.131 
rs3791675 rs6440003 0.024 (-0.008, 0.056) 0.138 
rs8041863 rs6060373 -0.021 (-0.048, 0.007) 0.140 
rs6440003 rs3116602 0.024 (-0.009, 0.057) 0.155 
rs2282978 rs8099594 -0.022 (-0.053, 0.009) 0.171 
rs11107116 rs3116602 0.027 (-0.013, 0.067) 0.183 
rs12735613 rs2814993 0.031 (-0.015, 0.078) 0.187 
rs3791675 rs11107116 -0.026 (-0.064, 0.013) 0.188 
rs2814993 rs3116602 -0.032 (-0.08, 0.016) 0.189 
rs11107116 rs6060373 -0.022 (-0.055, 0.011) 0.191 
rs6854783 rs4549631 -0.018 (-0.046, 0.009) 0.193 
rs6440003 rs8099594 -0.019 (-0.047, 0.01) 0.193 
rs6724465 rs10935120 -0.031 (-0.079, 0.016) 0.194 
rs2282978 rs3116602 0.022 (-0.014, 0.058) 0.233 
rs12735613 rs6440003 -0.019 (-0.05, 0.012) 0.238 
rs6724465 rs2814993 0.039 (-0.027, 0.106) 0.244 
rs8099594 rs1390401 0.022 (-0.015, 0.058) 0.246 
rs3791675 rs16896068 -0.025 (-0.068, 0.018) 0.248 
rs10512248 rs8099594 -0.018 (-0.048, 0.013) 0.252 
rs4549631 rs2282978 0.017 (-0.012, 0.047) 0.253 
rs3791675 rs1390401 0.023 (-0.017, 0.064) 0.258 
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rs2282978 rs6060373 -0.018 (-0.048, 0.013) 0.258 
rs1042725 rs1390401 0.020 (-0.015, 0.054) 0.270 
rs2814993 rs10906982 -0.022 (-0.063, 0.018) 0.274 
rs3116602 rs6060373 0.019 (-0.015, 0.053) 0.274 
rs6854783 rs1042725 0.015 (-0.012, 0.043) 0.275 
rs4549631 rs8041863 0.015 (-0.012, 0.042) 0.277 
rs6440003 rs10512248 -0.016 (-0.045, 0.013) 0.281 
rs2282978 rs8041863 0.016 (-0.013, 0.046) 0.282 
rs10512248 rs16896068 0.021 (-0.018, 0.061) 0.288 
rs6724465 rs1390401 0.031 (-0.026, 0.088) 0.292 
rs3116602 rs8041863 -0.017 (-0.051, 0.016) 0.301 
rs11107116 rs8099594 -0.018 (-0.052, 0.016) 0.302 
rs6854783 rs1390401 0.018 (-0.017, 0.053) 0.308 
rs6440003 rs2814993 0.021 (-0.019, 0.061) 0.308 
rs4549631 rs1390401 -0.018 (-0.052, 0.017) 0.311 
rs10935120 rs6854783 -0.015 (-0.044, 0.014) 0.311 
rs8099594 rs16896068 0.020 (-0.019, 0.06) 0.314 
rs6686842 rs4549631 0.014 (-0.014, 0.042) 0.326 
rs6440003 rs16896068 0.018 (-0.019, 0.056) 0.338 
rs6724465 rs10906982 0.022 (-0.023, 0.067) 0.339 
rs8041863 rs8099594 0.014 (-0.015, 0.042) 0.339 
rs6724465 rs8041863 -0.022 (-0.066, 0.023) 0.340 
rs6686842 rs1042725 -0.013 (-0.041, 0.014) 0.345 
rs2282978 rs11107116 -0.017 (-0.052, 0.019) 0.349 
rs12735613 rs10512248 -0.016 (-0.049, 0.018) 0.360 
rs3791675 rs6724465 0.025 (-0.028, 0.078) 0.360 
rs10935120 rs16896068 0.018 (-0.022, 0.058) 0.373 
rs6440003 rs2282978 0.013 (-0.016, 0.043) 0.373 
rs6686842 rs6854783 0.012 (-0.016, 0.041) 0.386 
rs8041863 rs16896068 0.016 (-0.021, 0.054) 0.389 
rs6440003 rs4549631 -0.012 (-0.039, 0.015) 0.392 
rs3791675 rs3116602 -0.017 (-0.055, 0.022) 0.393 
rs4549631 rs8099594 -0.012 (-0.041, 0.016) 0.393 
rs6724465 rs6060373 -0.020 (-0.067, 0.027) 0.398 
rs10935120 rs10906982 -0.012 (-0.041, 0.016) 0.401 
rs6440003 rs1390401 -0.015 (-0.049, 0.02) 0.401 
rs6686842 rs10906982 0.012 (-0.016, 0.039) 0.409 
rs2814993 rs10512248 0.018 (-0.025, 0.06) 0.416 
rs6854783 rs6060373 -0.012 (-0.04, 0.017) 0.416 
rs10906982 rs16896068 0.015 (-0.022, 0.052) 0.427 
rs6686842 rs11107116 0.013 (-0.02, 0.047) 0.430 
rs1042725 rs8041863 -0.011 (-0.038, 0.016) 0.438 
rs4549631 rs10906982 0.011 (-0.017, 0.038) 0.441 
rs6686842 rs10935120 -0.012 (-0.042, 0.018) 0.441 
rs4549631 rs1042725 -0.011 (-0.038, 0.017) 0.442 
rs4549631 rs11107116 -0.013 (-0.046, 0.02) 0.443 
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rs12735613 rs10906982 -0.012 (-0.043, 0.019) 0.452 
rs12735613 rs16896068 0.016 (-0.027, 0.06) 0.465 
rs6854783 rs8099594 0.011 (-0.018, 0.039) 0.473 
rs2814993 rs16896068 -0.020 (-0.075, 0.035) 0.474 
rs3791675 rs10512248 -0.012 (-0.046, 0.022) 0.486 
rs3791675 rs6854783 -0.011 (-0.043, 0.021) 0.491 
rs3116602 rs8099594 0.012 (-0.023, 0.047) 0.495 
rs6854783 rs10512248 0.010 (-0.019, 0.039) 0.507 
rs2282978 rs16896068 -0.014 (-0.054, 0.027) 0.508 
rs6440003 rs1042725 0.009 (-0.018, 0.036) 0.509 
rs1042725 rs6060373 -0.009 (-0.037, 0.019) 0.509 
rs10906982 rs6060373 -0.009 (-0.037, 0.019) 0.518 
rs6686842 rs12735613 0.010 (-0.022, 0.042) 0.522 
rs10935120 rs1390401 0.011 (-0.025, 0.048) 0.543 
rs3791675 rs8099594 -0.010 (-0.044, 0.023) 0.543 
rs10512248 rs8041863 -0.009 (-0.038, 0.02) 0.550 
rs4549631 rs6060373 0.008 (-0.019, 0.036) 0.553 
rs10512248 rs1042725 -0.009 (-0.037, 0.02) 0.554 
rs6686842 rs2814993 0.012 (-0.029, 0.053) 0.554 
rs6724465 rs3116602 -0.017 (-0.073, 0.04) 0.558 
rs3791675 rs6060373 -0.009 (-0.042, 0.023) 0.572 
rs8099594 rs6060373 0.008 (-0.021, 0.038) 0.578 
rs10512248 rs1390401 0.010 (-0.027, 0.047) 0.594 
rs10935120 rs2282978 -0.009 (-0.04, 0.023) 0.597 
rs6686842 rs3791675 -0.008 (-0.041, 0.024) 0.609 
rs3791675 rs2282978 0.009 (-0.026, 0.044) 0.618 
rs11107116 rs10906982 0.008 (-0.024, 0.041) 0.626 
rs6724465 rs2282978 -0.012 (-0.061, 0.037) 0.626 
rs2814993 rs1042725 0.010 (-0.03, 0.05) 0.627 
rs6854783 rs8041863 0.007 (-0.021, 0.034) 0.627 
rs12735613 rs2282978 -0.008 (-0.043, 0.026) 0.630 
rs2282978 rs10512248 -0.008 (-0.039, 0.023) 0.631 
rs2814993 rs1390401 0.012 (-0.039, 0.062) 0.646 
rs1042725 rs16896068 -0.009 (-0.046, 0.029) 0.654 
rs6854783 rs2814993 0.009 (-0.032, 0.05) 0.659 
rs1042725 rs8099594 0.006 (-0.022, 0.035) 0.660 
rs10935120 rs8099594 -0.007 (-0.037, 0.024) 0.666 
rs10512248 rs11107116 -0.007 (-0.042, 0.027) 0.680 
rs10935120 rs6440003 0.006 (-0.023, 0.035) 0.694 
rs3116602 rs10906982 -0.007 (-0.04, 0.027) 0.700 
rs12735613 rs1390401 -0.008 (-0.047, 0.032) 0.704 
rs12735613 rs8099594 0.006 (-0.027, 0.039) 0.710 
rs2282978 rs1390401 0.007 (-0.031, 0.045) 0.712 
rs12735613 rs3116602 0.007 (-0.031, 0.046) 0.715 
rs6060373 rs1390401 0.006 (-0.029, 0.041) 0.721 
rs6724465 rs4549631 0.008 (-0.037, 0.054) 0.723 
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rs10935120 rs8041863 -0.005 (-0.034, 0.024) 0.733 
rs8041863 rs1390401 -0.006 (-0.04, 0.029) 0.746 
rs10935120 rs10512248 0.005 (-0.026, 0.036) 0.754 
rs3116602 rs1390401 -0.006 (-0.048, 0.035) 0.763 
rs6686842 rs6060373 0.004 (-0.024, 0.033) 0.766 
rs10935120 rs2814993 0.006 (-0.036, 0.049) 0.768 
rs12735613 rs6854783 0.005 (-0.027, 0.036) 0.768 
rs2282978 rs1042725 0.004 (-0.025, 0.034) 0.769 
rs6686842 rs6724465 -0.007 (-0.053, 0.039) 0.770 
rs12735613 rs8041863 -0.004 (-0.036, 0.027) 0.782 
rs1042725 rs3116602 0.004 (-0.029, 0.038) 0.790 
rs10512248 rs6060373 -0.004 (-0.033, 0.025) 0.790 
rs12735613 rs6724465 -0.007 (-0.059, 0.045) 0.802 
rs6724465 rs6854783 0.006 (-0.04, 0.051) 0.807 
rs10906982 rs8041863 0.003 (-0.024, 0.03) 0.819 
rs6724465 rs16896068 0.007 (-0.056, 0.07) 0.825 
rs6686842 rs10512248 -0.003 (-0.033, 0.026) 0.838 
rs10935120 rs11107116 0.003 (-0.031, 0.038) 0.844 
rs6854783 rs10906982 0.003 (-0.025, 0.03) 0.845 
rs2814993 rs8099594 -0.004 (-0.047, 0.038) 0.845 
rs4549631 rs10512248 0.003 (-0.026, 0.032) 0.847 
rs10935120 rs6060373 -0.003 (-0.033, 0.027) 0.847 
rs12735613 rs6060373 -0.003 (-0.036, 0.029) 0.848 
rs6724465 rs11107116 0.005 (-0.048, 0.058) 0.850 
rs6686842 rs3116602 0.003 (-0.03, 0.037) 0.850 
rs6440003 rs11107116 -0.003 (-0.036, 0.029) 0.852 
rs11107116 rs16896068 -0.004 (-0.049, 0.041) 0.853 
rs6686842 rs8041863 -0.003 (-0.03, 0.025) 0.854 
rs1390401 rs16896068 -0.004 (-0.052, 0.043) 0.857 
rs10906982 rs8099594 0.002 (-0.026, 0.031) 0.867 
rs3791675 rs4549631 -0.003 (-0.034, 0.029) 0.868 
rs12735613 rs1042725 0.003 (-0.029, 0.034) 0.871 
rs2814993 rs8041863 0.003 (-0.036, 0.043) 0.871 
rs6724465 rs1042725 0.004 (-0.041, 0.049) 0.872 
rs6440003 rs6060373 0.002 (-0.026, 0.03) 0.876 
rs2282978 rs10906982 0.002 (-0.027, 0.032) 0.878 
rs11107116 rs8041863 -0.002 (-0.035, 0.03) 0.887 
rs3791675 rs10935120 -0.002 (-0.036, 0.031) 0.892 
rs10935120 rs1042725 -0.002 (-0.031, 0.027) 0.895 
rs10512248 rs3116602 0.002 (-0.033, 0.037) 0.898 
rs4549631 rs3116602 -0.002 (-0.036, 0.031) 0.905 
rs1042725 rs11107116 -0.002 (-0.034, 0.031) 0.909 
rs2814993 rs2282978 0.003 (-0.041, 0.046) 0.909 
rs10935120 rs3116602 -0.002 (-0.037, 0.033) 0.909 
rs6686842 rs8099594 -0.002 (-0.031, 0.028) 0.910 
rs6440003 rs10906982 -0.002 (-0.029, 0.026) 0.911 
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rs6724465 rs8099594 0.002 (-0.045, 0.049) 0.922 
rs6440003 rs8041863 -0.001 (-0.028, 0.026) 0.934 
rs6724465 rs6440003 0.002 (-0.043, 0.047) 0.943 
rs12735613 rs10935120 0.001 (-0.033, 0.035) 0.946 
rs6854783 rs16896068 -0.001 (-0.039, 0.037) 0.951 
rs12735613 rs11107116 -0.001 (-0.039, 0.037) 0.970 
rs2814993 rs11107116 0.001 (-0.047, 0.049) 0.970 
rs3791675 rs8041863 0.001 (-0.031, 0.032) 0.973 
rs6724465 rs10512248 0.001 (-0.048, 0.049) 0.984 
rs10906982 rs1390401 0 (-0.034, 0.035) 0.987 
rs6854783 rs3116602 0 (-0.033, 0.034) 0.995 
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Supplementary Figure 1. A comparison of EIGENSTRAT adjusted P-values to unadjusted P-values for each individual 
genome-wide association study. The adjustment is based on the first ten principal components obtained from EIGENSTRAT. 
Using the first three principal components produced similar results. The green dots represent the 20 SNPs which reached a 
P<5x10-7 in the overall analysis. DGI data were unavailable. 
 
 
 
 
 
 
 Chapter 2 78 
Supplementary Figure 2. LD Plots for the regions around SNPs that have a 
joint analysis P<5x10-7. Red dots are GWAS association P values. The grey bars 
represent recombination rates. The LD triangle is based on the r2 statistic, with 
darker shading of blue indicating higher r2 values. 
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Supplementary Figure 3. Manhattan plots for the 402,951 SNPs from the 
genome-wide association meta-analysis as more studies are added in. A: N = 
1914 (WTCCC-T2D); B: N = 4892 (adding DGI); C: N=6788 (adding WTCCC-HT); 
D: N=8668 (adding WTCCC-CAD); E: N=12228 (adding EPIC-Obesity); F: 
N=13665 (adding WTCCC-UKBS). Red dots represent SNPs that achieved a 
P<5x10-7 in the joint analysis with stage 2 samples. The solid black horizontal line 
is the P=5x10-7 line. 
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Supplementary Note 
Membership of WTCCC, DGI and Cambridge GEMS consortia 
Wellcome Trust Case Control Consortium: 
Management Committee: Paul R Burton1, David G Clayton2, Lon R Cardon3, Nick 
Craddock4, Panos Deloukas5, Audrey Duncanson6, Dominic P Kwiatkowski3,5, Mark I 
McCarthy3,7, Willem H Ouwehand8,9, Nilesh J Samani10, John A Todd2, Peter Donnelly 
(Chair)11 
Analysis Committee: Jeffrey C Barrett3, Paul R Burton1, Dan Davison11, Peter 
Donnelly11, Doug Easton12, David Evans3, Hin-Tak Leung2, Jonathan L Marchini11, Andrew 
P Morris3, Chris CA Spencer11, Martin D Tobin1, Lon R Cardon (Co-chair)3, David G 
Clayton (Co-chair)2 
UK Blood Services & University of Cambridge Controls: Antony P Attwood5,8, James 
P Boorman8,9, Barbara Cant8, Ursula Everson13, Judith M Hussey14, Jennifer D Jolley8, 
Alexandra S Knight8, Kerstin Koch8, Elizabeth Meech15, Sarah Nutland2, Christopher V 
Prowse16, Helen E Stevens2, Niall C Taylor8, Graham R Walters17, Neil M Walker2, 
Nicholas A Watkins8,9, Thilo Winzer8, John A Todd2, Willem H Ouwehand8,9 
1958 Birth Cohort Controls: Richard W Jones18, Wendy L McArdle18, Susan M Ring18, 
David P Strachan19, Marcus Pembrey18,20 
Bipolar Disorder (Aberdeen): Gerome Breen21, David St Clair21; (Birmingham): Sian 
Caesar22, Katherine Gordon-Smith22,23, Lisa Jones22; (Cardiff): Christine Fraser23, Elaine 
K Green23, Detelina Grozeva23, Marian L Hamshere23, Peter A Holmans23, Ian R Jones23, 
George Kirov23, Valentina Moskvina23, Ivan Nikolov23, Michael C O‟Donovan23, Michael J 
Owen23, Nick Craddock23; (London): David A Collier24, Amanda Elkin24, Anne Farmer24, 
Richard Williamson24, Peter McGuffin24; (Newcastle): Allan H Young25, I Nicol Ferrier25 
Coronary Artery Disease (Leeds): Stephen G Ball26, Anthony J Balmforth26, Jennifer H 
Barrett26, D Timothy Bishop26, Mark M Iles26, Azhar Maqbool26, Nadira Yuldasheva26, 
Alistair S Hall26; (Leicester): Peter S Braund10, Paul R Burton1, Richard J Dixon10, 
Massimo Mangino10, Suzanne Stevens10, Martin D Tobin1, John R Thompson1, Nilesh J 
Samani10 
Crohn’s Disease (Cambridge): Francesca Bredin27, Mark Tremelling27, Miles Parkes27; 
(Edinburgh): Hazel Drummond28, Charles W Lees28, Elaine R Nimmo28, Jack Satsangi28; 
(London): Sheila A Fisher29, Alastair Forbes30, Cathryn M Lewis29, Clive M Onnie29, 
Natalie J Prescott29, Jeremy Sanderson31, Christopher G Mathew29; (Newcastle): Jamie 
Barbour32, M Khalid Mohiuddin32, Catherine E Todhunter32, John C Mansfield32; (Oxford): 
Tariq Ahmad33, Fraser R Cummings33, Derek P Jewell33 
Hypertension (Aberdeen): John Webster34; (Cambridge): Morris J Brown35, David G 
Clayton2; (Evry, France): G Mark Lathrop36; (Glasgow): John Connell37, Anna 
Dominiczak37; (Leicester): Nilesh J Samani10; (London): Carolina A Braga Marcano38, 
Beverley Burke38, Richard Dobson38, Johannie Gungadoo38, Kate L Lee38, Patricia B 
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Munroe38, Stephen J Newhouse38, Abiodun Onipinla38, Chris Wallace38, Mingzhan Xue38, 
Mark Caulfield38; (Oxford): Martin Farrall39 
Rheumatoid Arthritis: Anne Barton40, The Biologics in RA Genetics and Genomics Study 
Syndicate (BRAGGS) Steering Committee*, Ian N Bruce40, Hannah Donovan40, Steve 
Eyre40, Paul D Gilbert40, Samantha L Hider40, Anne M Hinks40, Sally L John40, Catherine 
Potter40, Alan J Silman40, Deborah PM Symmons40, Wendy Thomson40, Jane 
Worthington40 
Type 1 Diabetes: David G Clayton2, David B Dunger2,41, Sarah Nutland2, Helen E 
Stevens2, Neil M Walker2, Barry Widmer2,41, John A Todd2 
Type 2 Diabetes (Exeter): Timothy M Frayling42,43, Rachel M Freathy42,43, Hana Lango 
Allen42,43, John R B Perry42,43, Beverley M Shields43, Michael N Weedon42,43, Andrew T 
Hattersley42,43; (London): Graham A Hitman44; (Newcastle): Mark Walker45; (Oxford): 
Kate S Elliott3,7, Christopher J Groves7, Cecilia M Lindgren3,7, Nigel W Rayner3,7, Nicholas 
J Timpson3,46, Eleftheria Zeggini3,7, Mark I McCarthy3,7 
Tuberculosis (Gambia): Melanie Newport47, Giorgio Sirugo47; (Oxford): Emily Lyons3, 
Fredrik Vannberg3, Adrian VS Hill3 
Ankylosing Spondylitis: Linda A Bradbury48, Claire Farrar49, Jennifer J Pointon48, Paul 
Wordsworth49, Matthew A Brown48,49 
AutoImmune Thyroid Disease: Jayne A Franklyn50, Joanne M Heward50, Matthew J 
Simmonds50, Stephen CL Gough50 
Breast Cancer: Sheila Seal51, Breast Cancer Susceptibility Collaboration (UK)*, Michael 
R Stratton51,52, Nazneen Rahman51 
Multiple Sclerosis: Maria Ban53, An Goris53, Stephen J Sawcer53, Alastair Compston53 
Gambian Controls (Gambia): David Conway47, Muminatou Jallow47, Melanie Newport47, 
Giorgio Sirugo47; (Oxford): Kirk A Rockett3, Dominic P Kwiatkowski3,5 
DNA, Genotyping, Data QC and Informatics (Wellcome Trust Sanger Institute, 
Hinxton): Suzannah J Bumpstead5, Amy Chaney5, Kate Downes2,5, Mohammed JR 
Ghori5, Rhian Gwilliam5, Sarah E Hunt5, Michael Inouye5, Andrew Keniry5, Emma King5, 
Ralph McGinnis5, Simon Potter5, Rathi Ravindrarajah5, Pamela Whittaker5, Claire 
Widden5, David Withers5, Panos Deloukas5; (Cambridge): Hin-Tak Leung2, Sarah 
Nutland2, Helen E Stevens2, Neil M Walker2, John A Todd2 
Statistics (Cambridge): Doug Easton12, David G Clayton2; (Leicester): Paul R Burton1, 
Martin D Tobin1; (Oxford): Jeffrey C Barrett3, David Evans3, Andrew P Morris3, Lon R 
Cardon3; (Oxford): Niall J Cardin11, Dan Davison11, Teresa Ferreira11, Joanne Pereira-
Gale11, Ingeleif B Hallgrimsdóttir11, Bryan N Howie11, Jonathan L Marchini11, Chris CA 
Spencer11, Zhan Su11, Yik Ying Teo3,11, Damjan Vukcevic11, Peter Donnelly11 
PIs: David Bentley5,54, Matthew A Brown48,49, Lon R Cardon3, Mark Caulfield38, David G 
Clayton2, Alistair Compston53, Nick Craddock23, Panos Deloukas5, Peter Donnelly11, 
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Abstract 
Most common human traits and diseases have a polygenic pattern of 
inheritance: DNA sequence variants at many genetic loci influence phenotype. 
Genome-wide association (GWA) studies have identified >600 variants associated 
with human traits 1, but these typically explain small fractions of phenotypic 
variation, raising questions about the utility of further studies. Here, using 183,727 
individuals, we show that hundreds of genetic variants, in at least 180 loci, 
influence adult height, a highly heritable and classic polygenic trait 2,3. The large 
number of loci reveals patterns with important implications for genetic studies of 
common human diseases and traits. First, the 180 loci are not random, but instead 
are enriched for genes that are connected in biological pathways (P=0.002), and 
that underlie skeletal growth defects (P<0.001). Second, the likely causal gene is 
often located near the most strongly associated variant: in 13 of 21 loci containing 
a known skeletal growth gene, that gene was closest to the associated variant. 
Third, at least 19 loci have multiple independently associated variants, suggesting 
that allelic heterogeneity is a frequent feature of polygenic traits, that 
comprehensive explorations of already-discovered loci should discover additional 
variants, and that an appreciable fraction of associated loci may have been 
identified. Fourth, associated variants are enriched for likely functional effects on 
genes, being over-represented amongst variants that alter amino acid structure of 
proteins. Our data explain ~10% of the phenotypic variation in height, and we 
estimate that unidentified common variants of similar effect sizes would increase 
this figure to ~16% of phenotypic variation (~20% of heritable variation). Although 
approaches that more comprehensively survey low frequency variants are needed 
to fully dissect the genetic architecture of polygenic human traits, our findings 
indicate that GWA studies can identify large numbers of loci that implicate 
biologically relevant genes and pathways.  
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In Stage 1 of our study, we performed a meta-analysis of GWA data from 
46 studies, comprising 133,653 individuals of recent European ancestry, to identify 
common genetic variation associated with adult height. To enable meta-analysis of 
studies across different genotyping platforms, we performed imputation of 
2,834,208 single nucleotide polymorphisms (SNPs) present in the HapMap Phase 
2 European-American reference panel 4 (Supplementary Methods). After 
applying quality control filters, each individual study tested the association of adult 
height with each SNP using an additive model (Supplementary Methods). The 
individual study statistics were corrected using the genomic control (GC) method 
5,6 and then combined in a meta-analysis. We then applied a second GC correction 
on the meta-analysis statistics, although this approach may be overly conservative 
when there are many real signals of association (Supplementary Methods). We 
detected 207 loci (defined as 1Mb on either side of the most strongly associated 
SNP) as potentially associated with adult height (P<5x10-6, a threshold at which 
we would only expect 5 by chance).  
To identify loci robustly associated with adult height, we took forward at 
least one SNP (Supplementary Methods) from each of the 207 loci reaching 
P<5x10-6 into an additional 50,074 samples (Stage 2). In the joint analysis of our 
Stage 1 and Stage 2 studies, SNPs representing 180 loci reached genome-wide 
significance (P<5x10-8; Figure 1 and Supplementary Table 1). Additional tests, 
including genotyping of a randomly-selected subset of 33 SNPs in an independent 
sample of individuals from the tails of the height distribution 7, provided further 
validation of our results, with all but two SNPs showing consistent direction of 
effect (sign test P<7x10-8) (Supplementary Methods and Supplementary Table 
2). Similarly, 206 of the 207 lead SNPs had consistent directions of effect in 
Stages 1 and 2 (sign test P<10-62), indicating that there are almost certainly 
additional associated variants amongst the loci that narrowly missed genome-wide 
significance. 
Genome wide association (GWA) studies can be susceptible to false 
positive associations from population stratification 7. We therefore performed a 
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family-based analysis, which is immune to population stratification in 7,336 
individuals from two cohorts with pedigree information. Alleles representing 150 of 
the 180 genome-wide significant loci were associated in the expected direction 
(sign test P<6x10-20; Supplementary Table 3). The estimated effects on height 
were essentially identical in the overall meta-analysis and the family-based sample 
(Supplementary Table 3). Together with several other lines of evidence 
(Supplementary Methods), this indicates that stratification is not substantially 
inflating the test statistics in our meta-analysis.  
The large number of associated loci allowed us to address a number of 
questions about the genetic architecture of height, which will likely provide useful 
insights about other polygenic traits. One of the most important issues arising from 
GWA studies has been the question of missing heritability 8. To date, common 
genetic variants have typically explained only a small proportion of the heritable 
component of phenotypic variation. This is particularly true for height, where >80% 
of the variation within a given population is estimated to be attributable to additive 
genetic factors 9,10,11, but over 40 previously published variants explain only 3 to 
5% of the variance 12,13,14,15,16,17,18,19. One possible explanation is that many 
common variants of small effects contribute to phenotypic variation, and current 
GWA studies remain underpowered to detect the majority of common variants. 
Using a set of five studies independent from the GWA study discovery samples, 
we found that the 180 associated SNPs explained on average 10.5% (range 
between studies 7.9-11.2%) of the variance in adult height, compared with 4.7% 
(3.7-5.6%) of the variance explained by the previously known loci 
(Supplementary Methods). Thus, the identified genome-wide significant loci from 
the increase in sample size resulted in a doubling of phenotypic variation 
explained.  
We considered the possibility that additional loci not reaching stringent 
thresholds of genome-wide significance even in this large sample could contribute 
to additional heritability. We, therefore, tested how much more of the variation in 
height could be explained by a more inclusive set of variants, using an approach 
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recently described for schizophrenia 20. We showed that including SNPs 
associated with height at lower significance levels (in the range of 0.05>P>5x10-8) 
increased the variance explained to 13.3% (range 9.7-16.8%) in the same five 
study set (Figure 2a) (Supplementary Methods). 
As a separate approach, we used a recently developed method (Park et al., 
submitted) to estimate the total number of independent height-associated variants 
that are likely to exist with effect sizes similar to the ones described by our study. 
We obtained this estimate using the distribution of effect sizes observed in Stage 2 
and the power to detect an association in Stage 1, given these effect sizes 
(Supplementary Methods). The cumulative distribution of height loci, including 
those we identified and others as yet undetected, is shown in Figure 2b. We 
estimate that there are 697 loci (95% confidence interval (CI): 483, 1040) with 
effects equal or greater than those identified, which together would explain 
approximately 15.7% of the phenotypic variation in height or 19.6% (95% CI: 16.2-
25.6) of height heritability (Supplementary Table 4). We estimated that a sample 
size of 500,000 would be needed to detect 99.6% of these loci at P<5x10-8. It is 
important to note that this figure does not account for variants that have effect 
sizes smaller than those observed in the current study and, therefore, 
underestimates the contribution of undiscovered common loci to phenotypic 
variation. 
GWA studies have identified few, if any, examples of non-additive effects. 
We therefore assessed dominant, recessive, and pairwise interaction effects for 
the 180 associated variants in a subset of 103,034 analyzed individuals. We found 
no evidence of deviation from an additive model of inheritance, either for single 
variants or pairwise between variants (Supplementary Methods). In addition, 
there was no evidence for heterogeneity between sexes for the 180 variants 
(Supplementary Table 1). We also assessed all pairwise joint effects genome-
wide, using a smaller subset of 10,500 individuals genotyped at 343,249 SNPs 
(Supplementary Methods) and saw no evidence of genome-wide pairwise 
interaction (Supplementary Methods and Supplementary Tables 5 and 6). 
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These results therefore do not support a role for non-additive models of 
inheritance substantially contributing to variation in height.  
A further possible source of missing heritability is allelic heterogeneity – the 
presence of multiple, independent variants influencing a trait at the same locus. 
Because we only considered the most strongly associated variant within each of 
the 2Mb loci, it is possible that additional variants in those loci could be 
contributing to phenotypic variation in height. We performed genome-wide 
conditional analyses in a subset of the studies used in Stage 1, including a total of 
106,336 analyzed individuals. Each participating study repeated the primary GWA 
analysis but additionally adjusted for the SNPs representing the 207 loci 
associated at P<5x10-6 (Supplementary Methods). We then meta-analysed these 
studies in the same way as for the primary GWA study meta-analysis. In this 
conditional analysis, 19 SNPs within the 207 loci were associated with height at 
P<3.3x10-7 (a Bonferroni-corrected significance threshold calculated from the 
~15% of the genome covered by the 207 2Mb loci; Supplementary Methods; 
Table 1, Figure 3). The distances of the second signals to the lead SNPs 
suggested that both are likely to be affecting the same gene, rather than being 
coincidentally in close proximity. At 17 of 17 loci (excluding two contiguous loci in 
the HMGA1 region), the second signal occurred within 500kb, rather than between 
500kb and 1 Mb, of this lead SNP (binomial test P=2x10-5). Further analyses of 
allelic heterogeneity may identify additional variants that increase the proportion of 
variance explained. For example, within the 207 2Mb loci, a total of 48 
independent SNPs (19 at P<3.3x10-7 plus an additional 29) reached P<1x10-5 
when we would expect <2 by chance at this level of significance. Finally, this 
analysis can only detect two independent signals at each locus, and at some loci, 
there are likely to be multiple independent signals that will require additional 
rounds of conditional analysis to be robustly identified. 
Whilst GWA studies have identified many variants robustly associated with 
common human diseases and traits, the biological significance of these variants, 
and the genes on which they act, is often unclear. We used the large number of 
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height loci to address two further questions of potential relevance to all polygenic 
traits: the extent to which associated variants are over-represented amongst 
putatively functional variants, and the extent to which associated loci contain 
genes of known relevance to the phenotype.  
We first tested the overlap between the 180 height-associated variants and 
missense polymorphisms, the putative functional variants, and copy number 
variants (CNVs). Height variants were 1.7-fold more likely to be closely correlated 
(r2 0.8 in HapMap CEU) with nonsynonymous SNPs (P=0.004) (Supplementary 
Methods, Supplementary Table 7), but there was no correlation with CNV-
tagging SNPs (Supplementary Methods). We also noted five loci where the 
height associated variant was strongly correlated (r2>0.8) with variants associated 
with other traits and diseases (at P<5x10-8), including bone mineral density, 
rheumatoid arthritis, type 1 diabetes, psoriasis and obesity, suggesting that these 
variants have pleiotropic effects on human phenotypes (Supplementary 
Methods; Supplementary Table 8). 
To address the extent to which height variants cluster near biologically relevant 
genes, we performed a number of analyses. First, we tested whether the signals of 
association cluster near genes mutated in human syndromes characterized by 
abnormal skeletal growth. We limited this analysis to the 652 genes occurring 
within the recombination hotspot-bounded regions surrounding each of the 180 
index SNPs. We showed that the 180 loci associated with variation in normal 
height contained 21 of 241 genes (8.7%) found to underlie such syndromes 
(Supplementary Table 9), compared to a median of 8 (range 1-19) genes 
identified in 1,000 matched control sets of regions (P<0.001). Interestingly, in 13 of 
these 21 loci the closest gene to the most associated height SNP in the region is 
the growth disorder gene, and in 9 of these cases, the most strongly associated 
height SNP is located within the growth disorder gene itself (Supplementary 
Methods; Supplementary Table 10). These results suggest that GWA studies 
may provide more clues about the identity of the functional genes at each locus 
than previously suspected.  
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Next, we investigated whether significant and relevant biological 
connections exist between the genes within the 180 loci, using two different 
approaches. We used the GRAIL text-mining algorithm to search for connectivity 
between genes near the associated SNPs, based on existing literature 21. Of the 
180 loci, 42 contained genes that were connected by existing literature to genes in 
the other associated loci (the pair of connected genes appear in articles that share 
scientific terms more often than expected at P<0.01). For comparison, when we 
used GRAIL to score 1,000 sets of 180 SNPs not associated with height (but 
matched for number of nearby genes, gene proximity, and allele frequency), we 
only observed 2 sets with 42 or more loci with a connectivity P<0.01, thus 
providing strong statistical evidence that the height loci are functionally related 
(P=0.002) (Figure 4a). For the 42 regions with GRAIL connectivity P<0.01, the 
implicated genes and SNPs are highlighted in Figure 4b. The most strongly 
connected genes include those in the Hedgehog, TGF-beta, and growth hormone 
pathways. 
Finally, we used a novel implementation of gene set enrichment analysis 
(GSEA) (Meta-Analysis Gene-set Enrichment of variaNT Associations, MAGENTA 
(Segrè et al., in revision)) and the biological process classification from the 
INGENUITY, KEGG, PANTHER and Gene Ontology databases to perform 
pathway analysis (Supplementary Methods). This analysis revealed 17 different 
biological pathways and 14 molecular functions nominally enriched (P<0.05) for 
associated genes, many of which lie within the validated height loci. These gene-
sets include previously reported12,14 (e.g. Hedgehog signaling) and novel (e.g. 
TGF-beta signaling, histones, and growth and development-related) pathways and 
molecular functions (Supplementary Table 11). These results provide 
complementary evidence for some of the genes and pathways highlighted in the 
GRAIL analysis. For instance, genes such as TGFB2 and LTBP1-3 highlight a role 
for the TGF-beta signaling pathway in regulating human height, consistent with the 
recent implication of this pathway in Marfan syndrome 22. 
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We have identified over a hundred novel loci that influence the classic, 
polygenic trait of normal variation in human height, bringing the total to 180. Our 
results have potential implications for studies seeking to understand the genetic 
component to common diseases and traits. We show that loci identified by GWA 
studies highlight relevant genes: the 180 loci associated with height are non-
randomly clustered within biologically relevant pathways and are enriched for 
genes that are involved in growth-related processes, that underlie syndromes of 
abnormal skeletal growth, and that even encode therapies or targets for therapies 
that modulate growth (GH1, IGF1R, CYP19A1, ESR1). The large number of loci 
with clearly relevant genes suggests that the remaining loci could provide potential 
clues to important and novel biology.  
We provide the strongest evidence yet that the causal gene will often be 
located near the most strongly associated DNA sequence variant. At the 21 loci 
containing a known growth disorder gene, that gene was on average 81 kb from 
the associated variant, and in over half of the loci, it was the closest gene to the 
associated variant. Despite recent doubts about the benefits of GWA studies 23, 
this finding suggests that GWA studies are useful mapping tools to highlight genes 
that merit further study. The presence of multiple variants within associated loci 
(allelic heterogeneity), could help localize the relevant genes within these loci. 
By increasing our sample size to over 100,000 individuals, we identified 
common variants that account for 10.5% of phenotypic variation, with another ~6% 
of the phenotypic variance explained by common variants of similar effects yet to 
be discovered. Although 10.5% of phenotypic variation (13% of genetic variation) 
accounted for by the 180 loci is larger than predicted under some models 23, this 
figure suggests that GWA studies, as currently implemented and when applied to 
realistic sample sizes, may not explain a majority of the estimated 80% 
contribution of genetic factors to variation in height. This conclusion supports the 
idea that biological insights, rather than predictive power, will be the main outcome 
of this initial wave of GWA studies, and that new approaches, which could include 
sequencing studies or GWA studies targeting variants of lower frequency, will be 
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needed to account for more of the “missing” heritability. Our finding that many loci 
exhibit allelic heterogeneity suggests that many as yet unidentified causal variants 
will map to the loci already identified in GWA studies, and that the fraction of 
causal loci that have been identified could be substantially greater than the fraction 
of causal variants that have been identified. 
The observed contributions of common and rare variants to heritability will 
be dependent on the particular phenotype, as well as on the power of future 
studies to detect both common and rare variants with modest effects. We note 
that, in our studies, many associated variants are tightly correlated with common 
nonsynonymous SNPs, which would not be expected if these associated common 
variants were proxies for collections of rare causal variants, as has been proposed 
24. Although a substantial contribution to heritability by less common and/or quite 
rare variants may be more plausible, our data do not rule out the regulation of 
height by a large number of common variants of very small effect. 
In summary, our findings indicate that additional approaches, including 
those aimed at less common or rare variants, will likely be needed to dissect more 
completely the genetic component to complex human traits. Our results also 
strongly demonstrate that GWA studies can identify large numbers of loci that 
together implicate biologically relevant pathways and mechanisms. We envision 
that thorough exploration of the genes at associated loci through additional 
genetic, functional, and computational studies will lead to novel insights into 
human height and other polygenic traits and diseases.  
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Methods summary 
The primary meta-analysis (Stage 1) included 46 GWA studies of 133,653 
individuals. The in-silico follow up (Stage 2) included 15 studies of 50,074 
individuals. All studied individuals were of European ancestry and >99.8% were 
adults. Details of genotyping, quality control, and imputation methods of each 
study are given in Supplementary Methods Tables 1 and 2. Each study provided 
summary results of a linear regression of age-adjusted, within-sex Z scores of 
height against the imputed SNPs, and an inverse-variance meta-analysis was 
performed in METAL (http://www.sph.umich.edu/csg/abecasis/METAL/). Validation 
of selected SNPs was performed through direct genotyping in an extreme height 
panel (N=3,190) using Sequenom iPLeX, and in 492 Stage 1 samples using the 
KASPar SNP System. Family-based testing was performed using QFAM, a linear 
regression-based approach that uses permutation to account for dependency 
between related individuals 25, and FBAT, which uses a linear combination of 
offspring genotypes and traits to determine the test statistic26. We used a 
previously described method to estimate the amount of genetic variance explained 
by the nominally associated loci (using significance threshold increments from 
P<5×10-8 to P<0.05) 20. To predict the number of height susceptibility loci, we took 
the height loci that reached a significance level of P<5x10-8 in Stage 1 and 
estimated the number of height loci that are likely to exist based on the distribution 
of their effect sizes observed in Stage 2 and the power to detect their association 
in Stage 1. Gene-by-gene interaction, dominant, recessive and conditional 
analyses are described in detail in Supplementary Methods. Empirical 
assessment of enrichment for coding SNPs used permutations of random sets of 
SNPs matched to the 180 height-associated SNPs on the number of nearby 
genes, gene proximity, and minor allele frequency. GRAIL and GSEA methods 
have been described previously 21 (Segre et al., submitted). To assess possible 
enrichment for genes known to be mutated in severe growth defects, we identified 
such genes in the OMIM database (Supplementary Table 10), and evaluated the 
extent of their overlap with the 180 height-associated regions through comparisons 
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with 1000 random sets of regions with similar gene content (+10%). The design of 
the study, SNPs taken forward and additional analyses are summarised below. 
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Table 1: Secondary signals at associated loci after conditional analysis. 19 independent SNPs reached a P<3.3x10-7, a 
Bonferroni significance threshold based on the proportion of the genome covered by the 207 loci. The results are based on a 
subset of 106,336 individuals. aHapMap CEU phase II release 23 was used; bthis is the nearest gene or a known skeletal growth 
disorder gene in the locus (underlined). Positions are based on NCBI build 36. *nearest conditioned SNP where second signal 
occurs within 1Mb of two conditioned SNPs. 
 
Second signal 
SNP 
Conditioned 
SNP Chr 
Second signal 
SNP position 
Distance of conditioned 
SNP from index SNP 
(bp) HapMap
a 
r
2
 
Second signal 
P-value after 
conditioning 
Second signal 
P-value pre-
conditioning Gene
b
 
rs2280470 rs16942341 15 87196630 6721 0.009 1x10
-14
 1x10
-15
 ACAN 
rs10859563 rs11107116 12 92644470 141835 0.003 3x10
-12
 8x10
-10
 SOCS2 
rs750460 rs5742915 15 72028559 95127 0.004 4x10
-12
 7x10
-08
 PML 
rs6938239 rs2780226* 6 34791613 484583 0.019 6x10
-12 
9x10
-14 
HMGA1 
rs7652177 rs572169 3 173451771 196650 0.006 7x10
-11
 1x10
-11
 GHSR 
rs7916441 rs2145998 10 80595583 196119 0.112 6x10
-10
 3x10
-07
 PPIF 
rs3792752 rs1173727 5 32804391 61887 0.02 7x10
-10
 4x10
-08
 NPR3 
rs10958476 rs7460090 8 57258362 98355 0.02 1x10
-09
 5x10
-13
 SDR16C5 
rs2353398 rs7689420 4 145742208 45594 0.022 2x10
-09
 1x10
-10
 HHIP 
rs2724475 rs6449353 4 17555530 87056 0.098 2x10
-09
 8x10
-16
 LCORL 
rs2070776 rs2665838 17 59361230 41033 0.15 9x10
-09
 1x10
-14
 GH region 
rs1401796 rs227724 17 52194758 60942 0.005 2x10
-08
 7x10
-07
 NOG 
rs4711336 rs2780226* 6 33767024 540046 0.111 3x10
-08
 5x10
-08
 HMGA1 
rs6892884 rs12153391 5 170948228 187815 0 4x10
-08
 2x10
-05
 FBXW11 
rs1367226 rs3791675 2 55943044 21769 0.204 4x10
-08
 0.1245 EFEMP1 
rs2421992 rs17346452 1 170507874 187964 0.019 5x10
-08
 1x10
-05
 DNM3 
rs225694 rs7763064 6 142568835 270147 0.001 1x10
-07
 2x10
-06
 GPR126 
rs10187066 rs12470505 2 219223003 393610 0.022 2x10
-07
 5x10
-08
 IHH 
rs879882 rs2256183 6 31247431 241077 0.016 2x10
-07
 8x10
-08
 MICA 
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Figure Legends 
Figure 1. 180 loci associated with adult height variation. (A) Karyogram 
displaying the genome location of the 180 height SNPs identified from the primary 
meta-analysis (green) and the 19 secondary signals (red) discovered in the 
conditional analysis to be associated with height. The closest genes to the SNPs 
(gray) are followed by a MIM (blue) label if the gene underlies a skeletal growth-
related Mendelian disorder described in OMIM. (B) Quantile-quantile plot of SNPs 
after Stage 1 GIANT GC-corrected meta-analysis (black), after removal of SNPs 
near 47 loci previously shown to associated with height in Caucasians (blue), and 
after removal of SNPs near 180 loci shown to associate with height in this study 
(red). All SNPs near (2Mb window) or in linkage disequilibrium (r2 ≥0.01) with the 
47 or 180 index height SNPs were excluded to draw the blue and red distributions, 
respectively. 
Figure 2. Phenotypic variance explained by common variants. (A) Variance 
explained is higher when SNPs not reaching genome-wide significance are 
included in the prediction model. The y-axis represents the proportion of variance 
explained at different P-value thresholds from Stage 1 meta-analysis. Results are 
given for five studies that were not part of the GWA discovery set (Stage 1). 
*Proportion of variation explained by 180 SNPs reaching genome-wide 
significance in Stage 1+2 meta-analysis. (B) Cumulative number of susceptibility 
loci expected to be discovered, including those we have already identified and 
others as yet undetected, by the expected percentage of phenotypic variation 
explained and sample size required assuming a GC correction utilized. The 
projections are based on loci that achieved a significance level of P<5x10-8 in the 
initial scan and the distribution of their effect sizes in Stage 2. The dotted red line 
corresponds to expected phenotypic variance explained by the 110 loci that 
reached genome-wide significance in Stage 1, were replicated in Stage 2 and had 
at least 1% power. 
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Figure 3. Example regional association plots of loci with secondary signals 
from conditional analysis before and after conditioning. The plots are 
centered on the conditioned SNP (shown as the yellow diamond) at the locus. The 
secondary signal SNP is highlighted as the pink diamond. r2 is based on the CEU 
HapMap II samples. The blue line and right hand Y axis represent CEU HapMap II 
based recombination rates. LD Plots were created by LocusZoom 
(http://csg.sph.umich.edu/locuszoom/). 
Figure 4. Loci associated with height contain genes related to each other. (A) 
180 SNPs associated with adult height variation. The y-axis plots GRAIL P-values 
on a log scale. The histogram on the left side corresponds to the distribution of 
GRAIL P-values for 1,000 sets of 180 matched SNPs. The scatter plot on the right 
represents GRAIL results for the 180 height SNPs found in this study (blue dots). 
The black horizontal line marks the median of the GRAIL P-values (P=0.14). The 
top 10 keywords linking the genes were: „growth‟, „kinase‟, „factor‟, „transcription‟, 
„signaling‟, „binding‟, „differentiation‟, „development‟, „insulin‟, „bone‟. (B) Graphical 
representation of the connections between SNPs and corresponding genes for the 
42 SNPs with GRAIL P<0.01. Thicker and redder lines imply stronger literature-
based connectivity. 
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Figure 1A: Genome locations of the 199 height SNPs associated with height. 
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Figure 1B: Quantile-quantile plot for height. 
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Figure 2A: Proportion of phenotypic variance explained. 
 
 
Figure 2B: Predicted number of height loci. 
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Figure 3. Examples of secondary signals before and after conditional 
analysis. 
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Figure 4: GRAIL analysis 
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Supplementary Methods 
1. Primary genome-wide association meta-analysis (Stage 1) 
In Stage 1, we combined the height summary statistics from 46 genome-
wide association (GWA) studies in a meta-analysis of 133,653 individuals (60,587 
males and 73,066 females).  
1.1 Description of individual cohorts and genotyping methods 
Descriptive characteristics, study design, sample size, sample quality 
control (QC) and anthropometric measurement technique for the studies included 
in Stage 1 are provided in Supplementary Methods Table 1. All individuals were 
Caucasians of European ancestry. Approximately 45% of the individuals were 
male, and the ages ranged from 14 to 103 years (99.7% of the samples were >18 
years old). All participants provided written informed consent and the studies were 
approved by the respective Local Research Ethics committees or Institutional 
Review Boards.  
Details on the genotyping platform used and genotype quality control 
procedures employed for each study are presented in Supplementary Methods 
Table 2.  
1.2 Imputation  
All cohorts were genotyped using commercially available Affymetrix 
(Affymetrix, Inc., Santa Clara, CA, USA), Illumina (Illumina, Inc., San Diego, CA, 
USA) genotyping arrays, or custom Perlegen (Perlegen Sciences, Inc., Mountain 
View, CA, USA) arrays. Quality control was performed independently for each 
study. To facilitate meta-analysis, each group performed genotype imputation 
using BIMBAM1, IMPUTE2, or MACH3 and genotypes from the Phase II CEU 
HapMap4. Each imputation software estimates an overall imputation quality score 
for each SNP. For example, IMPUTE calculates the „proper info‟ statistic which is a 
measure of the observed statistical information for the estimate of allele frequency 
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of the SNP, while MACH calculates the „rsq_hat‟, which is the estimated r2 
between each imputed genotype and its true underlying genotype. Study-specific 
details are presented in Supplementary Methods Table 2. 
1.3 GWA analyses in individual cohorts 
Details on study-specific analysis software are summarized in 
Supplementary Methods Table 2. Each GWA study tested association between 
each imputed or genotyped SNP and sex-standardized height, assuming an 
additive inheritance model and adjusting for age and other appropriate covariates 
specific to the study (e.g. genotype-based principal components). Studies with 
unrelated individuals tested association under a linear regression framework. 
Studies with related samples used variance component or other linear mixed 
effects modeling to account for relatedness in the regression. The uncertainty of 
the imputed genotypes was taken into account in the association analysis using 
methods appropriate for the imputation software used.  
The genomic control (GC) inflation factor was calculated for each of the 
GWA scans separately. The average GC inflation factor was 1.03 
(Supplementary Methods Table 2). Genomic control correction was applied to 
results for each study prior to meta-analysis by multiplying SNP standard errors by 
the square root of the inflation factor. 
1.4 Quality control checks of individual studies 
Where applicable, the Stage 1 studies calculated separate summary GWA 
data in males and females and disease cases and controls. Except for studies with 
related individuals, we used the sex-specific summary results. Each file going into 
meta-analysis had the following information (columns): SNP, strand, N (sample 
size), effect allele (allele to which regression coefficient refers), other allele, EAF 
(effect allele frequency), imputation (posterior probability of imputed genotype, 
available from some programs), information type (imputation software used), 
information (imputation quality scores), P-value, beta (regression coefficient), 
standard error, and NxMAF (sample size multiplied by minor allele frequency). 
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Each file was processed through a cleaning script that performed several quality 
checks, including calculating the number of markers, ranges of test statistics, the 
genomic correction inflation factor, and NxMAF. From each study we excluded 
monomorphic SNPs and SNPs with poor imputation quality: rsq_hat < 0.3 
(BIMBAM and MACH) or proper info < 0.4 (IMPUTE).  
1.5 Meta-analysis of GWA studies 
A total of 2,836,010 autosomal SNPs were meta-analyzed across 98 input 
files (many of the 50 cohorts had separate male-female and/or case-control files). 
We did not apply a minor allele frequency cut-off, but we did apply an arbitrary cut-
off of NxMAF > 3 (equivalent to a minor allele count of 6) to guard against 
extremely rare variants present in only one or two samples (possible 
genotyping/imputation errors or private mutations), for which regression 
coefficients are not estimated well using the standard statistical methods 
employed in most GWA statistical programs.  
We used the inverse-variance fixed effects meta-analysis method to 
combine the results from the individual studies. For comparison purposes, we also 
performed a sample size weighted Z-score-based fixed effects meta-analysis. The 
correlation coefficient between the log10 of the P-values of the inverse variance 
and sample size weighted meta-analysis was 0.99. SNP selection for follow-up 
was based on the meta-analysis of the inverse variance meta-analysis results. 
Meta-analyses were performed using the software program METAL 
(www.sph.umich.edu/csg/abecasis/metal).  
1.6 Overall genomic control correction  
After genomic control applied in each study the overall genomic control 
inflation factor ( GC) for the meta-analysis was 1.42. The possibility that such high 
inflation is due to effects of population stratification or genotyping biases alone is 
unlikely, considering the different results presented in Supplementary section 4 
which argue against this. In an attempt to identify other sources for such inflation, 
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we removed all SNPs within 1Mb from the leading SNP in loci with SNPs reaching 
P<5x10-8, which yielded a similarly high GC=1.33. Next, in a simulated phenotype 
dataset we evaluated the potential role of multiple causal variants failing to reach 
genome-wide significance. Using a model comprising 120,000 subjects, 294,831 
SNPs, and 1000 causal variants, the GC increased in a near linear way from 1.15 
to 1.32, as heritability (h2) increased from 0.2 to 0.8. Alternatively, increasing the 
number of causal variants from 100 to 4000 while keeping heritability constant (at 
0.52) increased the GC from 1.1 to 1.6 
5. The latter observed data are consistent 
with a model containing many causal variants that are in LD with multiple SNPs 
resulting in inflated test statistics. Although our data imply that a second GC 
correction on the meta-analysis statistics may be overly conservative, we decided 
to apply anyway a second genomic control correction to the meta-analysis 
standard errors and P-values. 
1.7 Selection of SNPs for subsequent analyses 
SNP selection criteria for validation by genotyping, in silico replication, and 
all additional analyses and simulations, based on the results of Stage 1 GWA 
meta-analysis, are described below. 
2. In silico follow-up (Stage 2) 
2.1 SNP selection  
We took forward for replication 309 SNPs. These included the 207 index 
SNPs representing each of the 207 2Mb loci reaching P<5x10-6 in Stage 1 and 
102 SNPs that lie within the same 2Mb windows as the 207, but which were poorly 
correlated (r2<0.05) with the index SNP in CEU HapMap II samples. No minimum 
sample size was used for SNPs taken forward for replication, although we note 
that the minimum N for the 207 variants taken forward from Stage 1 to Stage 2 
was 78,550 (for SNP rs11714558 that reached Stage 1+2 P-value of 1.7x10-10). 
Subsequent analyses are based on the index SNPs from the 207 loci and the 19 
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SNPs within the 2 Mb windows that were confirmed to be independent by the 
conditional analysis described below. 
2.2 Description of Stage 2 populations 
Our in silico replication (Stage 2) included 50,074 individuals (12,651 
males, 37,423 females) from 15 additional GWA studies. Approximately 26% of 
the subjects were male (one large study was entirely female), and ages ranged 
from 17 to 113 years (all but 5 individuals were >18 years old). Brief study 
descriptions, details on sample quality control, genotyping and imputation 
methods, and descriptive statistics, are provided in Supplementary Methods 
Tables 1-3.  
2.3 Quality control checks of individual studies in Stage 2 
The Stage 2 studies provided the same summary GWA statistics as Stage 
1 studies, but only for the requested 309 SNPs. In addition to the QC checks 
performed in the stage 1 studies (section 1.4 above), we checked the direction of 
effects for the 309 SNPs in replication studies compared to the overall effects in 
the Stage 1 meta-analysis. In only one of the cohorts (Sorbs), fewer than 50% of 
the SNPs had effects in the same direction (47% for males, N=371; 50% for 
females, N=536). As expected, the largest study showed greatest consistency with 
the stage 1 meta-analysis results: 98% of SNPs in the same direction in the 
WGHS, N=32,099). We meta-analyzed these studies in METAL assuming a fixed 
effects model. When we examined the heterogeneity between Stage 2 studies, 
only one SNP (rs7567288) had a heterogeneity P-value smaller that that expected 
by chance (Phet = 5.6x10
-6) (see Supplementary Table 1).  
3. Meta-analysis of Stage 1 and Stage 2 
The overall meta-analysis combined Stage 1 and Stage 2 results for the 
309 SNPs using a fixed effects model. No SNP showed evidence of heterogeneity 
between Stage 1 and Stage 2 after accounting for the number of tests performed, 
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and only a single SNP had the opposite direction of effect in Stage 2 compared to 
Stage 1. 
4. Validation analyses for genotyping and population stratification  
4.1 Imputation validation 
To validate genotype imputation, we directly genotyped 27 height 
associated SNPs from the 207 loci in 492 subjects from the WTCCC-T2D study. 
These 27 SNPs were tested because they were not present on any of the most 
commonly used arrays (used by >2 studies) and did not have any perfect directly-
typed proxies (HapMap r2=1). We also genotyped a random subset of 18 
additional height associated SNPs from these 207 loci in the same samples. 
Genotyping was performed by Kbioscience (Herts, UK) using a KASPar-based 
singleplex assay (details of which are available on their website 
www.kbioscience.co.uk/chemistry/chemistry_Kasp_intro.htm). Forty-three SNPs 
passed genotyping quality control (HWE P>0.01; genotype success rate > 0.9; 
duplicate error rate <0.5%). We assessed imputation quality by determining the 
correlation between the directly ascertained genotypes and the genotype dosages 
produced by IMPUTE (the imputation program used in WTCCC-T2D). We then 
compared the observed R2 to the proper_info statistic produced by IMPUTE (which 
is essentially a predicted R2 between imputed genotype and actual genotype). The 
correlation between the predicted and the observed R2 was high for both the 
random set of SNPs (r=0.92) and for SNPs that were not well captured (r=0.84). 
This suggests that imputation uncertainty has been appropriately accounted for in 
our analyses. 
4.2 Direct genotyping in subjects from tails of height distribution 
For additional validation, we genotyped randomly chosen SNPs 
representing 33 of the 207 associated loci in an independent samples of 2,181 
European-American and 1,009 Polish subjects from the tails of the height 
distribution (5-10th and 90-95th percentile)6. These height case-control samples 
and the genotyping methods have been described previously6. For both panels, all 
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individuals were self-described "white" or "Caucasian." For the US panel, all 
subjects were born in the US, and all of their grandparents were born in either the 
US or Europe. All subjects in the Polish panel were born in Poland, and all 
grandparents were born in Europe or Russia. All subjects gave informed consent, 
and approval was obtained from the Institutional Review Board of Children's 
Hospital, Boston. Statistical analysis was performed using a Cochran-Mantel-
Haenszel test, as implemented in PLINK7. The data set was stratified according to 
the country of origin of the grandparents to account for population stratification 
within the European American height panel6. 
Power to replicate the direction of effect of the top 180 height SNPs in the 
extreme height panel was calculated using the Genetic Power Calculator 
(http://pngu.mgh.harvard.edu/~purcell/gpc/) based on the following assumptions: a 
sample size of 3,190 equally divided between individuals in the lower tail (5th-10th 
percentile) and the upper tail (90th-95th percentile) of the height distribution, 
variance explained between 0.005-0.3% of the height variation (consistent with our 
effect size estimates of Stage 2 data, using the equation from quantitative genetics 
σ2g = 2*p*q*α
2, where σ2g is the additive genetic variance, p and q are the allele 
frequencies, and α is the effect size in SD units), and 3 different minor allele 
frequencies. Under these assumptions, power is minimally affected by minor allele 
frequency. 
Variance 
explained 
MAF=5% MAF=25% MAF=50% 
0.005% 56% 56% 56% 
0.01% 62% 62% 62% 
0.05% 88% 88% 88% 
0.1% 97% 97% 97% 
0.2% >99% >99% >99% 
0.3% >99% >99% >99% 
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4.3 Family-based association analyses 
The family-based analysis performed to assess the influence of population 
stratification as a potential source of false positive associations in the discovered 
180 loci, comprised the Framingham Heart (FramHS) and the Erasmus Rucphen 
Family-based (ERF) studies. The design of the studies has been described 
elsewhere8,9. The family-based analyses was performed in FramHS (n=5,510) 
using the QFAM --within procedure from PLINK, running 100,000 permutations to 
account for the dependence between related individuals. Effect sizes and 
directions in FramHS were the betas reported by PLINK from the within 
component but p values were empirical, based on the permutation testing. The 
extended pedigree of ERF was broken into nuclear families (totaling 1,826 
individuals) and analyzed with FBAT10 which uses a linear combination of offspring 
genotypes and traits to determine the test statistic. For imputed SNPs, only those 
with MACH rsq_hat>0.3 were analyzed, using the best guess genotypes from 
dosages (for FramHS, directly genotyped proxies were also analyzed for 
comparison and gave similar results). P-values were meta-analyzed using a 
weighted Z-score–based meta-analysis implemented in METAL; if data were only 
available from one study, the P-value from that study was used. Weights were 
defined based on effective sample size (actual sample size/lambda, where lambda 
is the genomic control inflation factor calculated from the GWA data of the family-
based samples when ignoring relatedness). The direction of the effect allele in the 
FHS/ERF meta-analysis was compared to that observed in the GIANT meta-
analysis using an exact sign-test statistic based on a binomial distribution. The 
average estimated effect sizes were essentially identical in the GIANT meta-
analysis and the FramHS family-based sample (Supplementary Table 3), 
suggesting that there is minimal if any inflation of the GIANT effect sizes due to 
stratification. 
4.4 Other population stratification analyses 
We checked if the 180 height-associated variants included ancestry 
informative marker (AIM) SNPs previously identified as highly informative of the 
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sub-structure in European populations. We tested the correlations between height 
loci and 683 AIMs from 3 different sources11,12,13. These included AIMs from both 
the HLA and lactase loci. The largest HapMap CEU r2 correlations between height 
SNPs and AIMs were observed for the GDF5 and EFEMP1 variants (r2 = 0.3 and 
0.35, respectively). All other pairwise correlations, including those at the HLA 
locus, had r2<0.2.  
We also assessed the absolute values of EIGENSTRAT14 loading scores 
along the principal component of ancestry that corresponds roughly to the North-
South intra-European axis that is correlated with height6 (absolute values of 
loading scores are a measure of allele frequency differentiation along this axis). 
The absolute values of loading scores for the height-associated SNPs was not 
significantly greater than those of 1,000 sets of allele frequency matched SNPs 
(P=0.08). We also compared Fst values (a measure of the proportion of genetic 
diversity due to differences among populations) for the 180 SNPs with sets of 
matched SNPs and the Fst values of the height-associated SNPs were not different 
when calculated by cohort, although they were nominally significantly higher 
(P=0.04) when grouped by country. Together with the family-based analysis, these 
results strongly suggest that the observed associations with height are unlikely to 
be appreciably affected by population stratification. 
5. Percentage variation explained and number of loci 
5.1 Estimation of variance explained and polygene analysis 
We used a method recently proposed by the International Schizophrenia 
Consortium15 to evaluate the amount of phenotypic variance explained by our 
associated loci in an independent validation set including the Fingesture (Finland), 
RS-II & RS-III (Netherlands), GOOD (Sweden) and QIMR (Australia or UK origin) 
studies. To avoid the influence of potential cryptic relatedness between discovery 
and validation set, a “leave one out” analysis was performed, namely excluding in 
the discovery set in turn, all studies from one of the four European countries of the 
validation set (Finland, Netherlands, Sweden and UK). 
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The method followed three steps: 1) selection of markers to build a prediction 
model, 2) scoring each individual based on model and 3) estimation of variation 
explained using the scores as predictor.  
First, we re-ran the meta-analysis using the “leave one out” approach and 
selected the SNPs that were genotyped in each validation study. For each of these 
four meta-analysis, a list of independent SNPs associated with height at various P-
value thresholds (from P<5×10-8 to P<0.05) was computed (using the clumping 
procedure implemented in PLINK, with an LD-based threshold of r2≥0.05, and a 
physical distance of 1 Mb from the top hit). 
Second, using the selected SNPs from the revised meta-analyses 
described above, we performed profile scoring for each individual of the five 
validation studies as implemented in PLINK, where: 
Scorei=∑j=1 to m b j xij , where 
m= number of SNPs 
b j =effect of allele at locus j  
xij=number of reference alleles of individual i at locus j 
Third, the measure of variance explained (adjusted R2) is estimated from a 
linear regression model incorporating the score as the predictor and the age-
adjusted standardized height residuals as outcome.  
This approach was applied for the estimation of variance explained by the 43 
previously published loci, the discovered 180 genome-wide significant loci and the 
polygene results incorporating different sets of markers at different significance 
thresholds.  
5.2 Prediction of number of susceptibility loci 
We utilized a new method (Park et al, submitted) to estimate the number of 
susceptibility loci that are likely to exist based on the distribution of effect sizes 
observed for established height loci and the power to detect those effects in the 
original scan. To be conservative and obtain unbiased estimates of the effect 
sizes, we only utilized the 118 loci that reach a significance threshold of P<5x10-8 
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in the Stage 1 meta-analysis, and the Stage 2 replication data was used to 
estimate the effect sizes for these loci.  Power was calculated based on the 
sample size for Stage 1 accounting for the number of SNPs that could be identified 
with the particular effect size. Only SNPs that had a power of at least 1% were 
used in the predication. The phenotypic variance explained was estimated by 
summing the product of each effect size and the number of loci predicted with that 
particular effect size. The genetic variance explained was estimated assuming 
heredity accounts for 80% of the variance in height. A parametric bootstrap 
method was used to obtain an estimate of the variability of the estimated number 
of loci.  
6. Gene by gene (GxG) interaction, dominant and recessive analyses 
6.1 Associated loci analyses 
To perform the GxG, dominant and recessive analyses for just the 
associated loci, each individual study extracted genotype imputation dosages for 
each of the 207 lead SNPs from the Stage 1 meta-analysis (based on 2Mb 
distance pruning; P<5x10-6). These dosages were also used for the conditional 
analysis described below. 
An R-script (available on request) was provided to each individual study 
and was run using the extracted dosages. The allele coding was such that the 
height increasing allele (based on the Stage 1 meta-analysis) was always the 
dosage increasing allele (i.e. the height increasing allele was coded as allele 2). 
For the additive dosage and pairwise interaction (Y=b0+b1.A+b2.B+b3.AB+e; Test 
of b3 = 0) analyses, the dosages were then regressed against residuals of sex-
standardized Z-score height, adjusted for age and appropriate covariates (e.g. 
principal components), as with the primary GWA study, under the appropriate 
models. For the additive best-guess (performed for quality control purposes), 
recessive, dominant and dominance deviation analyses “best guess” genotypes 
were assigned based on genotype dosage, and these genotypes were similarly 
regressed against Z-score height under the appropriate model. 
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We meta-analysed individual study results using METAL. We performed 
meta-analyses for the additive, dominant, recessive, dominant deviation and 
pairwise interaction terms. We excluded SNPs from individual studies where 
NxMAF < 10 and/or imputation quality was < 0.4. We also re-ran the meta-
analyses excluding SNPs with a NxMAF < 30 and imputation quality < 0.9, 
because deviation from additivity is harder to detect if the genotype has not been 
accurately imputed. The results were essentially the same. As an additional quality 
check we compared the additive dosage and additive best guess results from this 
meta-analysis to that from obtained from the primary Stage 1 meta-analysis files, 
and the correlation were very high (r>0.99). Results for the single SNP models, 
and the top results from the GxG interaction analysis are presented in 
Supplementary Table 5 and 6. 
6.2 Genome-wide joint effect analysis 
For the genome-wide analysis we used 10,618 individuals from four 
WTCCC studies (T2D, CAD, HT, NBS) and the EPIC-obesity study where we had 
access to individual level genotype data and study and sex-standardised, age-
adjusted height Z-scores. All the studies were genotyped using the Affymetrix 
500K platform (Affymetrix, Inc., Santa Clara, CA, USA). After quality control 
(including genotype success rate >95%; MAF>1% and HWE P>0.0001), 343,249 
autosomal SNPs were used in the analysis. 
As a genome-wide pairwise interaction analysis was not computationally 
feasible we performed two separate analyses. First, we performed a pairwise 
analysis of all SNPs with individual SNP P<0.01 with each other 
(Y=b0+b1.A+b2.B+b3.AB+e; Test of b3 = 0). Second, we performed a genome-
wide pairwise analysis testing the full model (an 8 d.f. model). SNP pairs 
generated here will include those driven by main effects as well as interaction. 
Therefore, we removed the 9 strongest single SNPs which accounted for a large 
fraction of the associated pairs, and assessed additive by additive interaction of 
the remaining pairs with a joint effects P<1x10-8 using PLINK. A total of 371 pairs 
of SNPs with an additive by additive interaction P<1x10-5 were taken forward into 
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replication in 16,100 samples from 4 cohorts, 3 of which (Rotterdam, CoLaus, 
DGI) were genotyped on the Affymetrix 500K platform (Affymetrix, Inc., Santa 
Clara, CA, USA). The fourth replication study, CGEMS, was genotyped on the 
Illumina platform (Illumina, Inc., San Diego, CA, USA), and where a SNP was not 
available an r2 > 0.8 proxy was used. Of the 371 SNP pairs that were taken 
forward into replication, none showed strong evidence of replication (top PReplication 
= 0.01; top POverall = 1x10
-6; N~26,000). 
7. Conditional analyses 
To perform the conditional analysis, each individual study repeated the 
Stage 1 GWAS analysis, but included a set of 225 imputation dosages as 
covariates (those from the 180 SNPs representing the novel loci, plus 27 SNPs 
from the remaining loci reaching P<5x10-6 in stage 1 and an additional 18 SNPs 
with P<8x10-6). For quality control purposes, the files obtained from each of the 
individual studies were put through the same checks as for the Stage 1 analysis 
(described in section 1.4). Additional checks were performed to ensure that each 
of the 225 conditioned SNPs was no longer associated with height (all P>0.2) and 
that SNPs outside the 225 conditioned loci had similar P-values and effect sizes to 
the primary stage 1 analysis. Meta-analysis was performed in the same way as for 
the GWA studies in Stage 1 (including a NxMAF>3 cut-off and double GC 
correction).  
8. Functional variant analyses 
8.1 Non-synonymous enrichment analysis 
For all 180 height SNPs, we retrieved all proxy SNPs in linkage 
disequilibrium (r2≥0.8 in HapMap phase II CEU) and annotated them according to 
whether they were missense, nonsense or neither. Annotation was based on the 
NCBI build 36.1. In total for the 180 height SNPs, we identified 2,550 proxies, 
including 0 nonsense and 31 missense SNPs. We repeated this analysis using 
1,000 sets of 180 SNPs that were matched based on allele frequency (+ 2.0%), 
nearby number of genes (+ 10% of seed SNP count), and gene proximity (+ 20kb). 
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Among these sets, the ranges for the number of proxies, nonsense SNPs, and 
missense SNPs were, respectively, 2566-4640, 0-1, and 8-49. After accounting for 
the number of proxy SNPs in each set, there were only four sets with a ratio 
(number of nonsynonymous SNPs / total number of proxies) equal or above the 
ratio observed for the 180 height SNPs (ratio: 0.0122, range of ratios observed in 
matched sets: 0.0024-0.0133). Similar results were obtained using a logistic 
regression framework, where control SNPs were matched only on allele frequency 
but the other matching parameters were used as covariates; here the “exposure” 
is being a height-associated SNP and the “outcome” is having a missense SNP as 
a proxy. 
8.2 Association with CNVs 
We used two different inventories of CNV that are in strong LD (HapMap 
CEU r2>0.8) with a near-by non-overlapping HapMap SNP. There a total of 1330 
unique CNV tags,  1138 from the Conrad et al. GSV data set16 and 261 from 
analysis of the HapMap 2 data by McCarroll et al.17. We looked to identify those 
CNV-tagging SNPs that were highly correlated with one of the 199 index SNPs 
representing 180 confirmed height loci, but there was no such overlap between 
our and the CNV datasets. We then looked at the overlap between the CNV-
tagging SNPs and our genome-wide Stage 1 results with P<5x10-8. The only 
overlap occurred at DLEU7 and chromosome 4 (near HHIP) loci; however, in both 
cases the height index SNP had much better P-value than the CNV-tagging SNP, 
and the index SNP was only either in weak LD (at DLEU7 locus, r2=0.56) or not at 
all correlated (at chromosome 4 locus) with the CNV tag. 
8.3 Association with other traits 
We downloaded from the NHGRI GWA study catalogue 
(http://www.genome.gov/26525384; accessed on 12th February 2010) all SNPs 
associated with diseases and traits other than height at genome-wide significance 
level of P<5x10-8. We then identified all SNPs that mapped within 1Mb of at least 
one height SNP and had some correlation (HapMap CEU r2>0.1) with the index 
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height SNP for each of the 180 associated loci. There were 22 such overlapping 
loci, some associated with multiple other traits and diseases (Supplementary 
Table 8). At 6 of the loci the height and „other‟ trait SNP were either identical or 
strongly correlated (r2>0.8). For one of these loci, LIN28B, the height effect is likely 
to be secondary to the large effect on pubertal timing, but the remaining five are 
likely to represent true pleiotropic effects.  
9. Biological enrichment analyses 
9.1 OMIM analysis 
We searched the Online Mendelian Inheritance in Man (OMIM) database 
and identified 241 genes that underlie human syndromes characterized by 
abnormal skeletal growth (Supplementary Table 9). The gene list was initially 
obtained using search keywords „short stature‟, „overgrowth‟, „skeletal dysplasia‟, 
and „brachydactyly‟, and was manually curated blindly to our results. We then 
grouped the 180 height-associated SNPs into 175 non-overlapping gene regions 
(to avoid double counting), containing a total of 652 genes. For each region, we 
set the genomic boundaries using linkage disequilibrium cutoffs (r2 0.3 from the 
index height SNP) and then next recombination hotspots. Although these 175 
regions contained only ~3.3% of all human genes, they included 21 genes from 
the curated OMIM height gene list (8.7%). We assessed the significance of this 
result by permutation: we generated 1,000 sets of 175 regions with similar gene 
content (±10%) and counted, in each set, the number of OMIM height genes within 
the regions. In these 1,000 permutations, the median number of OMIM height 
genes was 8 and the range was 1-19 (empirical P-value for an overlap of 21 OMIM 
genes is P<0.001). 
9.2 Text-mining using GRAIL 
The GRAIL algorithm was recently described18. As in the OMIM analysis, 
we used LD and recombination hotspots to define boundaries on the left and right 
of each height index SNP. This identified 652 genes in 175 regions (five regions 
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were overlapping when using our criteria to define genomic interval around height 
index SNP). 
9.3 Pathway analysis 
We applied an adaptation of the gene set enrichment analysis (GSEA) 
framework (Meta-Analysis Gene-set Enrichment of variaNT Associations, 
MAGENTA (Segrè et al., submitted)) to the height meta-analysis to determine 
whether the 180 height SNPs cluster near genes that belong to specific biological 
pathways and potentially to discover new pathways that may be enriched for 
modest height associations not yet identified. Specifically, for each gene in the 
genome we calculated a corrected gene association P-value based on the most 
significant SNP height association P-value of all SNPs in the gene region (110 kb 
upstream and 40 kb downstream to gene‟s most extreme transcript start and end 
sites, respectively), accounting for confounding effects such as gene size, number 
of SNPs per gene and linkage-related properties. Genes were grouped into 
pathways using annotations from the KEGG, PANTHER, and INGENUITY 
databases, downloaded from the Molecular Signatures Database (MsigDB, 
http://www.broad.mit.edu/gsea/msigdb/collections.jsp). Molecular function gene-
sets were downloaded from the PANTHER website (http://www.pantherdb.org/). 
For each pathway, enrichment of highly ranked gene scores above the 95th 
percentile of all gene scores in the height meta-analysis, was evaluated compared 
to 10,000 randomly sampled gene sets of identical size from the genome. Results 
from this analysis show strong enrichment for genes that belong to the hedgehog 
signalling pathway (nominal GSEA P=0.0009, FDR=0.078) and the histone 
molecular function category (nominal GSEA P=0.0001, FDR=0.0028), many of 
which are near the top GIANT height SNPs. In total, there were 20 pathways, 
including the TGF-beta pathway, and 14 molecular function sets that were 
nominally significant (P=0.05) in our GSEA using MAGENTA (Supplementary 
Table 11). 
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10. URLs 
Bayesian Imputation Based Association Mapping, BIMBAM, 
http://quartus.uchicago.edu/~yguan/bimbam/index.html;  
population stratification detection software, EIGENSTRAT, 
http://genepath.med.harvard.edu/~reich/EIGENSTRAT.htm;  
genotype imputation program, IMPUTE, 
http://www.stats.ox.ac.uk/~marchini/software/gwas/impute.html;  
Markov chain haplotyping package, MACH, 
http://www.sph.umich.edu/csg/abecasis/MACH; MACH2QTL, 
http://www.sph.umich.edu/csg/abecasis/MACH/download;  
pedigree analysis package, MERLIN, 
http://www.sph.umich.edu/csg/abecasis/Merlin;  
meta-analysis tool for GWASs, METAL, 
http://www.sph.umich.edu/csg/abecasis/Metal/index.html;  
whole-genome association analysis package, PLINK, 
http://pngu.mgh.harvard.edu/~purcell/plink;  
whole-genome association analysis of imputed data, ProbABEL, 
http://mga.bionet.nsc.ru/~yurii/ABEL;  
statistical computer software, R, http://www.r-project.org;  
whole-genome association analysis package, SNPTEST, 
http://www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html. 
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Supplementary Table 1. Association results for Stage 1 (discovery GWAS), Stage 2 (in-silico replication), Stage 1+2 combined, 
and Stage 1+2 sex-specific meta-analyses, for the 180 independent signals that reached genome-wide significance (P<5x10-8) in 
the combined Stage 1+2 analysis. I2 represents the % heterogeneity of effect size between Stage 1 studies. Phet is the heterogeneity 
P-value. 
 
SNP a Chr Position (bp) 
Nearest/OMIM 
height gene b 
Effect 
/other 
allele c 
Frequency 
(effect 
allele) 
STAGE 1 
up to 133,653 samples 
STAGE 2 
up to 50,074 samples 
STAGE 1 + STAGE 2 
up to 183,727 
samples 
STAGE 1 + STAGE 2 SEX-SPECIFIC 
up to 73,238 males and 110,489 females 
Beta P-value d I2 Phet Beta P-value 
d Beta P-value d Beta (M) 
P-value d 
(M) 
Beta (F) 
P-value d 
(F) 
Phet 
(MvsF) 
rs425277 1 2059032 PRKCZ T/C 0.28 0.024 1.70E-06 0 0.73 0.019 3.10E-03 0.022 2.10E-08 0.017 5.90E-03 0.027 6.70E-08 0.15 
rs2284746 1 17179262 MFAP2 C/G 0.48 -0.035 5.60E-15 17.77 0.07 -0.049 2.50E-16 -0.04 3.90E-29 -0.041 1.60E-13 -0.039 1.80E-18 0.76 
rs1738475 1 23409478 HTR1D C/G 0.59 0.022 1.90E-06 0 0.69 0.031 1.60E-07 0.025 3.00E-12 0.02 2.80E-04 0.028 5.20E-10 0.25 
rs4601530 1 24916698 CLIC4 T/C 0.26 -0.024 2.00E-06 15.60 0.10 -0.036 1.10E-07 -0.028 2.20E-12 -0.03 6.50E-07 -0.025 5.20E-07 0.47 
rs7532866 1 26614131 LIN28 A/G 0.67 0.022 3.30E-06 0 0.54 0.02 2.60E-03 0.021 3.40E-08 0.017 4.30E-03 0.025 1.30E-07 0.23 
rs2154319 1 41518357 SCMH1 T/C 0.75 -0.034 4.30E-10 0 0.86 -0.025 4.90E-04 -0.03 1.80E-12 -0.024 2.70E-04 -0.035 4.60E-11 0.13 
rs17391694 1 78396214 GIPC2 T/C 0.12 0.04 5.90E-07 7.76 0.27 0.045 5.60E-06 0.042 1.70E-11 0.041 7.00E-06 0.042 5.90E-08 0.95 
rs6699417 1 88896031 PKN2 T/C 0.61 0.022 1.70E-06 0 0.89 0.02 8.60E-04 0.021 5.00E-09 0.02 3.10E-04 0.02 6.40E-06 0.99 
rs10874746 1 93096559 RPL5 T/C 0.37 -0.022 1.70E-06 0 0.55 -0.027 7.90E-06 -0.024 6.70E-11 -0.024 1.30E-05 -0.022 7.30E-07 0.78 
rs9428104 1 118657110 SPAG17 A/G 0.24 -0.038 8.90E-13 0 0.98 -0.048 6.40E-12 -0.041 5.60E-23 -0.039 9.10E-10 -0.043 4.10E-17 0.55 
rs11205277 1 148159496 SF3B4 A/G 0.58 -0.045 1.20E-18 0.02 0.48 -0.048 8.10E-15 -0.046 4.80E-32 -0.042 9.60E-12 -0.049 2.00E-24 0.36 
rs17346452 1 170319910 DNM3 T/C 0.73 -0.038 3.30E-14 0 0.79 -0.045 4.00E-11 -0.04 1.40E-23 -0.037 1.10E-09 -0.042 6.60E-17 0.56 
rs1325598 1 175058872 PAPPA2 A/G 0.43 -0.026 1.60E-08 0 0.88 -0.016 9.60E-03 -0.022 1.10E-09 -0.025 4.10E-06 -0.021 2.70E-06 0.52 
rs1046934 1 182290152 TSEN15 A/C 0.64 -0.046 6.40E-22 0 0.80 -0.042 2.30E-11 -0.044 2.10E-31 -0.043 8.60E-14 -0.044 1.10E-20 0.94 
rs10863936 1 210304421 DTL A/G 0.53 -0.022 6.20E-07 3.05 0.40 -0.02 8.40E-04 -0.021 1.90E-09 -0.029 5.40E-08 -0.017 1.10E-04 0.06 
rs6684205 1 216676325 TGFB2 A/G 0.71 -0.033 2.00E-11 0 0.61 -0.019 4.00E-03 -0.028 1.50E-12 -0.032 7.20E-08 -0.026 8.50E-08 0.41 
rs11118346 1 217810342 LYPLAL1 T/C 0.47 -0.026 2.20E-09 9.57 0.22 -0.023 2.00E-04 -0.025 1.90E-12 -0.018 9.50E-04 -0.03 3.10E-11 0.05 
rs10799445 1 225978506 JMJD4 A/C 0.77 0.031 1.20E-08 0 0.51 0.033 2.80E-06 0.032 2.40E-13 0.026 4.00E-05 0.036 7.10E-12 0.21 
rs4665736 2 25041103 DNAJC27 T/C 0.54 0.034 1.40E-13 0 0.97 0.021 4.30E-04 0.029 7.30E-16 0.022 5.30E-05 0.034 3.40E-14 0.08 
rs6714546 2 33214929 LTBP1 A/G 0.28 -0.025 2.20E-06 0 0.99 -0.026 1.70E-04 -0.026 1.60E-09 -0.019 3.40E-03 -0.029 2.70E-08 0.19 
rs17511102 2 37814117 CDC42EP3 A/T 0.91 -0.06 1.30E-12 0 0.67 -0.061 1.70E-07 -0.06 1.60E-18 -0.061 1.80E-09 -0.06 1.20E-12 0.9 
rs2341459 2 44621706 C2orf34 T/C 0.27 0.028 3.60E-08 0 0.75 0.02 4.40E-03 0.025 7.90E-10 0.031 2.40E-07 0.021 4.70E-05 0.14 
rs12474201 2 46774789 SOCS5 A/G 0.35 0.023 1.00E-06 0 0.62 0.036 1.00E-08 0.028 2.60E-13 0.026 6.10E-06 0.028 2.90E-09 0.78 
rs3791675 2 55964813 EFEMP1 T/C 0.23 -0.05 2.40E-20 22.09 0.03 -0.059 3.20E-17 -0.053 2.50E-35 -0.055 1.20E-17 -0.052 3.60E-23 0.71 
rs11684404 2 88705737 EIF2AK3 T/C 0.67 -0.027 6.40E-09 14.78 0.12 -0.029 2.60E-06 -0.028 9.90E-14 -0.03 7.10E-08 -0.025 4.20E-08 0.46 
 Chapter 3 141 
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rs7567288 2 134151294 NCKAP5 T/C 0.8 -0.031 6.70E-08 0 0.92 -0.033 8.40E-06 -0.032 2.10E-12 -0.029 2.10E-05 -0.033 4.10E-09 0.6 
rs7567851 2 178392966 PDE11A C/G 0.08 0.041 7.50E-07 25.21 0.01 0.028 9.50E-03 0.037 3.30E-08 0.033 8.20E-04 0.038 3.60E-06 0.7 
rs1351164 2 217980143 TNS1 T/C 0.79 0.028 3.70E-07 0 0.87 0.044 2.70E-09 0.034 2.10E-14 0.033 4.30E-07 0.032 5.90E-09 0.83 
rs12470505 2 219616613 CCDC108/IHH T/G 0.9 0.048 1.30E-10 0 0.67 0.028 5.80E-03 0.041 8.90E-12 0.059 1.40E-10 0.032 2.50E-05 0.01 
rs2629046 2 224755988 SERPINE2 T/C 0.55 0.025 2.20E-08 0 0.89 0.023 1.00E-04 0.024 7.90E-12 0.019 3.80E-04 0.027 7.20E-10 0.2 
rs2580816 2 232506210 NPPC T/C 0.19 -0.041 1.80E-12 0 0.80 -0.051 4.60E-11 -0.045 5.80E-22 -0.05 9.30E-13 -0.041 1.70E-12 0.23 
rs12694997 2 241911659 SEPT2 A/G 0.24 -0.027 1.80E-07 3.06 0.40 -0.018 1.40E-02 -0.024 1.20E-08 -0.021 1.10E-03 -0.025 1.40E-06 0.61 
rs2597513 3 13530836 HDAC11 T/C 0.9 -0.039 1.10E-07 9.85 0.22 -0.031 1.40E-03 -0.036 7.40E-10 -0.036 4.90E-05 -0.038 1.10E-07 0.83 
rs13088462 3 51046753 DOCK3 T/C 0.94 -0.054 3.10E-07 0 0.80 -0.048 2.90E-04 -0.052 3.80E-10 -0.057 4.70E-06 -0.048 2.40E-06 0.56 
rs2336725 3 53093779 RTF1 T/C 0.55 -0.026 3.50E-08 8.25 0.26 -0.028 5.20E-06 -0.027 9.70E-13 -0.028 1.00E-06 -0.026 1.30E-08 0.85 
rs9835332 3 56642722 C3orf63 C/G 0.46 -0.022 8.70E-07 8.66 0.25 -0.032 5.70E-08 -0.026 5.30E-13 -0.026 2.10E-06 -0.025 2.10E-08 0.91 
rs17806888 3 67499012 SUCLG2 T/C 0.88 0.04 1.10E-07 7.76 0.28 0.028 3.70E-03 0.036 2.10E-09 0.036 7.10E-05 0.035 1.20E-06 0.93 
rs9863706 3 72520103 RYBP T/C 0.22 -0.03 1.50E-08 0 0.69 -0.033 4.70E-06 -0.031 4.10E-13 -0.034 2.50E-07 -0.03 1.80E-08 0.6 
rs6439167 3 130533446 C3orf47 T/C 0.21 -0.034 7.20E-10 0 0.89 -0.035 2.40E-06 -0.034 8.90E-15 -0.026 1.10E-04 -0.039 4.80E-13 0.09 
rs9844666 3 137456906 PCCB A/G 0.25 -0.028 3.10E-08 0 0.77 -0.017 1.70E-02 -0.024 3.50E-09 -0.016 8.60E-03 -0.029 1.80E-08 0.09 
rs724016 3 142588260 ZBTB38 A/G 0.56 -0.067 4.50E-52 20.23 0.05 -0.075 2.90E-36 -0.07 3.10E-86 -0.066 8.80E-35 -0.071 5.70E-60 0.42 
rs572169 3 173648421 GHSR T/C 0.31 0.036 9.90E-14 3.61 0.38 0.03 3.40E-06 0.033 2.80E-18 0.03 2.80E-07 0.036 4.20E-14 0.4 
rs720390 3 187031377 IGF2BP2 A/G 0.39 0.031 1.60E-10 19.54 0.05 0.026 1.80E-05 0.029 1.90E-14 0.036 4.40E-10 0.026 3.20E-08 0.14 
rs2247341 4 1671115 SLBP/FGFR3 A/G 0.36 0.025 6.80E-08 17.58 0.08 0.026 3.80E-05 0.025 1.50E-11 0.027 1.60E-06 0.024 1.80E-07 0.67 
rs6449353 4 17642586 LCORL T/C 0.85 0.071 1.30E-27 0 0.69 0.081 2.60E-20 0.075 7.10E-46 0.074 2.10E-21 0.076 3.20E-32 0.88 
rs17081935 4 57518233 POLR2B T/C 0.2 0.031 4.80E-08 6.60 0.30 0.028 1.80E-04 0.03 3.70E-11 0.038 1.70E-08 0.025 6.60E-06 0.09 
rs7697556 4 73734177 ADAMTS3 T/C 0.47 0.022 1.30E-06 0 0.71 0.038 2.90E-10 0.028 2.00E-14 0.03 4.80E-08 0.026 5.00E-09 0.56 
rs788867 4 82369030 PRKG2/BMP3 T/G 0.68 -0.039 1.80E-15 0 0.52 -0.05 2.10E-14 -0.043 8.90E-28 -0.042 9.00E-13 -0.042 1.60E-18 0.95 
rs10010325 4 106325802 TET2 A/C 0.49 0.021 2.30E-06 0 0.68 0.028 3.20E-06 0.024 3.90E-11 0.025 2.40E-06 0.022 3.40E-07 0.64 
rs7689420 4 145787802 HHIP T/C 0.16 -0.069 1.40E-29 10.51 0.20 -0.08 1.40E-23 -0.073 6.20E-51 -0.07 8.90E-22 -0.075 1.10E-35 0.61 
rs955748 4 184452669 WWC2 A/G 0.24 -0.024 2.20E-06 0 0.52 -0.019 5.70E-03 -0.023 4.40E-08 -0.027 1.50E-05 -0.019 1.60E-04 0.29 
rs1173727 5 32866278 NPR3 T/C 0.4 0.036 4.00E-15 1.45 0.44 0.032 1.10E-07 0.034 1.60E-21 0.038 4.60E-12 0.031 3.10E-12 0.27 
rs11958779 5 55037656 SLC38A9 A/G 0.7 -0.028 8.00E-09 0 0.92 -0.026 4.90E-05 -0.027 1.80E-12 -0.028 1.20E-06 -0.027 2.30E-08 0.8 
rs10037512 5 88390431 MEF2C T/C 0.56 0.027 3.80E-09 22.57 0.03 0.04 2.20E-11 0.032 2.00E-18 0.035 1.70E-10 0.029 1.40E-10 0.3 
rs13177718 5 108141243 FER T/C 0.07 -0.041 4.10E-06 12.78 0.16 -0.037 2.20E-03 -0.04 3.00E-08 -0.051 2.30E-06 -0.034 1.30E-04 0.16 
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rs1582931 5 122685098 CEP120 A/G 0.47 -0.025 2.10E-08 0 0.98 -0.019 1.90E-03 -0.023 1.50E-10 -0.019 3.50E-04 -0.026 8.10E-09 0.31 
rs274546 5 131727766 SLC22A5 A/G 0.4 -0.028 8.50E-10 0 0.92 -0.032 1.50E-07 -0.029 7.30E-16 -0.035 2.00E-10 -0.025 1.50E-08 0.13 
rs526896 5 134384604 PITX1 T/G 0.73 0.032 1.90E-09 2.86 0.40 0.029 3.20E-05 0.03 2.30E-13 0.024 1.70E-04 0.035 1.70E-11 0.15 
rs4282339 5 168188818 SLIT3 A/G 0.2 -0.035 3.40E-10 4.07 0.37 -0.038 3.10E-07 -0.036 6.60E-16 -0.034 4.40E-07 -0.037 1.70E-11 0.69 
rs12153391 5 171136043 FBXW11 A/C 0.25 -0.033 8.70E-10 0 0.83 -0.024 5.20E-04 -0.03 3.60E-12 -0.027 2.10E-05 -0.032 2.00E-09 0.57 
rs889014 5 172916720 BOD1 T/C 0.36 -0.029 4.50E-10 8.66 0.25 -0.032 2.10E-07 -0.03 9.40E-16 -0.032 9.70E-09 -0.028 8.30E-10 0.51 
rs422421 5 176449932 FGFR4/NSD1 T/C 0.22 -0.033 1.40E-09 27.96 0.01 -0.028 1.40E-04 -0.031 1.10E-12 -0.03 7.10E-06 -0.034 5.20E-10 0.64 
rs6879260 5 179663620 GFPT2 T/C 0.39 -0.028 5.60E-10 0 0.79 -0.01 9.70E-02 -0.022 1.60E-09 -0.02 3.40E-04 -0.025 3.00E-08 0.41 
rs3812163 6 7670759 BMP6 A/T 0.54 -0.037 6.70E-16 23.10 0.03 -0.035 4.30E-09 -0.036 1.20E-23 -0.033 2.80E-09 -0.039 1.50E-18 0.36 
rs1047014 6 19949472 ID4 T/C 0.75 -0.029 1.10E-07 0 0.55 -0.037 1.80E-07 -0.032 1.80E-13 -0.033 7.80E-07 -0.032 4.10E-09 0.9 
rs806794 6 26308656 Histone cluster A/G 0.7 0.053 5.50E-26 22.95 0.03 0.051 4.30E-15 0.052 1.20E-39 0.046 2.50E-14 0.057 5.30E-31 0.12 
rs3129109 6 29192211 OR2J3 T/C 0.39 -0.026 3.30E-08 16.96 0.09 -0.041 1.60E-11 -0.032 2.40E-17 -0.029 2.60E-07 -0.032 3.30E-12 0.64 
rs2256183 6 31488508 MICA A/G 0.45 0.035 2.70E-14 0 0.54 0.051 8.30E-17 0.04 7.80E-29 0.043 4.40E-14 0.037 3.60E-17 0.43 
rs6457620 6 32771977 HLA locus C/G 0.51 -0.024 3.60E-08 0 0.98 -0.037 2.50E-10 -0.029 2.10E-16 -0.03 2.50E-08 -0.028 1.00E-10 0.81 
rs2780226 6 34307070 HMGA1 T/C 0.92 -0.079 1.00E-18 20.61 0.05 -0.072 1.70E-10 -0.076 8.10E-28 -0.077 1.90E-12 -0.076 2.00E-19 0.96 
rs6457821 6 35510783 PPARD/FANCE A/C 0.02 -0.121 1.80E-11 3.24 0.40 -0.068 8.00E-03 -0.104 2.10E-12 -0.084 2.20E-04 -0.112 3.40E-10 0.29 
rs9472414 6 45054484 SUPT3H/RUNX2 A/T 0.22 -0.031 2.40E-08 26.80 0.01 -0.019 8.70E-03 -0.026 1.80E-09 -0.029 6.90E-06 -0.026 1.70E-06 0.66 
rs9360921 6 76322362 SENP6 T/G 0.89 -0.048 4.60E-11 17.19 0.08 -0.033 5.00E-04 -0.042 2.60E-13 -0.045 1.20E-07 -0.04 1.40E-08 0.62 
rs310405 6 81857081 FAM46A A/G 0.52 0.03 3.60E-11 0 0.89 0.02 8.10E-04 0.026 2.20E-13 0.023 2.60E-05 0.03 1.30E-11 0.25 
rs7759938 6 105485647 LIN28B T/C 0.68 -0.042 8.70E-18 6.39 0.30 -0.051 4.10E-15 -0.045 8.30E-31 -0.04 8.70E-12 -0.048 5.20E-23 0.26 
rs1046943 6 109890634 ZBTB24 A/G 0.58 0.022 8.60E-07 0 0.67 0.016 7.20E-03 0.02 2.50E-08 0.024 1.20E-05 0.019 1.90E-05 0.46 
rs961764 6 117628849 VGLL2 C/G 0.42 -0.023 2.40E-07 0 0.87 -0.026 1.20E-05 -0.024 1.30E-11 -0.024 1.20E-05 -0.025 8.90E-09 0.79 
rs1490384 6 126892853 C6orf173 T/C 0.5 0.037 3.20E-16 15.83 0.10 0.028 1.80E-06 0.034 3.90E-21 0.037 5.30E-12 0.033 3.40E-14 0.55 
rs6569648 6 130390812 L3MBTL3 T/C 0.76 -0.036 8.90E-12 16.88 0.08 -0.047 1.20E-11 -0.04 1.10E-21 -0.046 5.10E-13 -0.035 8.40E-12 0.14 
rs7763064 6 142838982 GPR126 A/G 0.29 -0.045 6.40E-19 6.91 0.29 -0.055 7.20E-17 -0.048 1.10E-33 -0.044 2.10E-13 -0.051 5.30E-26 0.29 
rs543650 6 152152636 ESR1 T/G 0.4 -0.032 1.40E-09 16.12 0.11 -0.037 2.10E-09 -0.034 1.20E-17 -0.029 3.30E-06 -0.036 1.30E-13 0.36 
rs9456307 6 158849430 TULP4 A/T 0.06 -0.05 4.60E-07 0.20 0.47 -0.045 1.20E-03 -0.048 2.20E-09 -0.041 7.90E-04 -0.053 6.20E-08 0.38 
rs798489 7 2768329 GNA12 T/C 0.3 -0.052 8.50E-25 0 0.55 -0.042 1.70E-10 -0.048 1.90E-33 -0.051 4.50E-17 -0.046 5.10E-21 0.53 
rs4470914 7 19583047 TWISTNB T/C 0.18 0.033 3.80E-08 5.76 0.32 0.023 3.40E-03 0.029 9.20E-10 0.03 4.80E-05 0.029 5.50E-07 0.93 
rs12534093 7 23469499 IGF2BP3 A/T 0.22 -0.03 5.60E-08 3.09 0.39 -0.04 4.10E-08 -0.034 2.00E-14 -0.032 1.70E-06 -0.033 5.30E-10 0.84 
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rs1708299 7 28156471 JAZF1 A/G 0.3 0.042 1.50E-17 14.38 0.12 0.038 5.80E-09 0.04 5.80E-25 0.036 4.10E-10 0.044 3.30E-20 0.25 
rs6959212 7 38094851 STARD3NL T/C 0.32 -0.023 2.80E-06 0 0.52 -0.025 1.30E-04 -0.024 1.60E-09 -0.021 3.40E-04 -0.024 5.90E-07 0.66 
rs42235 7 92086012 CDK6 T/C 0.31 0.055 7.30E-28 21.51 0.04 0.062 1.90E-20 0.057 7.70E-47 0.046 1.60E-14 0.063 3.70E-37 0.01 
rs822552 7 148281567 PDIA4 C/G 0.74 -0.03 1.30E-07 0 0.48 -0.017 2.70E-02 -0.025 2.60E-08 -0.032 2.30E-06 -0.022 9.40E-05 0.24 
rs2110001 7 150147955 TMEM176A C/G 0.69 -0.033 9.80E-10 17.78 0.08 -0.028 4.40E-05 -0.031 3.30E-13 -0.029 3.40E-06 -0.032 4.40E-10 0.71 
rs1013209 8 24172249 ADAM28 T/C 0.25 -0.029 4.50E-08 10.06 0.21 -0.019 7.30E-03 -0.025 1.60E-09 -0.026 4.80E-05 -0.026 8.90E-07 0.95 
rs7460090 8 57356717 SDR16C5 T/C 0.87 0.055 9.60E-16 0 0.70 0.064 7.70E-13 0.058 8.20E-27 0.051 7.00E-10 0.064 1.10E-21 0.16 
rs6473015 8 78341040 PEX2 A/C 0.72 -0.032 1.70E-10 12.48 0.16 -0.023 5.80E-04 -0.029 6.90E-13 -0.03 8.90E-07 -0.028 9.00E-09 0.84 
rs6470764 8 130794847 GSDMC T/C 0.2 -0.047 5.90E-17 17.64 0.07 -0.056 3.40E-13 -0.05 1.70E-28 -0.05 1.60E-13 -0.05 4.10E-18 0.95 
rs12680655 8 135706519 ZFAT C/G 0.6 0.03 4.80E-11 16.69 0.09 0.024 7.50E-05 0.028 1.60E-14 0.025 5.10E-06 0.029 3.70E-11 0.45 
rs7864648 9 16358732 BNC2 T/G 0.32 0.025 4.90E-07 3.83 0.37 0.017 7.80E-03 0.022 2.10E-08 0.027 5.40E-06 0.019 9.70E-05 0.23 
rs11144688 9 77732106 PCSK5 A/G 0.11 -0.055 1.50E-09 0 0.52 -0.04 9.10E-04 -0.049 9.60E-12 -0.044 3.30E-05 -0.057 3.90E-10 0.28 
rs7853377 9 85742025 C9orf64 A/G 0.77 -0.026 3.10E-06 0 0.65 -0.021 3.50E-03 -0.024 4.50E-08 -0.018 6.10E-03 -0.027 5.00E-07 0.26 
rs8181166 9 88306448 ZCCHC6 C/G 0.53 0.025 1.10E-07 26.48 0.01 0.028 3.90E-06 0.026 2.70E-12 0.019 8.30E-04 0.031 8.20E-12 0.07 
rs2778031 9 90025546 SPIN1 T/C 0.24 0.027 3.60E-07 0 0.81 0.037 2.40E-07 0.031 9.00E-13 0.031 1.50E-06 0.029 2.20E-08 0.78 
rs9969804 9 94468941 IPPK A/C 0.44 0.028 5.60E-10 0 0.61 0.033 1.90E-08 0.03 7.70E-17 0.028 1.50E-07 0.029 7.30E-11 0.92 
rs1257763 9 95933766 PTPDC1 A/G 0.04 0.069 2.50E-06 0 0.95 0.07 1.00E-04 0.069 9.90E-10 0.063 2.10E-04 0.075 1.00E-07 0.55 
rs473902 9 97296056 PTCH1/FANCC T/G 0.92 0.074 1.70E-14 0 0.61 0.05 6.80E-05 0.065 2.30E-17 0.061 6.70E-08 0.068 9.80E-13 0.62 
rs7027110 9 108638867 ZNF462 A/G 0.23 0.034 1.30E-10 0 0.85 0.025 3.80E-04 0.031 2.30E-13 0.032 4.80E-07 0.03 8.90E-09 0.72 
rs1468758 9 112846903 LPAR1 T/C 0.25 -0.026 1.50E-06 0 0.59 -0.026 1.90E-04 -0.026 1.40E-09 -0.031 1.20E-06 -0.022 2.50E-05 0.24 
rs751543 9 118162163 PAPPA T/C 0.72 0.029 4.50E-08 0 0.86 0.021 3.40E-03 0.026 6.50E-10 0.027 2.50E-05 0.026 6.70E-07 0.89 
rs7466269 9 132453905 FUBP3 A/G 0.64 0.036 1.20E-14 37.95 0.00 0.024 7.50E-05 0.032 2.60E-17 0.032 2.70E-08 0.032 2.30E-12 0.92 
rs7849585 9 138251691 QSOX2 T/G 0.33 0.032 3.40E-11 14.89 0.12 0.024 1.50E-04 0.029 4.70E-14 0.031 1.70E-07 0.028 3.30E-09 0.69 
rs7909670 10 12958770 CCDC3 T/C 0.44 -0.022 1.30E-06 0 0.85 -0.02 7.30E-04 -0.021 3.20E-09 -0.028 3.60E-07 -0.016 2.60E-04 0.06 
rs2145998 10 80791702 PPIF A/T 0.49 -0.025 2.70E-08 2.75 0.40 -0.027 3.80E-06 -0.026 3.60E-13 -0.027 4.80E-07 -0.025 2.60E-08 0.68 
rs11599750 10 101795432 CPN1 T/C 0.38 -0.023 7.60E-07 0 0.82 -0.036 6.90E-09 -0.028 1.60E-13 -0.023 3.40E-05 -0.03 9.00E-11 0.32 
rs2237886 11 2767307 KCNQ1 T/C 0.11 0.043 3.10E-08 6.34 0.31 0.05 1.00E-06 0.046 2.20E-13 0.037 7.50E-05 0.05 4.30E-11 0.25 
rs7926971 11 12654616 TEAD1 A/G 0.55 -0.024 7.30E-08 0 0.91 -0.019 1.40E-03 -0.023 4.40E-10 -0.025 3.50E-06 -0.02 8.30E-06 0.4 
rs1330 11 17272605 NUCB2 T/C 0.35 0.024 4.40E-07 17.47 0.08 0.019 2.10E-03 0.022 4.90E-09 0.02 4.70E-04 0.024 3.10E-07 0.56 
rs10838801 11 48054856 PTPRJ/SLC39A13 A/G 0.69 -0.031 1.80E-10 12.10 0.17 -0.02 1.90E-03 -0.027 3.50E-12 -0.024 5.40E-05 -0.031 7.70E-11 0.27 
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SNP a Chr Position (bp) 
Nearest/OMIM 
height gene b 
Effect 
/other 
allele c 
Frequency 
(effect 
allele) 
STAGE 1 
up to 133,653 samples 
STAGE 2 
up to 50,074 samples 
STAGE 1 + STAGE 2 
up to 183,727 
samples 
STAGE 1 + STAGE 2 SEX-SPECIFIC 
up to 73,238 males and 110,489 females 
Beta P-value d I2 Phet Beta P-value 
d Beta P-value d Beta (M) 
P-value d 
(M) 
Beta (F) 
P-value d 
(F) 
Phet 
(MvsF) 
rs1814175 11 49515748 FOLH1 T/C 0.34 0.023 2.60E-06 0 0.62 0.02 1.60E-03 0.022 1.60E-08 0.016 5.60E-03 0.027 2.20E-08 0.13 
rs5017948 11 51270794 OR4A5 A/T 0.18 0.027 4.70E-06 9.62 0.23 0.026 1.60E-03 0.027 3.10E-08 0.016 3.10E-02 0.036 1.60E-09 0.02 
rs3782089 11 65093395 SSSCA1 T/C 0.06 -0.058 5.90E-09 0 0.63 -0.057 1.40E-05 -0.058 3.60E-13 -0.071 2.00E-09 -0.049 7.70E-07 0.13 
rs7112925 11 66582736 RHOD T/C 0.35 -0.023 8.50E-07 0 0.48 -0.023 2.00E-04 -0.023 9.00E-10 -0.026 5.90E-06 -0.022 2.30E-06 0.57 
rs634552 11 74959700 SERPINH1 T/G 0.14 0.041 1.40E-09 2.32 0.42 0.035 4.40E-05 0.039 3.50E-13 0.036 7.00E-06 0.04 1.60E-09 0.69 
rs494459 11 118079885 TREH T/C 0.41 0.021 4.90E-06 19.42 0.05 0.02 1.10E-03 0.02 1.70E-08 0.023 1.90E-05 0.019 2.30E-05 0.5 
rs654723 11 128091365 FLI1 A/C 0.62 0.024 6.70E-07 0 0.93 0.028 8.00E-06 0.025 3.60E-11 0.026 4.70E-06 0.025 1.30E-07 0.82 
rs2856321 12 11747040 ETV6 A/G 0.64 -0.03 1.50E-10 0 0.99 -0.029 4.00E-06 -0.029 4.50E-15 -0.029 4.10E-07 -0.03 8.10E-11 0.83 
rs10770705 12 20748734 SLCO1C1 A/C 0.33 0.031 4.60E-11 0 0.75 0.036 2.20E-08 0.033 8.00E-18 0.031 8.40E-08 0.033 3.80E-12 0.77 
rs2638953 12 28425682 CCDC91 C/G 0.68 0.036 8.40E-14 2.95 0.40 0.026 5.40E-05 0.032 6.70E-17 0.024 3.10E-05 0.038 1.10E-15 0.04 
rs2066807 12 55026949 STAT2 C/G 0.93 -0.052 9.60E-09 0 0.71 -0.058 1.90E-06 -0.054 1.00E-13 -0.047 2.20E-05 -0.056 1.30E-10 0.49 
rs1351394 12 64638093 HMGA2 T/C 0.49 0.054 7.80E-34 24.54 0.02 0.073 1.60E-34 0.06 1.70E-65 0.054 1.40E-23 0.063 9.00E-48 0.14 
rs10748128 12 68113925 FRS2 T/G 0.35 0.035 3.80E-11 20.87 0.04 0.042 1.20E-10 0.038 2.10E-20 0.043 1.10E-11 0.034 8.10E-12 0.23 
rs11107116 12 92502635 SOCS2 T/G 0.22 0.052 1.70E-23 10.02 0.21 0.05 2.20E-12 0.052 1.40E-34 0.044 4.70E-12 0.057 1.90E-27 0.1 
rs7971536 12 100897919 CCDC53/GNPTAB A/T 0.46 -0.025 1.10E-07 0 0.64 -0.034 4.30E-08 -0.028 8.20E-14 -0.029 3.40E-07 -0.027 1.30E-08 0.75 
rs11830103 12 122389499 SBNO1 A/G 0.78 -0.035 3.80E-10 0 0.76 -0.035 2.50E-06 -0.035 3.90E-15 -0.041 1.40E-09 -0.032 4.50E-09 0.27 
rs7332115 13 32045548 PDS5B/BRCA2 T/G 0.62 -0.025 7.60E-08 0 0.86 -0.02 1.10E-03 -0.023 5.50E-10 -0.02 4.80E-04 -0.026 1.70E-08 0.37 
rs3118905 13 50003335 DLEU7 A/G 0.29 -0.052 3.00E-25 0 0.58 -0.063 3.10E-22 -0.056 1.10E-45 -0.05 4.00E-17 -0.06 1.60E-34 0.15 
rs7319045 13 90822575 GPC5 A/G 0.4 0.029 4.50E-10 0 0.89 0.019 1.80E-03 0.025 1.20E-11 0.027 8.40E-07 0.024 1.40E-07 0.6 
rs1950500 14 23900690 NFATC4 T/C 0.29 0.032 3.90E-11 0 0.95 0.038 8.70E-09 0.034 2.20E-18 0.038 2.00E-10 0.031 1.60E-10 0.32 
rs2093210 14 60027032 SIX6 T/C 0.58 -0.034 2.30E-12 0 0.56 -0.029 3.90E-06 -0.032 6.20E-17 -0.028 2.10E-06 -0.036 1.90E-14 0.23 
rs1570106 14 67882868 RAD51L1 T/C 0.2 -0.026 4.90E-06 0.50 0.47 -0.026 4.70E-04 -0.026 8.10E-09 -0.023 5.40E-04 -0.027 1.70E-06 0.67 
rs862034 14 74060499 LTBP2 A/G 0.36 -0.023 1.10E-06 12.90 0.15 -0.037 1.90E-09 -0.028 7.30E-14 -0.032 1.90E-08 -0.024 2.10E-07 0.24 
rs7155279 14 91555634 TRIP11 T/G 0.36 -0.029 8.90E-10 21.48 0.04 -0.016 9.20E-03 -0.024 1.40E-10 -0.028 8.70E-07 -0.022 1.10E-06 0.38 
rs16964211 15 49317787 CYP19A1 A/G 0.05 -0.051 2.50E-06 14.06 0.13 -0.049 1.60E-04 -0.05 1.70E-09 -0.067 8.10E-08 -0.036 5.30E-04 0.04 
rs7178424 15 60167551 C2CD4A T/C 0.47 -0.024 2.20E-07 0 0.62 -0.017 6.20E-03 -0.021 5.60E-09 -0.02 2.50E-04 -0.021 1.50E-06 0.88 
rs10152591 15 67835211 TLE3 A/C 0.91 0.045 3.50E-08 0 0.50 0.034 1.50E-03 0.041 2.70E-10 0.033 8.60E-04 0.046 6.60E-09 0.28 
rs12902421 15 69948457 MYO9A T/C 0.97 -0.069 1.70E-06 0 0.51 -0.051 3.70E-03 -0.062 2.90E-08 -0.049 2.80E-03 -0.072 2.50E-07 0.25 
rs5742915 15 72123686 PML T/C 0.54 -0.031 3.00E-10 0 0.71 -0.031 5.30E-07 -0.031 1.00E-15 -0.039 3.90E-11 -0.027 1.10E-08 0.08 
rs11259936 15 82371586 ADAMTSL3 A/C 0.48 -0.042 2.20E-21 3.92 0.37 -0.047 1.10E-15 -0.044 1.70E-35 -0.036 1.50E-11 -0.049 1.00E-29 0.03 
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allele) 
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up to 133,653 samples 
STAGE 2 
up to 50,074 samples 
STAGE 1 + STAGE 2 
up to 183,727 
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STAGE 1 + STAGE 2 SEX-SPECIFIC 
up to 73,238 males and 110,489 females 
Beta P-value d I2 Phet Beta P-value 
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(M) 
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(F) 
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rs16942341 15 87189909 ACAN T/C 0.03 -0.134 1.30E-17 24.62 0.03 -0.124 4.50E-11 -0.13 3.80E-27 -0.139 1.60E-14 -0.122 1.40E-16 0.43 
rs2871865 15 97012419 IGF1R C/G 0.88 0.054 1.10E-12 32.60 0.002 0.062 3.50E-10 0.057 2.90E-21 0.052 1.80E-08 0.058 2.80E-15 0.54 
rs4965598 15 98577137 ADAMTS17 T/C 0.68 -0.035 1.40E-13 0 0.81 -0.015 2.30E-02 -0.028 4.30E-13 -0.024 5.10E-05 -0.032 9.70E-12 0.21 
rs11648796 16 732191 NARFL A/G 0.74 -0.031 2.40E-07 0 0.87 -0.039 6.90E-08 -0.034 1.20E-13 -0.032 7.40E-06 -0.035 5.60E-10 0.71 
rs26868 16 2189377 CASKIN1 A/T 0.46 0.03 3.50E-08 0 0.78 0.04 2.40E-10 0.034 9.00E-17 0.036 1.20E-08 0.034 9.80E-12 0.73 
rs1659127 16 14295806 MKL2 A/G 0.34 0.024 2.90E-06 0 0.79 0.033 5.20E-07 0.027 1.10E-11 0.025 7.90E-05 0.027 2.90E-08 0.7 
rs8052560 16 87304743 CTU2/GALNS A/C 0.79 0.039 1.40E-08 0 0.63 0.015 7.40E-02 0.029 3.30E-08 0.025 2.20E-03 0.032 1.10E-06 0.47 
rs4640244 17 21224816 KCNJ12 A/G 0.61 0.028 2.00E-07 13.00 0.15 0.017 1.20E-02 0.024 2.30E-08 0.023 2.80E-04 0.025 1.70E-06 0.78 
rs3110496 17 24941897 ANKRD13B A/G 0.33 -0.023 1.60E-06 0 0.69 -0.021 1.10E-03 -0.022 7.30E-09 -0.03 1.10E-07 -0.016 6.40E-04 0.04 
rs3764419 17 26188149 ATAD5/RNF135 A/C 0.39 -0.037 8.90E-16 16.60 0.09 -0.032 1.50E-07 -0.035 1.80E-21 -0.034 1.30E-09 -0.036 7.80E-16 0.67 
rs17780086 17 27367395 LRRC37B A/G 0.15 0.035 4.40E-08 10.44 0.21 0.017 5.50E-02 0.028 2.60E-08 0.03 9.40E-05 0.028 5.30E-06 0.85 
rs1043515 17 34175722 PIP4K2B A/G 0.45 -0.022 1.30E-06 0 0.80 -0.024 6.60E-05 -0.023 2.90E-10 -0.028 2.00E-07 -0.019 2.20E-05 0.15 
rs4986172 17 40571807 ACBD4 T/C 0.35 -0.028 7.10E-09 30.83 0.003 -0.037 2.50E-09 -0.032 2.30E-16 -0.035 1.70E-09 -0.03 3.10E-10 0.41 
rs2072153 17 44745013 ZNF652 C/G 0.3 0.026 6.70E-08 0 0.86 0.013 4.30E-02 0.021 3.50E-08 0.031 1.60E-07 0.016 8.30E-04 0.03 
rs4605213 17 46599746 NME2 C/G 0.34 0.023 9.30E-07 0 0.88 0.018 5.90E-03 0.021 2.70E-08 0.026 5.40E-06 0.018 2.10E-04 0.21 
rs227724 17 52133816 NOG A/T 0.65 -0.027 1.20E-08 0 0.92 -0.034 6.60E-08 -0.03 7.40E-15 -0.035 8.10E-10 -0.027 1.10E-08 0.2 
rs2079795 17 56851431 TBX2 T/C 0.33 0.04 1.20E-16 0 0.81 0.04 1.50E-09 0.04 2.10E-24 0.033 7.80E-09 0.044 8.10E-20 0.12 
rs2665838 17 59320197 CSH1/GH1 C/G 0.73 -0.037 2.00E-13 11.25 0.19 -0.052 7.00E-14 -0.042 5.10E-25 -0.042 2.20E-11 -0.042 3.00E-17 0.92 
rs11867479 17 65601802 KCNJ16/KCNJ2 T/C 0.34 0.024 4.90E-07 0 0.87 0.026 5.40E-05 0.025 1.50E-10 0.023 7.00E-05 0.026 6.70E-08 0.68 
rs4800452 18 18981609 CABLES1 T/C 0.79 0.048 2.40E-17 0 0.84 0.056 1.20E-14 0.051 4.20E-30 0.052 7.40E-15 0.05 8.40E-20 0.8 
rs9967417 18 45213498 DYM C/G 0.58 -0.038 2.60E-16 30.04 0.004 -0.039 3.20E-10 -0.038 9.30E-25 -0.041 3.40E-13 -0.036 1.30E-15 0.44 
rs17782313 18 56002077 MC4R T/C 0.76 -0.025 3.50E-06 13.42 0.14 -0.035 1.20E-06 -0.028 3.80E-11 -0.03 4.00E-06 -0.025 1.20E-06 0.55 
rs12982744 19 2128193 DOT1L C/G 0.6 -0.033 2.80E-12 0 0.97 -0.027 1.10E-05 -0.03 3.40E-16 -0.028 4.90E-07 -0.032 3.80E-12 0.6 
rs7507204 19 3379834 NFIC C/G 0.24 0.028 2.30E-07 0 0.88 0.049 2.10E-11 0.036 4.30E-16 0.025 1.70E-04 0.041 2.60E-14 0.05 
rs891088 19 7135762 INSR A/G 0.74 -0.025 1.70E-06 2.38 0.41 -0.035 1.80E-07 -0.029 2.40E-12 -0.025 6.10E-05 -0.031 1.10E-09 0.45 
rs4072910 19 8550031 ADAMTS10 C/G 0.46 -0.029 2.50E-07 0 0.76 -0.034 2.20E-07 -0.031 3.60E-13 -0.025 1.30E-04 -0.033 3.10E-10 0.31 
rs2279008 19 17144303 MYO9B T/C 0.74 0.031 2.40E-07 0 0.63 0.018 9.50E-03 0.025 2.50E-08 0.022 2.00E-03 0.027 5.00E-07 0.48 
rs17318596 19 46628935 ATP5SL A/G 0.36 0.029 3.00E-09 0 0.79 0.037 2.10E-08 0.032 5.00E-16 0.043 1.30E-13 0.024 8.00E-07 0.01 
rs1741344 20 4049800 SMOX T/C 0.63 -0.026 3.50E-08 16.74 0.09 -0.016 1.00E-02 -0.023 3.30E-09 -0.02 4.10E-04 -0.024 2.60E-07 0.55 
rs2145272 20 6574218 BMP2 A/G 0.65 -0.039 5.90E-16 19.29 0.06 -0.04 4.60E-10 -0.039 2.10E-24 -0.039 1.50E-11 -0.04 2.30E-17 0.85 
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rs7274811 20 31796842 ZNF341 T/G 0.23 -0.04 6.80E-14 7.93 0.26 -0.042 1.10E-09 -0.041 5.90E-22 -0.044 1.60E-11 -0.039 1.30E-13 0.52 
rs143384 20 33489170 GDF5 A/G 0.58 -0.064 4.90E-39 21.58 0.04 -0.061 9.10E-22 -0.063 1.00E-58 -0.066 9.30E-30 -0.061 8.30E-38 0.47 
rs237743 20 47336426 ZNFX1 A/G 0.21 0.034 7.20E-10 0 0.69 0.053 3.10E-13 0.041 1.30E-20 0.035 1.20E-07 0.043 6.80E-16 0.28 
rs2834442 21 34612656 KCNE2 A/T 0.65 0.027 7.30E-09 0 0.80 0.024 9.70E-05 0.026 5.10E-12 0.025 9.10E-06 0.026 1.00E-08 0.9 
rs4821083 22 31386341 SYN3 T/C 0.84 0.033 4.80E-08 0 0.70 0.027 1.40E-03 0.031 3.10E-10 0.036 1.40E-06 0.028 4.20E-06 0.41 
 
a SNPs most likely to be representing a previously published height locus are highlighted in green.  
b Gene regions are named after the gene nearest to the index SNP. A near-by (within 500kb from the index SNP) OMIM height gene (defined as 
a gene that when mutated results in a monogenic skeletal growth defect) is also included if it is not the nearest. All OMIM height genes are 
highlighted in blue.  
c Alleles are indexed to the forward strand of NCBI Build 36.  
d All p-values are based on the inverse-variance weighted meta-analysis model (fixed effects). 
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Supplementary Table 2. Association results for 33 SNPs selected randomly among the 180 SNPs that reached genome-wide 
significance (P=5x10-8) in the Stage 1 meta-analysis and genotyped in European American (N=2,181) and Poland (N=1,009) 
extreme height panels. Results are combined using a Cochran-Mantel-Haenszel test.  
 
   GIANT height meta-analysis  Results in extreme height panels  
GIANT height 
SNP 
Chr Position 
Effect 
allele 
Other 
allele 
Effect 
size 
(Stage 1) 
Stage 1+2 
P-value 
 
Effect 
allele 
Other 
allele 
OR [95% CI] 
1-tailed 
P-value 
Comment 
rs143384 20 33489170 A G -0.0639 9.954E-59  G A 1.2 [1.08-1.33] 0.0002 Same direction, 1-tailed P-value <0.05 
rs2580816 2 232506210 T C -0.0412 5.837E-22  T C 0.8 [0.7-0.91] 0.0002 Same direction, 1-tailed P-value <0.05 
rs1738475 1 23409478 C G 0.0216 2.952E-12  G C 0.86 [0.78-0.96] 0.002 Same direction, 1-tailed P-value <0.05 
rs12474201 2 46774789 A G 0.0233 2.581E-13  A G 1.16 [1.04-1.29] 0.003 Same direction, 1-tailed P-value <0.05 
rs1351164 2 217980143 T C 0.0279 2.081E-14  C T 0.84 [0.74-0.96] 0.004 Same direction, 1-tailed P-value <0.05 
rs822552 7 148281567 C G -0.0302 2.613E-08  G C 1.15 [1.03-1.29] 0.007 Same direction, 1-tailed P-value <0.05 
rs7849585 9 138251691 T G 0.0324 4.724E-14  T G 1.13 [1.02-1.26] 0.011 Same direction, 1-tailed P-value <0.05 
rs1257763 9 95933766 A G 0.0685 9.865E-10  A G 1.33 [1.04-1.69] 0.012 Same direction, 1-tailed P-value <0.05 
rs12534093 7 23469499 A T -0.0298 2.019E-14  A T 0.87 [0.77-0.98] 0.012 Same direction, 1-tailed P-value <0.05 
rs2871865 15 97012419 C G 0.0535 2.862E-21  G C 0.83 [0.71-0.98] 0.013 Same direction, 1-tailed P-value <0.05 
rs310405 6 81857081 A G 0.03 2.245E-13  G A 0.89 [0.81-0.99] 0.016 Same direction, 1-tailed P-value <0.05 
rs10037512 5 88390431 T C 0.0267 2.011E-18  C T 0.82 [0.69-0.99] 0.018 Same direction, 1-tailed P-value <0.05 
rs1814175 11 49515748 T C 0.023 1.645E-08  T C 1.11 [1-1.24] 0.02 Same direction, 1-tailed P-value <0.05 
rs16942341 15 87189909 T C -0.1335 3.807E-27  T C 0.74 [0.55-1.01] 0.03 Same direction, 1-tailed P-value <0.05 
rs4665736 2 25041103 T C 0.0335 7.29E-16  C T 0.92 [0.83-1.02] 0.05 Same direction, 1-tailed P-value <0.05 
rs6684205 1 216676325 A G -0.0328 1.473E-12  G A 1.09 [0.97-1.22] 0.07 Same direction 
rs7567288 2 134151294 T C -0.0309 2.071E-12  C T 1.11 [0.97-1.26] 0.07 Same direction 
rs7697556 4 73734177 T C 0.0219 1.958E-14  T C 1.07 [0.96-1.18] 0.11 Same direction 
rs11599750 10 101795432 T C -0.023 1.604E-13  T C 0.94 [0.85-1.05] 0.13 Same direction 
rs2066807 12 55026949 C G -0.052 1.025E-13  G C 1.12 [0.92-1.35] 0.13 Same direction 
rs751543 9 118162163 T C 0.0287 6.537E-10  C T 0.94 [0.84-1.05] 0.13 Same direction 
rs7532866 1 26614131 A G 0.0222 3.372E-08  G A 0.94 [0.85-1.05] 0.14 Same direction 
rs11118346 1 217810342 T C -0.0264 1.879E-12  T C 0.96 [0.87-1.06] 0.20 Same direction 
rs6439167 3 130533446 T C -0.0338 8.925E-15  T C 0.93 [0.75-1.15] 0.24 Same direction 
rs274546 5 131727766 A G -0.0278 7.254E-16  A G 0.97 [0.87-1.07] 0.26 Same direction 
rs10863936 1 210304421 A G -0.022 1.922E-09  G A 1.03 [0.93-1.14] 0.27 Same direction 
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rs9360921 6 76322362 T G -0.0479 2.552E-13  G T 1.05 [0.89-1.25] 0.28 Same direction 
rs4986172 17 40571807 T C -0.0283 2.333E-16  T C 0.97 [0.87-1.08] 0.29 Same direction 
rs9456307 6 158849430 A T -0.0499 2.239E-09  A T 0.98 [0.78-1.22] 0.42 Same direction 
rs572169 3 173648421 T C 0.0355 2.765E-18  T C 1.02 [0.84-1.24] 0.42 Same direction 
rs2110001 7 150147955 C G -0.0328 3.319E-13 
 
G C 0.99 [0.88-1.1] 0.61 
Opposite direction (1-tailed P-value 
adjusted accordingly) 
rs8052560 16 87304743 A C 0.0392 3.324E-08 
 
C A 1.08 [0.95-1.23] 0.89 
Opposite direction (1-tailed P-value 
adjusted accordingly) 
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Supplementary Table 3. Family-based association results for the 180 confirmed height SNPs in the Framingham Heart Study 
(FHS) and the Erasmus Rucphen Family (ERF) study. For each study, and the meta-analysis FHS+ERF, we compare the direction 
of effect observed with respect to the effect of the height-increasing allele in the GIANT meta-analysis. 
 
SNP 
GIANT meta-analysis  FHS (family-based test)  ERF (family-based test)  
Meta-analysis FHS+ERF 
(family-based test) 
Height 
Increasing 
allele 
BETA P-value   
Direction of 
effect relative 
to GIANT 
P-value 
BETA 
relative to 
GIANT 
  
Direction of 
effect relative 
to GIANT 
P-value   
Direction of 
effect relative 
to GIANT 
P-value 
rs724016 G 0.067 4.5E-52  Same 0.02 0.066  Same 0.61  Same 0.02 
rs143384 G 0.064 4.9E-39  Same 3.5E-03 0.081  Same 0.65  Same 4.8E-03 
rs1351394 T 0.054 7.8E-34  Same 1.3E-03 0.089  Same 0.73  Same 2.3E-03 
rs7689420 C 0.069 1.4E-29  Same 0.06 0.068  Same 0.03  Same 0.01 
rs42235 T 0.055 7.3E-28  Opposite 0.91 -0.003  Opposite 0.85  Opposite 0.85 
rs6449353 T 0.071 1.3E-27  Same 0.04 0.070  Same 0.43  Same 0.03 
rs806794 A 0.053 5.5E-26  Same 1.7E-03 0.106  Same 0.02  Same 1.2E-04 
rs3118905 G 0.052 3.0E-25  Same 0.36 0.027  Same 0.57  Same 0.28 
rs798489 C 0.052 8.5E-25  Same 0.09 0.052  Same 0.04  Same 0.02 
rs11107116 T 0.052 1.7E-23  Same 0.05 0.065  Same 0.33  Same 0.03 
rs1046934 C 0.046 6.4E-22  Same 0.03 0.062  Same 0.89  Same 0.05 
rs11259936 C 0.042 2.2E-21  Same 0.06 0.053  Same 0.90  Same 0.09 
rs3791675 C 0.050 2.4E-20  Same 0.67 0.014  Same 0.25  Same 0.38 
rs7763064 G 0.045 6.4E-19  Same 0.43 0.023  Same 0.23  Same 0.22 
rs2780226 C 0.079 1.0E-18  Same 6.4E-04 0.171  Same 0.02  Same 4.9E-05 
rs11205277 G 0.045 1.2E-18  Same 0.12 0.043  Same 2.0E-03  Same 0.01 
rs7759938 C 0.042 8.7E-18  Same 0.15 0.041  Same 0.65  Same 0.13 
rs16942341 C 0.134 1.3E-17  Same 2.5E-03 0.236  Same 0.59  Same 3.1E-03 
rs1708299 A 0.042 1.5E-17  Same 4.5E-03 0.090  Same 0.29  Same 2.6E-03 
rs4800452 T 0.048 2.4E-17  Same 0.01 0.082  Same 0.49  Same 0.01 
rs6470764 C 0.047 5.9E-17  Same 0.22 0.041  Same 0.87  Same 0.24 
rs2079795 T 0.040 1.2E-16  Same 0.09 0.049  Same 0.69  Same 0.09 
rs9967417 G 0.038 2.6E-16  Same 0.22 0.031  Same 0.67  Same 0.20 
rs1490384 T 0.037 3.2E-16  Same 0.03 0.060  Opposite 0.45  Same 0.10 
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SNP 
GIANT meta-analysis  FHS (family-based test)  ERF (family-based test)  
Meta-analysis FHS+ERF 
(family-based test) 
Height 
Increasing 
allele 
BETA P-value   
Direction of 
effect relative 
to GIANT 
P-value 
BETA 
relative to 
GIANT 
  
Direction of 
effect relative 
to GIANT 
P-value   
Direction of 
effect relative 
to GIANT 
P-value 
rs2145272 G 0.039 5.9E-16  Same 0.01 0.069  Same 0.88  Same 0.02 
rs3812163 T 0.037 6.7E-16  Same 0.80 0.007  Same 0.18  Same 0.42 
rs3764419 C 0.037 8.9E-16  Same 0.09 0.046  Same 0.49  Same 0.07 
rs7460090 T 0.055 9.6E-16  Opposite 0.96 -0.002  Same 0.19  Same 0.60 
rs788867 G 0.039 1.8E-15  Same 0.56 0.017  Same 0.36  Same 0.36 
rs1173727 T 0.036 4.0E-15  Same 0.03 0.058  Same 0.40  Same 0.02 
rs2284746 G 0.035 5.6E-15  Same 0.69 0.011  Same 0.09  Same 0.28 
rs7466269 A 0.036 1.2E-14  Same 0.20 0.036  Same 0.05  Same 0.04 
rs473902 T 0.074 1.7E-14  Same 0.26 0.056  Same 0.83  Same 0.26 
rs2256183 A 0.035 2.7E-14  Same 0.79 0.008  Opposite 0.94  Same 0.84 
rs17346452 C 0.038 3.3E-14  Same 0.92 0.003  Same 0.21  Same 0.52 
rs7274811 G 0.040 6.8E-14  Same 0.01 0.080  Same 0.42  Same 0.01 
rs2638953 C 0.036 8.4E-14  Same 0.07 0.056  Opposite 0.97  Same 0.11 
rs572169 T 0.036 9.9E-14  Same 0.60 0.015  Same 0.03  Same 0.17 
rs4665736 T 0.034 1.4E-13  Same 0.28 0.030  Same 0.11  Same 0.09 
rs4965598 C 0.035 1.4E-13  Same 0.02 0.069  Same 0.52  Same 0.02 
rs2665838 G 0.037 2.0E-13  Same 0.09 0.051  Same 0.40  Same 0.06 
rs9428104 G 0.038 8.9E-13  Same 0.06 0.057  Opposite 0.19  Same 0.27 
rs2871865 C 0.054 1.1E-12  Same 0.10 0.074  Same 0.08  Same 0.02 
rs17511102 T 0.060 1.3E-12  Same 0.23 0.062  Same 0.50  Same 0.17 
rs2580816 C 0.041 1.8E-12  Same 0.37 0.031  Opposite 0.67  Same 0.54 
rs2093210 C 0.034 2.3E-12  Same 0.20 0.036  Same 0.07  Same 0.05 
rs12982744 G 0.033 2.8E-12  Same 0.69 0.012  Opposite 0.46  Same 0.97 
rs6569648 C 0.036 8.9E-12  Same 0.06 0.058  Same 0.46  Same 0.04 
rs6457821 C 0.121 1.8E-11  Opposite 0.93 -0.009  Same 0.26  Same 0.69 
rs6684205 G 0.033 2.0E-11  Same 0.47 0.021  Same 0.08  Same 0.16 
rs7849585 T 0.032 3.4E-11  Opposite 0.91 -0.003  Same 0.19  Same 0.64 
rs310405 A 0.030 3.6E-11  Opposite 0.81 -0.007  Same 0.16  Same 0.70 
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SNP 
GIANT meta-analysis  FHS (family-based test)  ERF (family-based test)  
Meta-analysis FHS+ERF 
(family-based test) 
Height 
Increasing 
allele 
BETA P-value   
Direction of 
effect relative 
to GIANT 
P-value 
BETA 
relative to 
GIANT 
  
Direction of 
effect relative 
to GIANT 
P-value   
Direction of 
effect relative 
to GIANT 
P-value 
rs10748128 T 0.035 3.8E-11  Opposite 0.65 -0.014  Same 0.35  Same 0.99 
rs1950500 T 0.032 3.9E-11  Same 0.28 0.033  Same 0.29  Same 0.15 
rs10770705 A 0.031 4.6E-11  Opposite 0.29 -0.031  Opposite 0.60  Opposite 0.24 
rs9360921 G 0.048 4.6E-11  Same 0.52 0.029  Opposite 0.65  Same 0.70 
rs12680655 C 0.030 4.8E-11  Opposite 0.50 -0.019  Same 0.39  Opposite 0.82 
rs12470505 T 0.048 1.3E-10  Same 0.22 0.053  Same 0.45  Same 0.15 
rs7027110 A 0.034 1.3E-10  Same 0.16 0.046  Opposite 0.81  Same 0.24 
rs2856321 G 0.030 1.5E-10  Same 0.32 0.028  Same 0.56  Same 0.25 
rs720390 A 0.031 1.6E-10  Same 0.10 0.048  Same 0.19  Same 0.04 
rs6473015 C 0.032 1.7E-10  Same 0.55 0.017  Opposite 0.62  Same 0.74 
rs10838801 G 0.031 1.8E-10  Same 0.01 0.075  Same 0.04  Same 1.7E-03 
rs5742915 C 0.031 3.0E-10  Same 0.05 0.059  Same 0.25  Same 0.02 
rs4282339 G 0.035 3.4E-10  Same 0.34 0.032  Same 0.75  Same 0.32 
rs2154319 C 0.034 4.3E-10  Same 0.27 0.035  Same 0.01  Same 0.03 
rs7319045 A 0.029 4.5E-10  Same 0.01 0.078  Same 0.57  Same 0.01 
rs889014 C 0.029 4.5E-10  Same 0.38 0.025  Same 0.70  Same 0.34 
rs6879260 C 0.028 5.6E-10  Same 0.99 0.000  Same 0.13  Same 0.50 
rs9969804 A 0.028 5.6E-10  Same 0.47 0.021  Opposite 0.71  Same 0.62 
rs237743 A 0.034 7.2E-10  Same 0.24 0.041  Same 0.05  Same 0.06 
rs6439167 C 0.034 7.2E-10  Same 0.12 0.049  Same 0.73  Same 0.12 
rs274546 G 0.028 8.5E-10  Same 0.01 0.066  Opposite 0.41  Same 0.07 
rs12153391 C 0.033 8.7E-10  Same 0.55 0.018  Same 0.15  Same 0.25 
rs7155279 G 0.029 8.9E-10  Opposite 0.74 -0.009  Same 0.53  Opposite 0.98 
rs2110001 G 0.033 9.8E-10  Same 0.15 0.042  Same 0.03  Same 0.03 
rs422421 C 0.033 1.4E-09  Same 9.0E-05 0.126  Same 0.05  Same 1.2E-05 
rs543650 G 0.032 1.4E-09  Same 0.27 0.037  Same 0.51  Same 0.20 
rs634552 T 0.041 1.4E-09  Same 0.74 0.014  Opposite 0.10  Opposite 0.68 
rs11144688 G 0.055 1.5E-09  Same 0.63 0.022  Same 0.34  Same 0.40 
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SNP 
GIANT meta-analysis  FHS (family-based test)  ERF (family-based test)  
Meta-analysis FHS+ERF 
(family-based test) 
Height 
Increasing 
allele 
BETA P-value   
Direction of 
effect relative 
to GIANT 
P-value 
BETA 
relative to 
GIANT 
  
Direction of 
effect relative 
to GIANT 
P-value   
Direction of 
effect relative 
to GIANT 
P-value 
rs526896 T 0.032 1.9E-09  Same 0.97 0.001  Opposite 0.37  Opposite 0.72 
rs1809889 T 0.032 1.9E-09  Opposite 0.48 -0.023  Same 0.10  Same 0.92 
rs11118346 C 0.026 2.2E-09  Same 0.04 0.057  Same 0.68  Same 0.04 
rs17318596 A 0.029 3.0E-09  Same 0.72 0.010  Opposite 0.62  Same 0.92 
rs10037512 T 0.027 3.8E-09  Same 0.06 0.051  Same 0.73  Same 0.07 
rs3782089 C 0.058 5.9E-09  Same 0.99 0.001  Same 0.57  Same 0.80 
rs11684404 C 0.027 6.4E-09  Same 0.20 0.038  Same 0.36  Same 0.12 
rs4986172 C 0.028 7.1E-09  Same 0.35 0.026  Opposite 0.12  Same 0.88 
rs2834442 A 0.027 7.3E-09  Same 0.08 0.049  Opposite 0.82  Same 0.13 
rs11958779 G 0.028 8.0E-09  Opposite 0.80 -0.008  Opposite 0.80  Opposite 0.73 
rs2066807 G 0.052 9.6E-09  Same 0.03 0.129  Opposite 0.44  Same 0.10 
rs10799445 A 0.031 1.2E-08  Same 0.51 0.021  Opposite 0.50  Same 0.77 
rs227724 T 0.027 1.2E-08  Same 0.15 0.043  Opposite 0.87  Same 0.23 
rs8052560 A 0.039 1.4E-08  Same 0.01 0.031  Opposite 0.34  Same 0.06 
rs9863706 C 0.030 1.5E-08  Same 0.01 0.086  Opposite 0.57  Same 0.03 
rs1325598 G 0.026 1.6E-08  Same 0.03 0.058  Same 0.62  Same 0.03 
rs1582931 G 0.025 2.1E-08  Same 0.01 0.074  Same 0.38  Same 0.01 
rs2629046 T 0.025 2.2E-08  Same 0.64 0.013  Same 0.62  Same 0.52 
rs9472414 T 0.031 2.4E-08  Same 0.33 0.094  Same 0.48  Same 0.24 
rs2145998 T 0.025 2.7E-08  Same 0.35 0.027  Opposite 0.80  Same 0.46 
rs2237886 T 0.043 3.1E-08  Same 0.02 0.117  Same 0.52  Same 0.02 
rs9844666 G 0.028 3.1E-08  Same 0.25 0.037  Opposite 0.25  Same 0.60 
rs3129109 C 0.026 3.3E-08  Opposite 0.43 -0.022  Opposite 0.72  Opposite 0.38 
rs10152591 A 0.045 3.5E-08  Same 0.20 0.063  Same 0.10  Same 0.06 
rs1741344 C 0.026 3.5E-08  Same 0.05 0.057  Same 0.26  Same 0.02 
rs2336725 C 0.026 3.5E-08  Same 0.05 0.051  Same 0.63  Same 0.05 
rs26868 A 0.030 3.5E-08  Same 0.79 0.008  Same 0.58  Same 0.63 
rs2341459 T 0.028 3.6E-08  Same 0.12 0.050  Opposite 0.82  Same 0.19 
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SNP 
GIANT meta-analysis  FHS (family-based test)  ERF (family-based test)  
Meta-analysis FHS+ERF 
(family-based test) 
Height 
Increasing 
allele 
BETA P-value   
Direction of 
effect relative 
to GIANT 
P-value 
BETA 
relative to 
GIANT 
  
Direction of 
effect relative 
to GIANT 
P-value   
Direction of 
effect relative 
to GIANT 
P-value 
rs6457620 G 0.024 3.6E-08  Same 0.93 0.003  Opposite 0.69  Opposite 0.93 
rs4470914 T 0.033 3.8E-08  Same 1.00 0.000  Same 1.00  Same 1.00 
rs17780086 A 0.035 4.4E-08  Same 0.31 0.041  Opposite 0.97  Same 0.36 
rs1013209 C 0.029 4.5E-08  Opposite 0.74 -0.011  Opposite 0.94  Opposite 0.74 
rs751543 T 0.029 4.5E-08  Same 0.95 0.002  Opposite 0.02  Opposite 0.32 
rs17081935 T 0.031 4.8E-08  Opposite 0.75 -0.011  Same 0.27  Same 0.85 
rs4821083 T 0.033 4.8E-08  Same 0.07 0.063  Same 0.54  Same 0.06 
rs12534093 T 0.030 5.6E-08  Same 0.59 0.018  Opposite 0.97  Same 0.64 
rs2072153 C 0.026 6.7E-08  Same 0.41 0.026  Same 0.42  Same 0.27 
rs7567288 C 0.031 6.7E-08  Opposite 0.93 -0.003  Same 0.90  Opposite 0.98 
rs2247341 A 0.025 6.8E-08  Same 0.42 0.022  Same 0.12  Same 0.16 
rs7926971 G 0.024 7.3E-08  Same 1.6E-03 0.082  Opposite 0.04  Same 0.05 
rs7332115 G 0.025 7.6E-08  Same 0.24 0.033  Same 0.15  Same 0.09 
rs1047014 C 0.029 1.1E-07  Same 0.41 0.028  Opposite 0.49  Same 0.66 
rs17806888 T 0.040 1.1E-07  Opposite 0.04 0.077  Same 0.42  Same 0.03 
rs2597513 C 0.039 1.1E-07  Same 0.08 0.078  Same 0.45  Same 0.06 
rs7971536 T 0.025 1.1E-07  Same 0.17 0.036  Same 0.72  Same 0.17 
rs8181166 C 0.025 1.1E-07  Opposite 0.35 -0.025  Opposite 0.82  Opposite 0.35 
rs822552 G 0.030 1.3E-07  Opposite 0.44 -0.025  Opposite 0.95  Opposite 0.47 
rs12694997 G 0.027 1.8E-07  Same 0.05 0.063  Opposite 0.20  Same 0.22 
rs4640244 A 0.028 2.0E-07  Opposite 0.67 0.013  Same 0.05  Same 0.21 
rs7178424 C 0.024 2.2E-07  Same 0.02 0.067  Opposite 0.29  Same 0.10 
rs7507204 C 0.028 2.3E-07  Same 0.05 0.071  Same 0.51  Same 0.04 
rs11648796 G 0.031 2.4E-07  NA 1.00 NA  Same 0.65  Same 0.65 
rs2279008 T 0.031 2.4E-07  Same 0.44 0.027  Same 0.15  Same 0.18 
rs961764 G 0.023 2.4E-07  Same 0.16 0.038  Same 0.48  Same 0.11 
rs4072910 G 0.029 2.5E-07  NA 1.00 NA  Same 0.49  Same 0.49 
rs13088462 C 0.054 3.1E-07  Same 0.96 0.003  Opposite 0.66  Opposite 0.88 
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SNP 
GIANT meta-analysis  FHS (family-based test)  ERF (family-based test)  
Meta-analysis FHS+ERF 
(family-based test) 
Height 
Increasing 
allele 
BETA P-value   
Direction of 
effect relative 
to GIANT 
P-value 
BETA 
relative to 
GIANT 
  
Direction of 
effect relative 
to GIANT 
P-value   
Direction of 
effect relative 
to GIANT 
P-value 
rs2778031 T 0.027 3.6E-07  Same 0.04 0.066  Same 0.59  Same 0.04 
rs1351164 T 0.028 3.7E-07  Same 0.78 0.010  Same 0.96  Same 0.78 
rs1330 T 0.024 4.4E-07  Opposite 0.49 -0.018  Same 0.58  Opposite 0.70 
rs9456307 T 0.050 4.6E-07  Opposite 0.56 -0.032  Same 0.94  Opposite 0.62 
rs11867479 T 0.024 4.9E-07  Same 0.07 0.051  Same 0.95  Same 0.10 
rs7864648 T 0.025 4.9E-07  Opposite 0.67 -0.013  Same 0.44  Opposite 0.97 
rs17391694 T 0.040 5.9E-07  Opposite 0.43 -0.042  Same 0.51  Opposite 0.67 
rs10863936 G 0.022 6.2E-07  Same 0.02 0.060  Opposite 0.90  Same 0.05 
rs654723 A 0.024 6.7E-07  Same 0.38 0.024  Opposite 0.86  Same 0.48 
rs7567851 C 0.041 7.5E-07  Same 0.32 0.046  Opposite 0.93  Same 0.40 
rs11599750 C 0.023 7.6E-07  Same 0.38 0.025  Same 0.18  Same 0.17 
rs7112925 C 0.023 8.5E-07  Same 0.23 0.034  Same 0.08  Same 0.06 
rs1046943 A 0.022 8.6E-07  Same 0.42 0.023  Same 0.28  Same 0.23 
rs9835332 G 0.022 8.7E-07  Same 0.13 0.038  Same 0.29  Same 0.07 
rs4605213 C 0.023 9.3E-07  Opposite 0.73 -0.011  Same 0.49  Opposite 0.99 
rs12474201 A 0.023 1.0E-06  Same 0.38 0.025  Opposite 0.37  Same 0.69 
rs862034 G 0.023 1.1E-06  Same 0.05 0.059  Same 0.43  Same 0.03 
rs1043515 G 0.022 1.3E-06  Same 0.15 0.039  Same 0.05  Same 0.03 
rs7697556 T 0.022 1.3E-06  Same 0.02 0.063  Opposite 0.62  Same 0.07 
rs7909670 C 0.022 1.3E-06  Opposite 0.77 -0.008  Same 0.71  Opposite 0.92 
rs1468758 C 0.026 1.5E-06  Same 0.76 0.009  Opposite 0.88  Same 0.84 
rs3110496 G 0.023 1.6E-06  Same 0.01 0.078  Same 0.12  Same 0.00 
rs10874746 C 0.022 1.7E-06  Opposite 0.29 -0.030  Same 0.03  Opposite 0.98 
rs12902421 C 0.069 1.7E-06  Same 0.11 0.145  Opposite 0.45  Same 0.27 
rs425277 T 0.024 1.7E-06  Same 0.09 0.052  Same 0.99  Same 0.13 
rs6699417 T 0.022 1.7E-06  Same 0.85 0.006  Opposite 0.51  Opposite 0.91 
rs891088 G 0.025 1.7E-06  Opposite 0.70 -0.012  Same 0.48  Opposite 0.96 
rs1738475 C 0.022 1.9E-06  Same 0.24 0.030  Opposite 0.90  Same 0.32 
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SNP 
GIANT meta-analysis  FHS (family-based test)  ERF (family-based test)  
Meta-analysis FHS+ERF 
(family-based test) 
Height 
Increasing 
allele 
BETA P-value   
Direction of 
effect relative 
to GIANT 
P-value 
BETA 
relative to 
GIANT 
  
Direction of 
effect relative 
to GIANT 
P-value   
Direction of 
effect relative 
to GIANT 
P-value 
rs4601530 C 0.024 2.0E-06  Opposite 0.79 -0.008  Same 0.69  Opposite 0.95 
rs6714546 G 0.025 2.2E-06  Same 0.16 0.045  Opposite 0.78  Same 0.25 
rs955748 G 0.024 2.2E-06  Same 0.57 0.018  Opposite 0.59  Same 0.78 
rs10010325 A 0.021 2.3E-06  Same 0.45 0.019  Same 0.33  Same 0.27 
rs1257763 A 0.069 2.5E-06  Same 0.02 0.150  Opposite 0.71  Same 0.05 
rs16964211 G 0.051 2.5E-06  Same 0.94 0.005  Opposite 0.14  Opposite 0.57 
rs1814175 T 0.023 2.6E-06  Same 0.43 0.023  Same 0.01  Same 0.07 
rs6959212 C 0.023 2.8E-06  Same 0.60 0.014  Same 0.19  Same 0.30 
rs1659127 A 0.024 2.9E-06  Opposite 0.41 -0.023  Opposite 0.16  Opposite 0.17 
rs7853377 G 0.026 3.1E-06  Same 0.90 0.004  Opposite 0.92  Same 0.94 
rs7532866 A 0.022 3.3E-06  Same 0.24 0.033  Opposite 0.78  Same 0.35 
rs17782313 C 0.025 3.5E-06  Opposite 0.60 -0.017  Same 0.28  Same 1.00 
rs13177718 C 0.041 4.1E-06  Opposite 0.51 -0.033  Opposite 0.70  Opposite 0.45 
rs5017948 A 0.027 4.7E-06  Same 8.9E-04 0.126  Same 0.07  Same 1.6E-04 
rs1570106 C 0.026 4.9E-06  Same 0.59 0.019  Opposite 0.14  Opposite 0.87 
rs494459 T 0.021 4.9E-06  Opposite 0.14 -0.040  Same 0.10  Opposite 0.56 
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Supplementary Table 4. Estimated number of height loci for each of the effect 
sizes observed in Stage 2 given the power to detect the association in Stage 1. 
 
 SNP MAF 
Mean 
Difference 
Standardized 
Effect size 
Power 
Estimated 
number of loci
†
 
1 rs1325598 0.435 -0.016 1.18E-04 0.0151 74.5 
2 rs9472414 0.217 -0.019 1.21E-04 0.0169 63.4 
3 rs7155279 0.356 -0.016 1.22E-04 0.0171 62.3 
4 rs1741344 0.375 0.016 1.23E-04 0.0178 59.3 
5 rs1013209 0.252 -0.019 1.30E-04 0.0226 47.6 
6 rs12470505 0.095 -0.028 1.35E-04 0.0263 41.5 
7 rs6684205 0.294 0.019 1.45E-04 0.0350 30.9 
8 rs2341459 0.279 0.020 1.53E-04 0.0434 24.6 
9 rs4470914 0.178 0.023 1.53E-04 0.0436 24.5 
10 rs6457821 0.018 -0.068 1.65E-04 0.0587 17.7 
11 rs751543 0.275 -0.021 1.68E-04 0.0619 16.9 
12 rs10838801 0.307 0.020 1.70E-04 0.0655 15.9 
13 rs7319045 0.403 0.019 1.72E-04 0.0681 15.2 
14 rs1582931 0.480 -0.019 1.82E-04 0.0848 12.2 
15 rs4821083 0.151 -0.027 1.91E-04 0.1018 10.1 
16 rs10152591 0.091 -0.034 1.93E-04 0.1044 9.8 
17 rs310405 0.478 -0.020 2.00E-04 0.1185 8.7 
18 rs6473015 0.274 0.023 2.10E-04 0.1426 7.3 
19 rs9360921 0.113 0.033 2.15E-04 0.1529 6.7 
20 rs12153391 0.250 -0.024 2.18E-04 0.1611 6.3 
21 rs4665736 0.455 -0.021 2.21E-04 0.1681 6.0 
22 rs7027110 0.230 0.025 2.21E-04 0.1692 6.0 
23 rs2154319 0.244 0.025 2.27E-04 0.1839 5.5 
24 rs17081935 0.203 0.028 2.48E-04 0.2444 4.2 
25 rs11118346 0.477 -0.023 2.57E-04 0.2721 3.7 
26 rs7849585 0.333 0.024 2.58E-04 0.2750 3.7 
27 rs2629046 0.440 -0.023 2.63E-04 0.2906 3.5 
28 rs422421 0.216 -0.028 2.64E-04 0.2927 3.5 
29 rs2834442 0.343 -0.024 2.68E-04 0.3079 3.3 
30 rs12680655 0.413 -0.024 2.75E-04 0.3286 3.1 
31 rs7466269 0.370 -0.024 2.78E-04 0.3381 3.0 
32 rs2638953 0.318 -0.026 2.82E-04 0.3529 2.9 
33 rs11958779 0.306 0.026 2.90E-04 0.3783 2.7 
34 rs634552 0.146 0.035 2.99E-04 0.4087 2.5 
35 rs11144688 0.106 -0.040 3.03E-04 0.4230 2.4 
36 rs720390 0.387 0.026 3.28E-04 0.5092 2.0 
37 rs526896 0.279 -0.029 3.29E-04 0.5119 2.0 
38 rs2110001 0.319 0.028 3.31E-04 0.5180 2.0 
39 rs12982744 0.389 0.027 3.41E-04 0.5519 1.8 
40 rs473902 0.079 -0.050 3.62E-04 0.6161 1.6 
41 rs3782089 0.060 -0.057 3.67E-04 0.6317 1.6 
42 rs9863706 0.216 -0.033 3.69E-04 0.6374 1.6 
43 rs572169 0.311 0.030 3.73E-04 0.6494 1.5 
44 rs2145998 0.499 0.027 3.75E-04 0.6564 1.5 
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 SNP MAF 
Mean 
Difference 
Standardized 
Effect size 
Power 
Estimated 
number of loci
†
 
45 rs2856321 0.358 0.029 3.76E-04 0.6587 1.5 
46 rs2336725 0.450 0.028 3.85E-04 0.6842 1.5 
47 rs10799445 0.235 -0.033 3.91E-04 0.6998 1.4 
48 rs11684404 0.349 0.029 3.93E-04 0.7038 1.4 
49 rs6439167 0.204 -0.035 3.97E-04 0.7163 1.4 
50 rs1490384 0.499 0.028 3.98E-04 0.7169 1.4 
51 rs11830103 0.213 0.035 4.01E-04 0.7253 1.4 
52 rs2093210 0.405 0.029 4.08E-04 0.7431 1.3 
53 rs2066807 0.070 0.058 4.43E-04 0.8183 1.2 
54 rs2237886 0.099 0.050 4.53E-04 0.8359 1.2 
55 rs4282339 0.203 -0.038 4.57E-04 0.8426 1.2 
56 rs889014 0.360 -0.032 4.72E-04 0.8669 1.2 
57 rs5742915 0.451 0.031 4.73E-04 0.8682 1.2 
58 rs274546 0.406 -0.032 4.88E-04 0.8890 1.1 
59 rs3764419 0.388 -0.032 4.89E-04 0.8910 1.1 
60 rs1173727 0.407 0.032 4.94E-04 0.8974 1.1 
61 rs227724 0.355 0.034 5.29E-04 0.9332 1.1 
62 rs9969804 0.447 0.033 5.52E-04 0.9500 1.1 
63 rs17511102 0.084 0.061 5.64E-04 0.9576 1.1 
64 rs10770705 0.326 0.036 5.66E-04 0.9589 1.0 
65 rs1950500 0.287 0.038 5.79E-04 0.9655 1.0 
66 rs1708299 0.300 0.038 5.91E-04 0.9709 1.0 
67 rs3812163 0.448 0.035 6.13E-04 0.9788 1.0 
68 rs17318596 0.347 0.037 6.27E-04 0.9828 1.0 
69 rs4986172 0.349 -0.037 6.35E-04 0.9848 1.0 
70 rs7274811 0.240 -0.042 6.50E-04 0.9878 1.0 
71 rs543650 0.415 -0.037 6.76E-04 0.9919 1.0 
72 rs2079795 0.322 0.040 6.88E-04 0.9933 1.0 
73 rs6457620 0.482 0.037 6.98E-04 0.9944 1.0 
74 rs2145272 0.346 0.040 7.06E-04 0.9950 1.0 
75 rs9967417 0.409 0.039 7.16E-04 0.9958 1.0 
76 rs798489 0.301 -0.042 7.43E-04 0.9973 1.0 
77 rs2780226 0.081 0.072 7.62E-04 0.9981 1.0 
78 rs26868 0.455 0.040 7.74E-04 0.9984 1.0 
79 rs2871865 0.115 -0.062 7.81E-04 0.9986 1.0 
80 rs17346452 0.269 0.045 7.83E-04 0.9987 1.0 
81 rs2580816 0.183 -0.051 7.91E-04 0.9988 1.0 
82 rs10037512 0.449 -0.040 7.96E-04 0.9989 1.0 
83 rs1046934 0.363 0.042 7.96E-04 0.9989 1.0 
84 rs6569648 0.231 0.047 7.99E-04 0.9990 1.0 
85 rs3129109 0.379 -0.041 8.06E-04 0.9991 1.0 
86 rs10748128 0.351 0.042 8.07E-04 0.9991 1.0 
87 rs9428104 0.241 -0.048 8.39E-04 0.9995 1.0 
88 rs16942341 0.029 -0.124 8.52E-04 0.9996 1.0 
89 rs11107116 0.228 0.050 8.68E-04 0.9997 1.0 
90 rs7460090 0.127 -0.064 9.18E-04 0.9999 1.0 
91 rs237743 0.214 0.053 9.26E-04 0.9999 1.0 
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92 rs6470764 0.189 -0.056 9.72E-04 1.0000 1.0 
93 rs4800452 0.214 -0.056 1.05E-03 1.0000 1.0 
94 rs788867 0.320 0.050 1.07E-03 1.0000 1.0 
95 rs2665838 0.268 0.052 1.07E-03 1.0000 1.0 
96 rs7759938 0.309 0.051 1.10E-03 1.0000 1.0 
97 rs806794 0.315 -0.051 1.10E-03 1.0000 1.0 
98 rs11259936 0.481 -0.047 1.12E-03 1.0000 1.0 
99 rs11205277 0.416 0.048 1.13E-03 1.0000 1.0 
100 rs2284746 0.482 -0.049 1.20E-03 1.0000 1.0 
101 rs7763064 0.291 -0.055 1.23E-03 1.0000 1.0 
102 rs3791675 0.236 -0.059 1.25E-03 1.0000 1.0 
103 rs2256183 0.450 0.051 1.29E-03 1.0000 1.0 
104 rs42235 0.308 0.062 1.62E-03 1.0000 1.0 
105 rs6449353 0.149 -0.081 1.65E-03 1.0000 1.0 
106 rs3118905 0.289 -0.063 1.65E-03 1.0000 1.0 
107 rs7689420 0.165 -0.080 1.76E-03 1.0000 1.0 
108 rs143384 0.435 0.061 1.83E-03 1.0000 1.0 
109 rs1351394 0.496 0.073 2.63E-03 1.0000 1.0 
110 rs724016 0.443 0.075 2.78E-03 1.0000 1.0 
Estimated # of total loci 697.3   
Total phenotypic variance explained (%)    15.7 
Total genotypic variance explained (%)    19.6 
 
† Projections are made only for effect sizes for SNPs that reached P<5x10-8 in Stage 1 
and had at least 1% power. 
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Supplementary Table 5. Dominant, recessive and dominance deviation results for nominally significant (dominance deviation 
P<0.05) lead SNPs at the 207 loci with P<5x10-6 in Stage 1. The effect allele is the height increasing allele from Stage 1. Only 
SNPs with a dominance deviation P<0.05 are presented. The analysis is based on a subset of 103,034 individuals from Stage 1. 
None of the results remain significant at P<0.05 after correcting for the number of tests performed. 
 
SNP 
Effect 
allele 
Other 
Allele 
Additive 
beta (SE) 
Additive 
P 
Dominant beta 
(SE) 
Dominant 
P 
Recessive 
beta (SE) 
Recessive 
P 
Dom Dev 
beta (SE) 
Dom Dev 
P 
rs1047014 C T 0.031 (0.006) 2.2x10
-08
 0.041 (0.006) 9.3x10
-11
 0.017 (0.013) 0.1991 0.026 (0.008) 0.002 
rs17122670 A G 0.032 (0.007) 8.8x10
-06
 0.038 (0.008) 3.6x10
-07
 -0.015 (0.027) 0.5645 0.044 (0.015) 0.003 
rs425277 T C 0.027 (0.005) 7.5x10
-08
 0.023 (0.006) 2.0x10
-04
 0.064 (0.012) 3.0x10
-08
 -0.021 (0.008) 0.005 
rs12982744 G C 0.033 (0.005) 2.0x10
-12
 0.049 (0.007) 9.1x10
-14
 0.029 (0.009) 6.8x10
-04
 0.018 (0.006) 0.006 
rs1257763 A G 0.077 (0.014) 4.0x10
-08
 0.054 (0.012) 1.3x10
-05
 0.358 (0.094) 1.3x10
-04
 -0.132 (0.049) 0.007 
rs2408058 G A 0.035 (0.006) 8.4x10
-09
 0.102 (0.02) 2.5x10
-07
 0.033 (0.007) 2.5x10
-06
 0.031 (0.012) 0.008 
rs1708299 A G 0.046 (0.005) 3.2x10
-22
 0.048 (0.006) 2.0x10
-14
 0.087 (0.01) 6.0x10
-17
 -0.019 (0.007) 0.009 
rs13177718 C T 0.046 (0.009) 1.8x10
-07
 0.164 (0.04) 4.3x10
-05
 0.038 (0.009) 1.6x10
-05
 0.055 (0.022) 0.012 
rs9456307 T A 0.056 (0.01) 1.7x10
-08
 0.221 (0.053) 3.3x10
-05
 0.05 (0.01) 8.5x10
-07
 0.071 (0.028) 0.013 
rs7601531 T C 0.022 (0.005) 2.8x10
-06
 0.041 (0.008) 6.5x10
-07
 0.018 (0.007) 7.0x10
-03
 0.015 (0.006) 0.019 
rs2341459 T C 0.031 (0.005) 7.1x10
-10
 0.041 (0.006) 5.3x10
-11
 0.028 (0.012) 1.9x10
-02
 0.017 (0.008) 0.028 
rs34651 C T 0.057 (0.009) 4.0x10
-11
 0.058 (0.009) 1.5x10
-11
 0.017 (0.038) 0.65 0.044 (0.021) 0.032 
rs1351394 T C 0.059 (0.004) 3.1x10
-40
 0.069 (0.007) 8.6x10
-22
 0.085 (0.007) 1.7x10
-32
 -0.013 (0.006) 0.032 
rs17318596 A G 0.032 (0.005) 3.5x10
-11
 0.043 (0.006) 1.7x10
-11
 0.029 (0.009) 8.4x10
-04
 0.014 (0.007) 0.036 
rs4072910 G C 0.033 (0.006) 6.0x10
-09
 0.051 (0.009) 1.2x10
-08
 0.028 (0.008) 5.1x10
-04
 0.015 (0.007) 0.036 
rs42235 T C 0.065 (0.005) 2.5x10
-38
 0.067 (0.006) 2.5x10
-26
 0.108 (0.011) 3.7x10
-24
 -0.015 (0.007) 0.037 
rs11648796 G A 0.028 (0.006) 2.3x10
-06
 0.034 (0.007) 3.6x10
-07
 0.019 (0.014) 0.1882 0.019 (0.009) 0.040 
rs10799445 A C 0.028 (0.005) 1.0x10
-07
 0.023 (0.014) 9.9x10
-02
 0.037 (0.006) 7.8x10
-09
 -0.018 (0.009) 0.043 
rs822552 G C 0.037 (0.006) 8.1x10
-11
 0.043 (0.006) 1.6x10
-11
 0.034 (0.013) 9.8x10
-03
 0.017 (0.008) 0.044 
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Supplementary Table 6. Nominally significant (P<0.001) results for all pairwise tests between the lead SNPs at 207 loci with 
P<5x10-6 in Stage 1. The betas refer to the height increasing alleles from Stage 1. The additive effect results for each individual 
SNP is based on the Stage 1 meta-analysis. The results for the pairwise interaction analysis are based on a subset of 103,034 
individuals from Stage 1.  
 
Markers 
(SNP1/SNP2) 
Additive effect 
SNP1  
Additive effect 
SNP1 P 
Additive effect 
SNP2 
Additive effect 
SNP2 P 
Pairwise interaction 
beta (SE) 
Interaction P 
rs2145998 rs6470764 0.025 2.7x10
-08
 0.047 5.9x10
-17
 0.036 (0.008) 7.7x10
-06
 
rs1741344 rs4800452 0.026 3.5x10
-08
 0.048 2.4x10
-17
 -0.035 (0.009) 3.8x10
-05
 
rs7853377 rs955748 0.026 3.1x10
-06
 0.024 2.2x10
-06
 0.035 (0.009) 6.1x10
-05
 
rs494459 rs6470764 0.021 4.9x10
-06
 0.047 5.9x10
-17
 -0.032 (0.008) 0.000104 
rs3110496 rs7759938 0.023 1.6x10
-06
 0.042 8.7x10
-18
 -0.028 (0.007) 0.000146 
rs1814175 rs9428104 0.023 2.6x10
-06
 0.038 8.9x10
-13
 -0.030 (0.008) 0.000163 
rs3110496 rs7697556 0.023 1.6x10
-06
 0.022 1.3x10
-06
 0.025 (0.007) 0.000218 
rs143384 rs17346452 0.064 4.9x10
-39
 0.038 3.3x10
-14
 -0.028 (0.008) 0.000231 
rs1351164 rs6684205 0.028 3.7x10
-07
 0.033 2.0x10
-11
 -0.031 (0.009) 0.000356 
rs1013209 rs16942341 0.029 4.5x10
-08
 0.134 1.3x10
-17
 0.095 (0.027) 0.000357 
rs16942341 rs5017948 0.134 1.3x10
-17
 0.027 4.7x10
-06
 0.107 (0.030) 0.00042 
rs2408058 rs6879260 0.035 2.2x10
-08
 0.028 5.6x10
-10
 -0.031 (0.009) 0.000507 
rs806794 rs9428104 0.053 5.5x10
-26
 0.038 8.9x10
-13
 -0.029 (0.008) 0.000535 
rs16892729 rs2154319 0.025 1.3x10
-06
 0.034 4.3x10
-10
 -0.031 (0.009) 0.000591 
rs17081935 rs2110001 0.031 4.8x10
-08
 0.033 9.8x10
-10
 0.032 (0.009) 0.00062 
rs4640244 rs9428104 0.028 2.0x10
-07
 0.038 8.9x10
-13
 -0.030 (0.009) 0.000658 
rs1173727 rs2580816 0.036 4.0x10
-15
 0.041 1.8x10
-12
 0.029 (0.009) 0.000713 
rs1046934 rs17017854 0.046 6.4x10
-22
 0.028 4.0x10
-06
 0.030 (0.009) 0.000817 
rs2154319 rs6772112 0.034 4.3x10
-10
 0.046 1.6x10
-06
 0.054 (0.016) 0.00088 
rs3791675 rs6684205 0.050 2.4x10
-20
 0.033 2.0x10
-11
 0.028 (0.008) 0.000935 
rs3791675 rs7759938 0.050 2.4x10
-20
 0.042 8.7x10
-18
 0.027 (0.008) 0.000972 
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Supplementary Table 7. Height SNPs in linkage disequilibrium (r2 0.8) with non-
synonymous SNPs, using the HapMap phase II CEU data. For each gene, we 
annotated all reported isoforms. 
 
Chr Position 
GIANT 
height SNP 
Non-
synonymous 
SNP 
r
2
 Amino acid change Gene name Gene isoform 
1 148173037 rs11205277 rs11205303 0.89 ATG (Met) => GTG (Val) [exon6] MTMR11 NM_001145862 
1 148173037 rs11205277 rs11205303 0.89 ATG (Met) => GTG (Val) [exon5] MTMR11 NM_181873 
1 182287568 rs1046934 rs2274432 1 GGC (Gly) => GAC (Asp) [exon1] TSEN15 NM_052965 
1 182287568 rs1046934 rs2274432 1 GGC (Gly) => GAC (Asp) [exon1] TSEN15 NM_001127394 
1 182290152 rs1046934 rs1046934 1 CAA (Gln) => CAC (His) [exon2] TSEN15 NM_052965 
1 182290152 rs1046934 rs1046934 1 CAA (Gln) => CAC (His) [exon2] TSEN15 NM_001127394 
2 88656006 rs11684404 rs1805165 0.87 GCT (Ala) => TCT (Ser) [exon13] EIF2AK3 NM_004836 
2 88676238 rs11684404 rs13045 1 CAA (Gln) => CGA (Arg) [exon3] EIF2AK3 NM_004836 
2 88694388 rs11684404 rs867529 0.87 TCC (Ser) => TGC (Cys) [exon2] EIF2AK3 NM_004836 
2 241841521 rs12694997 rs7578199 0.88 AAT (Asn) => AGT (Ser) [exon10] HDLBP NM_005336 
2 241841521 rs12694997 rs7578199 0.88 AAT (Asn) => AGT (Ser) [exon10] HDLBP NM_203346 
3 56603071 rs9835332 rs7637449 0.92 CGA (Arg) => CAA (Gln) [exon10] CCDC66 NM_001141947 
3 56603071 rs9835332 rs7637449 0.92 CGA (Arg) => CAA (Gln) [exon10] CCDC66 NM_001012506 
3 56642722 rs9835332 rs9835332 1 ACA (Thr) => AGA (Arg) [exon11] C3orf63 NM_015224 
3 56642722 rs9835332 rs9835332 1 ACA (Thr) => AGA (Arg) [exon18] C3orf63 NM_001112736 
3 56691962 rs9835332 rs958755 1 CAA (Gln) => CCA (Pro) [exon1] C3orf63 NM_001112736 
4 57492171 rs17081935 rs3796529 1 CCA (Pro) => CTA (Leu) [exon4] REST NM_005612 
5 131690961 rs274546 rs272893 1 ATA (Ile) => ACA (Thr) [exon5] SLC22A4 NM_003059 
5 176450403 rs422421 rs376618 0.87 CCC (Pro) => CTC (Leu) [exon3] FGFR4 NM_022963 
5 176450403 rs422421 rs376618 0.87 CCC (Pro) => CTC (Leu) [exon4] FGFR4 NM_002011 
5 176450403 rs422421 rs376618 0.87 CCC (Pro) => CTC (Leu) [exon4] FGFR4 NM_213647 
6 29071227 rs3129109 rs6456880 0.91 AAG (Lys) => CAG (Gln) [exon7] ZNF311 NM_001010877 
6 34322300 rs2780226 rs1150781 1 GGG (Gly) => GCG (Ala) [exon5] C6orf1 NM_178508 
6 34322300 rs2780226 rs1150781 1 GGG (Gly) => GCG (Ala) [exon5] C6orf1 NM_001008704 
6 34322300 rs2780226 rs1150781 1 GGG (Gly) => GCG (Ala) [exon5] C6orf1 NM_001008703 
6 35531864 rs6457821 rs7761870 1 TCA (Ser) => TTA (Leu) [exon2] FANCE NM_021922 
6 35873021 rs6457821 rs2766597 1 CTG (Leu) => CCG (Pro) [exon1] CLPS NM_001832 
6 109871228 rs1046943 rs1476387 0.96 AGG (Arg) => AGT (Ser) [exon9] SMPD2 NM_003080 
6 109934409 rs1046943 rs2277114 0.87 GTA (Val) => ATA (Ile) [exon35] AKD1 NM_001145128 
9 85807085 rs7853377 rs1982151 0.84 AAT (Asn) => AGT (Ser) [exon3] RMI1 NM_024945 
9 94324803 rs9969804 rs10120210 0.93 CAG (Gln) => CCG (Pro) [exon2] ECM2 NM_001393 
12 28303639 rs2638953 rs11049488 0.91 GCA (Ala) => ACA (Thr) [exon2] CCDC91 NM_018318 
12 55026949 rs2066807 rs2066807 1 ATG (Met) => ATC (Ile) [exon20] STAT2 NM_005419 
15 60046929 rs7178424 rs3784634 0.81 AGG (Arg) => AAG (Lys) [exon27] VPS13C NM_017684 
15 60046929 rs7178424 rs3784634 0.81 AGG (Arg) => AAG (Lys) [exon29] VPS13C NM_020821 
15 60046929 rs7178424 rs3784634 0.81 AGG (Arg) => AAG (Lys) [exon27] VPS13C NM_018080 
15 60046929 rs7178424 rs3784634 0.81 AGG (Arg) => AAG (Lys) [exon29] VPS13C NM_001018088 
15 72123686 rs5742915 rs5742915 1 TTC (Phe) => CTC (Leu) [exon9] PML NM_033238 
15 82373128 rs11259936 rs4842838 1 GTG (Val) => TTG (Leu) [exon16] ADAMTSL3 NM_207517 
19 46595060 rs17318596 rs10853751 0.80 ACG (Thr) => ATG (Met) [exon1] EXOSC5 NM_020158 
19 46624115 rs17318596 rs284662 0.80 AGC (Ser) => GGC (Gly) [exon3] B3GNT8 NM_198540 
20 47275067 rs237743 rs11908296 0.97 GGA (Gly) => GTA (Val) [exon6] DDX27 NM_017895 
20 47299191 rs237743 rs6512577 1 ATG (Met) => ATA (Ile) [exon14] ZNFX1 NM_021035 
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Supplementary Table 8. GIANT height variants associated with other traits and diseases reported in the NHGRI catalog of 
published GWAS at genome-wide level of significance (P<5x10-8), based on a 1 megabase maximum distance and linkage 
disequilibrium (r2>0.1) between the SNPs. Highlighted rows are those for which the GIANT height SNP and the NHGRI SNP 
showed a strong correlation (r2>0.8).  
 
GIANT 
height SNP 
Chr Position 
Nearest or 
OMIM gene 
GWAS SNP 
from 
NHGRI 
catalogue 
GIANT height 
P-value for 
NHGRI SNP 
Disease/Trait 
r
2 
D' 
Distance 
(kb) Height-
increasing 
allele 
Effect relative to 
height-increasing 
allele 
Reference 
between GIANT height 
and NHGRI SNP 
rs11118346 1 217810342 LYPLAL1 rs2605100 1.42E-03 WHR (women) 0.17 0.69 99.495 A lower WHR Lindgren et al., PLoS Genet 2009 
rs720390 3 187031377 IGF2BP2 rs4402960 6.30E-01 Type 2 diabetes 0.48 0.86 36.996 T higher T2D risk Saxena et al., Science 2007 
    rs4402960 6.30E-01 Type 2 diabetes 0.48 0.86 36.996 T higher T2D risk Scott et al., Science 2007 
    rs6769511 6.45E-01 Type 2 diabetes 0.48 0.86 18.393 C higher T2D risk Unoki et al., Nat Genet 2008 
    rs4402960 6.30E-01 Type 2 diabetes 0.48 0.86 36.996 T higher T2D risk Zeggini et al., Science 2007 
rs10010325 4 106325802 TET2 rs7679673 2.12E-01 Prostate cancer 0.12 0.37 44.819 A higher cancer risk Eeles et al., Nat Genet 2009 
rs10037512 5 88390431 MEF2C rs1366594 4.98E-09 BMD (hip) 0.97 1 21.386 A lower BMD Rivadeneira et al., Nat Genet 2009 
rs274546 5 131727766 SLC22A5 rs2188962 5.46E-07 Crohn's disease 0.42 1 70.938 T higher Crohn's risk Barrett et al., Nat Genet 2008 
    rs2522056 6.55E-04 Fibrinogen 0.21 0.81 101.859 G lower fibrinogen 
Dehghan et al., Circ Cardiovasc 
Genet 2009 
    rs1016988 1.34E-03 Fibrinogen 0.17 0.87 44.707 T lower fibrinogen 
Danik et al., Circ Cardiovasc Genet 
2009 
    rs4143832 1.40E-01 
Plasma eosinophil 
count 
0.12 0.61 163.11 G 
higher eosinophil 
count 
Gudbjartsson et al., Nat Genet 2009 
rs2256183 6 31488508 MICA rs2844479 9.64E-10 Weight 0.12 0.46 192.427 A increased weight Thorleifsson et al., Nat Genet 2008 
rs6457620 6 32771977 HLA locus rs2187668 8.87E-03 Celiac disease 0.10 1 58.115 T higher Celiac risk van Heel et al., Nat Genet 2007 
    rs9271366 7.17E-06 Multiple sclerosis 0.35 1 77.145 G higher MS risk Bahlo et al., Nat Genet 2009 
    rs6457617 6.89E-08 Rheumatoid arthritis 1 1 0.148 C lower RA risk Julia et al., Arthritis Rheum 2008 
    rs6457617 6.89E-08 Rheumatoid arthritis 1 1 0.148 C lower RA risk WTCCC, Nature 2007 
    same SNP 3.65E-08 Rheumatoid arthritis - - - G n/a 
Raychaudhuri et al., Nat Genet 
2008 
    rs660895 4.65E-01 Rheumatoid arthritis 0.40 1 86.619 A lower RA risk Plenge et al., N Engl J Med 2007 
    rs2187668 8.87E-03 SLE 0.10 1 58.115 T higher SLE risk Hom et al., N Engl J Med 2008 
    rs9272346 6.12E-01 Type 1 diabetes 0.18 0.47 59.627 G higher T1D risk WTCCC, Nature 2007 
    rs9272346 6.12E-01 Type 1 diabetes 0.18 0.47 59.627 G higher T1D risk Cooper et al., Nat Genet 2008 
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GIANT 
height SNP 
Chr Position 
Nearest or 
OMIM gene 
GWAS SNP 
from 
NHGRI 
catalogue 
GIANT height 
P-value for 
NHGRI SNP 
Disease/Trait 
r
2 
D' 
Distance 
(kb) Height-
increasing 
allele 
Effect relative to 
height-increasing 
allele 
Reference 
between GIANT height 
and NHGRI SNP 
    rs2395185 6.38E-01 Ulcerative colitis 0.22 0.59 230.832 T lower UC risk Silverberg et al., Nat Genet 2009 
    rs9268877 2.80E-01 Ulcerative colitis 0.12 0.39 232.852 G lower UC risk Franke et al., Nat Genet 2008 
    rs2395185 6.38E-01 Ulcerative colitis 0.22 0.59 230.832 T lower UC risk Asano et al., Nat Genet 2009 
    rs9268877 2.80E-01 Ulcerative colitis 0.12 0.39 232.852 G n/a Barrett et al., Nat Genet 2009 
rs7759938 6 105485647 LIN28B rs314276 1.03E-16 
Menarche (age at 
onset) 
0.96 1 29.045 A later menarche Ong et al., Nat Genet 2009 
    rs314280 1.35E-10 
Menarche (age at 
onset) 
0.52 1 21.883 A later menarche Sulem et al., Nat Genet 2009 
    same SNP 8.69E-18 
Menarche (age at 
onset) 
- - - C later menarche Perry et al., Nat Genet 2009 
    rs314277 3.65E-12 
Menarche (age at 
onset) 
0.25 1 28.708 A later menarche He et al., Nat Genet 2009 
rs1490384 6 126892853 C6orf173 rs9388489 1.03E-13 Type 1 diabetes 0.84 1 152.441 G higher T1D risk Barrett et al., Nat Genet 2009 
rs7763064 6 142838982 GPR126 rs3817928 1.97E-11 Pulmonary function 0.59 0.89 46.773 A 
reduced pulmonary 
function 
Hancock et al., Nat Genet 2009 
rs1708299 7 28156471 JAZF1 rs864745 1.31E-12 Type 2 diabetes 0.40 0.94 9.39 T higher T2D risk Zeggini et al., Nat Genet 2008 
rs6959212 7 38094851 STARD3NL rs1524058 9.39E-05 BMD (spine) 0.73 1 7.951 C lower BMD Rivadeneira et al., Nat Genet 2009 
rs2110001 7 150147955 KCNH2 rs2968863 1.33E-04 QT interval 0.10 0.85 106.115 C longer QT interval Pfeufer et al., Nat Genet 2009 
    rs3807375 4.30E-05 QT interval 0.14 1.00 40.278 T longer QT interval Holm et al., Nat Genet 2010 
rs11599750 10 101795432 CPN1 rs11597390 1.54E-04 Liver enzymes levels 0.51 0.82 55.993 G lower enzyme levels Yuan et al., Am J Hum Genet 2008 
rs1330 11 17272605 KCNJ11 rs5215 6.70E-02 Type 2 diabetes 0.26 0.53 92.601 C higher T2D risk Zeggini et al., Science 2007 
rs494459 11 118079885 DDX6 rs4639966 2.77E-01 SLE 0.22 1 1.156 T lower SLE risk Han et al., Nat Genet 2009 
rs2066807 12 55026949 STAT2 rs2066808 2.75E-08 Psoriasis 1 1 2.709 G lower psoriasis risk Nair et al., Nat Genet 2009 
rs3110496 17 24941897 ANKRD13B rs2138852 5.11E-01 
Mean platelet 
volume 
0.10 0.45 214.422 T 
higher platelet 
volume 
Soranzo et al., Nat Genet 2009 
    rs2138852 5.11E-01 
Mean platelet 
volume 
0.10 0.45 214.422 T 
lower platelet 
volume 
Meisinger et al., Am J Hum Genet 
2008 
rs4986172 17 40571807 ACBD4 rs12946454 3.23E-07 
Systolic blood 
pressure 
0.76 0.94 8.16 A lower systolic b.p. Newton-Cheh et al., Nat Genet 2009 
rs2072153 17 44745013 ZNF652 rs16948048 4.22E-04 
Diastolic blood 
pressure 
0.32 1.00 50.452 A lower diastolic b.p. Newton-Cheh et al., Nat Genet 2009 
rs17782313 18 56002077 MC4R rs12970134 5.52E-04 Body mass index 0.81 0.96 33.653 A higher BMI Thorleifsson et al., Nat Genet 2008 
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GIANT 
height SNP 
Chr Position 
Nearest or 
OMIM gene 
GWAS SNP 
from 
NHGRI 
catalogue 
GIANT height 
P-value for 
NHGRI SNP 
Disease/Trait 
r
2 
D' 
Distance 
(kb) Height-
increasing 
allele 
Effect relative to 
height-increasing 
allele 
Reference 
between GIANT height 
and NHGRI SNP 
    same SNP 3.48E-06 Body mass index - - - C higher BMI Willer et al., Nat Genet 2008 
    same SNP 3.48E-06 Body mass index - - - C higher BMI Loos et al., Nat Genet 2008 
    same SNP 3.48E-06 Obesity - - - C higher obesity risk Meyre et al., Nat Genet 2009 
    rs12970134 5.52E-04 Waist circumference 0.81 0.96 33.653 A lower WC Chambers et al., Nat Genet 2008 
    rs12970134 5.52E-04 Weight 0.81 0.96 33.653 A increased weight Thorleifsson et al., Nat Genet 2008 
rs2834442 21 34612656 KCNE2 rs9982601 4.66E-01 MI (early onset) 0.17 0.66 91.658 C lower MI risk Kathiresan et al., Nat Genet 2009 
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Supplementary Table 9. List of 241 abnormal skeletal/growth genes identified in 
the OMIM database using the following keywords: short stature, overgrowth, 
skeletal dysplasia, brachydactyly, and manually curating the list blind to GIANT 
height results.  
ACAN COL9A3 GJA1 NEU1 SIL1 
ADAMTS10 COMP GLB1 NF1 SLC26A2 
ADAMTS2 CRTAP GLI3 NIPBL SLC29A3 
ADAMTSL2 CTDP1 GNAS NOG SLC2A2 
AGPS CTSK GNPAT NPR2 SLC34A3 
ALG12 CUL4B GNPTAB NSD1 SLC35C1 
ALMS1 CUL7 GPC3 OCRL SLC35D1 
ALPL CYP11B1 GUSB OFD1 SLC37A4 
ANKH CYP19A1 HCCS PAPSS2 SLC39A13 
ARL6 CYP21A2 HESX1 PAX3 SLC4A4 
ARSB CYP27B1 HMGA2 PAX8 SLC6A8 
ARSE DHCR7 HOXD13 PCNT SMARCAL1 
ATP6V0A2 DYM HPRT1 PEX7 SMC1A 
ATP7A EBP HRAS PHEX SMC3 
ATP8B1 EFNB1 HSPG2 PHF6 SMPD1 
ATR EIF2AK3 HYAL1 PITX2 SMS 
ATRX ERCC2 ICK POU1F1 SOS1 
B3GALTL ERCC3 IDUA PQBP1 SOST 
B4GALT7 ESCO2 IFT80 PROP1 SOX3 
BBS1 EVC IGBP1 PTCH1 SPG20 
BBS10 EVC2 IGF1 PTCH2 SRY 
BBS12 EXT1 IGF1R PTEN STAT5B 
BBS2 EXT2 IGF2 PTH1R TAZ 
BBS4 FANCA IHH PTPN11 TBCE 
BBS5 FANCB IKBKG RAB23 TBX1 
BBS7 FANCC JAG1 RAB3GAP1 TBX15 
BBS9 FANCD2 KCNJ2 RAB3GAP2 TCF4 
BMPR1B FANCE KDM5C RAF1 TGFBR1 
BRAF FANCF KIAA1279 RAI1 TGFBR2 
BRCA2 FANCG KRAS RBM28 THRB 
BTK FANCI LBR RECQL4 TNFRSF11B 
BUB1B FANCL LEMD3 RMRP TP63 
C7orf11 FANCM LEPRE1 RNF135 TRAPPC2 
CA2 FBN1 LHX4 ROR2 TRIM32 
CCDC28B FBN2 LIFR RPL11 TRIM37 
CEP290 FGD1 LIG4 RPL35A TRPS1 
CHD7 FGF23 LMNA RPL5 TRPV4 
CHRNG FGFR2 LRP5 RPS17 UBR1 
CHST3 FGFR3 MAP2K1 RPS19 WNT7A 
CLCN5 FLNA MAP2K2 RPS24 WRN 
COL10A1 FLNB MATN3 RPS6KA3 ZBTB16 
COL11A1 FOXC1 MC4R RPS7  
COL11A2 FUCA1 MECP2 RUNX2  
COL1A1 G6PC MGP SBDS  
COL1A2 GALNS MKKS SDHA  
COL2A1 GDF5 MKS1 SECISBP2  
COL5A1 GH1 MMP13 SEMA3E  
COL5A2 GHR MRPS16 SHH  
COL9A1 GHRHR MYCN SHOX  
COL9A2 GHSR NBN SHROOM4  
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Supplementary Table 10. Height SNPs found to be located near or in the 
abnormal skeletal/growth genes identified in the OMIM database.  
 
SNP 
Abnormal 
skeletal/growth 
gene (OMIM) 
The closest gene to 
the height SNP is the 
abnormal 
skeletal/growth gene 
The height SNP is in 
the abnormal 
skeletal/growth gene 
rs16942341 ACAN yes yes 
rs4072910 ADAMTS10 yes no 
rs16964211 CYP19A1 yes yes 
rs9967417 DYM yes yes 
rs11684404 EIF2AK3 yes yes 
rs6457821 FANCE no no 
rs143384 GDF5 yes yes 
rs2665838 GH1 no no 
rs572169 GHSR yes yes 
rs7971536 GNPTAB no no 
rs1351394 HMGA2 yes yes 
rs2871865 IGF1R yes yes 
rs12470505 IHH yes no 
rs17782313 MC4R yes no 
rs227724 NOG yes no 
rs422421 NSD1 no no 
rs473902 PTCH1 yes yes 
rs3764419 RNF135 no no 
rs10874746 RPL5 no no 
rs9472414 RUNX2 no no 
rs10838801 SLC39A13 no no 
 
 Chapter 3 167 
Supplementary Table 11. Nominally significant biological pathways following gene set enrichment analysis of height meta-
analysis. 
 
Database Biological pathway or gene-set 
Original # 
genes in 
gene-set 
# genes in 
gene-set 
analyzed 
by GSEA
§
 
# genes in 
gene set 
<300kb from 
validated 
height SNPs 
Nominal 
GSEA 
P-value 
False 
discovery 
rate (FDR) 
Genes 300 kb or less from validated height SNPs 
KEGG Hedgehog signaling pathway 54 50 9 0.0009 0.0777* 
BMP6, IHH, PTCH1, WNT6, WNT9A, FBXW11, HHIP, 
WNT10A, WNT3A 
KEGG 
Gamma-hexachlorocyclohexane 
degradation 
26 21 2 0.0028 0.0568* DHRS1, LOC283871 
KEGG MAPK signaling pathway 269 243 23 0.0040 0.2796 
ARRB1, CACNB1, CHUK, FGFR3, FGFR4, GNA12, 
MKNK2, MEF2C, MAP3K3, MOS, GADD45B, NF1, 
NFATC4, PPM1A, MAPK9, MAP2K3, RASA2, 
RPS6KA1, TGFB1, TGFB2, TNF, MAP3K14, 
RASGRP3 
KEGG 
Antigen processing and 
presentation 
77 52 16 0.0132 0.3014 
HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOB, HLA-
DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, 
HLA-DRB5, LTA, PSME1, PSME2, TAP1, TAP2 
KEGG TGF-beta signaling pathway 83 80 10 0.0167 0.3131 
AMH, BMP6, ID4, LTBP1, TGFB1, TGFB2, TNF, GDF5, 
CUL1, NOG 
KEGG Type II diabetes mellitus 45 43 9 0.0172 0.2934 
INSR, KCNJ11, PKM2, PRKCD, PRKCZ, MAPK9, 
ABCC8, TNF, SOCS2 
KEGG FC epsilon RI signaling pathway 79 73 8 0.0282 0.3237 CSF2, IL5, IL13, LYN, PRKCD, MAPK9, MAP2K3, TNF 
KEGG Folate biosynthesis 37 36 1 0.0305 0.3549 ATP13A2 
KEGG Citrate cycle TCA cycle 27 26 5 0.0417 0.3464 CS, PC, PCK2, SDHB, SUCLG2 
        
Ingenuity Hepatic Cholestasis 61 57 12 0.0237 1.5076 
ABCC2, CYP27A1, ESR1, FGFR4, INSR, SLC4A2, 
TAP1, TAP2, TNF, MAP3K14, SLCO1B3, SLCO1C1 
Ingenuity VDR/RXR Activation 63 62 6 0.0341 0.6864 CSF2, GTF2B, PPARD, PSMC5, TGFB2, NCOA1 
Ingenuity 
Role of BRCA1 in DNA Damage 
Response 
29 29 4 0.0507 0.4980 BRCA2, FANCC, FANCE, RAD50 
Ingenuity Fc Epsilon RI Signaling 20 17 5 0.0531 0.8701 CSF2, IL5, IL13, LYN, TNF 
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Database Biological pathway or gene-set 
Original # 
genes in 
gene-set 
# genes in 
gene-set 
analyzed 
by GSEA
§
 
# genes in 
gene set 
<300kb from 
validated 
height SNPs 
Nominal 
GSEA 
P-value 
False 
discovery 
rate (FDR) 
Genes 300 kb or less from validated height SNPs 
PANTHER TGF-beta signaling pathway 64 59 8 0.0025 0.1844* 
AMH, BMP3, BMP6, SKI, TGFB1, TGFB2, GDF5, 
DCP1A 
PANTHER Hedgehog signaling pathway 14 14 3 0.0042 0.2033* IHH, PTCH1, FBXW11 
PANTHER Apoptosis signaling pathway 53 49 10 0.0109 0.2250* 
BOK, CMA1, CTSG, GZMH, GZMB, LTA, LTB, 
TNFSF10, MAP3K14, RIPK3 
PANTHER Endothelin signaling pathway 19 19 4 0.0144 0.2319* ADCY3, EDN2, PRKG2, ADCY4 
PANTHER Parkinson disease 43 41 5 0.0171 0.2348* LYN, SEPT2, PSMB3, CUL1, STUB1 
PANTHER B cell activation 24 22 4 0.0223 0.2368* CD79B, NFKBIL1, PRKCD, PRKCZ 
PANTHER 
Nicotinic acetylcholine receptor 
signaling pathway 
42 39 3 0.0453 0.3888 MYO1F, MYO6, MYO9B 
        
PANTHER, 
MF 
Histone 86 31 29 0.0001† 0.0028* 
HIST1H1C, HIST1H1D, HIST1H1E, HIST1H1T, 
HIST1H2AE, HIST1H2AD, HIST1H1A, HIST1H2AC, 
HIST1H2AB, HIST2H2AC, HIST1H3A, HIST1H3D, 
HIST1H3C, HIST1H3E, HIST1H3G, HIST1H3B, 
HIST1H4A, HIST1H4D, HIST1H4F, HIST1H4C, 
HIST1H4H, HIST1H4B, HIST1H4E, HIST1H4G, 
HIST1H3F, H1FX, H1FOO, HIST2H2AB, HIST2H3D 
PANTHER, 
MF 
Extracellular matrix glycoprotein 111 85 16 0.0015 0.1157* 
ACAN, FBLN2, EFEMP1, GPC5, GP9, LTBP1, LTBP2, 
LTBP3, MFAP2, MSLN, FBLN5, EFEMP2, ADAMTSL3, 
HAPLN3, SCUBE3, MPFL 
PANTHER, 
MF 
Annexin 71 64 13 0.0038 0.1821* 
AIF1, FBLN2, EFEMP1, LETM1, LTBP1, LTBP2, 
LTBP3, NUCB2, PRKCD, PKN2, PRKCZ, FBLN5, 
EFEMP2 
PANTHER, 
MF 
Transcription factor 198 127 13 0.0041 0.2089* 
NR2F6, ESR1, NFIC, PPARD, BAT2, YEATS4, 
NCOA1, SCMH1, SFMBT1, MBTD1, GATAD1, 
L3MBTL3, VGLL2 
PANTHER, 
MF 
Exoribonuclease 35 25 7 0.0069 0.2009* 
ISG20, PAN2, EXOSC2, EXOSC5, CNOT6, ISG20L1, 
PNPT1, 
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Database Biological pathway or gene-set 
Original # 
genes in 
gene-set 
# genes in 
gene-set 
analyzed 
by GSEA
§
 
# genes in 
gene set 
<300kb from 
validated 
height SNPs 
Nominal 
GSEA 
P-value 
False 
discovery 
rate (FDR) 
Genes 300 kb or less from validated height SNPs 
PANTHER, 
MF 
Other transcription factor 349 298 30 0.0117 0.3260 
RUNX3, E2F1, E2F2, ETS1, ETV5, ETV6, FLI1, ID4, 
IRF1, MEF2C, ATXN3, NFATC4, NRL, PA2G4, RELA, 
SKI, SNAPC4, STAT2, TEAD1, TEAD3, TBX4, CREB5, 
IRF9, FEV, UTP6, GNPTAB, LIN28, RFXDC1, FOXR1, 
LIN28B 
PANTHER, 
MF 
Metalloprotease 158 133 10 0.0158 0.4290 
CPN1, PAPPA, ADAM7, ADAMTS3, ADAM28, MMP24, 
PMPCA, ADAMDEC1, PAPPA2, ADAMTS10 
PANTHER, 
MF 
Ligase 69 57 5 0.0206 0.3908 CTPS, DCI, SUCLG2, ZMIZ1, GDPD5 
PANTHER, 
MF 
ATP-binding cassette (ABC) 
transporter 
46 34 7 0.0240 0.4536 ABCA3, ABCC2, TAP1, TAP2, ABCB6, RAD50, ABCB8 
PANTHER, 
MF 
Other phosphatase 82 71 8 0.0260 0.3693 
PPAP2A, FIG4, MTMR11, NUDT4, NUDT3, INPP5E, 
ACPL2, LOC283871 
PANTHER, 
MF 
Damaged DNA-binding protein 27 25 3 0.0327 0.3545 BRCA2, RAD50, UTP6 
PANTHER, 
MF 
Other RNA-binding protein 192 151 14 0.0382 0.4413 
CARS, STAU1, SLBP, FUBP1,  FUBP3, IGF2BP3, 
IGF2BP2, CPSF6, HNRPUL1, ANKZF1, BRUNOL5, 
RBM45, ZFAND2B, C14orf21 
PANTHER, 
MF 
Major histocompatibility complex 
antigen 
46 26 14 0.0386 0.3567 
HFE, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-
DOB,HLA-DQA1, HLA-DQA2,HLA-DQB1, HLA-DRA, 
HLA-DRB1, HLA-DRB5, MICA, MICB 
PANTHER, 
MF 
Kinase 30 29 2 0.0518 0.4439 DGKE, DCAKD 
        
GO:0005694 Chromosome 147 111 29 5e-5† 0.0905* 
HIST1H1C, HIST1H1D, HIST1H1E, HIST1H1T, 
HIST1H2AD, HIST1H2BD, HIST1H2BB, HIST1H1A, 
HMGA1, HMGA2, HIST1H2AC, HIST1H2AB, 
HIST2H2AC, HIST1H2BH, HIST1H2BC, HIST2H2BE, 
HIST1H4G, HIST1H3F, H1FX, RAD50, TINF2, CENPO, 
H1FOO, HIST2H2AB, C6orf173, SETD8, CENPP, 
HIST2H2BF, HIST2H3D 
GO:0060389 
Pathway-restricted SMAD protein 
phosphorylation 
14 14 3 0.0001 0.0984* BMP6, TGFB1, TGFB2 
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Database Biological pathway or gene-set 
Original # 
genes in 
gene-set 
# genes in 
gene-set 
analyzed 
by GSEA
§
 
# genes in 
gene set 
<300kb from 
validated 
height SNPs 
Nominal 
GSEA 
P-value 
False 
discovery 
rate (FDR) 
Genes 300 kb or less from validated height SNPs 
GO:0000786 Nucleosome 64 34 21 0.0002 0.0650* 
HIST1H1C, HIST1H1D, HIST1H1E, HIST1H1T, 
HIST1H2AD, HIST1H2BD, HIST1H2BB, HIST1H1A, 
HIST1H2AC, HIST1H2AB, HIST2H2AC, HIST1H2BH, 
HIST1H2BC, HIST2H2BE, HIST1H4G, HIST1H3F, 
H1FX, H1FOO, HIST2H2AB, HIST2H2BF, HIST2H3D 
GO:0006334 Nucleosome assembly 80 47 22 0.0003 0.0966* 
HIST1H1C, HIST1H1D, HIST1H1E, HIST1H1T, 
HIST1H2AD, HIST1H2BD, HIST1H2BB, HIST1H1A, 
NAP1L4, HIST1H2AC, HIST1H2AB, HIST2H2AC, 
HIST1H2BH, HIST1H2BC, HIST2H2BE, HIST1H4G, 
HIST1H3F, H1FX, H1FOO, HIST2H2AB, HIST2H2BF, 
HIST2H3D 
GO:0050680 
Negative regulation of epithelial cell 
proliferation 
22 21 9 0.0006 0.0705* 
RUNX3, CDK6, CDKN1C, PPARD, PTCH1, TGFB1, 
TGFB2, TSC2, TINF2 
GO:0009653 
Anatomical structure 
morphogenesis 
103 94 15 0.0007 0.1567* 
CHUK, RPL10A, NEDD8, PITX1, PKD1, POU5F1, 
PTCH1, WHSC1, LST1, IGF2BP3, IGF2BP2, RCAN3, 
SCMH1, SIX4, WNT3A 
GO:0032147 Activation of protein kinase activity 10 10 3 0.0008 0.0994* INSR, TGFB2, LYK5 
GO:0002474 
Antigen processing and 
presentation of peptide antigen via 
MHC class I 
11 10 3 0.0010 0.0764* HFE, HLA-B, HLA-C 
GO:0000175 3'-5'-exoribonuclease activity 10 10 4 0.0013 0.0679* ISG20, EXOSC2, EXOSC5, PNPT1 
GO:0007259 JAK-STAT cascade 27 26 7 0.0016 0.1300* FGFR3, GH1, IL6ST, PKD1, STAT2, SOCS2, IL31RA 
GO:0003007 Heart morphogenesis 29 28 4 0.0021 0.1520* INSR, PTCH1, TGFB2, ZMIZ 
GO:0030879 Mammary gland development 29 29 5 0.0023 0.1692* BRCA2, IGF1R, PTCH1, TGFB1, WNT3A 
GO:0043560 Insulin receptor substrate binding 12 12 4 0.0024 0.0888* IGF1R, INSR, PRKCD, PRKCZ 
GO:0000421 Autophagic vacuole membrane 13 12 3 0.0026 0.0907* TM9SF1, ATG9A, ATG9B 
GO:0005578 Proteinaceous extracellular matrix 225 198 25 0.0026 0.2502* 
ACAN, ECM2, FBLN2, EFEMP1, GPC5, LOXL1, 
LTBP1, LTBP2, MFAP2, NTN2L, OMD, OGN, TGFB1, 
WNT6, WNT9A, ADAMTS3, FBLN5, MMP24, 
ANGPTL4, ASPN, ADAMTSL3, WNT10A, ADAMTS10, 
WNT3A, HAPLN3 
GO:0007405 Neuroblast proliferation 14 14 3 0.0035 0.1436* ID4, FRS2, HHIP 
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Database Biological pathway or gene-set 
Original # 
genes in 
gene-set 
# genes in 
gene-set 
analyzed 
by GSEA
§
 
# genes in 
gene set 
<300kb from 
validated 
height SNPs 
Nominal 
GSEA 
P-value 
False 
discovery 
rate (FDR) 
Genes 300 kb or less from validated height SNPs 
GO:0000080 G1 phase of mitotic cell cycle 10 7 4 0.0041 0.0909* CDK6, CDKN1C, E2F1, MAP3K11 
GO:0032355 Response to estradiol stimulus 53 53 7 0.0041 0.2674 GH1, IHH, INSR, NOS3, PTCH1, TGFB1, SOCS2 
GO:0031965 Nuclear membrane 86 81 12 0.0058 0.3132 
ABL1, MYO6, PML, TRIM27, NUPL2, NUP210, 
TMEM176B, DTL, INTS2, SENP2, QSOX2, LASS3 
GO:0005743 Mitochondrial inner membrane 254 222 19 0.0059 0.3414 
CYP27A1, DCI, LETM1, NDUFA7, NDUFB1, 
NDUFB10, PC, PHB, SDHB, SLC3A1, PPIF, ACAA2, 
ATP5L, ABCB8, PMPCA, C4orf14, COQ10A, DHRS1, 
SLC25A45 
GO:0010628 
Positive regulation of gene 
expression 
27 25 3 0.0059 0.2293* CSF2, MAPK9, TGFB1 
GO:0000398 
Nuclear mRNA splicing, via 
spliceosome 
45 45 7 0.0061 0.2757 
HNRPM, SFRS10, BAT1, SF3A2, SF3B4, TRA2A, 
LSM7 
GO:0005242 
Inward rectifier potassium channel 
activity 
18 16 5 0.0061 0.1952* KCNH2, KCNJ1, KCNJ2, KCNJ5, KCNJ12 
GO:0017148 Negative regulation of translation 16 16 3 0.0063 0.1969* EIF2AK3, IGF2BP3, IGF2BP2 
GO:0016604 Nuclear body 16 16 3 0.0067 0.1936* SKI, PCGF2, BTBD14A 
GO:0042612 MHC class I protein complex 22 16 6 0.0076 0.2048* HFE, HLA-B, HLA-C, MICA, MICB, PROCR 
GO:0007067 Mitosis 192 180 16 0.0081 0.3591 
CCNF, E4F1, SEPT2, YEATS4, HMGA2, TIMELESS, 
STAG1, SSSCA1, RGS14, PDS5B, FZR1, NCAPG, 
NUP37, FAM44B, NY-SAR-48, SETD8 
GO:0007569 Cell aging 27 26 3 0.0083 0.2728 BRCA2, PML, ZMIZ1 
GO:0060395 SMAD protein signal transduction 10 9 2 0.0085 0.1814* BMP6, SKI 
GO:0001763 
Morphogenesis of a branching 
structure 
10 9 2 0.0087 0.1781* IHH, TGFB1 
GO:0001501 Skeletal system development 126 113 11 0.0088 0.3536 PCSK5, NOG 
 
Nominal gene set enrichment analysis (GSEA) p-values and false discovery rates are presented for the nominally significant pathways (p<0.01 for Gene 
Ontology (GO) and p<0.05 for the other databases), using MAGENTA (Segrè et al., in revision) applied to the height meta-analysis. The Bonferroni 
corrected cutoffs for the different databases are: KEGG (135 pathways): p<0.0004, Ingenuity (81 pathways): p<0.0006, PANTHER (94 pathways): 
p<0.0005, PANTHER, MF (Molecular Function classification; 217 gene sets): p<0.0002, and Gene Ontology (GO) biological process and molecular 
function terms (1,785 gene sets): p<0.00003.  
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† specifies a gene set that passes or is close to the Bonferroni cutoff. Since Bonferroni correction is stringent due to considerable gene overlap between 
pathways within each database, we further evaluated the statistical significance of each gene-set using a false discovery rate (FDR). FDR is defined for 
gene set g as the fraction of all randomized gene sets generated for all GSEA tests (10,000 permutations times the total number of gene sets tested) 
whose score is more significant than that of gene-set g divided by the fraction of tested gene-sets whose score is more significant than that of gene set g. 
A gene-set score refers here to the fraction of genes in a gene set whose gene p-value exceeds the 95
th
 percentile of all gene p-values. For FDR 
calculation purposes, the differences in gene set size across the observed and randomized gene sets were accounted for by subtracting from each gene-
set score the mean score of all randomized genes-sets of identical size, and dividing by the standard deviation of scores of all randomized genes-sets of 
identical size.  
An asterisk (*) refers to pathways with an FDR<0.25 (i.e. one in four pathways more significant than the given gene-set is likely to be false). 
 
§ 
The number of genes per gene-set analyzed by MAGENTA refers to the gene-set size after removal of genes with no SNPs in their gene region, and 
removal of all but one gene in each subset of genes in a given pathway that were assigned the same best local SNP due to physically proximity in the 
genome. Gene set size was restricted to between 10 and 1,000 genes. All genes within 300 kb of the validated height SNPs are listed, including those 
removed due to physical clustering adjustment. 
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Supplementary Methods Table 1. Study design, number of individuals and sample quality control for genome-wide 
association study cohorts 
 
Study 
Study 
design 
Total 
sample 
size (N) 
Sample QC Samples 
in 
analyses 
(N) 
Anthropo-
metric 
assessment 
method 
References 
Short name Full name 
Call 
rate* 
other exclusions 
Stage 1 (GWA studies) 
ADVANCE Atherosclerotic 
Disease, VAscular 
FunctioN, and 
GenetiC 
Epidemiology 
Population-
based case-
control (multi 
ethnic) 
599 
(Europeans) 
>98.5% 1) duplicates 
2) missing weight or height  
584: 
275 cases 
309 ctrls 
measured Assimes T.L. et al.  Susceptibility locus for clinical and 
subclinical coronary artery disease at chromosome 9p21 
in the multi-ethnic ADVANCE study. Hum Mol Genet. 
(2008) 17(15):2320-8. 
AGES Age, 
Gene/Environment 
Susceptibility-
Reykjavik Study 
Population-
based 
3219 ≥ 97% 1) mismatch with previous 
genotypes;  
2) remove A/T & G/C SNPs;  
3) remove SNPs not in HapMap 
3219 measured Harris T.B. et al. Age, Gene/Environment Susceptibility-
Reykjavik Study: multidisciplinary applied phenomics. 
American Journal of Epidemiology (2007) 165 (9): 1076-
87 
Amish HAPI 
Heart Study 
Amish Heredity and 
Phenotype 
Intervention Heart 
Study 
Founder 
population 
918 ≥ 93% 1) Misidentified pedigree 
relationships 
2) Misidentified sex 
907 measured Mitchell B.D. et al.  The genetic response to short-term 
interventions affecting cardiovascular function:  Rationale 
and design of the Heredity and Phenotype Intervention 
(HAPI) Heart Study.  Am Heart J  (2008) 823:828, 
ARIC Atherosclerosis Risk 
in Communities 
Study 
Population-
based 
8861 
(whites) 
≥ 90% 1) True sex mismatch  
2) Discordant genotype with earlier 
TaqMan genotyping.  If >10/47 
genotypes discordant -> exclude  
3) First-degree relative  
4) PC>8SD in Eigenstrat run (10 
iterations with 10 PCs)  
5) Outlier based on average IBS  
6) missing height or other covariate 
8110 measured (1) The ARIC Investigators. Atherosclerosis Risk in 
Communities (ARIC) Study: design and objectives. Am. J. 
Epidemiol. (1989) 129: 687-702. 
(2) Heard-Costa N.L. et al. NRXN3 is a novel locus for 
waist circumference: a genome-wide association study 
from the CHARGE Consortium. Plos Genet. (2009) 5(6): 
e1000539. 
B58C-T1DGC British 1958 birth 
cohort (Type 1 
Diabetes Genetic 
Consortium controls) 
Population-
based 
2592 ≥ 98% 1) contamination;  
2) non-European identity; 
3) Missing body height. 
2591 measured  (1) Strachan D.P. et al. Lifecourse influences on health 
among British adults: effects of region of residence in 
childhood and adulthood. Int J Epidemiol (2007) 36:522-
531  
(2) Barrett J.C. et al.  The Type 1 Diabetes Genetics 
Consortium. Genome-wide association study and meta-
analysis find that over 40 loci affect risk of type 1 
diabetes. Nat Genet (2009) 41:703-707 
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B58C-WTCCC British 1958 birth 
cohort (Wellcome 
Trust Case Control 
Consortium controls) 
Population-
based birth 
cohort 
1502 ≥97% 1) contamination;  
2) non-European identity and 
relatedness; 
3) Missing body height. 
1479 measured The Wellcome Trust Case Control Consortium 
Genome‐wide association study of 14,000 cases of seven 
common diseases and 3,000 shared controls. Nature 
(2007) 447: 661-678  
BRIGHT British Genetic of 
Hypertension 
(BRIGHT) study 
Hypertension 
cases 
2000 ≥ 97% 1) heterozygosity <23% or >30%; 
2) external discordance; 
3) non-European ancestry;  
4) duplicate/first/second degree 
relatives. 
1806 measured  Caulfield M. et al. Genome-wide mapping of human loci 
for essential hypertension. Lancet.(2003) 361:2118-23. 
CAPS1 cases Cancer Prostate in 
Sweden 1 
Case-control 505 > 95% 1) related individuals and 
duplicates; 
2) ethnic outliers;  
3) missing body weight and height. 
489 self-reported Duggan D. et al. Two genome-wide association studies of 
aggressive prostate cancer implicate putative prostate 
tumor suppressor gene DAB2IP. J Natl Cancer Inst 
(2007) 99:1836-44 
CAPS1 controls Cancer Prostate in 
Sweden 1 
Case-control 506 > 95% 1) related individuals and 
duplicates; 
2) ethnic outliers;  
3) missing body weight and height. 
491 self-reported Duggan D. et al. Two genome-wide association studies of 
aggressive prostate cancer implicate putative prostate 
tumor suppressor gene DAB2IP. J Natl Cancer Inst 
(2007) 99:1836-44  
CAPS2 cases Cancer Prostate in 
Sweden 2 
Case-control 1483 > 95% 1) related individuals and 
duplicates; 
2) ethnic outliers;  
3) missing body weight and height. 
1483 self-reported Duggan D. et al. Two genome-wide association studies of 
aggressive prostate cancer implicate putative prostate 
tumor suppressor gene DAB2IP. J Natl Cancer Inst 
(2007) 99:1836-44. 
CAPS2 controls Cancer Prostate in 
Sweden 2 
Case-control 519 > 95% 1) related individuals and 
duplicates; 
2) ethnic outliers;  
3) missing body weight and height. 
519 self-reported Duggan D. et al. Two genome-wide association studies of 
aggressive prostate cancer implicate putative prostate 
tumor suppressor gene DAB2IP. J Natl Cancer Inst 
(2007) 99:1836-44 
CAD-WTCCC WTCCC Coronary 
Arteryt Disease 
cases 
Case series 2000 ≥ 97% 1) heterozygosity <23% or >30%; 
2) discrepancy with external 
identifying information;  
3) ethnic outliers;  
4) related individuals and 
duplicates; 
1879 self reported The Wellcome Trust Case Control Consortium 
Genome‐wide association study of 14,000 cases of seven 
common diseases and 3,000 shared controls. Nature 
(2007) 447: 661-678 
CHS Cardiovascular 
Health Study 
Population-
based 
3232 >95% 1) Prevalent clinical CVD 
2) African-americans 
3) Sex discordant 
4) Missing body weight and height 
3228 measured Fried L.P. et al. The Cardiovascular Health Study: design 
and rationale. Ann Epidemiol. (1991) 1: 263-276. 
CoLaus Cohorte 
Lausannoise 
Population-
based 
6188 >90% 1) ethnic outliers;  
2) related individuals and 
duplicates; 
3) Missing height 
5409 measured  Firmann M. et al. The CoLaus study: a population-based 
study to investigate the epidemiology and genetic 
determinants of cardiovascular risk factors and metabolic 
syndrome BMC Cardiovascular Disorders (2008)  8:6  
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deCODE deCODE genetics 
sample set 
Population-
based 
38446 ≥ 96% Missing body weight and height. 26799 measured  Thorleifsson G. et al. Genome-wide association yields 
new sequence variants at seven loci that associate with 
measures of obesity. Nat Genet. (2009) 41, 18-24. 
DGI cases Diabetes Genetics 
Initiative 
Case-control 1464 ≥ 95% 1) Related individuals and 
duplicates 
2) Sex mismatch 
3) Phenotype missing 
1317 measured  Saxena R. et al. Genome-wide association analysis 
identifies loci for type 2 diabetes and triglyceride levels. 
Science (2007) 316:1331-6. 
DGI controls Diabetes Genetics 
Initiative 
Case-control 1467 ≥ 95% 1) Related individuals and 
duplicates 
2) Sex mismatch 
3) Phenotype missing 
1090 measured Saxena R. et al. Genome-wide association analysis 
identifies loci for type 2 diabetes and triglyceride levels. 
Science (2007) 316:1331-6.. 
EGCUT Estonian Genome 
Center, University of 
Tartu 
Population-
based 
1428 ≥ 95% 1) Related individuals and 
duplicates 
2) Sex mismatch 
3) Phenotype missing 
1417 measured  (1) Nelis M. et al. Genetic Structure of Europeans: A View 
from the North–East. PLoS ONE (2009) 4(5): e5472. 
(2) Metspalu A. et al. The Estonian Genome Project. 
Drug Development Research  (2004) 62, 97-101. 
EPIC-Obesity 
Study 
European 
Prospective 
Investigation into 
Cancer and Nutrition 
- Obesity Study 
Population-
based 
3821 ≥ 94% 1) heterozygosity <23% or >30%; 
2) >5.0% discordance in SNP pairs 
with r2= 1 in HapMap;  
3) ethnic outliers;  
4) related individuals and 
duplicates; 
5) Missing body weight and height. 
3552 measured  (1) Day N.E. et al. EPIC-Norfolk: study design and 
characteristics of the cohort. European Prospective 
Investigation of Cancer. British Journal of Cancer (1999) 
80: 95-103. 
(2) Loos R.J. et al. Common variants near MC4R are 
associated with fat mass, weight and risk of obesity. Nat 
Genet (2008) 40: 768-775. 
ERF 
(EUROSPAN) 
Erasmus Rucphen 
Family  
Family based 2300 > 95% 1)excess heterozygosity based on 
FDR 
2)ehtnic outliers 
3)sex mismatch 
4)missing phenotype 
2060 measured  (1) Aulchenko Y.S. et al. Linkage disequilibrium in young 
genetically isolated Dutch population. Eur J Hum Genet  
(2004) 12: 527-534 
(2) Axenovich T.I. et al. Linkage analysis of adult height in 
a large pedigree from a Dutch genetically isolated 
population. Hum Genet. (2010) 126: 457-71. 
Fenland Fenland Study Population-
based 
1500 ≥ 95% 1) heterozygosity <27.3% or 
>28.8%; 
2) duplicate check;  
3) relatedness check 
1402 measured  Willer C.J. et al. Six new loci associated with body mass 
index highlight a neuronal influence on body weight 
regulation. Nat Genet. (2009) 41:25-34  
FHS controls Family Heart Study Case-control 434 ≥ 98% 1) technical errors 
2) discrepancies between reported 
sex and sex-diagnostic markers 
415 measured  Higgins M. et al. NHLBI Family Heart Study: objectives 
and design, Am J Epidemiol (1996) 143, 1219–1228. 
FHS cases Family Heart Study Case-control 463 ≥ 98% 1) technical errors 
2) discrepancies between reported 
sex and sex-diagnostic markers 
441 measured  Higgins M. et al. NHLBI Family Heart Study: objectives 
and design, Am J Epidemiol (1996) 143, 1219–1228. 
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FRAM Framingham Heart 
Study 
Population-
based, multi-
generational 
9274 ≥ 97% 1) pHWE<1e-6call rate<97%  
2) mishap p<1e-9  
3) MAF<0.01  
4) Mendelian errors>100  
5) SNPs not in Hapmap or 
strandedness issues merging with 
Hapmap 
8089 measured  (1) Dawber T.R. et al. An approach to longitudinal studies 
in a community: the Framingham Study. Ann N Y Acad 
Sci. (1963)107:539-556.  
(2) Feinleib M. et al. The Framingham Offspring Study. 
Design and preliminary data. Prev Med. (1975) 4:518-
525.  
(3) Splansky G.L. et al. The Third Generation Cohort of 
the National Heart, Lung, and Blood Institute's 
Framingham Heart Study: design, recruitment, and initial 
examination. Am J Epidemiol. (2007) 165:1328-1335. 
FTC Finnish Twin Cohort Monozygotic 
twins 
152 pairs ≥ 95% 1) ethnic outliers;  
2) related individuals and 
duplicates; 
3) Missing body weight and body 
mass index. 
125 measured  (1) Aulchenko Y.S. et al. Loci influencing lipid levels and 
coronary heart disease risk in 16 European population 
cohorts. Nat Genet. (2009) 41:47-55. 
FUSION controls Finland-United 
States Investigation 
of NIDDM Genetics 
Case-control 1174 > 97.5% related individuals; missing BMI or 
height 
1167 measured  Scott L.J. et al. A genome-wide association study of type 
2 diabetes in Finns detects multiple susceptibility 
variants. Science (2007) 316:1341-1345. 
FUSION cases Finland-United 
States Investigation 
of NIDDM Genetics 
Case-control 1161 > 97.5% related individuals; missing BMI or  
height 
1082 measured  Scott L.J. et al. A genome-wide association study of type 
2 diabetes in Finns detects multiple susceptibility 
variants. Science (2007) 316:1341-1345. 
GENMETS 
controls 
Health 2000 / 
GENMETS substudy 
of Metabolic 
syndrome 
Case-control 948 ≥ 95% 1) ethnic outliers;  
2) related individuals and 
duplicates; 
3) Missing body weight and body 
mass index. 
823 height 
calculated 
using BMI and 
weight 
http://www.terveys2000.fi/indexe.html 
GENMETS 
cases 
Health 2000 / 
GENMETS substudy 
of Metabolic 
syndrome 
Case-control 932 ≥ 95% 1) ethnic outliers;  
2) related individuals and 
duplicates; 
3) Missing body weight and body 
mass index. 
824 height 
calculated 
using BMI and 
weight 
http://www.terveys2000.fi/indexe.html 
GerMiFSI (cases 
only) 
German Myocard 
Infarct Family Study 
I 
Case-control 875 > 97% 1) related individuals and 
duplicates; 
2)missin phenotypes 
3) heterozygosity  mean +- 3*sd 
outlier 
600 measured  Samani N.J. et al. Genomewide association analysis of 
coronary artery disease. N Engl J Med.( 2007) 357:443-
453. 
GerMiFSII 
(cases only) 
German Myocard 
Infarct Family Study 
II 
Case-control 1222 > 97% 1) related individuals and 
duplicates; 
2)missin phenotypes 
3) heterozygosity mean +- 3*sd 
outlier  
1124 measured  Erdmann J. et al. New susceptibility locus for coronary 
artery disease on chromosome 3q22.3. Nat Genet. 
(2009) 41:280-282. 
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KORA S3 Cooperative Health 
Research in the 
Region of Augsburg, 
KOoperative 
Gesundheitsforschu
ng in der Region 
Augsburg 
Population-
based 
1644 ≥ 93% 1) german passport; 
2) missing height. 
1643 measured Wichmann H.E. et al. KORA-gen--resource for population 
genetics, controls and a broad spectrum of disease 
phenotypes. Gesundheitswesen (2005) 67 Suppl 1, S26-
30. 
KORA S4 Cooperative Health 
Research in the 
Region of Augsburg, 
KOoperative 
Gesundheitsforschu
ng in der Region 
Augsburg 
Population-
based 
1814 ≥ 93% 1) german passport; 
2) missing height. 
1811 measured Wichmann H.E. et al. KORA-gen--resource for population 
genetics, controls and a broad spectrum of disease 
phenotypes. Gesundheitswesen (2005) 67 Suppl 1, S26-
30. 
MICROS MICROS 
(EUROSPAN) 
Population-
based 
1098 ≥ 97% 1) ethnic outliers;  
2) duplicates; 
3) Missing  height. 
1079 measured  Pattaro C. et al. The genetic study of three population 
microisolates in South Tyrol (MICROS): study design and 
epidemiological perspectives. BMC Med Genet (2007) 
8:29 
MIGEN Myocardial Infarction 
Genetics 
Consortium 
Case-control 6042 ≥ 95% 1) Related individuals and 
duplicates 
2) Sex mismatch 
3) Phenotype missing 
2652 measured Kathiresan S. et al. Genome-wide association of early-
onset myocardial infarction with single nucleotide 
polymorphisms and copy number variants. Nat Genet. 
(2009) 41:334-41. 
NBS-WTCCC WTCCC National 
Blood Service 
donors 
Population-
based 
1500 ≥ 97% 1) heterozygosity <23% or >30%; 
2) discrepancy with external 
identifying information;  
3) ethnic outliers;  
4) related individuals and 
duplicates; 
1441 self reported The Wellcome Trust Case Control Consortium. 
Genome‐wide association study of 14,000 cases of seven 
common diseases and 3,000 shared controls. Nature 
(2007) 447, 661-678 
NFBC1966 Northern Finland 
Birth Cohort 1966 
Population-
based 
5654 ≥ 95% 1) sex discrepancy with genetic 
data from X-linked markers;  
2) withdrawn consent; 
3) duplicates and first and second 
degree relatives; 
4) contaminated samples 
4499 measured (1) Sabatti C. et al. Genome-wide association analysis of 
metabolic traits in a birth cohort from a founder 
population. Nat Genet (2008) 41: 35-46.  
(2) Sovio U. et al. Genetic determinants of height growth 
assessed longitudinally from infancy to adulthood in the 
northern Finland birth cohort 1966. PLoS Genet (2009) 
5(3): e1000409  
NHS The Nurses' Health 
Study 
Nested case-
control 
2368 >90% 1) Low genotying completion 
(<90%); 
2) Unclear identity and admixed 
origin; 
3) Missing  height. 
2265 self-reported Hunter D. et al. A genome-wide association study 
identifies alleles in FGFR2 associated with risk of 
sporadic postmenopausal breast cancer. Nat Genet. 
(2007) 39: 870-874. 
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NSPHS Northern Sweden 
Population Health 
Study (EUROSPAN) 
Population-
based 
720 ≥ 97% 1) ethnic outliers;  
2) duplicates; 
3) Missing  height. 
652 measured  (1) Johansson A. et al. Common variants in the JAZF1 
gene associated with height identified by linkage and 
genome-wide association analysis. Hum Mol Genet 
(2009) 18: 373-80. 
(2) Hicks A.A. et al. Genetic determinants of circulating 
sphingolipid concentrations in European populations. 
PLoS Genet. (2009) 5(10):e1000672 
NTRNESDA Netherlands Twin 
Register & the 
Netherlands Study 
of Depression and 
Anxiety 
Case-control 3720 ≥ 95% 1) evidence of sample 
contamination (heterozygosity); 
2) ethnic outliers;  
3) related individuals and 
duplicates; 
5) missing body height. 
3522 questionnaire 
and measured 
(1) Boomsma D.I. et al. Netherlands Twin Register: from 
twins to twin families. Twin Res Hum Genet (2006) 9: 
849–857.  
(2) Penninx B. et al. The Netherlands Study of 
Depression and Anxiety (NESDA): rationales, objectives 
and methods. Int J Methods Psychiatr Res (2008) 17: 
121-140.  
(3) Boomsma D.I. et al. Genome-wide association of 
major depression: Description of samples for the GAIN 
major depressive disorder study: NTR and NESDA 
Biobank Projects. Eur J Hum Genet (2008) 16: 335–342. 
ORCADES Orkney Complex 
Disease Study (part 
of EUROSPAN) 
Population-
based 
719 ≥ 97% 1) ethnic outliers;  
2) duplicates; 
3) missing height. 
695 measured  (1) Johansson A. et al. Common variants in the JAZF1 
gene associated with height identified by linkage and 
genome-wide association analysis. Hum Mol Genet. 
(2009) 18: 373-380. 
(2) Hicks A.A. et al. Genetic determinants of circulating 
sphingolipid concentrations in European populations. 
PLoS Genet. (2009) 5(10):e1000672 
PLCO The Prostate, Lung 
Colorectal and 
Ovarian Cancer 
Screening Trial 
Case-control 2298 ≥ 94% 1) Sex discordance  
2) Non-European ancestry 
3) Related individuals and 
duplicates; 
4) Missing height. 
2244 self-reported Yeager M. et al. Genome-wide association study of 
prostate cancer identifies a second risk locus at 8q24. 
Nat Genet (2007) 39: 645-649. 
PROCARDIS Precocious 
Coronary Artery 
Disease 
Case-control 2573 > 95% none 2312 measured Broadbent H.M. et al. Susceptibility to coronary artery 
disease and diabetes is encoded by distinct, tightly linked 
SNPs in the ANRIL locus on chromosome 9p. Hum Mol 
Genet (2008) 17: 806-814. 
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RS-I Rotterdam Study I Population-
based 
7983 ≥ 97.5% 1) sex mismatch with typed X-
linked markers; 
2) excess autosomal 
heterozygosity > 
0.336~FDR>0.1%;  
3) duplicates and/or 1st or 2nd 
degree relatives using IBS 
probabilities >97% from PLINK;  
4) ethnic outliers using IBS 
distances > 3SD from PLINK; 
5) Missing body weight and height. 
5744 measured  (1) Estrada K. et al. A genome-wide association study of 
northwestern Europeans involves the C-type natriuretic 
peptide signaling pathway in the etiology of human height 
variation. Hum Mol Genet (2009) 18:3516-3524 
(2) Estrada K. et al. GRIMP: a web- and grid-based tool 
for high-speed analysis of large-scale genome-wide 
association using imputed data. Bioinformatics (2009) 
25:2750-2752 
(3) Hofman A. et al. The Rotterdam Study: 2010 
objectives and design update. Eur J Epidemiol (2009) 24: 
553-572 
(4) Hofman A. et al. Determinants of disease and 
disability in the elderly: the Rotterdam Elderly Study. Eur 
J Epidemiol (1991) 7: 403-422 
RUNMC Nijmegen Bladder 
Cancer Study 
(NBCS) & Nijmegen 
Biomedical Study 
(NBS), Radboud 
University Nijmegen 
Medical Centre 
Population-
based 
3081 ≥ 96% Missing body weight and height. 2873 self-assessed 
and reported 
by 
questionnaire 
(1) Wetzels J.F. et al. Age- and sex-specific reference 
values of estimated GFR in Caucasians: the Nijmegen 
Biomedical Study. Kidney Int (2007) 72, 632-637.  
(2) Kiemeney L.A. et al. Sequence variant on 8q24 
confers susceptibility to urinary bladder cancer. Nat 
Genet (2008) 40: 1307-1312. 
SardiNIA SARDINIA Population-
based 
6148 ≥ 90% 1) Morquio syndrome 
2) Missing height 
4298 measured Pilia G. et al. Heritability of cardiovascular and personality 
traits in 6,148 Sardinians. PLoS Genet (2006) 2: e132  
SASBAC cases Swedish And 
Singapore Breast 
Association 
Consortium 
Case-control 803 ≥ 96% 1) related individuals and 
duplicates; 
2) ethnic outliers;  
3) missing body weight and height. 
794 self-reported (1) Magnusson C. et al. Breast-cancer risk following long-
term oestrogen- and oestrogen-progestin-replacement 
therapy. Int J Cancer (1999) 81: 339-344. 
(2) Einarsdóttir K. et al. Comprehensive analysis of the 
ATM, CHEK2 and ERBB2 genes in relation to breast 
tumour characteristics and survival: a population-based 
case-control and follow-up study. Breast Cancer Res 
(2006) 8: R67. 
SASBAC 
controls 
Swedish And 
Singapore Breast 
Association 
Consortium 
Case-control 764 ≥ 96% 1) related individuals and 
duplicates; 
2) ethnic outliers;  
3) missing body weight and height. 
758 self-reported (1) Magnusson C. et al. Breast-cancer risk following long-
term oestrogen- and oestrogen-progestin-replacement 
therapy. Int J Cancer (1999) 81: 339-344. 
(2) Einarsdóttir K. et al. Comprehensive analysis of the 
ATM, CHEK2 and ERBB2 genes in relation to breast 
tumour characteristics and survival: a population-based 
case-control and follow-up study. Breast Cancer Res 
(2006) 8: R67. 
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SEARCH / 
UKOPS 
Studies of 
Epidemiology and 
Risk factors in 
Cancer Heredity / 
UK Ovarian Cancer 
Population Study 
Population-
based 
1710 ≥ 80% 1) ethnic outliers 
2) duplicates 
3) Missing height 
1592 self-assessed Song H. et al. A genome-wide association study identifies 
a new ovarian cancer susceptibility locus on 9p22.2. Nat 
Genet (2009) 41: 996-1000. 
SHIP Study of Health in 
Pomerania 
Population-
based 
4310 ≥ 92% 1) missing genotype or phenotype 
data 
4092 measured  John U. et al. Study of health in Pomerania (SHIP): a 
health examination survey in an east German region: 
objectives and design. Soz-Präventivmed (2001) 46: 186-
194. 
T2D-WTCCC WTCCC Type 2 
Diabetes cases 
case series 1999 ≥ 97% 1) heterozygosity <23% or >30%; 
2) discrepancy with external 
identifying information;  
3) ethnic outliers;  
4) related individuals and 
duplicates; 
1903 measured The Wellcome Trust Case Control Consortium 
Genome‐wide association study of 14,000 cases of seven 
common diseases and 3,000 shared controls. Nature 
(2007) 447: 661-678 
TwinsUK TwinsUK Twins pairs 2226 ≥ 95% 1) heterozygosity <33% or >37%; 
2) ethnic outliers;  
3) related individuals and 
duplicates; 
4) Missing body weight and height. 
1479 measured  (1) Spector T.D., Williams F.M. The UK Adult Twin 
Registry (TwinsUK). Twin Res Hum Genet (2006) 9: 899-
906. 
(2) Spector T.D., MacGregor A.J. The St. Thomas' UK 
Adult Twin Registry. Twin Res (2002) 5: 440-443. 
VIS VIS (EUROSPAN) 
and KORCULA 
Population-
based 
795 ≥ 97% 1) ethnic outliers;  
2) duplicates; 
3) Missing  height. 
784 measured  (1) Johansson A. et al. Common variants in the JAZF1 
gene associated with height identified by linkage and 
genome-wide association analysis. Hum Mol Genet. 
(2009) 18: 373-380. 
(2) Hicks A.A. et al. Genetic determinants of circulating 
sphingolipid concentrations in European populations. 
PLoS Genet. (2009) 5(10):e1000672 
Stage 2 (in-silico replication studies) 
BHS Busselton Health 
Study 
Population-
based 
1366 ≥ 75% 1) ethnic outliers;  
2) related individuals and 
duplicates; 
3) Missing body waist and hip. 
1328 measured  (1) James A.L. et al. Decline in lung function in the 
Busselton Health Study: the effects of asthma and 
cigarette smoking. Am J Respir Crit Care Med (2005) 
171:109-114. 
(2) Hui J. et al. A genome-wide association scan for 
asthma in a general Australian population. Hum Genet 
(2008) 123:297-306 
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Corogene Genetic 
Predisposition of 
Coronary Heart 
Disease in Patients 
Verified with 
Coronary 
Angiogram  
Population-
based 
4130 ≥ 95% 1) missing sex 
2) related individuals and 
duplicates 
3) (For this specific analysis) 
Missing body height 
3758 measured  Soranzo, N. et al. A genome-wide meta-analysis 
identifies 22 loci associated with eight hematological 
parameters in the HaemGen consortium. Nat. Genet 
(2009). 41: 1182-1190. 
EGCUT Estonian Genome 
Center, University of 
Tartu 
Population-
based 
345 ≥ 95% 1) Related individuals and 
duplicates 
2) Sex mismatch 
3) Phenotype missing 
345 measured  (1) Nelis M. et al. Genetic Structure of Europeans: A View 
from the North–East. PLoS ONE (2009) 4(5): e5472. 
(2) Metspalu A. The Estonian Genome Project. Drug 
Development Research (2004) 62: 97-101. 
FHS Family Heart Study Case-control 1808 ≥ 98% 1) technical errors                                                                                                              
2) discrepancies between reported 
sex and sex-diagnostic markers 
1463 measured Higgins M. et al. NHLBI Family Heart Study: objectives 
and design, Am J Epidemiol (1996) 143: 1219-1228. 
FINGESTURE 
cases 
Finnish Genetic  
Study of Arrhythmic 
Events  
Disease 
cohort 
(MI cases 
only) 
1103 ≥ 97% 1) PLINK heterozygosity F-value <-
0.05 or >0.05; 
2) ethnic outliers;  
3) related individuals and 
duplicates; 
4) Missing body weight and height. 
943 measured  Kaikkonen K.S. et al. Family history and the risk of 
sudden cardiac death as a manifestation of an acute 
coronary event. Circulation (2006) 114, 1462-7 
GOOD Gothenburg 
Osteoporosis and 
Obesity 
Determinants Study 
Population-
based 
1056 ≥ 97.5% 1) heterozygosity > 33%; 
2) ethnic outliers; 
3) related individuals and 
duplicates. 
938 measured  Lorentzon M. et al. Free testosterone is a positive 
whereas free estradiol is a negative predictor of cortical 
bone size in young Swedish men-The GOOD Study. J 
Bone Miner Res (2005) 20: 1334-1341. 
HBCS Helsinki Birth Cohort 
Study 
Birth cohort 
study 
1872 ≥ 95% 1) related individuals and 
duplicates 
2) (From this specific analysis) 
Missing body height 
1726 measured  Ylihärsilä H. et al. Body mass index during childhood and 
adult body composition in men and women aged 56-70 y. 
Am J Clin Nutr. (2008) 87:1769-1775. 
Kajantie E. et al. Size at birth as a predictor of mortality in 
adulthood: a follow-up of 350 000 person-years. Int J 
Epidemiol (2005) 34:655-663. 
HYPERGENES 
controls 
HYPERGENES Case-control 1934 >90% 1) ethnic outliers 
2) Missing body weight and height. 
1838 measured  http://www.hypergenes.eu/ 
HYPERGENES 
cases 
HYPERGENES Case-control 2124 >90% 1) ethnic outliers 
2) Missing body weight and height. 
1787 measured  http://www.hypergenes.eu/ 
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MGS Molecular Genetics 
of 
Schizophrenia/NIMH 
Repository Control 
Sample 
Population-
based 
(survey 
research 
method) 
2681 99.7% 1) call rate < 97% for samples,95% 
for SNPs 
2) heterozygosity <26% or >28.5%; 
3) excess duplicate discordancies 
or mendelian errors (SNPs);  
4) ethnic outliers (principal 
component scores);  
5) related individuals and 
duplicates; 
6) Missing body weight or height. 
2597 self-reported (1) Shi J. et al. Common variants on chromosome 6p22.1 
are associated with schizophrenia. Nature. (2009) 460: 
753-757.  
(2) Sanders A.R. et al. No significant association of 14 
candidate genes with schizophrenia in a large European 
ancestry sample: implications for psychiatric genetics. Am 
J Psychiatry. (2008) 165: 497-506. 
NHS The Nurses' Health 
Study 
Nested case-
control 
3221 >98% 1) Low genotying completion 
(<98%);  2) Unclear identity and 
admixed origin; 3) related 
individuals and duplicates;  4) DNA 
contamination; 5) Missing height; 
3217 self-reported Qi L. et al. Genetic variants in ABO blood group region, 
plasma soluble E-selectin levels, and risk of type 2 
diabetes. Hum Mol Genet. (2010) Feb 10, 
doi:10.1093/hmg/ddq057 
RS-II Rotterdam Study II Population-
based 
3011 ≥ 97.5% 1) sex mismatch with typed X-
linked markers; 
2) excess autosomal 
heterozygosity (F<-0.055);  
3) duplicates and/or 1st degree 
relatives using IBD PiHAT >40% 
from PLINK;  
4) ethnic outliers IBS distances > 
4SD mean HaMAP CEU cluster 
from PLINK; 
5) Missing body weight and height. 
2124 measured  (1) Estrada K. et al. A genome-wide association study of 
northwestern Europeans involves the C-type natriuretic 
peptide signaling pathway in the etiology of human height 
variation. Hum Mol Genet (2009) 18:3516-3524 
(2) Estrada K. et al. GRIMP: a web- and grid-based tool 
for high-speed analysis of large-scale genome-wide 
association using imputed data. Bioinformatics (2009) 
25:2750-2752 
(3) Hofman A. et al. The Rotterdam Study: 2010 
objectives and design update. Eur J Epidemiol (2009) 24: 
553-572 
(4) Hofman A. et al. Determinants of disease and 
disability in the elderly: the Rotterdam Elderly Study. Eur 
J Epidemiol (1991) 7: 403-422 
RS-III Rotterdam Study III Population-
based 
3932 ≥ 97.5% 1) sex mismatch with typed X-
linked markers; 
2) excess autosomal 
heterozygosity (F<-0.055);  
3) duplicates and/or 1st degree 
relatives using IBD PiHAT >40% 
from PLINK;  
4) ethnic outliers IBS distances > 
4SD mean HaMAP CEU cluster 
from PLINK; 
5) Missing body weight and height. 
2009 measured  (1) Estrada K. et al. A genome-wide association study of 
northwestern Europeans involves the C-type natriuretic 
peptide signaling pathway in the etiology of human height 
variation. Hum Mol Genet (2009) 18:3516-3524 
(2) Estrada K. et al. GRIMP: a web- and grid-based tool 
for high-speed analysis of large-scale genome-wide 
association using imputed data. Bioinformatics (2009) 
25:2750-2752 
(3) Hofman A. et al. The Rotterdam Study: 2010 
objectives and design update. Eur J Epidemiol (2009) 24: 
553-572 
(4) Hofman A. et al. Determinants of disease and 
disability in the elderly: the Rotterdam Elderly Study. Eur 
J Epidemiol (1991) 7: 403-422 
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Sorbs Sorbs are self-
contained population 
from Eastern 
Germany, European 
Descent 
Population-
based 
1097 ≥ 94% 1) sex mismatch;  
2) ethnic outliers;  
3) duplicates; 
4) Missing body weight and height. 
907 measured  Tönjes A. et al. Association of FTO variants with BMI and 
fat mass in the self-contained population of Sorbs in 
Germany. Eur J Hum Genet. (2010) 18:104-10. 
WGHS Women's Genome 
Health Study 
Population-
based 
23,294 >98% 1)  includes only WGHS 
participants with confirmed, self-
reported European ancestry; 
2) all SNPs have HWE p>10E-6;  
3) all SNPs have genotype for 
>90% samples  
4) only samples with biometric 
measures included in analysis 
23099 self-report Ridker P.M. et al. Rationale, design, and methodology of 
the Women's Genome Health Study: a genome-wide 
association study of more than 25,000 initially healthy 
American women. Clin Chem. (2008) 54:249-55. . 
YFS The Cardiovascular 
Risk in Young Finns 
Study 
Population-
based cohort 
2,443 ≥ 95% 1) missing sex 
2) related individuals and 
duplicates 
3) (From this specific analysis) 
Missing body height 
1995 measured  Raitakari O.T. et al. Cohort profile: The cardiovascular 
risk in Young Finns Study. Int J Epidemiol. (2008) 
37:1220-6 
Polygene analysis study 
QIMR Twin studies at the 
Queensland Instutite 
of Medical Research  
Population-
based 
2,654 ≥ 95% 1) close relatives based on 
pedigree information; 
2) ethnic outliers;  
3) Missing height. 
1475 measured or 
self-report 
Medland et al. Common Variants in the Trichohyalin 
Gene Are Associated with Straight Hair in Europeans. 
Amer J Hum Genet (2009) 85:750-5. 
* Sample genotyping success rate; i.e. minimum percentage of successfully genotyped SNPs of GWAs per sample 
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Supplementary Methods Table 2. Information on genotyping methods, quality control of SNPs, imputation, and statistical 
analysis. 
 
 
Genotyping Imputation Association analyses 
Platform 
Genotype 
calling 
algorithm 
Inclusion criteria 
SNPs that 
met QC 
criteria 
Imputation 
software 
Inclusion criteria SNPs in meta-
analysis (after 
MAFxN>3 
filter) 
lGC 
Analyses 
software 
Cohort 
MAF Call rate* p for HWE MAF Imputation quality all men women 
Stage 1 (GWA studies) 
ADVANCE 
cases 
Illumina 550k BeadStudio none ≥98.5% >10
-3 
543,985 BIMBAM >0% none 2,193,902 NA 1.047 1.022 SNPTEST 
ADVANCE 
controls 
Illumina 550k BeadStudio none ≥98.5% >10
-3 
543,985 BIMBAM >0% none 2,206,332 NA 1.046 0.996 SNPTEST 
AGES Illumina 
Human370CNV 
BeadStudio ≥1% ≥95% >10
-6 
308,340 MACH >0% r2-hat≥0.30 2,458,927 NA 1.075 1.082 ProbABEL 
Amish HAPI 
Heart Study 
Affymetrix GeneChip 
Human Mapping 500K 
BRLMM ≥1% ≥95% >10
-6 
338,598 MACH >0% r2-hat≥0.30 2,291,092 1.057 0.938 1.045 MMAP 
ARIC Affymetrix Genome-
Wide Human SNP 
Array 6.0 
Birdseed >1% ≥95% >10
-5 
685,812 MACH >0% r2-hat≥0.30 2,511,301 NA 1.021 1.039 ProbABEL 
B58C-T1DGC Illumina HumanHap 
550 V.1 
ILLUMINUS >0% none none 539,458 MACH >0% r2-hat≥0.30 2,507,988 NA 1.024 1.014 ProbABEL 
B58C-WTCCC Affymetrix GeneChip 
Human Mapping 500K 
CHIAMO >5% none none 392,575 IMPUTE >0% proper-info≥0.40 2,448,428 NA 0.999 1.003 SNPTEST 
BRIGHT Affymetrix GeneChip 
Human Mapping 500K 
CHIAMO ≥5% ≥95% >10
-6 
387,666 IMPUTE >0% proper-info≥0.40 2,429,136 NA 1.015 0.995 SNPTEST 
CAPS1 cases Affymetrix GeneChip 
Human Mapping 500K 
BRLMM ≥1% ≥95% >10
-7 
330,124 IMPUTE >0% proper-info≥0.40 2,387,578 NA 0.993 NA SNPTEST 
CAPS1 
controls 
Affymetrix GeneChip 
Human Mapping 500K 
BRLMM ≥1% ≥95% >10
-7 
330,124 IMPUTE >0% proper-info≥0.40 2,390,475 NA 0.995 NA SNPTEST 
CAPS2 cases Affymetrix GeneChip 
Human Mapping 5.0K 
BLRMM-P ≥1% ≥95% >10
-7 
348,163 IMPUTE >0% proper-info≥0.40 2,416,296 NA 1.044 NA SNPTEST 
CAPS2 
controls 
Affymetrix GeneChip 
Human Mapping 5.0K 
BLRMM-P ≥1% ≥95% >10
-7 
348,163 IMPUTE >0% proper-info≥0.40 2,391,556 NA 1.041 NA SNPTEST 
CAD-WTCCC Affymetrix GeneChip 
Human Mapping 500K 
CHIAMO >5% ≥95% >10
-6 
387,667 IMPUTE >0% proper-info≥0.40 2,430,482 NA 1.025 1.009 SNPTEST 
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CHS Illumina 370-CNV BeadStudio  >97% >10
-5 
306,655 BimBam >0% r2-hat ≥0.30 2,191,645 NA 1.11 1.15 R 
CoLaus Affymetrix GeneChip 
Human Mapping 500K 
BRLMM ≥1% ≥70% >10
-7 
390,631 IMPUTE >0%  proper-info ≥0.40 2,479,491 NA 1.013 1.034 QUICKTEST 
deCODE Illumina HumanHap300 
or HumanHapCNV370 
BeadStudio ≥1% ≥96% >10
-6 
290,447 IMPUTE >0% proper-info≥0.40 2,456,118 0.948 0.977 0.986 SNPTEST 
DGI cases Affymetrix 500K BRLMM ≥1% ≥95% >10
-6 
386,731 MACH >0% r2-hat≥0.30 2,410,247 1.029 0.977 1.049 MACH2QTL 
DGI controls Affymetrix 500K BRLMM ≥1% ≥95% >10
-6 
386,731 MACH >0% r2-hat≥0.30 2,408,993 1.029 1.045 0.995 MACH2QTL 
EGCUT Illumina Beadarray 
Human370CNV 
BeadStudio ≥1% ≥98% >10
-6 
299,484 IMPUTE >0% proper-info≥0.40 2,429,620 NA 1.032 1.013 SNPTEST 
EPIC-Obesity 
Study 
Affymetrix GeneChip 
Human Mapping 500K 
BRLMM ≥1% ≥90% >10
-6 
397,438 IMPUTE >0% proper-info≥0.40 2,420,624 NA 1.018 1.027 SNPTEST 
ERF 
(EUROSPAN) 
Illumina 318K, 370K, 
Affymetrix 250K 
BRLMM, 
BeadStudio 
>0.5% >95% >10
-6
 NA MACH >0% r2-hat≥0.30 2,463,846 1.031 1.012 1.019 ProbABEL 
Fenland Affymetrix SNP5.0 BRLMM ≥1% ≥90% >10
-6 
362,055 IMPUTE >0% proper-info≥0.40 2,406,753 NA 1.039 1.04 SNPTEST 
FHS (cases + 
controls) 
Illumina 1Million 
GeneChip 
BeadStudio ≥1% ≥98% >10
-6 
874,830 MACH >0% r2-hat≥0.30 2,375,010 1.066 1.06 1.064 SAS 
FRAM Affymetrix 500K  
Affymetrix 50K 
supplemental 
BRLMM ≥1% ≥97% >10
-6 
378,163 MACH >0% r2-hat≥0.30 2,455,455 1.071 1.027 1.062 R 
FTC Illumina HumanHap 
318K 
BeadStudio ≥1% ≥90% >10
-6 
304,582 MACH >0% r2-hat≥0.30 2,268,674 NA NA 1.005 ProbABEL 
FUSION 
controls 
Illumina Infinium™ II 
HumanHap300 
BeadChip 
BeadStudio >1% ≥90% ≥10
-6
 315,635 MACH >0% r2-hat≥0.30 2,466,546 1.112 1.056 1.074 MACH2QTL 
FUSION cases Illumina Infinium™ II 
HumanHap300 
BeadChip 
BeadStudio >1% ≥90% ≥10
-6
 315,635 MACH >0% r2-hat≥0.30 2,466,546 1.08 1.077 1.027 MACH2QTL 
GENMETS 
controls 
Illumina HumanHap 
610K 
Illuminus ≥1% ≥95% >10
-6 
555,388 MACH >0% r2-hat≥0.30 2,345,066 NA 1.043 1.006 ProbABEL 
GENMETS 
cases 
Illumina HumanHap 
610K 
Illuminus ≥1% ≥95% >10
-6 
555,388 MACH >0% r2-hat≥0.30 2,343,751 NA 1.016 1.007 ProbABEL 
GerMiFSI Affymetrix NSP/STY  BRLMM >1% >97% >10
-5
 282,215 MACH >0% r2-hat≥0.30 2,333,219 NA 1.014 1.026 GenABEL 
GerMiFSII Affymetrix 6.0 Birdseed >1% >97% >10
-5
 653,149 MACH >0% r2-hat≥0.30 2,492,325 NA 1.07 1.015 GenABEL 
KORA S3 Affymetrix 500K BRLMM none none none 490,032 MACH >0% r2-hat≥0.30 2,415,072 NA 1.018 1.016 MACH2QTL 
KORA S4 Affymetrix 6.0 Birdseed none none none 909,622 IMPUTE >0% proper-info≥0.40 2,109,266 NA 1.009 1.036 SNPTEST 
MICROS  ILLUMINA318K BeadStudio ≥1% ≥98% >10
-6 
318,237 MACH >0% r2-hat ≥0.30 2,435,539 1.004 1 0.994 ProbABEL 
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MIGEN Affymetrix 6.0 Birdseed ≥1% ≥95% >10
-6 
727,496 MACH >0% r2-hat ≥0.30 2,288,269.4 
(average) 
NA 1.002 
(average) 
1.0015 
(average) 
MACH2QTL 
NBS-WTCCC Affymetrix GeneChip 
Human Mapping 500K 
CHIAMO >5% ≥95% >10
-6 
387,667 IMPUTE >0% proper-info ≥0.40 2,415,926 NA 1.002 1.008 SNPTEST 
NFBC1966 Illumina HumanCNV-
370DUO Analysis 
BeadChip 
Standard 
Illumina 
BeadStudio 
≥5% ≥95% >10
-4
 328,007 IMPUTE >0% proper-info ≥0.40 2,460,379 NA 1.037 1.053 SNPTEST 
NHS Illumina HumanHap550 Standard 
Illumina 
BeadStudio 
≥1% ≥90% none 510,073 MACH >0% r2-hat ≥0.30 2,520,546 NA NA 1.005 MACH2QTL 
NSPHS  ILLUMINA318K BeadStudio ≥1% ≥98% >10
-6 
318,236 MACH >0% r2-hat≥0.30 2,382,373 1.023 1.03 1.015 ProbABEL 
NTRNESDA  Perlegen - Affymetrix 
gene chip 600K 
Proprietary 
Perlegen 
>1% ≥95% none 435,291 IMPUTE >0% proper-info≥0.40 2,493,317 NA 1.028 1.062 SNPTEST 
ORCADES  ILLUMINA318K BeadStudio ≥ 1% ≥98% >10
-6 
318,235 MACH >0% r2-hat≥0.30 2,433,999 1.004 0.966 1.042 ProbABEL 
PLCO Illumina HumanHap300 
and Illumina 
HumanHap240 
Illumina Bead 
Studio 
none ≥90% none 523,231 MACH >0% r2-hat≥0.30 2,527,780 NA 1.006 NA MACH2QTL 
PROCARDIS HumanHap300 
BeadChips  
Illumina 
Beadstudio 
2.0 software 
>5% ≥95% >5x10
-7 
~820k IMPUTE >0% proper-info≥0.40 2,580,770 NA 1.084 1.014 SNPTEST 
RS-I Illumina /HumanHap 
550K V.3 
ADHumanHap 550 V.3 
DUO; 
BeadStudio 
Genecall 
≥1% ≥97.5% >10
-6 
512,349 MACH >0% (O/E)σ2 ratio≥0.1 
r2-hat≥0.30 
2,488,215 NA 1.045 1.064 MACH2QTL 
RUNMC Illumina 
HumanHapCNV370  
BeadStudio ≥1% ≥96% >10
-6 
312,199 IMPUTE >0% proper-info≥0.40 2,465,662 0.996 0.996 0.996 SNPTEST 
SardiNIA Affymetrix 500K and 
Affymetrix 10K 
BRLMM ≥5% ≥90% >10
-6 
356,359 MACH >0% r2-hat≥0.30 2,251,689 1.313 1.171 1.213 Merlin 
SASBAC 
cases 
Illumina 
HumanHap300+240S 
Standard 
Illumina 
BeadStudio 
(GenCall) 
≥3% ≥90% >10
-7
 510,578 IMPUTE >0% proper-info≥0.40 2,491,965 NA NA 1.009 SNPTEST 
SASBAC 
controls 
Illumina HumanHap550 Standard 
Illumina 
BeadStudio 
(GenCall) 
≥3% ≥90% >10
-7
 512,223 IMPUTE >0% proper-info≥0.40 2,474,508 NA NA 1.012 SNPTEST 
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SEARCH / 
UKOPS 
Illumina HumanHap 
610 Quad 
Illuminus ≥1% ≥95% >10
-4 
495,229 In-house 
method 
similar to 
IMPUTE 
>0% r2-hat≥0.30 2,486,650 NA NA 1.02 Regression 
analysis on 
dosages 
SHIP Affymetrix Human SNP 
Array 6.0 
Birdseed V2 ≥0% ≥0% ≥0 869,224 IMPUTE >0% proper-info≥0.40 2,609,015 NA 1.034 1.046 SNPTEST 
v1.1.5 
InforSense 
T2D-WTCCC Affymetrix GeneChip 
Human Mapping 500K 
CHIAMO >5% ≥95% >10
-6 
387,667 IMPUTE >0% proper-info≥0.40 2,425,374 NA 1.008 1.011 SNPTEST 
TWINSUK Illumina / HumanHap 
300 & 550 
Illuminus ≥1% ≥95% >10
-6 
295,702 IMPUTE >0% proper-info≥0.40 2,460,943 NA NA 1.022 SNPTEST 
VIS Illumina 
HumanHap300v1 
BeadStudio ≥1% ≥98% >10
-6 
317,465 MACH >0% r2-hat≥0.30 2,423,083 0.989 1.002 0.991 ProbABEL 
Stage 2 (in-silico replication studies) 
BHS Illumina Human 610-
Quad 
Illuminus ≥1% ≥95% >5.7x10
-7 
549,294 MACH ≥1% r2-hat≥0.30 664 - - - R 
Corogene Illumina BeadChip 
Human 610-Quad 
Illuminus ≥1% ≥95% >10
-6 
554,988 MACH ≥1% r2-hat≥0.30 663 - 1.079 1.084 PLINK 
EGCUT Illumina Beadarray 
Human370CNV 
BeadStudio ≥1% ≥98% >10
-6 
316,924 IMPUTE ≥1% proper-info≥0.30 662 - 1.034 1.025 SNPtest 
FHS Illumina 1Million 
GeneChip 
BeadStudio ≥1% ≥98% >10
-6 
874,830 MACH  ≥1% r2-hat≥0.30 665 - - - SAS 
FINGESTURE 
cases 
Affymetrix Genome-
Wide Human SNP 
Array 6.0 
Birdseed ≥5% ≥95% >10
-6
 606,717 MACH >0% r2-hat≥0.30 663 - - - MACH2QTL 
GOOD Illumina Infinium 
HumanHap 610K 
BeadStudio ≥1% ≥98% >10
-6 
521,160 MACH >0% r2-hat≥0.30 664 - - - MACH2QTL 
HBCS Illumina custom made 
BeadChip Human 670-
Quad 
Illuminus ≥1% ≥95% >10
-6 
533491 MACH ≥1% r2-hat≥0.30 663 - 1.000 1.002 PLINK 
HYPERGENE
S controls 
Illumina Human1M-
Duov3_B 
GenCall, 
BeadStudio 
≥1% ≥90% >10
-7 
Center I: 
861759, 
Center II: 
872576 
MACH >0% r2-hat≥0.30 642 - - - Matlab 
HYPERGENE
S cases 
Illumina Human1M-
Duov3_B 
GenCall, 
BeadStudio 
≥1% ≥90% >10
-7 
Center I: 
861759, 
Center II: 
872576 
MACH >0% r2-hat≥0.30 642 - - - Matlab 
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MGS Affymetrix Genome-
Wide Human SNP 
Array 6.0 
Birdsuite 2.0 ≥1% ≥95% >10
-6 
696,492 MACH ≥1% r2-hat≥0.30 662 -  -   -  PLINK and 
local 
software 
NHS Affymetrix Genome-
Wide Human 6.0 array 
Birdseed 
algorithm v2 
≥2% ≥98% >10
-4
 704,409 MACH ≥2% r2-hat≥0.30 392 - - - ProbABEL 
RS-II Illumina / HumanHap 
550 V.3 DUO; Illumina / 
HumanHap 610 QUAD 
Genomestudi
o Genecall 
≥1% ≥97.5% >10
-6 
466,389 MACH ≥1% (O/E)σ2 ratio≥0.1 
r2-hat ≥0.30 
664 - 1.004 1.012 MACH2QTL 
RS-III Illumina / HumanHap 
610 QUAD 
Genomestudi
o Genecall 
≥1% ≥97.5% >10
-6 
514,073 MACH ≥1% (O/E)σ2 ratio≥0.1 
r2-hat ≥0.30 
664 - 1.004 1.018 MACH2QTL 
Sorbs 500K Affymetrix 
GeneChip (250K Sty 
and 250K Nsp arrays) 
and Affymetrix 
Genome-Wide Human 
SNP Array 6.0 
BRLMM 
algorithm for 
500K and 
Birdseed 
Algorithm for 
SNP Array 6.0 
≥1% ≥95% >10
-4 
378,513 IMPUTE >1% proper-info>0.40 650 - - - SNPTEST 
WGHS Illumina HumanHap300 
Duo "+" 
Beadstudio v 
3.3 
NA ≥90% >10
-6 
339,596 MACH >0% r2-hat≥0.30 663 - - - R 
YFS Illumina custom made 
BeadChip Human 670-
Quad 
Illuminus ≥1% ≥95% >10
-6 
546,674 MACH ≥1% r2-hat≥0.30 663 - 1.017 1.043 PLINK 
Polygene analysis study 
QIMR Illumina HumanHap 
610 Quad 
BeadStudio ≥1% ≥95% >10
-6 
493,578         
* SNP genotyping success rate; i.e. minimum percentage of successfully genotyped samples per SNP     
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Supplementary Methods Table 3: Study-specific descriptive statistics 
 
Study Trait 
Men Women 
n mean SD median min max 
correlation 
with BMI 
correlation 
with height n mean SD median min max 
correlatio
n with BMI 
correlation 
with height 
Stage 1 (GWA studies) 
ADVANCE 
cases 
Age (yrs) 114 40.42 3.98 41.20 20.40 45.10 -0.10 -0.12 161 49.46 4.68 50.50 34.00 55.00 0.01 -0.15 
Height (m) 114 1.77 0.07 1.77 1.61 1.95 0.15 1.00 161 1.64 0.07 1.64 1.48 1.84 -0.14 1.00 
BMI (kg/m²) 114 31.39 5.77 30.89 19.48 54.32 1.00 0.15 161 31.40 8.17 30.65 17.30 61.08 1.00 -0.14 
Weight (kg) 114 99.03 21.16 97.59 64.05 181.44 0.92 0.49 161 83.98 21.78 81.74 48.58 153.00 0.95 0.16 
ADVANCE 
controls 
Age (yrs) 128 40.46 3.23 41.20 33.40 46.80 -0.03 0.15 183 48.69 4.45 49.80 34.80 55.40 0.09 -0.03 
Height (m) 128 1.79 0.07 1.78 1.58 1.96 0.02 1.00 181 1.66 0.06 1.66 1.45 1.80 -0.14 1.00 
BMI (kg/m²) 128 27.00 4.48 26.21 17.86 49.38 1.00 0.02 181 26.08 6.36 24.65 15.76 54.12 1.00 -0.14 
Weight (kg) 128 86.45 16.38 84.37 51.48 158.76 0.88 0.43 182 71.35 17.13 68.27 40.23 140.71 0.92 0.21 
AGES Midlife Age (yrs) 1352 49.69 5.87 50.00 34.00 75.00 0.05 -0.21 1867 52.00 6.54 52.00 34.00 77.00 0.15 -0.23 
Height (m) 1352 1.78 0.06 1.78 1.56 1.98 0.01 1.00 1867 1.64 0.05 1.64 1.45 1.83 -0.15 1.00 
BMI (kg/m²) 1351 25.62 3.09 25.48 16.94 38.61 1.00 0.01 1856 24.89 3.81 24.31 13.65 50.41 1.00 -0.15 
Weight (kg) 1351 81.32 11.41 80.40 51.00 139.00 0.87 0.51 1856 67.13 10.51 66.00 32.80 140.60 0.91 0.27 
Amish HAPI 
Heart Study 
Age (yrs) 471 46.2 16.9 43.0 20.0 99.0 0.25 -0.41 437 47.5 15.1 48.0 20.0 95.0 0.25 -0.40 
Height (m) 470 1.73 0.07 1.73 1.48 1.94 -0.05 1.00 437 1.61 0.06 1.61 1.39 1.75 -0.22 1.00 
BMI (kg/m²) 468 26.3 3.5 26.0 18.6 39.0 1.00 -0.05 437 28.5 5.7 28.3 16.9 47.1 1.00 -0.22 
Weight (kg) 468 78.6 11.7 77.0 49.4 112.8 0.86 0.45 437 73.5 14.4 71.9 37.8 114.3 0.93 0.16 
ARIC Age (yrs) 3823 54.69 5.70 55.00 44.00 66.00 -0.04 -0.16 4287 53.97 5.67 54.00 44.00 66.00 0.04 -0.15 
Height (m) 3823 1.76 0.06 1.76 1.49 1.99 -0.03 1.00 4287 1.62 0.06 1.62 1.37 1.87 -0.08 1.00 
BMI (kg/m²) 3822 27.48 4.01 26.97 17.21 56.26 1.00 -0.03 4286 26.63 5.52 25.45 14.38 55.20 1.00 -0.08 
Weight (kg) 3822 85.54 13.76 84.09 44.55 182.27 0.89 0.43 4286 70.00 14.99 66.82 36.36 141.82 0.94 0.26 
B58C-T1DGC Age (yrs) 1259 45.31 0.34 45.33 44.50 46.00 -0.02 -0.05 1328 45.27 0.34 45.25 44.50 46.00 0.00 -0.04 
Height (m) 1261 1.76 0.07 1.76 1.55 1.99 -0.03 1.00 1330 1.63 0.06 1.63 1.40 1.85 -0.07 1.00 
BMI (kg/m²) 1259 28.02 4.19 27.56 16.84 51.63 1.00 -0.03 1328 26.97 5.58 25.73 17.18 52.20 1.00 -0.07 
Weight (kg) 1259 87.05 14.41 86.00 50.80 177.10 0.89 0.43 1328 71.63 15.45 68.40 43.00 155.30 0.93 0.29 
B58C-WTCCC Age (yrs) 741 44.89 0.34 44.75 44.50 45.60 -0.01 -0.04 738 44.89 0.35 44.75 44.50 45.60 0.02 0.02 
Height (m) 741 1.76 0.07 1.76 1.52 2.02 -0.05 1.00 738 1.62 0.06 1.63 1.42 1.80 -0.10 1.00 
BMI (kg/m²) 741 27.84 4.29 27.23 15.93 48.41 1.00 -0.05 738 26.92 5.44 25.56 17.34 56.55 1.00 -0.10 
Weight (kg) 741 86.56 14.63 85.20 51.00 137.50 0.87 0.39 738 70.96 14.68 68.20 41.80 139.40 0.91 0.29 
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BRIGHT Age (yrs) 719 56.29 11.15 57.00 21.00 84.00 -0.12 -0.24 1087 57.43 11.23 58.00 21.00 85.00 0.07 -0.24 
Height (m) 719 1.74 0.07 1.74 1.51 1.95 -0.06 1.00 1087 1.61 0.06 1.61 1.39 1.81 -0.08 1.00 
BMI (kg/m²) 719 27.74 3.28 27.68 17.20 38.26 1.00 -0.06 1087 27.36 4.04 27.03 16.85 41.66 1.00 -0.08 
Weight (kg) 719 84.22 11.90 83.45 51.00 121.00 0.80 0.54 1087 71.19 11.55 69.90 41.70 122.80 0.87 0.41 
CAPS1 cases Age (yrs) 505 68.15 7.38 67.90 49.50 81.10 -0.16 -0.19 NA NA NA NA NA NA NA NA 
Height (m) 489 1.77 0.07 1.77 1.58 1.97 -0.04 1.00 NA NA NA NA NA NA NA NA 
BMI (kg/m²) 484 26.42 3.48 26.01 18.36 41.77 1.00 -0.04 NA NA NA NA NA NA NA NA 
Weight (kg) 485 82.50 12.26 82.00 47.00 135.00 0.86 0.47 NA NA NA NA NA NA NA NA 
CAPS1 controls Age (yrs) 506 66.36 7.50 65.90 44.90 79.80 -0.17 -0.25 NA NA NA NA NA NA NA NA 
Height (m) 491 1.77 0.07 1.76 1.58 2.01 0.04 1.00 NA NA NA NA NA NA NA NA 
BMI (kg/m²) 483 26.49 3.58 26.25 16.60 58.36 1.00 0.04 NA NA NA NA NA NA NA NA 
Weight (kg) 485 82.75 13.10 82.00 53.00 187.00 0.88 0.51 NA NA NA NA NA NA NA NA 
CAPS2 cases Age (yrs) 1483 66.13 7.07 65.40 44.90 82.20 -0.09 -0.24 NA NA NA NA NA NA NA NA 
Height (m) 1483 1.77 0.06 1.77 1.54 2.00 0.02 1.00 NA NA NA NA NA NA NA NA 
BMI (kg/m²) 1423 26.34 3.37 25.95 15.74 55.24 1.00 0.02 NA NA NA NA NA NA NA NA 
Weight (kg) 1424 82.53 12.24 82.00 47.00 185.00 0.88 0.49 NA NA NA NA NA NA NA NA 
CAPS2 controls Age (yrs) 519 67.24 7.35 66.90 49.10 80.10 -0.05 -0.09 NA NA NA NA NA NA NA NA 
Height (m) 519 1.76 0.06 1.76 1.59 1.98 -0.07 1.00 NA NA NA NA NA NA NA NA 
BMI (kg/m²) 500 26.03 3.32 25.75 17.56 45.20 1.00 -0.07 NA NA NA NA NA NA NA NA 
Weight (kg) 504 80.80 11.38 80.00 55.00 140.00 0.88 0.42 NA NA NA NA NA NA NA NA 
CAD-WTCCC Age (yrs) 1491 59.96 7.98 61.00 35.00 82.00 -0.16 -0.10 388 60.28 8.47 61.00 36.00 81.00 -0.09 -0.12 
Height (m) 1491 1.74 0.07 1.74 1.40 1.98 -0.08 1.00 388 1.60 0.07 1.59 1.42 1.78 -0.09 1.00 
BMI (kg/m²) 1489 27.55 3.91 27.13 16.53 53.40 1.00 -0.08 387 27.84 5.23 27.18 12.81 51.73 1.00 -0.09 
Weight (kg) 1489 83.25 13.07 82.50 37.70 173.00 0.86 0.44 387 71.04 14.13 69.20 29.20 149.50 0.91 0.33 
CHS Age (yrs) 1281 73.00 5.66 72.00 65.00 95.00 -0.15 -0.22 1957 71.90 5.15 71.00 65.00 98.00 -0.14 -0.23 
Height (m) 1277 1.73 0.07 1.73 1.51 1.93 -0.04 1.00 1955 1.59 0.06 1.59 1.24 1.78 -0.04 1.00 
BMI (kg/m²) 1276 26.40 3.50 26.10 18.60 44.20 1.00 -0.04 1952 26.40 4.78 25.80 18.50 48.30 1.00 -0.05 
Weight (kg) 1276 79.70 11.90 79.00 50.00 145.00 0.86 0.46 1952 67.10 12.90 65.50 37.30 133.20 0.91 0.04 
CoLaus Age (yrs) 2547 52.92 10.77 52.20 34.90 75.10 0.18 -0.19 2862 53.88 10.72 53.70 35.00 75.40 0.16 -0.20 
Height (m) 2547 1.75 0.07 1.75 1.33 1.98 -0.15 1.00 2862 1.63 0.07 1.63 1.31 1.85 -0.21 1.00 
BMI (kg/m²) 2547 26.64 4.19 26.20 11.70 81.10 1.00 -0.15 2861 25.15 4.91 24.20 8.10 59.20 1.00 -0.21 
Weight (kg) 2547 81.54 13.41 79.90 36.50 175.40 0.85 0.38 2861 66.43 12.98 64.00 21.40 171.00 0.91 0.22 
deCODE Age (yrs) 9213 64.74 15.93 78.00 18.00 103.00 -0.15 -0.31 17586 57.94 18.46 43.00 11.50 108.00 0.08 -0.34 
Height (m) 9213 1.78 0.07 1.80 1.30 2.07 0.02 1.00 17586 1.65 0.06 1.69 1.34 1.99 -0.07 1.00 
BMI (kg/m²) 9213 27.71 4.70 45.99 14.52 72.14 1.00 0.02 17586 26.83 5.49 18.56 13.67 73.51 1.00 -0.07 
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Weight (kg) 9213 87.89 16.57 149.00 40.00 216.00 0.88 0.44 17586 73.49 15.77 53.00 33.00 220.00 0.92 0.30 
DGI cases Age (yrs) 687 63.22 10.32 64.28 31.36 91.04 -0.19 -0.24 630 65.43 10.45 66.46 31.12 93.09 -0.26 -0.21 
Height (m) 687 1.74 0.06 1.74 1.43 2.00 -0.02 1.00 630 1.61 0.06 1.61 1.41 1.85 -0.08 1.00 
BMI (kg/m²) 687 28.15 3.87 27.97 18.05 46.71 1.00 -0.02 630 28.78 4.86 28.20 18.51 53.73 1.00 -0.08 
Weight (kg) 687 85.58 13.34 84.80 53.40 148.00 0.87 0.47 630 74.60 13.38 73.50 43.80 141.00 0.90 0.35 
DGI controls Age (yrs) 553 58.11 10.34 58.28 31.71 84.78 -0.01 -0.03 537 59.11 10.27 59.60 33.74 89.94 -0.02 -0.27 
Height (m) 553 1.76 0.06 1.76 1.57 2.00 -0.03 1.00 537 1.63 0.06 1.63 1.42 1.87 -0.10 1.00 
BMI (kg/m²) 553 26.62 3.20 26.37 16.95 43.89 1.00 -0.03 537 26.72 4.16 26.20 17.67 45.37 1.00 -0.10 
Weight (kg) 553 82.21 11.39 80.30 50.80 143.00 0.86 0.49 537 70.52 11.69 69.50 43.00 124.00 0.89 0.35 
EGCUT Age (yrs) 697 40.62 16.78 38.00 18.00 90.00 0.41 -0.39 720 42.88 15.93 42.00 18.00 92.00 0.35 -0.26 
Height (m) 697 1.79 0.07 1.79 1.58 2.03 -0.15 1.00 720 1.65 0.06 1.65 1.45 1.84 -0.14 1.00 
BMI (kg/m²) 697 26.05 4.61 25.39 15.82 54.00 1.00 -0.15 720 26.25 6.02 25.08 15.90 58.40 1.00 -0.14 
Weight (kg) 697 83.32 15.27 82.00 49.00 191.00 0.90 0.30 720 71.41 16.36 68.00 39.00 160.00 0.94 0.20 
EPIC-Obesity 
Study 
Age (yrs) 1621 59.8 9.0 60.0 39.0 77.0 0.03 -0.25 1931 58.8 8.9 59.0 39.0 77.0 0.08 -0.26 
Height (m) 1621 1.74 0.07 1.74 1.49 1.97 -0.05 1.00 1931 1.61 0.06 1.61 1.25 1.83 -0.13 1.00 
BMI (kg/m²) 1621 28.3 3.9 28.2 16.9 43.6 1.00 -0.05 1931 28.6 5.2 28.4 16.1 47.6 1.00 -0.13 
Weight (kg) 1621 85.5 13.3 85.0 42.8 137.6 0.87 0.45 1931 74.0 14.1 72.8 44.6 126.6 0.92 0.27 
ERF 
(EUROSPAN) 
Age (yrs) 890 50.14 14.98 50.67 18.00 88.60 0.14 -0.49 1170 49.30 15.34 49.52 18.03 92.10 0.27 -0.42 
Height (m) 890 1.75 0.07 1.75 1.52 1.96 -0.08 1.00 1170 1.61 0.07 1.62 1.41 1.83 -0.11 1.00 
BMI (kg/m²) 890 27.14 3.98 26.78 15.85 42.44 1.00 -0.08 1170 26.36 4.77 25.64 15.54 45.37 1.00 -0.11 
Weight (kg) 890 82.70 13.52 81.40 48.00 133.30 0.86 0.43 1170 68.96 13.14 67.00 42.10 133.90 0.90 0.32 
Fenland Age (yrs) 615 44.48 7.32 45.00 30.00 57.00 0.08 -0.09 787 45.34 7.18 46.00 30.00 57.00 0.09 -0.11 
Height (m) 615 1.77 0.07 1.77 1.59 2.01 -0.01 1.00 787 1.64 0.06 1.64 1.43 1.90 -0.07 1.00 
BMI (kg/m²) 615 27.62 4.07 27.27 18.62 56.66 1.00 -0.01 787 26.68 5.46 25.44 17.27 55.39 1.00 -0.07 
Weight (kg) 615 86.76 13.87 85.50 49.40 155.70 0.83 0.46 787 71.48 15.25 68.30 42.40 142.50 0.93 0.28 
FHS controls Age (yrs) 218 52.09 12.20 54.19 26.99 76.86 0.10 -0.18 216 58.25 8.57 59.10 27.33 81.09 -0.06 -0.11 
Height (m) 208 1.77 0.07 1.78 1.55 1.98 -0.07 1.00 207 1.62 0.06 1.63 1.46 1.81 0.04 1.00 
BMI (kg/m²) 208 27.74 3.59 27.10 19.56 42.51 1.00 -0.07 207 26.64 4.66 25.61 17.48 43.39 1.00 0.04 
Weight (kg) 208 87.22 13.09 84.80 57.61 131.09 0.83 0.50 207 70.34 13.59 67.59 43.09 122.05 0.93 0.41 
FHS cases Age (yrs) 220 54.20 11.87 55.75 26.38 74.14 0.02 -0.27 243 57.43 10.08 58.42 26.48 84.00 -0.04 -0.32 
Height (m) 208 1.77 0.07 1.77 1.58 1.96 -0.18 1.00 233 1.62 0.06 1.62 1.42 1.79 -0.02 1.00 
BMI (kg/m²) 208 28.51 4.68 28.15 15.96 45.72 1.00 -0.18 233 28.27 6.51 26.75 18.43 50.18 1.00 -0.02 
Weight (kg) 208 89.04 15.03 87.77 51.71 146.51 0.89 0.27 233 73.87 17.94 69.40 45.36 1.00 0.95 0.29 
FRAM Age (yrs) 3700 38.72 8.73 38.00 21.00 72.00 0.16 -0.05 4389 38.23 8.63 38.00 21.00 70.00 0.27 -0.08 
Height (m) 3700 1.77 0.07 1.77 1.52 2.00 -0.04 1.00 4389 1.63 0.06 1.63 1.40 1.85 -0.07 1.00 
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BMI (kg/m²) 3700 27.07 4.18 26.61 16.91 56.54 1.00 -0.04 4384 24.88 5.25 23.57 14.96 60.58 1.00 -0.07 
Weight (kg) 3700 84.43 14.43 82.56 44.00 177.36 0.86 0.44 4384 65.84 14.64 62.60 38.10 170.10 0.89 0.35 
FTC Age (yrs) NA NA NA NA NA NA NA NA 126 63.49 12.08 66.28 26.52 75.94 0.27 -0.22 
Height (m) NA NA NA NA NA NA NA NA 125 1.61 0.06 1.61 1.47 1.78 -0.18 1.00 
BMI (kg/m²) NA NA NA NA NA NA NA NA 125 25.07 3.41 24.65 18.69 35.04 1.00 -0.18 
Weight (kg) NA NA NA NA NA NA NA NA 126 65.53 9.68 64.25 46.50 100.50 0.86 0.30 
FUSION controls Age (yrs) 572 63.41 7.62 64.00 46.00 90.91 -0.05 -0.24 599 63.71 7.27 64.75 42.60 89.15 0.05 -0.29 
Height (m) 569 1.74 0.06 1.74 1.56 1.91 -0.05 1.00 598 1.60 0.06 1.60 1.44 1.79 -0.12 1.00 
BMI (kg/m²) 572 27.02 3.53 26.78 19.22 51.07 1.00 -0.05 599 27.24 4.15 26.80 17.50 45.90 1.00 -0.12 
Weight (kg) 572 81.40 11.98 80.65 52.10 151.10 0.84 0.46 599 69.99 11.44 68.80 45.70 127.10 0.88 0.33 
FUSION cases Age (yrs) 623 62.06 7.33 62.41 40.77 77.81 -0.21 -0.18 469 63.66 7.75 64.01 45.00 83.19 -0.21 -0.22 
Height (m) 617 1.73 0.06 1.73 1.52 1.97 0.00 1.00 465 1.60 0.06 1.59 1.40 1.76 0.02 1.00 
BMI (kg/m²) 623 29.44 4.02 29.14 18.19 43.14 1.00 0.00 469 31.20 5.25 30.71 16.00 47.59 1.00 0.02 
Weight (kg) 623 88.43 13.58 88.00 50.90 144.00 0.89 0.42 469 79.51 14.70 76.90 35.00 125.50 0.91 0.39 
GENMETS 
controls 
Age (yrs) 401 48.91 10.15 49.00 30.00 74.00 0.03 -0.27 422 48.60 10.18 49.00 30.00 74.00 0.04 -0.26 
Height (m) 401 1.75 0.07 1.75 1.55 1.80 -0.16 1.00 422 1.75 0.07 1.75 1.55 1.96 -0.16 1.00 
BMI (kg/m²) 401 25.41 3.08 24.94 17.09 39.04 1.00 -0.16 422 25.34 3.15 24.92 17.09 39.04 1.00 -0.16 
Weight (kg) 401 78.03 10.33 77.00 54.00 116.00 0.82 0.43 422 77.62 10.60 77.00 51.00 113.00 0.81 0.45 
GENMETS 
cases 
Age (yrs) 410 49.11 10.55 49.00 30.00 75.00 -0.07 -0.24 414 52.25 11.62 51.00 30.00 75.00 -0.07 -0.27 
Height (m) 410 1.76 0.07 1.76 1.58 1.97 -0.13 1.00 414 1.61 0.07 1.61 1.35 1.82 -0.13 1.00 
BMI (kg/m²) 410 29.45 3.62 28.84 23.19 47.07 1.00 -0.13 414 29.62 4.88 28.68 20.58 45.78 1.00 -0.13 
Weight (kg) 410 91.16 12.56 89.00 65.00 151.00 0.81 0.47 414 76.60 13.40 75.00 49.00 123.00 0.87 0.36 
GerMiFSI Age (yrs) 394 57.27 8.57 59.00 32.00 82.00 -0.08 -0.17 206 60.39 8.67 61.00 36.00 82.00 0.04 -0.02 
Height (m) 394 1.75 0.06 1.75 1.59 1.97 -0.05 1.00 206 1.63 0.06 1.63 1.44 1.79 0.00 1.00 
BMI (kg/m²) 394 27.36 3.30 26.83 18.42 46.24 1.00 -0.05 206 27.17 4.17 26.91 19.05 40.75 1.00 0.00 
Weight (kg) 394 83.92 11.67 83.00 60.00 140.00 0.86 0.46 206 72.29 12.24 71.00 48.00 115.00 0.90 0.42 
GerMiFSII Age (yrs) 901 60.14 12.17 59.00 29.00 88.00 -0.01 -0.01 223 62.80 12.76 61.00 34.00 90.00 -0.17 0.17 
Height (m) 901 1.74 0.07 1.74 1.52 2.00 0.02 1.00 223 1.62 0.06 1.61 1.50 1.79 -0.20 1.00 
BMI (kg/m²) 901 27.82 3.54 27.41 18.44 54.08 1.00 -0.02 223 28.06 4.76 27.69 16.90 46.30 1.00 -0.20 
Weight (kg) 901 83.00 12.49 83.00 50.20 160.00 0.85 0.50 223 73.55 12.62 72.10 47.00 130.00 0.90 0.23 
KORA S3 Age (yrs) 813 52.96 10.09 54.00 25.00 69.00 0.22 -0.33 831 52.09 10.08 53.00 25.00 69.00 0.33 -0.32 
Height (m) 813 1.74 0.07 1.74 1.51 1.96 -0.14 1.00 830 1.61 0.06 1.61 1.44 1.80 -0.25 1.00 
BMI (kg/m²) 813 27.69 3.45 27.29 18.73 40.67 1.00 -0.14 829 26.98 4.64 26.40 16.71 45.43 1.00 -0.25 
Weight (kg) 813 83.58 11.46 83.30 59.00 132.50 0.79 0.44 829 69.87 11.88 68.30 42.50 121.80 0.88 0.19 
KORA S4 Age (yrs) 884 54.22 8.92 54.00 28.00 72.00 0.13 -0.31 930 53.62 8.80 53.00 25.00 74.00 0.32 -0.27 
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Height (m) 883 1.74 0.07 1.74 1.56 1.95 -0.13 1.00 928 1.61 0.06 1.61 1.44 1.83 -0.18 1.00 
BMI (kg/m²) 883 27.99 3.91 27.59 18.31 55.11 1.00 -0.13 928 27.49 5.07 26.78 18.21 51.22 1.00 -0.18 
Weight (kg) 883 85.13 12.93 84.00 54.20 192.70 0.83 0.40 929 71.46 13.30 69.60 43.90 142.00 0.90 0.23 
MICROS Age (yrs) 475 45.09 15.67 41.97 18.19 87.85 0.28 -0.45 622 45.38 16.41 42.55 18.00 83.88 0.40 -0.52 
Height (m) 467 1.73 0.07 1.73 1.53 1.95 -0.07 1.00 612 1.61 0.07 1.61 1.40 1.79 -0.28 1.00 
BMI (kg/m²) 475 26.07 3.96 25.62 18.13 42.75 1.00 -0.07 622 25.28 5.32 24.27 14.03 71.26 1.00 -0.28 
Weight (kg) 468 78.38 13.32 76.90 47.00 127.50 0.86 0.43 612 65.16 13.19 63.00 36.60 169.00 0.91 0.13 
MIGEN Age (yrs) 1622 45.40 6.97 45.70 19.40 92.00 0.03 -0.08 1030 49.39 7.40 51.00 18.71 61.00 0.09 -0.14 
Height (m) 1622 1.76 0.08 1.75 1.53 2.08 0.02 1.00 1030 163.10 0.08 1.63 1.10 1.96 -0.06 1.00 
BMI (kg/m²) 1622 27.93 4.57 27.40 17.49 54.30 1.00 0.02 1030 27.96 7.03 26.35 14.78 78.41 1.00 -0.06 
Weight (kg) 1622 86.57 16.30 84.00 52.00 181.60 0.88 0.47 1030 74.42 19.71 70.00 43.09 205.02 0.94 0.27 
NBS-WTCCC Age (yrs) 696 45.41 11.77 47.00 17.00 69.00 0.06 -0.15 745 41.44 12.58 42.00 17.00 69.00 0.15 -0.19 
Height (m) 696 1.78 0.07 1.78 1.50 2.00 -0.07 1.00 745 1.65 0.07 1.65 1.48 1.83 -0.20 1.00 
BMI (kg/m²) 694 26.76 4.12 26.30 18.13 53.19 1.00 -0.07 743 25.75 4.46 24.86 18.08 47.22 1.00 -0.20 
Weight (kg) 694 85.03 14.35 82.73 54.09 173.00 0.88 0.41 743 69.74 12.21 66.82 50.00 127.27 0.89 0.25 
NFBC1966 Age (yrs) 2250 31.00 0.00 31.00 31.00 31.00 NA NA 2249 31.00 0.00 31.00 31.00 31.00 NA NA 
Height (m) 2250 1.78 0.06 1.78 1.52 2.03 -0.04 1.00 2249 1.65 0.06 1.65 1.05 1.87 -0.10 1.00 
BMI (kg/m²) 2250 25.18 3.62 24.86 15.32 47.58 1.00 -0.04 2247 24.16 4.68 23.13 15.43 54.35 1.00 -0.10 
Weight (kg) 2250 80.15 12.72 78.70 49.40 150.40 0.89 0.42 2247 65.52 13.24 63.00 29.20 165.40 0.92 0.28 
NHS Age (yrs) NA NA NA NA NA NA NA NA 2265 54.32 6.67 55.00 21.00 66.00 0.05 -0.02 
Height (m) NA NA NA NA NA NA NA NA 2265 1.64 0.06 1.63 1.45 1.98 -0.10 1.00 
BMI (kg/m²) NA NA NA NA NA NA NA NA 2265 25.13 4.53 24.13 16.40 53.14 1.00 -0.10 
Weight (kg) NA NA NA NA NA NA NA NA 2265 149.16 27.78 144.00 84.00 310.00 0.92 0.29 
NSPHS Age (yrs) 309 47.56 20.83 48.00 15.00 87.00 0.31 -0.32 347 46.47 20.60 45.00 14.00 91.00 0.49 -0.40 
Height (m) 308 1.71 0.07 1.72 1.48 1.89 -0.04 1.00 344 1.58 0.07 1.59 1.40 1.75 -0.16 1.00 
BMI (kg/m²) 307 26.75 4.54 26.23 17.78 46.49 1.00 -0.04 340 25.97 5.07 24.98 16.44 46.68 1.00 -0.16 
Weight (kg) 307 78.42 14.66 77.00 51.00 138.00 0.88 0.42 342 64.99 13.11 63.00 38.00 121.00 0.89 0.29 
NTRNESDA Age (yrs) 1211 46.08 13.43 48.00 18.00 81.00 0.26 -0.29 2311 42.64 13.23 42.00 18.00 78.00 0.23 -0.23 
Height (m) 1211 1.82 0.07 1.82 1.59 2.07 -0.14 1.00 2311 1.69 0.06 1.69 1.50 1.96 -0.15 1.00 
BMI (kg/m²) 1210 26.05 3.92 25.62 15.95 50.21 1.00 -0.14 2306 25.15 4.82 24.19 14.61 53.27 1.00 -0.15 
Weight (kg) 1210 85.89 13.80 84.15 50.10 170.00 0.87 0.36 2306 71.83 14.06 69.20 44.00 167.00 0.92 0.24 
ORCADES Age (yrs) 332 54.27 15.73 54.66 17.29 93.75 0.29 -0.38 384 53.01 15.68 54.27 17.71 97.62 0.25 -0.38 
Height (m) 324 1.75 0.07 1.75 1.59 1.99 -0.22 1.00 371 1.61 0.06 1.61 1.38 1.78 -0.17 1.00 
BMI (kg/m²) 332 28.08 4.27 27.67 16.97 47.10 1.00 -0.22 384 27.48 5.18 26.60 18.47 47.63 1.00 -0.17 
Weight (kg) 324 85.76 13.21 84.25 44.40 148.40 0.87 0.28 371 71.06 13.69 69.10 45.60 123.10 0.92 0.22 
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PLCO Age (yrs) 2244 64.2 5.1 64.0 55.0 74.0 -0.11 -0.11 NA NA NA NA NA NA NA NA 
Height (m) 2244 1.78 0.07 1.78 1.55 2.03 -0.04 1.00 NA NA NA NA NA NA NA NA 
BMI (kg/m²) 2236 27.5 3.8 27.1 13.3 48.2 1.00 -0.04 NA NA NA NA NA NA NA NA 
Weight (kg) 2236 87.4 13.6 86.2 38.6 176.9 0.88 0.44 NA NA NA NA NA NA NA NA 
PROCARDIS Age (yrs) 1700 59.29 7.08 60.00 34.00 82.00 -0.07 -0.14 612 61.21 6.72 62.00 33.00 81.00 0.03 -0.21 
Height (m) 1700 1.75 0.07 1.75 1.51 2.06 -0.10 1.00 612 1.63 0.07 1.64 1.44 1.85 -0.22 1.00 
BMI (kg/m²) 1700 27.60 3.80 27.14 18.34 48.23 1.00 -0.10 612 26.71 5.00 25.94 15.43 51.37 1.00 -0.22 
Weight (kg) 1700 84.51 12.91 83.50 51.00 159.00 0.84 0.44 612 71.21 13.30 69.00 42.00 145.00 0.89 0.23 
RS-I Age (yrs) 2427 68.13 8.16 67.05 55.01 97.81 -0.08 -0.31 3547 70.32 9.60 69.40 55.00 99.22 0.05 -0.38 
Height (m) 2372 1.75 0.07 1.75 1.51 1.98 -0.05 1.00 3375 1.61 0.07 1.62 1.01 1.92 -0.15 1.00 
BMI (kg/m²) 2372 25.68 2.99 25.61 14.19 38.19 1.00 -0.05 3372 26.74 4.10 26.31 15.43 59.50 1.00 -0.15 
Weight (kg) 2375 78.58 10.74 77.80 41.00 122.30 0.82 0.53 3383 69.59 11.29 68.70 40.10 146.50 0.85 0.37 
RUNMC Age (yrs) 1839 63.47 8.34 64.00 24.00 91.00 -0.02 -0.12 1132 55.41 11.14 64.00 25.00 91.00 0.17 -0.23 
Height (m) 1777 1.77 0.07 1.85 1.55 2.00 -0.10 1.00 1096 1.66 0.06 1.75 1.38 1.85 -0.15 1.00 
BMI (kg/m²) 1777 25.98 3.66 21.90 16.10 61.30 1.00 -0.10 1096 25.44 4.26 24.50 17.30 52.70 1.00 -0.15 
Weight (kg) 1777 81.49 12.33 75.00 46.00 185.00 0.87 0.40 1096 70.30 12.16 75.00 46.00 150.00 0.90 0.29 
SardiNIA Age (yrs) 1886 44.08 18.10 42.90 14.00 93.90 0.51 -0.46 2419 43.19 17.30 42.10 14.00 101.30 0.55 -0.50 
Height (m) 1883 1.66 0.07 1.66 1.44 1.96 -0.22 1.00 2415 1.55 0.06 1.55 1.31 1.78 -0.31 1.00 
BMI (kg/m²) 1885 26.15 4.11 25.90 14.90 42.90 1.00 -0.22 2416 24.75 5.03 23.80 13.90 53.30 1.00 -0.31 
Weight (kg) 1883 72.27 11.71 72.00 34.00 135.00 0.84 0.33 2415 59.17 11.40 57.00 32.00 145.00 0.90 0.11 
SASBAC cases Age (yrs) NA NA NA NA NA NA NA NA 795 62.64 6.26 63.00 50.00 75.00 0.11 -0.08 
Height (m) NA NA NA NA NA NA NA NA 794 1.64 0.06 1.65 1.47 1.82 -0.16 1.00 
BMI (kg/m²) NA NA NA NA NA NA NA NA 793 25.79 4.00 25.21 16.22 46.67 1.00 -0.16 
Weight (kg) NA NA NA NA NA NA NA NA 794 69.68 11.18 68.00 40.00 117.00 0.86 0.30 
SASBAC 
controls 
Age (yrs) NA NA NA NA NA NA NA NA 764 62.77 6.34 63.00 49.00 75.00 0.02 -0.05 
Height (m) NA NA NA NA NA NA NA NA 758 1.64 0.05 1.64 1.28 1.81 -0.06 1.00 
BMI (kg/m²) NA NA NA NA NA NA NA NA 755 25.52 4.10 25.22 16.94 59.52 1.00 -0.06 
Weight (kg) NA NA NA NA NA NA NA NA 760 68.67 11.69 67.00 42.00 168.00 0.89 0.33 
SEARCH 
/UKOPS 
Age (yrs) NA NA NA NA NA NA NA NA 1710 57.15 10.20 58.00 20.00 91.00 -0.09 -0.13 
Height (m) NA NA NA NA NA NA NA NA 1592 1.63 0.07 1.63 1.35 1.83 -0.14 1.00 
BMI (kg/m²) NA NA NA NA NA NA NA NA 1556 26.99 5.20 25.99 17.47 53.67 1.00 -0.14 
Weight (kg) NA NA NA NA NA NA NA NA 1581 71.32 13.99 69.00 44.00 135.17 0.91 0.27 
SHIP Age (yrs) 2019 50.88 16.43 52.00 20.00 80.00 0.25 -0.48 2073 48.58 16.02 48.00 20.00 81.00 0.41 -0.48 
Height (m) 2019 1.75 0.07 1.75 1.48 1.98 -0.12 1.00 2073 1.63 0.07 1.63 1.42 1.94 -0.26 1.00 
BMI (kg/m²) 2019 27.68 4.04 27.41 18.06 48.07 1.00 -0.12 2073 26.92 5.31 26.16 16.10 52.40 1.00 -0.26 
 Chapter 3 195 
Weight (kg) 2019 85.06 13.56 83.80 49.90 156.40 0.83 0.40 2073 71.20 13.74 69.20 41.30 133.30 0.89 0.16 
T2D-WTCCC Age (yrs) 1105 58.95 9.91 59.00 29.00 96.00 -0.31 -0.17 798 57.94 10.45 59.00 27.00 85.00 -0.30 -0.16 
Height (m) 1105 1.75 0.07 1.75 1.50 1.98 -0.02 1.00 798 1.61 0.07 1.61 1.37 1.83 0.01 1.00 
BMI (kg/m²) 1105 30.29 5.36 29.71 18.02 55.91 1.00 -0.02 798 32.56 6.87 31.52 17.91 62.37 1.00 0.01 
Weight (kg) 1105 93.37 17.86 91.17 47.63 161.94 0.91 0.40 798 85.04 19.29 82.56 43.00 155.70 0.93 0.37 
TwinsUK Age (yrs) NA NA NA NA NA NA NA NA 1479 46.19 12.31 47.55 16.62 76.54 0.15 -0.20 
Height (m) NA NA NA NA NA NA NA NA 1479 1.62 0.06 1.63 1.42 1.80 -0.12 1.00 
BMI (kg/m²) NA NA NA NA NA NA NA NA 1477 25.02 4.80 24.06 13.22 52.71 1.00 -0.12 
Weight (kg) NA NA NA NA NA NA NA NA 1477 66.03 12.97 64.00 35.10 140.90 0.92 0.27 
VIS Age (yrs) 328 55.95 14.94 57.00 18.00 88.00 0.23 -0.40 467 56.97 15.64 57.00 18.00 93.00 0.30 -0.45 
Height (m) 325 1.76 0.07 1.76 1.58 2.04 -0.10 1.00 459 1.62 0.07 1.62 1.43 1.91 -0.20 1.00 
BMI (kg/m²) 328 27.55 3.69 27.49 18.36 40.69 1.00 -0.10 467 27.18 4.50 27.08 17.01 52.02 1.00 -0.20 
Weight (kg) 325 85.56 13.01 84.80 50.90 136.50 0.83 0.47 445 70.99 12.45 69.80 46.60 153.00 0.89 0.26 
Stage 2 (in-silico replication studies) 
BHS Age (yrs) 558 53.47 17.15 53.65 17.60 91.40 0.15 -0.38 770 53.71 17.07 53.05 17.30 90.50 0.11 -0.43 
Height (m) 558 1.75 0.07 1.75 1.53 1.99 -0.09 1.00 770 1.62 0.06 1.62 1.35 1.90 -0.15 1.00 
BMI (kg/m²) 558 26.62 3.57 26.25 15.77 40.12 1.00 -0.09 769 25.49 4.42 24.66 16.82 40.77 1.00 -0.15 
Weight (kg) 558 81.80 12.31 80.25 46.40 127.00 0.83 0.47 769 67.06 12.02 65.00 34.80 109.00 0.90 0.29 
Corogene Age (yrs) 2266 59.66 12.83 61.00 25.00 92.00 -0.03 -0.26 1490 62.61 13.47 65.00 25.00 94.00 0.09 -0.30 
Height (m) 2267 1.76 0.07 1.76 1.34 2.03 -0.04 1.00 1491 1.62 0.07 1.62 1.05 1.85 -0.14 1.00 
BMI (kg/m²) 2265 27.39 4.23 26.79 15.95 54.88 1.00 -0.04 1491 26.87 5.21 26.07 13.63 57.68 1.00 -0.14 
Weight (kg) 2265 85.00 14.42 83.50 44.00 170.00 0.89 0.41 1491 70.14 13.88 68.30 36.00 144.00 0.90 0.28 
EGCUT Age (yrs) 135 40.93 17.81 36.50 18.00 80.00 0.33 -0.55 210 41.03 16.46 39.00 18.00 87.00 0.41 -0.37 
Height (m) 135 1.79 0.07 1.80 1.58 2.04 -0.14 1.00 210 1.66 0.07 1.66 1.44 1.84 -0.25 1.00 
BMI (kg/m²) 135 26.03 4.95 25.11 17.30 43.65 1.00 -0.14 210 25.63 6.09 24.02 17.00 48.24 1.00 -0.25 
Weight (kg) 135 83.68 16.41 80.50 50.00 143.00 0.91 0.27 210 70.46 16.22 66.50 40.00 136.00 0.93 0.10 
FHS Age (yrs) 662 48.20 13.70 46.30 25.60 85.70 0.15 -0.24 880 47.50 13.00 45.00 25.70 85.80 0.19 -0.26 
Height (m) 632 1.77 0.07 1.77 1.57 2.03 -0.09 1.00 831 1.63 0.06 1.63 1.41 1.96 -0.12 1.00 
BMI (kg/m²) 632 27.80 4.30 27.20 18.40 46.20 1.00 -0.09 831 27.10 6.10 26.10 16.50 55.00 1.00 -0.12 
Weight (kg) 632 87.10 14.60 85.30 55.30 140.60 0.88 0.39 831 72.30 16.60 68.90 41.70 144.20 0.94 0.22 
FINGESTURE 
cases 
Age (yrs) 745 61.19 10.58 62.00 34.00 85.00 -0.13 -0.33 198 67.44 10.33 68.00 31.00 85.00 -0.05 -0.28 
Height (m) 745 1.74 0.07 1.74 1.55 1.97 0.10 1.00 198 1.60 0.06 1.60 1.46 1.76 -0.02 1.00 
BMI (kg/m²) 739 27.22 3.93 27.02 16.20 44.80 1.00 0.10 196 28.14 5.17 27.98 16.67 46.09 1.00 -0.02 
Weight (kg) 743 82.32 14.09 81.00 42.00 150.00 0.89 0.53 197 71.91 14.06 71.60 37.50 112.00 0.92 0.38 
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GOOD Age (yrs) 938 18.90 0.60 18.80 18.00 20.10 0.03 0.01 NA NA NA NA NA NA NA NA 
Height (m) 938 1.82 0.07 1.82 1.61 2.03 -0.05 1.00 NA NA NA NA NA NA NA NA 
BMI (kg/m²) 938 22.40 3.20 21.90 16.10 41.60 1.00 -0.05 NA NA NA NA NA NA NA NA 
Weight (kg) 938 73.90 11.60 72.00 51.30 127.00 0.88 0.42 NA NA NA NA NA NA NA NA 
HBCS Age (yrs) 737 61.41 2.75 60.80 57.00 69.30 -0.03 -0.15 991 61.55 3.05 60.90 56.70 69.80 -0.10 0.03 
Height (m) 736 1.77 0.06 1.77 1.59 1.97 -0.03 1.00 990 1.63 0.06 1.63 1.46 1.83 -0.09 1.00 
BMI (kg/m²) 736 27.56 4.30 27.01 18.75 68.39 1.00 -0.03 990 27.75 5.06 26.98 14.79 50.10 1.00 -0.09 
Weight (kg) 737 86.33 14.51 84.50 56.20 213.30 0.92 0.36 990 73.90 13.89 71.70 37.30 133.80 0.93 0.28 
HYPERGENES - 
controls 
Age (yrs) 1072 62.27 10.71 59.81 28.00 98.00 -0.09 -0.12 766 64.30 11.28 61.00 44.93 113.00 -0.15 -0.14 
Height (m) 1072 1.71 0.07 1.70 1.50 1.96 -0.14 1.00 766 1.60 0.06 1.60 1.40 1.81 -0.16 1.00 
BMI (kg/m²) 1072 25.95 3.27 25.59 10.15 40.77 1.00 -0.14 766 24.98 3.73 24.60 16.53 41.35 1.00 -0.16 
Weight (kg) 1072 76.10 10.59 75.00 29.00 118.00 0.81 0.46 766 64.25 10.13 63.00 41.00 110.00 0.87 0.34 
HYPERGENES - 
cases 
Age (yrs) 1189 49.41 10.42 50.00 17.63 84.00 0.04 -0.33 598 48.45 9.57 49.00 18.38 93.00 0.10 -0.19 
Height (m) 1189 1.72 0.07 1.72 1.48 1.96 -0.08 1.00 598 1.60 0.07 1.60 1.40 1.97 -0.10 1.00 
BMI (kg/m²) 1189 27.42 3.52 27.13 16.00 47.43 1.00 -0.08 598 26.88 4.96 26.21 17.45 52.35 1.00 -0.10 
Weight (kg) 1189 81.33 12.06 80.00 49.00 139.50 0.82 0.51 598 68.59 13.66 67.00 44.00 164.00 0.89 0.36 
MGS Age (yrs) 1247 52.67 16.01 52.00 18.00 90.00 0.02 -0.13 1350 48.48 16.29 48.00 18.00 90.00 0.03 -0.20 
Height (m) 1247 1.79 0.07 1.78 1.58 2.06 0.04 1.00 1350 1.64 0.07 1.65 1.35 2.01 -0.04 1.00 
BMI (kg/m²) 1247 30.85 6.45 29.84 15.83 72.56 1.00 0.04 1350 31.92 8.55 30.32 16.34 69.09 1.00 -0.04 
Weight (kg) 1247 98.77 22.67 95.25 53.98 249.48 0.93 0.38 1350 86.13 24.22 81.65 47.63 201.85 0.95 0.26 
NHS Age (yrs) NA NA NA NA NA NA NA NA 3217 53.22 6.96 54.00 22.00 65.00 -0.02 -0.07 
Height (m) NA NA NA NA NA NA NA NA 3217 1.64 0.08 1.63 1.35 1.83 -0.04 1.00 
BMI (kg/m²) NA NA NA NA NA NA NA NA 2988 27.13 5.63 26.00 17.01 54.87 1.00 -0.04 
Weight (kg) NA NA NA NA NA NA NA NA 2988 160.87 35.21 155.00 90.00 340.00 0.94 0.30 
RS-II Age (yrs) 973 64.48 7.59 61.89 55.14 93.95 -0.13 -0.22 1156 65.04 8.33 62.03 55.12 95.33 -0.03 -0.31 
Height (m) 971 1.76 0.06 1.76 1.57 2.03 -0.10 1.00 1153 1.63 0.06 1.63 1.42 1.90 -0.06 1.00 
BMI (kg/m²) 971 26.92 3.36 26.72 16.78 40.52 1.00 -0.10 1151 27.52 4.45 26.89 16.66 50.12 1.00 -0.06 
Weight (kg) 972 83.32 11.58 82.20 54.00 126.80 0.85 0.44 1151 72.77 12.74 71.10 36.20 150.00 0.90 0.38 
RS-III Age (yrs) 879 55.94 5.43 56.12 45.46 84.15 0.09 -0.24 1130 56.20 6.03 56.42 45.75 97.22 0.07 -0.23 
Height (m) 879 1.79 0.07 1.79 1.61 2.00 -0.07 1.00 1130 1.65 0.06 1.65 1.47 1.85 -0.10 1.00 
BMI (kg/m²) 879 28.03 4.07 27.31 18.42 46.68 1.00 -0.07 1130 27.48 5.06 26.55 14.02 56.87 1.00 -0.10 
Weight (kg) 879 89.75 14.32 87.70 58.30 153.50 0.88 0.41 1130 74.89 14.28 72.80 35.00 158.60 0.92 0.29 
Sorbs Age (yrs) 371 48.10 16.70 48.10 18.10 82.10 0.39 -0.43 536 48.00 15.90 48.60 18.00 88.40 0.49 -0.54 
Height (m) 371 1.77 0.07 1.77 1.58 1.95 -0.24 1.00 536 1.64 0.07 1.64 1.44 1.82 -0.32 1.00 
BMI (kg/m²) 371 27.20 4.00 26.80 19.00 43.90 1.00 -0.24 536 26.90 5.50 26.20 15.40 47.40 1.00 -0.32 
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Weight (kg) 371 85.40 12.70 84.00 58.00 139.00 0.85 0.30 536 72.10 14.00 70.00 43.00 126.00 0.92 0.07 
WGHS Age (yrs) NA NA NA NA NA NA NA NA 23294 54.70 7.12 52.90 38.71 89.89 -0.02 -0.07 
Height (m) NA NA NA NA NA NA NA NA 23099 1.64 0.06 1.65 1.30 2.01 -0.06 1.00 
BMI (kg/m²) NA NA NA NA NA NA NA NA 22888 25.91 4.96 24.89 14.23 59.58 1.00 -0.06 
Weight (kg) NA NA NA NA NA NA NA NA 23046 70.00 14.18 68.04 38.56 175.09 0.92 0.32 
YFS Age (yrs) 1123 37.55 5.06 39.00 30.00 45.00 0.13 -0.12 1320 37.57 5.01 39.00 30.00 45.00 0.11 -0.06 
Height (m) 911 1.80 0.07 1.80 1.57 2.03 0.04 1.00 1084 1.66 0.06 1.66 1.45 1.89 -0.06 1.00 
BMI (kg/m²) 908 26.76 4.29 26.11 17.54 49.35 1.00 0.04 1081 25.32 5.03 24.34 16.56 58.82 1.00 -0.06 
Weight (kg) 908 86.56 15.65 85.00 54.00 166.00 0.91 0.45 1083 69.82 14.55 67.00 42.00 166.00 0.94 0.29 
Polygene analysis study 
QIMR Age (yrs) 527 23.20 12.00 16.33 15.40 74.00 NA 0.15 948 29.86 14.95 26.00 15.70 84.00 NA -0.15 
Height (m) 527 1.77 0.07 1.77 1.58 1.99 NA 1.00 948 1.64 0.07 1.64 1.44 1.93 NA 1.00 
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(chair), Cornelia M van Duijn, Sailaja Vedantam, Michael N Weedon 
Imputation and signal validation by direct genotyping analyses 
WTCCC-T2D cohort (imputation validation): Timothy M Frayling, Hana Lango Allen, Michael N 
Weedon (chair); GCI cohort (signal validation): Kristin G Ardlie, Joel N Hirschhorn (chair), 
Guillaume Lettre, Rany M Salem, Michael C Turchin 
Cohort-specific contributions 
Stage 1 – Genome-wide association cohorts 
Cohort Author 
Overseeing 
(PI) 
Geno-
typing 
Pheno-
typing 
Data 
analysis 
ADVANCE Devin Absher   X X X 
Themistocles L Assimes   X X X 
Carlos Iribarren X       
Joshua W Knowles   X X X 
Thomas Quertermous X       
AGES Thor Aspelund       X 
Gudny Eiriksdottir X       
Vilmundur Gudnason X       
Tamara B Harris X       
Lenore J Launer X       
Albert Vernon Smith       X 
Amish Quince Gibson       X 
Shen Haiqing   X X   
Jeffrey R O'Connell       X 
Alan R Shuldiner X       
ARIC Eric Boerwinkle X X X   
Keri L Monda       X 
Tom H Mosley, Jr X       
Kari E North X     X 
B58C-T1DGC and 
B58C-WTCCC 
Wendy L McArdle   X     
David P Strachan X   X X 
BRIGHT Mark J Caulfield X       
Anna Dominiczak     X   
Martin Farrall     X   
Toby Johnson       X 
Patricia B Munroe X       
CAD-WTCCC Anthony J Balmforth     X   
Alistair S Hall X       
Suzanne Rafelt       X 
Nilesh J Samani X       
John R Thompson       X 
CAPS Henrik Grönberg X   X   
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Cohort Author 
Overseeing 
(PI) 
Geno-
typing 
Pheno-
typing 
Data 
analysis 
Erik Ingelsson X     X 
Fredrik Wiklund     X X 
Jianfeng Xu     X X 
CHS Alice Arnold X   X   
Nicole L Glazer       X 
Talin Haritunians   X     
Robert Kaplan X   X   
Barbara McKnight       X 
Jerome I Rotter   X     
CoLaus Jacques S Beckmann X       
Sven Bergmann X       
Toby Johnson       X 
Zoltán Kutalik       X 
Vincent Mooser X X     
Dawn Waterworth X X     
deCODE Daniel Gudbjartsson       X 
Kari Stefansson X       
Valgerdur Steinthorsdottir       X 
Gudmar Thorleifsson       X 
Unnur Thorsteinsdottir X       
G. Bragi Walters     X   
DGI Peter Almgren     X   
Leif C Groop X   X   
Joel N Hirschhorn         
Guillaume Lettre       X 
Martin Ridderstråle     X   
Elizabeth K Speliotes       X 
Sailaja Vedantam       X 
EGCUT Helene Alavere     X   
Tõnu Esko       X 
Andres Metspalu X       
Mari Nelis   X     
Mari-Liis Tammesoo       X 
EPIC Inês Barroso   X     
Ruth JF Loos   X   X 
Nicholas J Wareham X       
Eleanor Wheeler   X   X 
Jing Hua Zhao         
ERF (EUROSPAN) Najaf Amin       X 
Yurii S Aulchenko       X 
Ben Oostra X       
Cornelia M van Duijn X   X X 
M. Carola Zillikens       X 
Family Heart Study Ingrid B Borecki X X X   
Mary F Feitosa     X X 
Shamika Ketkar     X X 
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Cohort Author 
Overseeing 
(PI) 
Geno-
typing 
Pheno-
typing 
Data 
analysis 
Michael A Province X       
FENLAND Ruth JF Loos X   X   
Jian'an Luan   X   X 
Nicholas J Wareham X       
FRAM Larry D Atwood X X     
Adrienne L Cupples X     X 
Nancy L Heard-Costa       X 
Julius Suh Ngwa       X 
Charles White       X 
FTC Jaakko Kaprio X       
Kirsi Pietiläinen     X   
Samuli Ripatti       X 
Aila Rissanen X       
Ida Surakka       X 
FUSION Richard N Bergman X       
Michael Boehnke X       
Francis S Collins X       
Anne U Jackson       X 
Karen L Mohlke X       
Heather M Stringham     X   
Jaakko Tuomilehto X       
Cristen J Willer       X 
Genmets Antti Jula     X   
Seppo Koskinen     X   
Leena Peltonen X X     
Samuli Ripatti       X 
Veikko Salomaa X   X   
Ida Surakka       X 
GerMIFSI and 
GerMIFSIII 
Jeanette Erdmann X       
Christian Hengstenberg X   X   
Inke R König       X 
Michael Preuss       X 
Stefan Schreiber X   X   
Heribert Schunkert X       
H.-Erich Wichmann     X   
Andreas Ziegler       X 
KORA S3 Christian Gieger X     X 
Iris M Heid       X 
Thomas Meitinger   X     
Martina Müller       X 
KORA S4 Eva Albrecht       X 
Thomas Illig   X     
H.-Erich Wichmann X   X   
Thomas Winkler       X 
MICROS 
(EUROSPAN) 
Alessandro De Grandi   X X   
Andrew A Hicks   X     
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Cohort Author 
Overseeing 
(PI) 
Geno-
typing 
Pheno-
typing 
Data 
analysis 
Åsa Johansson       X 
Irene Pichler     X   
Peter P Pramstaller X       
MIGEN Roberto Elosua         
Aki S Havulinna     X   
Sekar Kathiresan  X       
Olle Melander X       
Christopher J O'Donnell  X       
David S Siscovick X       
Elizabeth K Speliotes       X 
Benjamin F Voight X       
NFBC1966 Lachlan Coin       X 
Paul Elliott   X X   
Nelson Freimer   X     
Anna-Liisa Hartikainen   X X   
Marjo-Riitta Jarvelin X X X   
Markku Koiranen     X   
Jaana Laitinen     X   
Mark I McCarthy   X     
Leena Peltonen   X     
Anneli Pouta     X   
Ulla Sovio       X 
Paavo Zitting   X X   
NBS-WTCCC Willem H Ouwehand X       
Jennifer G Sambrook     X   
NHS Frank B Hu X X X   
David J Hunter X X X   
Peter Kraft   X   X 
Lu Qi   X X X 
NSPHS 
(EUROSPAN) 
Ulf Gyllensten X       
Wilmar Igl   X     
Åsa Johansson   X X X 
NTRNESDA Dorret I Boomsma X       
Eco JC Geus   X     
Jouke-Jan Hottenga   X   X 
Brenda W Penninx X       
Jan H Smit     X   
Gonneke Willemsen     X   
ORCADES 
(EUROSPAN) 
Harry Campbell   X     
Åsa Johansson       X 
Veronique Vitart       X 
Sarah H Wild     X   
James F Wilson X       
Alan F Wright X   X   
PLCO Sonja I Berndt X   X X 
Stephen J Chanock X X     
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Cohort Author 
Overseeing 
(PI) 
Geno-
typing 
Pheno-
typing 
Data 
analysis 
Richard B Hayes X       
Kevin B Jacobs   X   X 
PROCARDIS Martin Farrall         
Anders Hamsten  X       
Mark Lathrop X X     
John F Peden     X   
Hugh Watkins X       
RS-I Yurii S Aulchenko       X 
Karol Estrada   X   X 
Albert Hofman X   X   
Manfred Kayser X       
Marjolein J Peters   X     
Fernando Rivadeneira X X X X 
André G Uitterlinden X X X X 
Cornelia M van Duijn X   X X 
Joyce B J van Meurs   X     
M. Carola Zillikens       X 
RUNMC Katja K Aben X       
Martin den Heijer X       
Lambertus Kiemeney X       
SardiNIA Goncalo R Abecasis X     X 
Andrea Maschio   X     
Antonella Mulas   X     
Serena Sanna       X 
David Schlessinger X       
Manuela Uda X   X   
SASBAC Per Hall X   X   
Erik Ingelsson X     X 
Jianjun Liu     X   
SEARCH/UKOPS Jonathan Patrick Tyrer       X 
SHIP Florian Ernst   X   X 
Wolfgang Hoffmann X   X   
Thomas Kocher X       
Astrid Petersmann   X     
Carsten Oliver Schmidt     X   
Henry Völzke X       
T2D-WTCCC Teresa Ferreira       X 
Timothy M Frayling X   X   
Andrew T Hattersley X   X   
Hana Lango Allen       X 
Cecilia M Lindgren X X   X 
Reedik Mägi       X 
Mark I McCarthy X X X   
Andrew P Morris       X 
John RB Perry       X 
Inga Prokopenko       X 
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Cohort Author 
Overseeing 
(PI) 
Geno-
typing 
Pheno-
typing 
Data 
analysis 
Joshua C Randall       X 
Nigel W Rayner   X   X 
Neil R Robertson   X   X 
Michael N Weedon       X 
Andrew R Wood       X 
TwinsUK Massimo Mangino   X X X 
Nicole Soranzo X X   X 
Tim D Spector X   X   
VIS (EUROSPAN) 
and KORCULA 
Caroline Hayward   X   X 
Åsa Johansson       X 
Ivana Kolcic     X   
Ana Marusic     X   
Ozren Polasek     X X 
Igor Rudan X   X   
Lina Zgaga     X   
 
Stage 2 – in silico replication cohorts 
Cohort Author 
Overseeing 
(PI) 
Geno-
typing 
Pheno-
typing 
Data 
analysis 
BHS John P Beilby X   X   
Matthew N Cooper       X 
Jennie Hui   X     
Robert Lawrence       X 
Arthur W Musk X   X   
Lyle J Palmer X       
Corogene Marja-Liisa Lokki   X     
Markku S Nieminen X       
Niina Pellikka       X 
Leena Peltonen X X     
Markus Perola       X 
Juha Sinisalo     X   
EGCUT Helene Alavere     X   
Tõnu Esko       X 
Andres Metspalu X       
Mari Nelis   X     
Mari-Liis Tammesoo       X 
Family Heart Study Ingrid B Borecki X X X   
Mary F Feitosa     X X 
Shamika Ketkar     X X 
Michael A Province X       
FINGESTURE Gabrielle Boucher       X 
Heikki V Huikuri X   X X 
Juhani Junttila     X X 
John D Rioux X     X 
GOOD Mattias Lorentzon   X X X 
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Claes Ohlsson X X X X 
Liesbeth Vandenput     X X 
HBCS Johan Eriksson X     X   
Eero Kajantie      X  
Markus Perola    X    X 
Samuli Ripatti    X    X 
Elisabeth Widen    X     
HYPERGENES Lorena Citterio     X   
Daniele Cusi X       
Nicola Glorioso   X X   
Carlo Rivolta X X     
Erika Salvi       X 
Laura Zagato     X   
MGS Jubao Duan   X     
Pablo V Gejman X X X   
Douglas F Levinson X     X 
Alan R Sanders   X X   
Jianxin Shi       X 
NHS Frank B Hu X X X   
David J Hunter X X X   
Peter Kraft   X   X 
Lu Qi   X X X 
RS-II and RS-III Yurii S Aulchenko       X 
Karol Estrada   X   X 
Albert Hofman X   X   
Manfred Kayser X       
Marjolein J Peters   X     
Fernando Rivadeneira X X X X 
André G Uitterlinden X X X X 
Cornelia M van Duijn X   X X 
Joyce B J van Meurs   X     
M. Carola Zillikens       X 
Sorbs Peter Kovacs   X X   
Reedik Mägi        X 
Inga Prokopenko       X 
Michael Stumvoll X       
Anke Tönjes X   X   
WGHS Daniel I Chasman   X   X 
Guillaume Paré   X     
Alex N Parker   X     
Paul M Ridker X       
YFS Mika Kähönen X   X   
Johannes Kettunen   X   X 
Terho Lehtimäki X   X   
Niina Pellikka   X   X 
Olli Raitakari X   X   
Jorma Viikari X   X   
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Additional analyses cohorts 
Cohort Author 
Overseeing 
(PI) 
Geno-
typing 
Pheno-
typing 
Data 
analysis 
GCI height 
extremes 
(additional 
genotyping) 
Kristin G Ardlie X       
Joel N Hirschhorn X       
Guillaume Lettre     X X 
Rany M Salem       X 
Michael C Turchin   X   X 
QIMR  
(polygene analysis) 
Andrew C Heath X   X   
Nick G Martin X X X   
Grant W Montgomery X X     
Dale R Nyholt X X   X 
Peter M Visscher   X   X 
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Abstract 
Objectives Genome-wide association studies have dramatically increased 
the number of common genetic variants that are robustly associated with type 2 
diabetes (T2D). A possible clinical use of this information is to identify individuals 
at high risk of developing the disease, so that preventative measures may be more 
effectively targeted. Here we assess the ability of 18 confirmed T2D variants to 
differentiate between T2D cases and controls. 
Research design and methods We assessed index SNPs for the 18 
independent loci in 2598 controls and 2309 cases from the GoDARTS study. The 
discriminatory ability of the combined SNP information was assessed by grouping 
individuals based on number of risk alleles carried and determining relative odds 
of T2D, and by calculating the area-under the receiver-operator characteristic 
curve (AUC). 
Results Individuals carrying more risk alleles had higher risk of T2D. For 
example, 1.2% of individuals with 25-28 risk alleles had an odds ratio of 4.2 (95% 
CI: 2.11, 8.56) against the 1.8% with 10-12 risk alleles. The AUC (a measure of 
discriminative accuracy) for these variants was 0.60. The AUC for age, BMI and 
sex was 0.78, and adding the genetic risk variants only marginally increased this 
to 0.80.  
Conclusions Currently, common risk variants for T2D do not provide strong 
predictive value at a population level. However, the joint effect of risk variants 
identified sub-groups of the population at substantially different risk of disease. 
Further studies are needed to assess whether individuals with extreme numbers of 
risk alleles may benefit from genetic testing.
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Introduction 
Recent genome-wide association (GWA) studies, which assay >300,000 
single nucleotide polymorphisms (SNPs) across many thousands of individuals, 
have led to the discoveries of variants predisposing to many common complex 
diseases, including: type 2 diabetes 1-6, coronary artery disease 7-9, prostate 
cancer 10, 11, Crohn‟s disease 12-14 and many others (see 
http://www.genome.gov/26525384 for an up to date list of all GWA studies). The 
variants identified by these GWA studies are common in the general population 
(minor allele frequency [MAF] > 1%), but most have, individually, only small effects 
on disease risk, with odds ratios (ORs) typically <1.3.  
Despite the relatively small predisposing effects conferred, these variants 
provide important, novel, insights into disease biology. For example, variants of a 
number of genes, such as HHEX, CDKN2A/B and CDKAL1 implicate defects in 
pancreatic beta-cell development and function as important in type 2 diabetes 
etiology 4, 15, 16, whereas the discovery that variants in FTO are associated with 
BMI, opened up novel areas of investigation for obesity biology 17-19. By gaining 
further knowledge of the underlying biology, and promoting potential therapeutic 
and preventative approaches, these insights are likely to be the most important 
outcome from these GWA studies.  
A more immediate clinical utility may be to use the identified risk variants to 
aid the determination of an individual‟s risk of developing a particular disease. 
Several companies such as deCODE genetics and 23andme have begun to use 
SNPs identified from these GWA studies, offering up to 1 million SNP GWA scans 
(http://www.decodeme.com, https://www.23andme.com) or individual disease-
associated SNP tests (http://www.decodediagnostics.com). It is, however, unclear 
how useful the currently identified variants will be in predicting disease. 
One of the disease traits for which the GWA approach has been most 
successful is type 2 diabetes. Together with candidate gene approaches, eighteen 
common variants, including FTO and two independent signals in the CDKN2A/B 
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region, have now been convincingly shown to associate with the disease 1-6, 20-26. 
In this study, we aimed to assess the combined discriminatory power of these 
common, modest effect variants, using over 4900 individuals from the GoDARTS 
(Genetics of Diabetes Audit and Research Tayside) study, which was also used as 
for replication of associated signals in the WTCCC-T2D GWA study5.
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Methods 
SNP selection and genotyping 
We only included variants that have been convincingly shown to associate 
with type 2 diabetes. We used variants reviewed in 27 and those described in 5 and 
6, except for: the E23K (rs5219; r2 with GWA-SNP rs5215 = 0.89) variant of 
KCNJ11 22 and rs7903146 (r2 with GWA-SNP rs7901695 = 0.80) of TCF7L2 23, 28 
where we genotyped a SNP shown to have stronger association with type 2 
diabetes, but which were not genotyped on the genome-wide association chips; 
the TCF2 locus where we used rs757210 26, instead of rs4430796 24 (r2 = 0.61); 
and the ADAM30/NOTCH2 locus where we used rs2641348 in ADAM30 as a 
proxy for rs2934381 (r2 = 0.92).  
Genotyping was performed by KBioscience (Herts., UK) who designed and 
used assays based on either their proprietary competitive allele-specific PCR 
(KASPar) method or a modified TaqMan-based assay, details of which are 
available on their website (www.kbioscience.co.uk/chemistry/index.htm). 
Genotyping quality control measures for the SNPs are described in 5, 6, 25.  
GoDARTS study and participants 
The GoDARTS study is a sub-study of the Diabetes Audit and Research 
Tayside (DARTS) study 29, which aims to identify all known diabetes patients in the 
Tayside region of Scotland using electronic database retrieval. The samples used 
in this study are a sub-sample of the type 2 diabetes patients identified and are 
described previously 6. Briefly, the GoDARTS study includes individuals of white 
European descent, living in the Tayside region when recruited. The diagnosis of 
diabetes in cases was based on either current treatment with diabetes-specific 
medication, or laboratory evidence of hyperglycaemia if treated with diet alone. 
Patients with confirmed diagnosis of monogenic diabetes and those treated with 
regular insulin therapy within 1 year of diagnosis were excluded. Cases in this 
study had an age at diagnosis between 35 and 70, inclusive. Controls had not 
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been diagnosed with diabetes at the time of recruitment or subsequently, and were 
excluded if there was evidence of hyperglycaemia during recruitment (fasting 
glucose >7.0 mmol/l, HbA1c >6.4%) or were > 80 years old. The study was 
approved by the Tayside Medical Ethics Committee. Informed consent was 
obtained from all study participants. Table 1 presents the clinical characteristics of 
subjects used in this study.  
Statistical analysis 
All statistical analyses were performed in StataSE v10.0 for Windows 
(StataCorp LP, Texas, USA). We used logistic regression for all individual SNP 
analyses. To test for deviation from a within-loci additive model, we performed 
likelihood ratio test of an additive model against a general 2df model. To test for 
gene-gene interaction across all pairs of loci, we used likelihood ratio tests to 
compare an additive model to a model with an interaction term. We combined 
information from multiple SNPs by using an allele count model, where we summed 
the number of risk alleles carried by each individual. This assumes that each of the 
alleles has an equal and additive effect on type 2 diabetes risk.  
We used logistic regression on the general model (i.e. individual SNP 
genotypes as indicator variables) to construct the ROC curves and calculate the 
AUCs. We also performed these ROC analyses on the allele count model for 
comparison to the general model.
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Results 
Genotyping data on all of the variants were available for 2309 type 2 
diabetes cases and 2598 controls. Characteristics of these participants are shown 
in Table 1. Supplementary Table 1 presents a comparison of clinical 
characteristics for these subjects against the 1739 who were not successfully 
genotyped across all SNPs. Individually, the variants have similar effect sizes in 
this study compared to those reported in other large studies (Table 2; 1-6, 20-26) and 
the range of odds ratios from 1.00 to 1.36 most likely reflects stochastic variation. 
Several variants are not associated at P<0.05 in the sample used here, but are still 
included in the analyses as they are confirmed type 2 diabetes risk variants, and 
the lack of significance is the result of relatively low power in this number of 
subjects.  
Based on these and larger datasets, all the variants appear to have an 
additive mode of inheritance 1-6, 20-26. The CDKAL1 locus was reported by 
Steinthorsdottir et al. to fit a recessive model 4, but other large studies do not 
support this. There is no evidence of interaction between any of the SNPs based 
on these data (Supplementary Table 2), or on the larger analyses previously 
published. Therefore, we assumed an additive genetic model. We found no 
evidence of any interaction between the individual variants and BMI or age (lowest 
interaction P values = 0.14 and 0.02, respectively). We performed the analysis 
with and without the FTO variant, the one variant shown to predispose to type 2 
diabetes through a primary effect on BMI 18. 
Comparing extremes 
The proportion of case subjects and control subjects grouped according to 
the number of risk alleles they carry is shown in Figure 1. The distribution of risk 
alleles follows a normal distribution in both cases and controls, with a shift towards 
a higher number of risk alleles in the case subjects. There is an increase in odds 
ratios for type 2 diabetes with the increasing number of risk alleles, against the 
baseline group of 1.8% of individuals carrying 10-12 risk alleles. 1.2% of 
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individuals with 25 or more risk alleles have an odds ratio of 4.2 (95% CI: 2.11, 
8.56) against the baseline reference group. Similarly, 11.5% of this study 
population carrying 22 or more risk alleles had an OR of 2.3 (95% CI: 1.73, 2.93) 
for type 2 diabetes compared to the 8.2% of individuals with <15 risk alleles.  
Figure 2 plots the odds ratios relative to the median number of 18 risk 
alleles. Those with 25 or more risk alleles were over twice as likely to have type 2 
diabetes (OR: 2.18, 95% CI: 1.24, 3.81) compared to those with the median 
number of risk alleles. The TCF7L2 variant had a stronger effect than the other 
variants (OR = 1.36, compared to 1.00-1.25 for the rest), so these results may be 
slight underestimates, since the additive model used for the allele counting 
assumes equal effects across all SNPs.  
We performed the same analyses for two sub-groups of the cohort, one 
including only obese individuals (with BMI of 30 kg/m2 or greater, n=1803), the 
other non-obese individuals (BMI less than 30 kg/m2, n=3083). The results were 
similar across these sub-groups. For example, the 1.4% of obese individuals with 
>24 risk alleles had an OR = 5.5 (95% CI: 2.11, 14.36) compared to the 1.9% of 
obese individuals with <13 risk alleles. The corresponding odds ratio for the non-
obese subjects was 3.31 (95% CI: 1.34, 8.16), for the 1.8% and 1.1% of 
individuals with <13 and >24 risk alleles, respectively. 
ROC curve 
We evaluated the discriminatory power of a genetic test based on the 18 
type 2 diabetes variants by calculating the area under the receiver-operating 
characteristic (ROC) curve. Using the general model (as opposed to the additive 
model which assumes equal and additive effects), the ROC curve for the 18 type 2 
diabetes variants studied here is 0.60 (Figure 3). We performed the same analysis 
for the obese and non-obese sub-groups of the cohort. The AUCs for the obese 
and non-obese groups were 0.58 and 0.60, respectively. Similar result was 
obtained when we removed the FTO variant (obese 0.58, non-obese 0.59). We 
also tested whether the risk variants would add to the discriminatory power of BMI, 
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age and sex alone (AUC = 0.78 in our study). A model that includes BMI, age, sex 
and the 18 variants has an AUC of 0.80 (Figure 3); although marginal, the 
increase in the AUC was statistically significant (P=2.88x10-12). The AUC remained 
virtually the same (AUC=0.80) when the FTO variant was removed from the 
model.  
The effect of BMI and age 
Supplementary Table 3 presents the individual SNP type 2 diabetes 
associations adjusted for BMI. As expected, the FTO association is weakened on 
adjusting for BMI (OR = 1.00 [0.92, 1.10]), and the TCF7L2 strengthened (OR = 
1.46 [1.32, 1.61]). Testing the combined effect of the risk variants on clinical 
features of the type 2 diabetes patients, we found that the number of risk alleles 
was associated with an earlier age at diagnosis of 0.15 years per risk allele (95% 
CI: -0.29, -0.01; P=0.038). We also observed an overall modifying effect on BMI (-
0.14 BMI units per risk allele, 95% CI: -0.23, -0.05, P=3.41x10-3), but this finding is 
mainly explained by the known association of the TCF7L2 variant alone with BMI, 
in type 2 diabetes cases 30, 31. Here, each TCF7L2 risk allele was associated with 
a difference in BMI of -0.69 kg/m2 (95% CI: -1.06, -0.31; P=3.18x10-4), while the 
combined effect of all other variants without TCF7L2 could just be detected (-0.10 
kg/m2 per risk allele; 95% CI: -0.20, 0.01; P=0.036). The difference in BMI and age 
at diagnosis was more noticeable when we compared individuals with low and 
high number of risk alleles. For example, carriers of 23 or more risk alleles (11.8%) 
were, on average, diagnosed 4.2 years earlier (95% CI: -6.45, -1.87; P=4.21x10-4) 
and had 1.60 kg/m2 lower BMI (95% CI: -3.35, 0.08; P=0.062) than those carrying 
fewer than 15 (8.6%) risk alleles. 
 Chapter 4 225 
Discussion 
Recent success in identifying common variants predisposing to type 2 
diabetes has led to suggestions that they may be useful in predicting an 
individual‟s risk of the disease. In this study we evaluated the ability of 18 
confirmed predisposing variants to discriminate between individuals with and 
without type 2 diabetes, using the GoDARTS study. The samples used in this 
study were not enriched for family history or low BMI, factors that may inflate effect 
sizes. Although the GoDARTS cohort was a part of the WTCCC-T2D GWA study 5, 
6, it was only used as a stage 2 replication set for the follow-up of the initial hits. 
This means that there should be a minimal effect of the “winner‟s curse” 32, the 
upward bias of the effect size in the discovery samples compared to subsequent 
replication studies. 
The combined information identifies individuals at different risks of disease  
By comparing individuals with fewest type 2 diabetes risk alleles with those 
carrying the most risk alleles, combining genetic information allowed us to identify 
subgroups of the population at a distinctly differing risk of disease. For example, 
we were able to distinguish about 1% of the population carrying more than 25 risk 
alleles that had over four times increased risk of diabetes compared to the 2% with 
10-12 risk alleles. The high-risk group also had over twice the odds for type 2 
diabetes, than those with the median number of risk alleles. These figures were 
similar in individuals who were obese and not obese, a major risk factor for type 2 
diabetes and easily measurable. Obese individuals carrying large numbers of type 
2 diabetes risk alleles may therefore be a particular group worth studying to test 
potential intervention strategies. This may be important given that the escalating 
rates of obesity and type 2 diabetes suggest that efforts aimed at the whole 
population are not effective, and that intensive, but expensive, lifestyle 
interventions aimed at increasing exercise and improving diet can result in weight 
loss and a reduced risk of type 2 diabetes 33-36.  
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The current variants are not particularly discriminative, but explain only a 
small amount of the heritability of type 2 diabetes  
Rather than focusing on individuals with “extreme” numbers of risk alleles, 
at a population level the utility of genetic tests may be better classified by receiver-
operating characteristic (ROC) curves. One of the most important factors in the 
validity of a genetic test in clinical practice is its ability to discriminate between 
individuals who will and will not develop the disease. A clinically relevant AUC 
threshold clearly depends on a whole range of factors (for example, the cost of the 
test, and the availability of preventative measures), but as an example from 
current clinical practice, oxidized-LDL cholesterol has an AUC of ~0.80 for 
coronary artery disease 37, making it a good discriminator between patients and 
healthy controls. The 18 type 2 diabetes variants had an inadequate discriminatory 
ability with an AUC of 0.60, a slight improvement on the AUC of 0.55 based on 
TCF7L2 alone. These data imply that genetic tests for type 2 diabetes (and many 
other complex diseases) that are offered by several commercial companies 
currently have limited predictive value. However, there are many more variants to 
be identified, since these 18 variants only explain a small amount of the heritability 
of type 2 diabetes: the sibling relative risk for type 2 diabetes is ~3 38, and the 
combination of these variants would only account for a sibling relative risk of 
~1.07. As more susceptibility variants are found for type 2 diabetes, genetic testing 
that utilizes the inexpensive and rapid genotyping technologies may eventually 
become more clinically useful. 
The use of genetic information in addition to age, sex and BMI 
For many complex diseases, there are already well-established risk factors 
that can be used to predict someone‟s chances of developing the disease. 
Incorporating genetic information may be justified on the basis that current 
preventative measures are expensive, and that prevention at a population level is 
not effective, so the more selective we can be the better. In type 2 diabetes, family 
history, age, BMI, ethnicity and lifestyle all contribute to an individual‟s risk of the 
disease. In our study the AUC for BMI, age and sex (we did not have family history 
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data) combined was 0.78, a moderate diagnostic value. The genetic risk variants 
had a poor discriminatory ability alone (AUC=0.60), and only marginally increased 
the discriminatory power of the test when combined with BMI, age and sex 
(AUC=0.80), suggesting that they add little to the already known predictive factors.  
Risk variants modify clinical characteristics of individuals with type 2 
diabetes 
Type 2 diabetes often occurs in individuals who are not overweight or 
obese, and can be diagnosed at a relatively young age. This may be because 
these individuals have a stronger genetic risk component than more “typical” type 
2 diabetes patients. Therefore, we tested the extent to which patients with the 
stronger genetic predisposition tended to be leaner, and how much younger they 
were at diagnosis. There were notable differences between the 11.8% and 8.6% of 
the population carrying either high or low number of disease predisposing alleles, 
respectively. Patients with high genetic risk had an average BMI of 30.3 kg/m2 
compared with 31.9 kg/m2 in those with low genetic risk, and were diagnosed at an 
average age of 55.2 years, compared to 59.3 years for patients with relatively low 
genetic risk. These results support an important role for genetic predisposition to 
type 2 diabetes in non-obese, young-onset cases. 
Weighting variants and the optimal ROC curve 
The simple allele count model we used for some of our analyses of 
“extremes” assumes that each risk allele has the same effect size, and the effects 
are additive both within and between loci. While we found no strong evidence for 
deviation from additivity, clearly some SNPs have stronger effects than others. 
This is most evident for TCF7L2, where the allelic odd ratio is 1.37, significantly 
larger than any of the other variants. One way to overcome this is to weigh SNPs 
differently; however, we decided not to do this in this study for a number of 
reasons. First, all our AUC analyses are based on a general model, where the 
assumption of equal effects is not made. Second, as Janssens et al. 39 previously 
showed, when the odds ratios of the individual variants are relatively low (as here) 
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there is little difference in the discriminative accuracy of the test based on the 
simple allele count model and a model which allows each variant to have a 
different effect size (the AUCs here are 0.583 and 0.603, respectively, although 
this was statistically significant (P=0.001)). Third, it is unclear what the most 
appropriate weights to use would be. Fourth, an allele count model provides 
important advantages for simplicity and visualization of the results. 
Recently, Lu and Elston 40 proposed using an optimal ROC analysis 
approach rather than the standard approach we have used. While the authors 
proved theoretically that their method is more powerful, the results presented by 
Lu and Elston 40 showed that the two methods produce the same results when 
there are few loci, and no interactive effects. As we still have only a relatively few 
loci, there is no evidence of any non-additive effects within or between loci, and 
the ROC curve is concave 40 the two methods should produce the same results. 
We tested this using the 10 SNPS that were significant (at P<0.05) in our study. 
Using these variants the results were the same for both methods (AUC for the Lu 
and Elston method = 0.596; AUC for the standard method = 0.596). 
Strengths and limitations of our study 
Our study was relatively large in terms of the number of samples, and 
number of common variants used. We had over 2000 cases and 2000 controls, 
after excluding individuals who were not successfully genotyped for all of the 
variants included in the study. The 18 variants we used had all been convincingly 
shown in previous studies to associate with type 2 diabetes. 
One of the main limitations of our study is that it was not prospective and, 
therefore, we are unable to truly determine the predictive power of these variants. 
Although the results of this study only apply to the Tayside population, it is likely, 
based on previous data 41-43, that our prediction estimates are reasonably 
accurate, and that the effect sizes observed are likely to be representative of those 
in similar populations. A second limitation is that, although the results are 
applicable to the Tayside and similar populations, they may not apply to 
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populations of substantially different ethnic origin or those exposed to different 
social and environmental circumstances. A third limitation concerns the caveat that 
the majority of the type 2 diabetes associated SNPs identified to date and used in 
this study are not the causal variants. This means that the predictive power of 
these susceptibility loci is likely to be an underestimate. Fine mapping and 
sequencing approaches are needed to identify the variants causal to these 
associations, which often have stronger effects than the currently identified 
variants. These follow-up studies may also reveal additional causal variants at 
these loci that cannot be detected by GWA methods because of, for example, low 
frequency, but that may have higher penetrance and, therefore, would be much 
more powerful predictors. 
In conclusion, the combined information from the currently known 
susceptibility variants allows us to identify subgroups of the population at 
substantially increased odds of getting type 2 diabetes. These individuals could be 
targeted with more effective preventative measures. On a population level, these 
variants appear to be of limited use in discriminating between individuals who will 
and will not develop type 2 diabetes. As more variants are identified, tests with 
better predictive performance should become available, and could eventually 
become a valuable addition to clinical practice.
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Table 1. Characteristics of study participants. 
Variable Cases Controls 
Number 2309 2598 
Males, % 56 51 
Age at diagnosis, years (SD) 55.7 (9.0) NA 
Body mass index, kg/m2 (SD) 31.5 (6.1) 26.9 (4.5) 
HbA1c, % (SD) 7.8 (1.5) 5.5 (0.3) 
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Table 2. Summary of type 2 diabetes variants in 2598 controls and 2309 cases from the Dundee cohort.  
SNP Gene / Region 
Risk allele 
frequency 
Additive model 
test P 
Odds ratio (95% 
CI) 
P value 
rs7903146 TCF7L2 0.30 0.70 1.36 (1.24, 1.48) 3.97 x 10-12 
rs5219 KCNJ11 0.36 0.058 1.25 (1.15, 1.36) 8.54 x 10-8 
rs10811661 CDKN2A/2B 0.85 0.24 1.21 (1.08, 1.35) 8.82 x 10-4 
rs1801282 PPARG 0.87 0.46 1.21 (1.07, 1.36) 2.18 x 10-3 
rs2641348* ADAM30 / NOTCH2 0.11 0.68 1.15 (1.01, 1.30) 3.20 x 10-2 
rs564398 CDKN2A/2B 0.59 0.95 1.13 (1.04, 1.22) 3.61 x 10-3 
rs4402960 IGF2BP2 0.33 0.76 1.12 (1.03, 1.22) 7.62 x 10-3 
rs8050136 FTO 0.41 0.32 1.11 (1.02, 1.20) 1.43 x 10-2 
rs10946398 CDKAL1 0.34 0.19 1.11 (1.02, 1.21) 1.47 x 10-2 
rs13266634 SLC30A8 0.70 0.60 1.10 (1.01, 1.20) 2.57 x 10-2 
rs7961581 TSPAN8 / LGR5 0.29 0.87 1.09 (1.00, 1.19) 5.56 x 10-2 
rs12779790 CDC123 0.20 0.15 1.10 (0.99, 1.21) 7.58 x 10-2 
rs10010131 WFS1 0.60 0.54 1.07 (0.99, 1.16) 9.19 x 10-2 
rs757210 TCF2 0.37 0.18 1.07 (0.99, 1.16) 1.09 x 10-1 
rs4607103 ADAMTS9 0.77 0.60 1.05 (0.96, 1.16) 2.89 x 10-1 
rs1111875 HHEX-IDE 0.62 0.19 1.02 (0.94, 1.11) 5.98 x 10-1 
rs7578597 THADA 0.91 0.33 1.04 (0.90, 1.19) 6.07 x 10-1 
rs864745 JAZF1 0.50 0.50 1.00 (0.93, 1.09) 9.70 x 10-1 
 
Only samples that were successfully genotyped for all 18 variants are included. Additive model test P refers to a test of deviation from additivity of 
alleles at each SNP. *This SNP falls within the ADAM30 gene and is a proxy (r2=0.92 in HapMap CEU) for rs2934381 in the NOTCH2 gene, which 
showed stronger association in 5. 
 Chapter 4 233 
Figure 1. Distribution of risk alleles in type 2 diabetes cases (black bars) and 
controls (grey bars). 
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Figure 2. A plot showing odds ratios (OR) by number of type 2 diabetes risk 
alleles. The odds ratios are given relative to the median number of 18 risk alleles 
(black circle). The vertical bars represent 95% confidence intervals. 
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Figure 3. ROC plot for a model containing all type 2 diabetes variants, BMI, 
age and sex (gray line; AUC = 0.80), and the 18 variants alone (black line, 
AUC = 0.60). 
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Supplementary Table 1. Clinical characteristics of individuals from the 
original sample who were excluded from the analyses owing to incomplete 
genotype data, compared to the individuals successfully genotyped for all 18 
SNPs and included in the analyses. 
Variable 
Individuals 
excluded from the 
analyses 
Individuals 
used in the 
analyses 
P-value for 
difference 
Total number 1739 4907 NA 
Percentage of cases 45.0 47.1 0.14 
Percentage of males 55.7 53.5 0.12 
Age at diagnosis (cases), 
years (SD) 
55.2 (8.8) 55.7 (9.0) 0.20 
Body mass 
index, kg/m2 
(SD) 
cases 
controls 
31.9 (6.3) 
26.6 (4.6) 
31.5 (6.1) 
26.9 (4.5) 
0.07 
0.12 
 Chapter 4 242 
Supplementary Table 2. Interaction test P values for all combinations of 18 
type 2 diabetes SNPs. 
 
SNP1 SNP2 Interaction P 
rs7903146 rs12779790 0.0038 
rs4402960 rs13266634 0.012 
rs13266634 rs1801282 0.019 
rs7903146 rs7961581 0.043 
rs10010131 rs12779790 0.052 
rs5219 rs7578597 0.056 
rs564398 rs757210 0.056 
rs4402960 rs757210 0.057 
rs12779790 rs864745 0.085 
rs10811661 rs757210 0.090 
rs1111875 rs13266634 0.092 
rs12779790 rs7961581 0.093 
rs13266634 rs5219 0.11 
rs757210 rs12779790 0.15 
rs1111875 rs5219 0.15 
rs10946398 rs5219 0.16 
rs5219 rs2641348 0.16 
rs564398 rs12779790 0.17 
rs5219 rs1801282 0.17 
rs7903146 rs5219 0.19 
rs10811661 rs10946398 0.21 
rs10946398 rs864745 0.21 
rs5219 rs12779790 0.22 
rs10946398 rs12779790 0.22 
rs10811661 rs5219 0.22 
rs8050136 rs5219 0.23 
rs1111875 rs2641348 0.24 
rs8050136 rs1801282 0.24 
rs10946398 rs10010131 0.25 
rs564398 rs10010131 0.25 
rs10811661 rs7961581 0.25 
rs4402960 rs12779790 0.25 
rs8050136 rs4607103 0.26 
rs757210 rs2641348 0.27 
rs1111875 rs757210 0.28 
rs2641348 rs7578597 0.28 
rs10811661 rs4402960 0.29 
rs7903146 rs10010131 0.29 
rs8050136 rs10946398 0.30 
rs7903146 rs7578597 0.30 
rs4402960 rs4607103 0.31 
rs10946398 rs564398 0.31 
rs8050136 rs1111875 0.32 
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rs5219 rs10010131 0.32 
rs5219 rs4607103 0.32 
rs8050136 rs7903146 0.32 
rs2641348 rs864745 0.32 
rs10811661 rs7903146 0.34 
rs5219 rs757210 0.36 
rs1111875 rs12779790 0.37 
rs5219 rs7961581 0.37 
rs10946398 rs1801282 0.38 
rs1111875 rs10010131 0.38 
rs12779790 rs7578597 0.38 
rs10946398 rs1111875 0.38 
rs4402960 rs5219 0.39 
rs1111875 rs7578597 0.40 
rs564398 rs7961581 0.40 
rs10811661 rs7578597 0.41 
rs12779790 rs4607103 0.41 
rs8050136 rs564398 0.41 
rs5219 rs864745 0.41 
rs1111875 rs864745 0.42 
rs10010131 rs4607103 0.42 
rs10946398 rs4402960 0.43 
rs564398 rs4607103 0.44 
rs10811661 rs8050136 0.45 
rs10811661 rs864745 0.46 
rs13266634 rs2641348 0.46 
rs10811661 rs1111875 0.46 
rs10946398 rs13266634 0.46 
rs564398 rs5219 0.46 
rs7903146 rs4607103 0.47 
rs757210 rs4607103 0.47 
rs4607103 rs7961581 0.47 
rs8050136 rs7961581 0.48 
rs7903146 rs1801282 0.48 
rs10946398 rs7903146 0.49 
rs4607103 rs7578597 0.49 
rs10946398 rs7578597 0.50 
rs13266634 rs10010131 0.51 
rs8050136 rs7578597 0.51 
rs10811661 rs12779790 0.52 
rs2641348 rs7961581 0.52 
rs4402960 rs7961581 0.52 
rs564398 rs2641348 0.54 
rs10946398 rs757210 0.55 
rs4402960 rs7578597 0.57 
rs10811661 rs10010131 0.57 
rs564398 rs13266634 0.57 
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rs8050136 rs757210 0.58 
rs7903146 rs2641348 0.58 
rs1111875 rs7903146 0.58 
rs8050136 rs864745 0.59 
rs1801282 rs864745 0.61 
rs13266634 rs4607103 0.61 
rs1111875 rs1801282 0.61 
rs10811661 rs13266634 0.62 
rs10946398 rs7961581 0.62 
rs1111875 rs4402960 0.63 
rs10946398 rs2641348 0.63 
rs7578597 rs864745 0.64 
rs1801282 rs4607103 0.65 
rs757210 rs7578597 0.65 
rs10811661 rs2641348 0.65 
rs7903146 rs757210 0.65 
rs4402960 rs864745 0.67 
rs2641348 rs4607103 0.67 
rs1801282 rs7578597 0.67 
rs1801282 rs7961581 0.68 
rs1111875 rs7961581 0.69 
rs757210 rs7961581 0.70 
rs12779790 rs2641348 0.70 
rs10010131 rs757210 0.72 
rs8050136 rs12779790 0.72 
rs10811661 rs1801282 0.72 
rs8050136 rs4402960 0.73 
rs13266634 rs757210 0.73 
rs1801282 rs12779790 0.74 
rs7961581 rs864745 0.74 
rs10811661 rs564398 0.76 
rs10010131 rs7961581 0.76 
rs10811661 rs4607103 0.77 
rs13266634 rs864745 0.77 
rs13266634 rs7578597 0.78 
rs13266634 rs7961581 0.78 
rs564398 rs7578597 0.80 
rs8050136 rs2641348 0.80 
rs13266634 rs12779790 0.80 
rs1111875 rs4607103 0.81 
rs757210 rs864745 0.81 
rs1801282 rs2641348 0.81 
rs1801282 rs757210 0.83 
rs4402960 rs1801282 0.83 
rs4402960 rs7903146 0.84 
rs7578597 rs7961581 0.85 
rs13266634 rs7903146 0.88 
 Chapter 4 245 
rs1111875 rs564398 0.89 
rs10010131 rs864745 0.90 
rs4402960 rs10010131 0.90 
rs10946398 rs4607103 0.92 
rs8050136 rs13266634 0.92 
rs10010131 rs2641348 0.92 
rs8050136 rs10010131 0.93 
rs4607103 rs864745 0.93 
rs1801282 rs10010131 0.96 
rs10010131 rs7578597 0.97 
rs564398 rs7903146 0.97 
rs564398 rs864745 0.98 
rs7903146 rs864745 0.98 
rs564398 rs1801282 0.98 
rs564398 rs4402960 0.99 
rs4402960 rs2641348 1.00 
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Supplementary Table 3 BMI-adjusted odds ratios (OR) for 4886 individuals 
with non-missing values for both 18 SNPs and BMI. The SNPs are in the same 
order as in Table 2. 
 
SNP Gene / Region 
OR adjusted for 
BMI (95% CI) 
Adjusted 
OR P value 
rs7903146 TCF7L2 1.46 (1.32, 1.61) 5.33x10-15 
rs5219 KCNJ11 1.28 (1.17, 1.40) 1.10x10-7 
rs10811661 CDKN2A/2B 1.27 (1.13, 1.44) 1.09x10-4 
rs1801282 PPARG 1.24 (1.09, 1.41) 1.47x10-3 
rs2641348 ADAM30 / NOTCH2 1.20 (1.05, 1.38) 8.05x10-3 
rs564398 CDKN2A/2B 1.11 (1.02, 1.21) 2.20x10-2 
rs4402960 IGF2BP2 1.11 (1.01, 1.22) 2.44x10-2 
rs8050136 FTO 1.00 (0.92, 1.10) 9.14x10-1 
rs10946398 CDKAL1 1.10 (1.01, 1.21) 3.40x10-2 
rs13266634 SLC30A8 1.15 (1.05, 1.27) 3.85x10-3 
rs7961581 TSPAN8 / LGR5 1.09 (0.99, 1.20) 6.88x10-2 
rs12779790 CDC123 1.10 (0.98, 1.22) 1.01x10-1 
rs10010131 WFS1 1.09 (1.00, 1.18) 6.29x10-2 
rs757210 TCF2 1.13 (1.03, 1.23) 8.29x10-3 
rs4607103 ADAMTS9 1.07 (0.97, 1.19) 1.74x10-1 
rs1111875 HHEX-IDE 1.05 (0.96, 1.15) 2.85x10-1 
rs7578597 THADA 1.07 (0.92, 1.24) 3.86x10-1 
rs864745 JAZF1 1.01 (0.93, 1.11) 7.51x10-1 
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Abstract 
Objective: Mutations in the HNF1A gene are the most common cause of MODY. 
There is a substantial variation in the age at diabetes diagnosis, even within 
families where diabetes is caused by the same mutation. We investigated the 
hypothesis that common polygenic variants that predispose to type 2 diabetes 
might account for the difference in age at diagnosis. 
Research Design and Methods: Fifteen robustly associated T2D variants were 
successfully genotyped in 410 individuals from 203 HNF1A-MODY families, from 
two study centers in the UK and Norway. We assessed their effect on the age at 
diagnosis both individually and in a combined genetic score by summing the 
number of T2D risk alleles carried by each patient. 
Results: We confirmed the effects of environmental and genetic factors known to 
modify the age at HNF1A-MODY diagnosis, namely intrauterine hyperglycemia (-
5.1 years if present, P=1.6x10-10), and HNF1A mutation position (-5.2 years if at 
least two isoforms affected, P=1.8x10-2). Additionally, our data showed strong 
effects of sex (females diagnosed 3.0 years earlier, P=6.0x10-4), and age at study 
(0.3 years later diagnosis per year increase in age, P=4.7x10-38). There were no 
strong individual SNP effects; however, in the combined genetic score model, 
each additional risk allele was associated with 0.35 years earlier diabetes 
diagnosis (P=5.1x10-3). 
Conclusions: We show that T2D risk variants of modest effect sizes reduce the 
age at diagnosis in HNF1A-MODY. This is one of the first studies to demonstrate 
that clinical characteristics of a monogenic disease can be modified by common 
polygenic variants. 
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Introduction 
Maturity onset diabetes of the young (MODY) is a young-onset, dominantly 
inherited non-insulin dependent diabetes mellitus resulting from -cell 
dysfunction1. There are at least eight genetic subgroups of MODY 1, 2, with most 
patients having mutations in transcription factor genes. Hepatocyte nuclear factor 
1 alpha (HNF1A) mutations are the commonest cause of MODY in many series 3, 
4. HNF1A diabetes is characterized by progressive failure of -cell function, 
resulting in increasing hyperglycemia throughout life 1. Initially, basal insulin 
secretion is maintained but it cannot be increased in the presence of 
hyperglycaemia 5. 
The severity and clinical presentation of MODY varies according to MODY 
genetic subtype 6. In addition, there can be considerable variation both between 
and within families where diabetes is caused by mutations in the same gene. In 
HNF1A diabetes the age of diagnosis is widely variable (4 - 74 years 7), and, 
although the mutations are highly penetrant, only 63% of mutation carriers develop 
diabetes by the age of 25 8. The variation in diagnosis is influenced by social and 
environmental factors. Within families early age at diagnosis tends to fall in the 
younger generations, in part owing to increased awareness of the familial nature of 
the condition 9, 10. If the mother had diabetes during pregnancy, intrauterine 
exposure to hyperglycemia of maternal diabetes is associated with diabetes being 
diagnosed on average 12 years earlier compared to subjects not exposed to 
maternal hyperglycaemia 9, 10.  
It is likely that there are genetic modifiers of the age of onset of HNF1A 
diabetes, namely the position of the HNF1A mutation 11, 12. However, much of the 
variation in age at diagnosis within families, where diabetes is caused by the same 
mutation, cannot be explained by social or environmental factors and this supports 
the notion that there are likely to be genetic modifiers independent of the HNF1A 
mutation. A genome-wide search for genetic modifiers of diagnosis age found no 
single large linkage peak 13, suggesting that the age of onset is a complex genetic 
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trait. A previous study of one large pedigree has shown that severity of the HNF1A 
diabetes phenotype was increased (earlier age of diagnosis and more severe 
hyperglycaemia) when type 2 diabetes was present in the non-carrier parent 14. 
We, therefore, hypothesised that common genetic variants that predispose to type 
2 diabetes might modify the severity of the disease and explain some of the 
variation in the age at HNF1A diabetes diagnosis. 
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Methods 
HNF1A mutation patients 
The subjects were 410 HNF1A mutation carriers with diabetes from two 
sources: The Department of Molecular Genetics, Royal Devon and Exeter NHS 
Foundation Trust, Exeter, UK (N=298 from 140 families) and the Center for 
Diabetes Genetics, Department of Pediatrics, Haukeland University Hospital, 
Bergen, Norway (N=112 from 63 families). They were all established MODY 
patients previously recruited for HNF1A sequencing on the basis of clinical criteria, 
such as family history or first degree relative with diabetes, onset of diabetes 
typically before age 25, or low dose insulin requirement (full details are available at 
http://www.diabetesgenes.org and http://www.mody.no).  
All patients gave consent for genetic testing and had HNF1A mutations 
identified by direct sequencing. To avoid population heterogeneity, individuals who 
were not Caucasian Europeans were excluded. Clinical characteristics of the 
patients are shown in Table 1. Two thirds were females, and the majority of the 
probands had an HNF1A mutation in exons 1-6. Such mutations are regarded as 
clinically most severe as they affect all 3 isoforms of the gene product. The most 
common HNF1A mutation, P291fsinsC in exon 4, accounted for 32% of all cases 
in this study. 
Classification and assessment of non-polygenic modifiers 
We assessed the association between age at diagnosis and the following 
non-polygenic factors: sex, age at study, BMI, exposure to in-utero hyperglycemia, 
and the position of HNF1A mutation. Mother‟s diabetic status at pregnancy was 
calculated from the age of diagnosis and the date of birth of the mother and child. 
Where this information was incomplete (usually owing to mother‟s information not 
being available as deceased), we assumed that the patient was not exposed to in-
utero hyperglycaemia. Previous studies showed that mutation position impacts the 
severity of the disease by determining the number of the affected HNF1A 
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isoforms: patients with mutations in exons 1-7, affecting two or all three isoforms, 
were diagnosed earlier than patients with mutations in exons 8-10, affecting only 
one isoform 11, 12. To account for this effect, we classified mutations of patients in 
this study according to those two groups. Intronic mutations were assigned to a 
group according to the mutation position and hence HNF1A isoform impacted on.  
SNP Selection and Genotyping 
We decided to include in this study only those variants, or their proxies, 
robustly shown to predispose to type 2 diabetes in Caucasians. Seventeen 
common susceptibility variants had been identified and robustly replicated at the 
time of our study 15-20, recently reviewed in 21, 22. These include SNPs in or near 
PPARG, KCNJ11, TCF7L2, IGF2BP2, CDKN2A/2B, CDKAL1, SLC30A8, 
HHEX/IDE, FTO, WFS1, HNF1B (TCF2), MC4R, NOTCH2, ADAMTS9, THADA, 
TSPAN8/LGR5, CDC123/CAMK1D and JAZF1 genes. Table 3 lists all 17 SNPs 
assessed in our study, of which we were able to combine 15 for the joint analysis, 
because JAZF1 and NOTCH2 loci failed genotyping in the Norwegian samples. At 
four of the 15 loci different SNPs were genotyped by the two study centres: 
rs757210 (UK) and rs4430796 (Norway) at the HNF1B locus (HapMap CEU 
r2=0.61, D‟=0.96); rs10946398 and rs7754840 at CDKAL1 (r2 and D‟=1); 
rs8050136 and rs9939609 at FTO (r2 and D‟=1); and rs1111875 and rs5015480 at 
HHEX/IDE (r2 and D‟=1). We combined genotypes for each of the four proxy pairs, 
coded with respect to the type 2 diabetes risk allele. 
In the UK samples, genotyping of TCF7L2, KCNJ11 and PPARG SNPs was 
performed in-house, using a TaqMan-based assay. The probes were supplied by 
AppliedBiosystems (Foster City, CA). Genotyping of the remaining 14 variants was 
performed by KBiosciences (Herts, UK), who designed and used assays based on 
either their proprietary competitive allele-specific PCR (KASPar) method or a 
modified TaqMan assay, details of which are available on their website 
(www.kbioscience.co.uk/chemistry/index.htm). Genotyping success rate was 
>96% for each SNP, overall duplicate concordance rate was 99.9% (1 discrepancy 
from 1153 comparisons), and in the Hardy-Weinberg equilibrium test, used as an 
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additional genotyping quality check, all P-values were >0.01 for the full dataset 
and >0.05 for 140 unrelated probands.  
In the Norwegian samples, genotyping was carried out by the multiplex 
MassARRAY  iPLEX  System (SEQUENOM Inc., San Diego, CA, USA) at the 
Norwegian national technology platform CIGENE. NOTCH2 SNP (rs2934381) 
failed the assay design, while JAZF1 SNP (rs864745) had a poor genotype call 
rate. For the remaining 15 SNPs, which we were able to combine with the UK 
data, genotype concordance rate was 100% for internal controls (n=108 
genotypes). Final genotyping call-rate was 99.2% after exclusion of samples with 
bad quality or lacking DNA. All tests for Hardy-Weinberg equilibrium had P-values 
>0.05. 
Statistical methods 
We performed family-based association analyses using ASSOC program 
from S.A.G.E. (Statistical Analysis for Genetic Epidemiology) software package, 
version 5.4.2 for Linux 23. Assuming randomly sampled independent pedigrees, 
ASSOC simultaneously tests for associations between a quantitative trait and one 
or more covariates of interest, and estimates familial variance components from 
the given familial correlations. In our study, the trait of interest was age at diabetes 
diagnosis, while the main covariate of interest was the number of type 2 diabetes 
risk alleles. As one of the parameters for the ASSOC program we set the family 
effect option to “true”, thus including the random nuclear family effect as an 
additional term in the regression model. Relationships between family members 
were fully established for most pedigrees. In some of the large pedigrees we 
included parents and relatives that had no data for the analyses, but were used by 
the program to accurately connect all related individuals. Singletons, and 5 UK 
family members for whom we could not establish how they were related to other 
members of their pedigrees, were automatically treated as one-person pedigrees 
and required no special handling in the model.  
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We assessed the effect of each risk variant on the age at diagnosis 
individually, jointly and by using an allele counting method to assign a genetic risk 
score to each patient (the sum of the number of risk alleles a person carries). The 
allele counting method assumed equal and additive effects of the individual 
variants. We repeated this analysis using a weighted allele approach, where the 
genetic score was based on the previously reported odds ratios for type 2 diabetes 
(obtained from a recent review 22). For each patient we first calculated the sum 
across SNPs of the number of risk alleles at each SNP multiplied by the log of the 
odds ratio (OR) for that SNP (i.e. genotypes were coded as 0, log(OR), 2xlog(OR), 
rather than 0, 1, 2 in the allele count model). To obtain a rescaled “weighted allele 
count” score, we multiplied each log(OR) score by 30 (maximum number of risk 
alleles), and divided the product by 1.81, the sum of the 15 risk homozygote 
log(OR) weights .   
Although family relationships were fully accounted for in the analyses, it is 
possible that the results could have been affected by the skewed allele 
distributions. Therefore, we analysed the effects of both individual SNPs and the 
combined genetic score on age at diagnosis in 203 unrelated probands, using the 
youngest individual from each pedigree (Supplementary Table 1). 
We used StataSE v10.0 for Windows (StataCorp LP, Brownsville, TX, USA) 
to generate adjusted age at diagnosis, using the „predict‟ function after running 
linear regression that fitted family id, study, sex, age at study, presence of 
intrauterine hyperglycemia and mutation position in the same regression model. 
This enabled us to use the full dataset, with adjusted ages at diagnosis, for linear 
regression and cumulative diabetes incidence analyses (Figures 1 and 2), rather 
than a much smaller sample of unrelated singletons and phenotypically 
homogeneous individuals. All figures were generated using SigmaPlot (Systat 
Software Inc., CA, USA). Power calculations were performed using QUANTO 
power calculator, version 1.2.4 24. 
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Results 
The analyses included 410 diabetic HNF1A mutation carriers from 203 
families who were successfully genotyped for all 15 type 2 diabetes risk variants.  
We confirmed the strong effects of age at study, mutation position and 
intrauterine hyperglycemia on the severity of HNF1A diabetes clinical presentation 
(Table 2). These associations were independent of the polygenic risk factors 
(Table 2). On average, patients were diagnosed 5.1 years earlier if the mother 
was diabetic during pregnancy (P = 1.6x10-10), 5.2 years earlier if the mutation 
affected at least two HNF1A isoforms (P = 1.8x10-2), and 0.3 years later for every 
additional year of their age at study (P = 4.7x10-38). In addition we observed a 
strong effect of sex in our data, where females were diagnosed 3.0 years earlier 
than males (P = 6.0x10-4), but there was no association with BMI (available for 305 
subjects; P = 0.99).  
We included those variables that had individual effect on age at diagnosis 
(i.e. all of the above apart from BMI) as covariates in the individual and joint SNP 
models, to reduce the remaining variance in the age at diagnosis and, therefore, 
increase our power to detect the effect of polygenic modifiers. We repeated these 
analyses excluding age at study, to make sure that its strong association with age 
at diagnosis did not drive the SNP association (Supplementary table 2). As 
expected, the results were not statistically significantly different to the fully 
adjusted model (all t-test P > 0.32). Although for some of the SNPs the effects on 
age at diagnosis were slightly stronger when age at study was excluded, the 
standard errors were larger, resulting in similar overall P-values. 
Individual type 2 diabetes risk variants were not strongly associated with the 
age at diagnosis, as shown in Table 3. However, of the 15 variants, 11 risk alleles 
for type 2 diabetes in the unadjusted analyses, and 10 in the adjusted analyses, 
were associated with reduced age at diagnosis, in a direction consistent with 
polygenic studies. When we included all 15 variants in the regression model, there 
was borderline evidence of an overall joint effect on the age at diagnosis (P = 
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0.062). The 15 variants explain 6.4% of the total proportion of diagnosis age 
variance, whilst the non-polygenic factors (sex, age at study, mutation position, 
and presence of intrauterine hyperglycemia) explain 37.9%; combining these 
together, they explain 42.1% of the total variance in the HNF1A-MODY age at 
diagnosis in these families. 
We then generated a single genetic risk score representing the combined 
genetic susceptibility for type 2 diabetes (Table 3). In the allele count model, each 
additional risk allele was associated with 0.35 years reduction in age at diagnosis 
(P = 0.005). The association strength was weaker when we used unrelated 
probands (0.28 years earlier age at diagnosis per one additional risk allele; P = 
0.094; Supplementary Table 1), which most probably reflects reduced power. 
The correlation between the decreasing age at diagnosis and the increasing 
number of risk alleles appears to be linear for the full dataset of 410 patients 
(Figure 1A). Figure 1B presents the results for 203 unrelated probands only. 
Looking at the impact of risk alleles on the cumulative incidence of diabetes, the 
effect was most noticeable around age 30, where diabetes developed in 80% of 
HNF1A mutation carriers with 9-14 polygenic risk alleles, compared to 93% with 
17-22 risk alleles (Figure 2). 
The weighted allele score yielded similar results to the allele count model (P 
= 0.005). Stratified analysis showed that the impact of the allele count score was 
of similar magnitude in the two cohorts individually, with all t-test P-values > 0.1 
(Supplementary table 3).  
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Discussion 
We have shown that type 2 diabetes risk variants of modest effect sizes 
when combined are associated with a reduced age at diagnosis in monogenic 
HNF1A diabetes. This association is independent of other genetic and 
environmental modifiers, namely the HNF1A mutation position, age at study, sex, 
and mother‟s diabetes status during pregnancy. Thus, this is one of the first 
studies to demonstrate that clinical characteristics of a monogenic disease can be 
influenced by common variants that predispose to the polygenic form of that 
disease. To our knowledge, only two other studies, of breast cancer 25 and 
Alzheimer‟s disease 26, have identified polygenic variants that act as modifiers of 
disease onset age. 
In support of previous findings, an increase in the age of patients at the time 
of genetic testing is strongly associated with an older age at diabetes diagnosis. It 
is not known if this represents an earlier diagnosis as a result of the increasing 
awareness of diabetes in the family by their physicians, or a genuine decrease in 
age of onset in succeeding generations. The former is likely to be a large 
contributor. In addition, there is strong evidence that the age at diagnosis is 
affected by genetic factors. We confirm previous findings by Harries et al. 11 and 
Bellanné-Chantelot 12 that patients with mutations affecting at least two of the 
three known HNF1A isoforms were diagnosed earlier than patients with mutations 
affecting only one HNF1A isoform.  
In our study we provide evidence for additional genetic modifiers, the 
robustly replicated type 2 diabetes risk variants. Combining the effect of the 
variants by adding up the total number of risk alleles carried, each additional risk 
allele was associated with 0.49 and 0.35 year earlier age at diagnosis, in the 
unadjusted and adjusted models, respectively. Most of the genetic variants 
predisposing to type 2 diabetes act through reducing -cell function, rather than 
increasing insulin resistance. This is true of the three risk variants with strongest 
effects observed in this study, the SNPs in the HNF1B, SLC30A8 and CDKAL1 
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genes. It is possible that they interact with the -cell dysfunction resulting from the 
HNF1A mutation, leading to an increased rate of -cell destruction and, therefore, 
earlier onset of diabetes. Furthermore, mutations of HNF1B, also known as TCF2, 
are another known cause of MODY, accounting for about 2% of cases 27.  
This study does have limitations. Although we included 410 subjects, one of 
the largest cohorts of HNF1A patients ever reported, some simple power 
calculations suggest that we were still under-powered to detect the impact of 
individual loci. For example, we had only 29% power to detect an individual SNP 
explaining 1% of the variation in age at diagnosis (and this is assuming 
independence of the individuals in the study) at P<0.01; in singleton-only analysis 
the power was 13%. These patients were not studied prospectively and, therefore, 
the age at diagnosis does not accurately reflect the age at onset of diabetes. We 
would anticipate that if age of onset was studied using prospective data, the 
impact of these type 2 diabetes loci would be greater. 
In conclusion, we show that type 2 diabetes risk variants of modest effect 
sizes act as an additional modifier of age at diagnosis in HNF1A-MODY. This is 
one of the first studies to demonstrate that common variants associated with a 
polygenic disease can also influence clinical characteristics of a monogenic form 
of the disease. 
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Table 1. Characteristics of the 410 HNF1A-MODY patients included in the analyses.  
 UK Norway 
Families / singletons, N  140 / 87 63 / 41 
Examined individuals, N 298 112 
Males, N (%) 100 (33.6) 41 (36.6) 
Average number of individuals in 
non-singleton families (range) 
3.0 (2-9) 3.1 (2-8) 
Number of individuals with HNF1A 
mutations affecting  
  
Isoform A only (exons 8-10) 
Isoforms A and B only (exon 7)  
Isoforms A, B and C (exons 1-6) 
30 (10.1%) 
22 (7.4%) 
246 (82.5%) 
3 (2.7%) 
4 (3.6%) 
105 (93.7%) 
Age at study, years * 37.1 + 17.0 (8-87) 33.4 + 17.6 (6-73) 
Age at diabetes diagnosis, years * 21.9 + 11.2 (4-70) 20.3 + 10.0 (6-60) 
BMI, kg/m2 *† 24.1 + 4.1 (15.9-50.7) 23.9 + 3.7 (15.8-33.6) 
 
* Data are presented as means + SD (range).  
† BMI was only available for 224 and 81 individuals in UK and Norway studies, respectively. 
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Table 2. Results of regression analyses of non-polygenic factors on the age at diabetes diagnosis in 410 HNF1A-MODY 
patients, with and without the inclusion of the polygenic risk score in the regression model. All effect sizes are in years. 
Genetic score is the number of risk alleles, carried by each patient, from the 15 type 2 diabetes susceptibility variants. 
 
 Without genetic score With genetic score 
 Effect size Std Error P-value Effect size Std Error P-value 
Study (Norway=0, UK=1) 1.31 0.99 0.18 1.44 0.97 0.14 
Sex (effect w.r.t. females) -2.97 0.86 6.0 x 10-4 -2.93 0.85 5.7 x 10-4 
BMI, kg/m2 (per unit increase) * 0.0009 0.13 0.99 0.033 0.13 0.80 
Presence of intrauterine 
hyperglycaemia 
-5.06 0.79 1.6 x 10-10 -4.86 0.79 6.5 x 10-10 
Position of HNF1A mutation † -5.22 2.21 1.8 x 10-2 -5.67 2.18 9.4 x 10-3 
Age at study (per year increase) 0.29 0.02 4.7 x 10-38 0.29 0.02 1.5 x 10-37 
 
w.r.t. = with respect to. 
* BMI was only available for 305 individuals.  
†The position of the mutation has been dichotomised into those affecting exons 8-10 (isomer A only; N=33) versus those affecting exons 1-
7 (N=377). The age at diagnosis is lower for patients with mutations affecting exons 1-7. 
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Table 3. Effects of individual type 2 diabetes risk variants and the combined 
genetic scores on the age at diabetes diagnosis in 410 HNF1A-MODY 
patients. All effect sizes are in years change of age at diagnosis per risk allele. 
The 410 patients were successfully genotyped for all 15 SNPs that were included 
in the combined genetic scores. All analyses took into account family relationships 
and included a random family effect in the regression model. Individual SNP 
effects are based on risk allele count method. P values are unadjusted for multiple 
testing. Results are presented in order of the adjusted effect sizes. 
 
  Unadjusted results Adjusted results ‡ 
  
Effect 
Size 
Std 
Error 
P-
value 
Effect 
Size 
Std 
Error 
P-
value 
Individual SNP effects       
Gene region SNP       
HNF1B (TCF2) * rs757210 / rs4430796 -1.85 0.58 0.0014 -1.07 0.43 0.014 
SLC30A8 rs13266634 -1.07 0.64 0.095 -0.90 0.50 0.070 
CDKAL1 * rs10946398 / rs7754840 -1.22 0.59 0.038 -0.87 0.46 0.059 
TCF7L2 rs7903146 -0.55 0.63 0.39 -0.65 0.46 0.16 
ADAMTS9 rs4607103 0.27 0.69 0.70 -0.59 0.51 0.25 
TSPAN8 rs7961581 -0.97 0.63 0.13 -0.53 0.44 0.22 
JAZF1 † rs864745 -0.45 0.72 0.53 -0.46 0.53 0.38 
FTO * rs8050136 / rs9939609 -0.30 0.63 0.63 -0.42 0.47 0.37 
KCNJ11 rs5219 -0.15 0.63 0.82 -0.34 0.50 0.50 
CDKN2A/2B rs10811661 -0.89 0.87 0.31 -0.25 0.65 0.70 
WFS1 rs10010131 -0.08 0.61 0.89 -0.21 0.46 0.65 
CDC123 rs12779790 0.83 0.75 0.27 0.07 0.55 0.91 
HHEX/IDE * rs1111875 / rs5015480 -0.27 0.61 0.66 0.19 0.44 0.66 
PPARG rs1801282 -1.46 0.99 0.14 0.36 0.76 0.64 
IGF2BP2 rs4402960 0.45 0.64 0.48 0.43 0.47 0.36 
THADA rs7578597 0.50 1.00 0.62 0.55 0.78 0.48 
NOTCH2 † rs2934381 1.31 1.32 0.32 0.82 1.00 0.41 
Combined SNP effect       
Allele count score -0.49 0.17 0.0043 -0.35 0.13 0.0051 
Weighted score (log odds) -0.49 0.15 0.0013 -0.33 0.12 0.0046 
 
*At 4 loci different SNPs, representing the same signal, were genotyped by the two study 
centres, in which case they are shown as UK / Norway SNPs.  
† Results for JAZF1 and NOTCH2 SNPs were available only for UK samples (N=296 and 
297, respectively). 
‡ Adjusted results include study, sex, age at study, presence of intrauterine 
hyperglycaemia, and mutation position (2 groups, according to exon affected, 1-7 or 8-10) 
as covariates in the regression model. 
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Figure 1. Mean age at diabetes diagnosis (black triangles) and frequency 
(bars) of HNF1A-MODY patients at each number of the type 2 diabetes risk 
alleles carried. Only individuals genotyped for all 15 variants are included. A = full 
dataset of 410 patients; B = 203 unrelated probands (youngest family members). 
Ages at diagnosis were adjusted for family (A only), study, sex, age at study, 
exposure to mother‟s hyperglycemia in utero, and position of HNF1A mutation. 
Black lines are fitted age at diagnosis linear regression lines. Both y-axis are on 
the same scale in panels A and B.  
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Figure 2. Cumulative incidence of diabetes in 410 HNF1A-MODY patients, by 
type 2 diabetes risk allele count category. Black circles = 9-14 risk alleles, 
N=138; white triangles = 15-16 risk alleles, N=130; black squares = 17-22 risk 
alleles, N=142. Only individuals genotyped for all 15 variants are included. The 
ages at diabetes diagnosis ware adjusted for family, study, sex, age at study, 
exposure to mother‟s hyperglycemia in utero, and position of HNF1A mutation.  
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Supplementary table 1. Effects of individual type 2 diabetes risk variants and 
the combined genetic scores on the age at diabetes diagnosis in 203 HNF1A-
MODY unrelated probands (youngest family members). All effect sizes are in 
years change of age at diagnosis per risk allele. The 203 patients were 
successfully genotyped for all 15 SNPs that were included in the combined genetic 
score. Individual SNP effects are based on risk allele count method. P values are 
unadjusted for multiple testing. Results are presented in order of Table 3 adjusted 
results. 
 
  
Unadjusted 
analysis 
Adjusted analysis‡ 
  
Effect 
Size 
Std 
Error 
P-
value 
Effect 
Size 
Std 
Error 
P-
value 
Individual SNP effects       
Gene region SNP       
HNF1B (TCF2) * rs757210 / rs4430796 -0.64 0.74 0.39 -0.37 0.58 0.52 
SLC30A8 rs13266634 -2.09 0.82 0.011 -1.29 0.66 0.052 
CDKAL1 * rs10946398 / rs7754840 -0.93 0.79 0.24 -0.64 0.62 0.30 
TCF7L2 rs7903146 0.76 0.85 0.37 -0.46 0.69 0.51 
ADAMTS9 rs4607103 0.13 0.89 0.89 -0.89 0.70 0.20 
TSPAN8 rs7961581 -1.15 0.82 0.16 -0.79 0.64 0.22 
JAZF1 † rs864745 -1.23 0.93 0.19 -1.31 0.74 0.078 
FTO * rs8050136 / rs9939609 0.05 0.81 0.95 -0.38 0.64 0.55 
KCNJ11 rs5219 -0.33 0.87 0.71 0.17 0.68 0.81 
CDKN2A/2B rs10811661 -0.54 1.13 0.63 -0.42 0.88 0.64 
WFS1 rs10010131 0.35 0.79 0.66 0.05 0.62 0.94 
CDC123 rs12779790 0.73 0.96 0.45 0.42 0.76 0.58 
HHEX/IDE * rs1111875 / rs5015480 -0.04 0.78 0.96 -0.33 0.61 0.59 
PPARG rs1801282 -0.99 1.37 0.47 0.46 1.08 0.67 
IGF2BP2 rs4402960 0.17 0.83 0.84 0.28 0.66 0.67 
THADA rs7578597 0.65 1.44 0.65 0.67 1.13 0.55 
NOTCH2 † rs2934381 2.41 1.70 0.16 1.70 1.33 0.20 
Combined SNP effect       
Allele count score -0.26 0.21 0.23 -0.28 0.17 0.094 
*At 4 loci different SNPs, representing the same signal, were genotyped by the two study 
centres, in which case they are shown as UK / Norway SNPs.  
† Results for JAZF1 and NOTCH2 variants were available only for UK samples (N=140 
and 139, respectively). 
‡ Adjusted results include study, sex, age at study, presence of intrauterine 
hyperglycaemia, and mutation position (2 groups, according to exon affected, 1-7 or 8-10) 
as covariates in the regression model.
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Supplementary table 2. Effects of individual type 2 diabetes risk variants and 
the combined genetic scores on the age at diabetes diagnosis in 410 HNF1A-
MODY patients, in an adjusted analysis excluding age at study. All effect sizes 
are in years change of age at diagnosis per risk allele. The 410 patients were 
successfully genotyped for all 15 SNPs that were included in the combined genetic 
score. All analyses took into account full family relationships and included a 
random family effect in the regression model. Individual SNP effects are based on 
risk allele count method. P values are unadjusted for multiple testing. Results are 
presented in order of the Table 3 adjusted effect sizes. 
 
Adjusted results 
excluding age at study 
T-test P for 
difference 
between results 
with age at 
study 
  
Effect 
Size 
Std 
Error 
P-value 
Individual SNP effects     
Gene region SNP     
HNF1B (TCF2) * rs757210 / rs4430796 -1.19 0.52 0.023 0.86 
SLC30A8 rs13266634 -1.00 0.59 0.092 0.90 
CDKAL1 * rs10946398 / rs7754840 -1.36 0.52 0.0095 0.48 
TCF7L2 rs7903146 -0.34 0.57 0.54 0.67 
ADAMTS9 rs4607103 0.07 0.62 0.91 0.41 
TSPAN8 rs7961581 -0.79 0.56 0.16 0.72 
JAZF1 † rs864745 (n=296) -0.47 0.64 0.46 0.99 
FTO * rs8050136 / rs9939609 -0.60 0.57 0.29 0.81 
KCNJ11 rs5219 0.20 0.56 0.72 0.47 
CDKN2A/2B rs10811661 -0.79 0.78 0.31 0.59 
WFS1 rs10010131 -0.36 0.55 0.51 0.83 
CDC123 rs12779790 0.22 0.67 0.74 0.86 
HHEX/IDE * rs1111875 / rs5015480 -0.36 0.53 0.50 0.42 
PPARG rs1801282 -0.81 0.90 0.37 0.32 
IGF2BP2 rs4402960 0.72 0.58 0.22 0.70 
THADA rs7578597 0.70 0.93 0.45 0.90 
NOTCH2 † rs2934381 (n=297) 1.31 1.15 0.26 0.75 
Combined SNP effect     
Allele count score, adjusted -0.40 0.15 0.0072 0.80 
 *At 4 loci different SNPs, representing the same signal, were genotyped by the two study 
centres, in which case they are shown as UK / Norway SNPs.  
† Results for JAZF1 and NOTCH2 SNPs were available only for UK samples (N=296 and 
297, respectively). 
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Supplementary table 3. Stratified-by-study analysis of non-polygenic factors, 
individual type 2 diabetes risk variants, and the combined genetic scores on 
the age at diabetes diagnosis in 410 HNF1A-MODY patients. All analyses took 
into account full family relationships and, except for those marked ‡, included a 
random family effect in the regression model All effect sizes are in years change of 
age at diagnosis per risk allele. Individual SNP effects are based on risk allele 
count method adjusted for sex, age at study, presence of intrauterine 
hyperglycaemia, and mutation position. All P values are unadjusted for multiple 
testing. Individual SNP results are in the same order as in Table 3.  
 
  UK (N=298) Norway (N=112) T-test P 
for 
difference   
Effect 
size 
Std 
Error 
P-value 
Effect 
size 
Std 
Error 
P-value 
Non-polygenic factors (without 
genetic score) 
       
Sex (effect w.r.t. females) -3.63 1.06 6.3x10-4 -1.48 1.49 0.32 0.27 
Presence of intrauterine 
hyperglycaemia 
-5.27 0.96 4.1x10-8 -4.58 1.29 4.0x10-4 0.69 
Position of HNF1A mutation -5.27 2.34 0.024 -3.11 5.57 0.58 0.67 
Age at study (per year increase) 0.29 0.03 3.3x10-26 0.30 0.04 1.1x10-13 0.86 
Individual SNP effects        
Gene region SNP        
HNF1B * rs757210 / rs4430796 -0.76 0.57 0.18 -1.53 0.65 0.018 0.45 
SLC30A8 rs13266634 -0.74 0.60 0.22 -0.83 0.28 0.003 0.93 
CDKAL1 * rs10946398 / rs7754840 -1.18 0.53 0.026 -0.08 0.92 0.93 0.29 
TCF7L2 rs7903146 -0.39 0.54 0.48 -1.19 0.55 0.031 0.40 
ADAMTS9 ‡ rs4607103 -0.65 0.61 0.29 -0.70 0.86 0.42 0.96 
JAZF1 † rs864745 -0.46 0.53 0.38 NA NA NA NA 
FTO * rs8050136 / rs9939609 -0.47 0.57 0.41 -0.24 0.63 0.70 0.81 
TSPAN8 ‡ rs7961581 -0.47 0.52 0.37 -0.56 0.82 0.49 0.93 
CDKN2A/2B rs10811661 0.38 0.74 0.61 -1.16 0.40 0.004 0.21 
KCNJ11 rs5219 -0.43 0.59 0.46 0.22 0.94 0.82 0.56 
WFS1 rs10010131 -0.20 0.55 0.71 -0.56 0.80 0.48 0.72 
CDC123 ‡ rs12779790 -0.09 0.64 0.89 0.13 0.96 0.89 0.85 
HHEX-IDE * rs1111875 / rs5015480 -0.002 0.54 1.00 0.34 0.23 0.15 0.70 
THADA rs7578597 0.69 0.87 0.43 -0.45 1.97 0.82 0.54 
IGF2BP2 rs4402960 -0.09 0.55 0.88 1.46 0.90 0.10 0.14 
PPARG rs1801282 0.08 0.92 0.93 1.04 1.25 0.41 0.57 
NOTCH2 † rs2934381 0.82 1.00 0.41 NA NA NA NA 
Combined SNP effects        
Allele count score, unadjusted -0.43 0.20 0.036 -0.73 0.32 0.021 0.43 
Allele count score, adjusted -0.35 0.15 0.020 -0.43 0.24 0.069 0.78 
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*At 4 loci different SNPs, representing the same signal, were genotyped by the two study 
centres, in which case they are shown as UK / Norway SNPs.  
† Results for JAZF1 and NOTCH2 SNPs were available only for UK samples (N=296 and 
297, respectively). 
‡ Because of the small sample size relative to the number of covariates, the random 
family effect could not be fully fitted in the regression model for the Norwegian sample. 
Therefore, for these 3 variants, this term was excluded from the model in both studies (in 
the Exeter sample the results with and without the random family term were nearly 
identical). 
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The field of complex trait genetics has progressed substantially throughout 
the duration of research that is included in this thesis. Owing to the success of 
genome-wide association (GWA) studies, the number of common variants robustly 
associated with common human traits and diseases has substantially increased 
(listed in the NHGRI GWAS catalogue, http://www.genome.gov/26525384). 
Genome-wide association studies are based on two major advancements in the 
field of genetics: the dissection of human genome into distinct linkage 
disequilibrium (LD) blocks, catalogued by the HapMap project 1, 2, and the 
technological advances in high-throughput genotyping. Rather than testing one 
SNP at a time, it is possible to test 300,000 – 1 million SNPs simultaneously, and 
capture up to ~80% of the common (>5% MAF) genetic variation owing to the 
underlying LD structure. Following some essential GWAS procedures such as 
selection of subjects with well characterized phenotypes, as well as stringent 
quality checks of samples and genotypes for artifacts of DNA preparation and 
genotyping process, has become standard practice among many research groups. 
Importantly, though, as demonstrated in Chapter 2, there has been a realization 
that, rather than trying to replicate GWA findings in additional independent cohorts, 
a more powerful approach for discovering the contributing common variants is to 
combine efforts and, since it is often not possible to share raw genotype data, 
perform a meta-analysis of a much larger set of samples. The necessity for 
organized data sharing and agreements has led to the formation of many trait-
specific consortia, discussed below. In such meta-analyses there are usually no 
additional, independent, suitably sized cohorts left to confirm positive associations, 
so only those that reach a conservative statistical significance level, usually 
P<5x10-8, are reported.  
Because different genotyping platforms include different subsets of HapMap 
SNPs, initially it was difficult for many collaborating studies to exchange or 
combine their data, unless they used the same platform. However, it is now 
possible to use genotype imputation programs that combine the information from 
the known genotypes and LD structure around them to infer missing genotypes of 
nearly 2.5 million HapMap SNPs 3. Although sharing of individual level data is 
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often not possible because of ethical restrictions, Chapter 3 describes a combined 
analysis of association statistics (effect sizes and p-values) of these imputed 
SNPs, a meta-analysis approach that is now being adopted for many other traits 
and diseases.  
Common variants have small effects and have explained small 
proportion of the heritable component 
As Chapters 2 and 3 demonstrate, many of the associated variants have 
modest effect sizes and can only be identified once a GWA study has large 
enough sample size and is sufficiently powered to detect them. In many cases, 
including height, the model polygenic trait used here, only a small fraction of the 
heritable component is accounted for. This may be because GWA studies are not 
designed to detect rare and structural variants, gene-by-gene and gene-by-
environment interactions 4, or epigenetic effects 5, all of which have been 
suggested to contribute to the heritability of the trait (although epigenetic effects by 
definition do not, as explained below). Unsurprisingly, this perceived lack of 
success has caused some to start questioning the usefulness of performing ever-
larger GWA studies and investing resources into what appears to be diminishing 
genetic returns, since one will either find associations with random variants across 
the genome, or the effect sizes will be so small that they become irrelevant 6. 
This thesis tackles some of these questions by performing the largest GWA 
study to date, as part of the Genetic Investigation of Anthropometric Traits 
(GIANT) consortium. The Chapter 2 study 7 was published in parallel with another 
three large height GWA studies 8-10. It was apparent that each study was in fact 
underpowered to detect many of the associations it reported (at the genome-wide 
significance level), suggesting that more could be discovered if the sample sizes 
are increased. This led to the formation of the GIANT consortium and data sharing 
between many research groups. Crucial to this was the availability of imputation 
methods, which allowed for meta-analysis of summary statistics of 2.5 million 
HapMap SNPs polymorphic in populations of European origin, regardless of which 
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one of the many available genotyping platforms was used by each individual 
group.  
In addition to GIANT, several other international consortia have been 
established over the past couple of years to investigate common diseases and 
related intermediate traits. These include the Diabetes Genetics Replication and 
Meta-analysis (DIAGRAM) consortium, a collaboration between DGI, FUSION and 
WTCCC-T2D groups that were part of the initial wave of successful GWA studies 
11-15. The first meta-analysis by DIAGRAM provided evidence for 6 additional type 
2 diabetes loci 16, and since then the consortium has been expanded to include 
additional cohorts. Other consortia have been established to look at intermediate, 
often quantitative, disease traits. A good example is the Meta-Analyses of Glucose 
and Insulin Related Traits Consortium (MAGIC), which has investigated diabetes-
related traits in non-diabetic individuals. The initial analysis identified MTNR1B as 
a novel fasting glucose and type 2 diabetes locus 17, and was followed by an even 
larger, imputation facilitated meta-analysis that identified nine novel loci associated 
(P<5x10-8) with fasting glucose and one with fasting insulin, five of which were also 
associated, in the expected direction, with type 2 diabetes 18. Interestingly, one of 
the five signals, in ADCY5 gene, was also associated with birth weight in the Early 
Growth Genetics (EGG) Consortium meta-analysis of six GWA studies with 
imputed genotypes 19.  
Despite the increasing number of variants identified, the percentage of the 
explained genetic variance still remains relatively small for most common traits 
studied so far. The GIANT consortium height study, presented in Chapter 3, with a 
sample size of over 130,000 individuals showed that some of the genetic 
component of the „missing heritability‟ can indeed be found among additional 
common variants of small effect sizes identified by expanding the sample size and 
thus increasing power to detect them. However, the proportion of the genetic 
variance explained for height is still only ~20%, and up to 50% if all variants of 
similar effect sizes are identified. The study found no evidence that epistasis or 
non-additive effects are associated with height. Although it is often suggested that 
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these and epigenetic effects might explain additional heritable variance, these 
factors do not contribute to genetic variance because they are not part of the 
heritability calculations (ratio of additive genetic factors to total phenotypic 
variation) 20. The question then remains, where is the „missing‟ genotypic 
heritability, and what can our knowledge of the associated variants be used for?  
Insights into genetic architecture and biological mechanisms 
Although it is possible that the associated variants are tagging rare, as yet 
unidentified, causal variants of larger effects, the GIANT height study does not rule 
out the common variant / common disease hypothesis 21. A recent study 
suggested that most of the heritability is not missing, but has not yet been 
detected because most of it can be explained by large number of common variants 
with effect sizes too small to reach statistical significance in the GWA studies 22. It 
is likely that insertions/deletion or large structural variants contribute to common 
traits. Although these are not represented directly on the genotyping platforms, 
they can be assessed indirectly because many of the SNPs on the chips are tags 
for a large number of known copy-number variants (CNVs). However, the GIANT 
height study did not identify any strong associations, and this has mainly been the 
case for common complex diseases. Rare deletions and/or duplications have, so 
far, only been shown to associate with schizophrenia 23, 24 and autism 25, while 
some of the signals associated with autoimmune diseases and type 2 diabetes do 
tag common CNVs 26. 
Chapters 2 and 3 show that, even though many common variants for height 
have been identified, they are not randomly distributed across the genome. 
Rather, they implicate functionally relevant genes and pathways, and are 
themselves functional (amino acid changing) polymorphisms more often than 
expected by chance. Therefore, the identified common variants are likely to 
implicate genes relevant to trait or disease under study, thus providing a number 
of novel candidate regions for drug and therapeutic targeting, or for mutations in 
biologically related monogenic diseases with unknown causes. Even though the 
proportion of variance explained by the common variants is relatively small, the 
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increase in our understanding of the biological mechanisms disease aetiology may 
be substantial.  
Several interesting features of the common trait architecture have emerged 
through the height studies: there are multiple variants with independent effects at 
individual gene loci (allelic heterogeneity), and the same variants can affect 
multiple traits (pleiotropy). Thus, they may represent the genetic links between 
traits and diseases that are suspected to share some of their aetiology, and 
provide cause/effect distinctions between those that the epidemiological studies 
have shown to be correlated. For example, a variant in LIN28B gene that is 
associated with reduced adult height 10 is also associated with earlier onset of 
puberty 27, 28, which is consistent with epidemiological observations. 
The GIANT height study has provided several good candidate genes that 
might have mutations responsible for as-yet unexplained skeletal and 
developmental disorders. For example, the study identified associations in FGFR4 
and STAT2 genes, which have similar functions to already known human growth-
related genes, FGFR3 and STAT5B, respectively. In type 2 diabetes, common 
variants in the KCNJ11 gene region have only small effect on the disease, yet the 
membrane protein coded by this gene forms a potassium channel that is the target 
of sulphonylureas, major anti-diabetic drugs that act by increasing insulin from the 
pancreatic beta cells. It is worth noting that KCNJ11 was already known to the 
diabetes community before the GWA studies, because its association with 
diabetes was discovered through candidate gene studies 29, 30. Among the type 2 
diabetes genes identified through the GWA approach, a zinc transporter gene 
SLC30A8 seems particularly interesting for drug targeting, since it has been 
shown that down-regulation of the gene in beta cells leads to reduced insulin 
secretion in response to hyperglycemia 31.  
Disease prediction 
The immediate utility of disease associated variants discovered through 
GWA studies appears to be the identification of molecular pathways involved in 
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the disease and intermediate quantitative traits, which should eventually lead to 
new therapeutic targets. In the long-term, there is the prospect of disease 
susceptibility prediction, which would be useful for diseases where preventative 
measures are effective. Chapter 4 assesses how well the variants robustly 
associated with type 2 diabetes predict disease status. The study shows that they 
would not be useful for disease prediction, and add little to the discriminatory 
power of other well-established diabetes risk factors. However, a combined 
genetic score could be used to identify individuals with high genetic predisposition 
to disease.  
One of the limitations of this study was that it was not prospective 
population-based study, and consequently, the predictive power of the variants 
could not be accurately determined. Since then, several prospective studies have 
assessed the combined effect of the known type 2 diabetes variants 32-34. They 
have all reached similar conclusions – the combined genetic score had only 
modest ability to predict the future development of diabetes (all had AUC of 
around 0.6), and provided only slightly improved prediction when added to the 
other known risk factors. 
Combined with an individual‟s lifestyle and environmental exposures, the 
genetic information can be then used to guide decisions about disease prevention, 
monitoring and management. For example, those at higher genetic risk of breast 
and bowel cancer could be offered more regular screening. Similar discriminatory 
ability of the combined genetic score was observed for the 20 height associated 
variants described in Chapter 2. This information may be used in medicine, for 
example to determine if a child‟s growth is reaching its genetic potential, as well as 
in forensics 35. 
Another clinical application of common variants may be in better clinical 
characterisation of monogenic diseases, which are often heterogeneous in terms 
of disease onset, severity, progression and other clinical characteristics. A good 
starting point is to investigate variants that have been shown to associate with 
biologically related common diseases and traits. This is the case in Chapter 5, 
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which showed that HNF1A-MODY patients with higher load of common type 2 
diabetes predisposing variants had earlier age at diabetes diagnosis, and required 
smaller load of other risk factors, namely their BMI, to get the disease. Another 
disease where common variants have been shown to have a strong modifying 
effect includes sickle cell anaemia, where foetal haemoglobin (HbF) expression is 
an established and heritable disease modifier, such that high HbF levels lead to 
slower disease progression and fewer complications in patients with the sickle cell 
disease. Several common variants have now been shown to affect HbF 
persistence in adults 36, 37, so an immediate clinical application would be the ability 
to better predict disease severity and, therefore, improve disease management. In 
the long term, these variants are potential targets of new therapies based on 
increasing HbF expression. 
Future directions 
Most of the associated signals detected through GWA studies are not the 
causal variants themselves, but are detected because they are correlated with 
rarer, more penetrant variants. A recent study suggested that many of the current 
GWA signals could reflect effects of several rare, deleterious variants that have 
emerged more recently, on the same haplotypes as the common SNP for which 
the „synthetic‟ association is observed 38. However, rare variants cannot be directly 
detected through the current GWA approaches, and imputation of deeper sets of 
SNPs can only help to narrow down the region containing the causal variant(s).  
There are several emerging tools and technologies that can be used in 
future studies to get closer to the causal variants. These include deeper imputation 
with 1000 Genomes data, fine mapping of the associated loci with custom-
designed genotyping chips, and studying more non-European populations that 
have different LD structure (especially African populations, who have shorter LD 
blocks and thus narrower regions of associated loci). One fine-mapping project 
currently underway is the genotyping of samples with metabolic trait phenotypes 
on the metabochip, an Illumina custom-made chip based on GWA results and 
designed by several collaborating consortia including DIAGRAM, MAGIC and 
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GIANT. The most direct way of detecting rare functional variants, however, is 
sequencing of the associated regions, possibly in samples enriched for genetic 
predisposition, for example those with familial background, or at the extremes of 
the trait distribution or young-onset disease cases. 
This was the approach I took to search for rare variants in height genes 
selected from the 20 presented in Chapter 2: HMGA2 and ZBTB38 that contained 
the two most-associated signals, JAZF1 that is also a type 2 diabetes locus; and 
two hedgehog signaling genes IHH and HHIP. After designing primers to cover all 
exons and flanking regulatory and intronic regions, these genes were sequenced 
in a panel of 48 tall and 48 short individuals at the extremes of the height 
distribution in the Exeter Family Study (EFS) cohort. Several novel missense 
variants were identified, and so far those in JAZF1 have been genotyped in 1700 
unrelated individuals from the EFS cohort. These included 229Phe>Leu variant 
initially seen in two tall individuals, and an intron4 variant identified in four short 
individuals. Genotyping results, shown in the table below, show a directionally 
consistent trend for association, but are not statistically significant and the new 
variants probably do not confer a major effect on height. Sequencing of JAZF1 in 
300 type 2 diabetes young-onset cases and 300 controls is currently under way. 
Variant Genotype Genotype count Mean Z-height P-value 
F229L 
AA 
AG 
GG 
1681 
6 
0 
-0.007 
0.418 
NA 
0.296 
Intron4 
(ex3+68nt) 
GG 
GA 
AA 
1591 
92 
1 
0.006 
-0.125 
-0.931 
0.164 
 
Owing to the emergence to the next generation sequencing technologies 
and the substantial reduction in costs, many researchers are now embarking on 
whole-exome, whole-genome and sequence-capture sequencing projects. Whole 
genome sequencing will clearly be needed to identify rare variants where 
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associated loci lie outside the known gene and regulatory regions, although 
proving causality in such cases will be more difficult. Examples of common 
disease rare variant detection by whole genome/exome sequencing are still rare. 
The most exciting success story is perhaps in type 1 diabetes, where 
resequencing of exomes and splice sites identified four rare protective variants in 
IFIH1 gene 39, a locus already implicated through type 1 diabetes GWA studies.  
To follow up the height GWA study, a Nimblegen Capture Array has been 
designed to cover 3.7 megabases around the height associated loci, including 
entire smaller regions between recombination hotspots, and exons of all genes in 
larger regions. Four individuals have now been „captured‟ on this array and 
sequenced on one of the next-generation sequencers, the Illumina Genome 
Analyzer II. Furthermore, for quality control purposes the same individuals have 
been genotyped on the Affymetrix 6.0 platform, and the sequencing and 
genotyping data will be analysed shortly. In a separate multi-centre project, we are 
currently sequencing 1500 type 2 diabetes patients and 1500 controls.  
Undoubtedly, as the targeted sequencing within my own research group 
has hinted, a large number of novel non-synonymous variants will be identified, 
and deciding which are functionally relevant will be the next major challenge. 
Furthermore, as the preliminary metabochip analyses are already demonstrating, 
genotyping and correctly calling rare variants is tricky because the approach is 
based on genotype clustering. In my project I knew which samples had the rare 
variants and was, therefore, able to include positive controls that served as rare 
genotype reference during clustering process. However, many of the next-
generation sequencing projects use pooled samples to reduce costs, in which 
case sample tagging approaches can be used to identifying which rare variant 
comes from which sample. New developments in genotyping methodology and 
clustering algorithms are needed to facilitate the search for rare variants in 
common traits and diseases. 
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Conclusions 
Using human height, type 2 diabetes and HNF1A-MODY as examples of a 
quantitative trait, polygenic disease and monogenic disease, respectively, this 
thesis has explored the role of common genetic variation identified through 
genome-wide association approaches in these types of human traits. It has 
demonstrated that common variants are not only statistically associated with 
common traits and diseases, but can reveal novel biology, disease aetiology, and 
genetic architecture; explain epidemiological observations; help better characterise 
both complex and single-gene diseases; and have potential to be used in disease 
prediction, therapeutic targeting, and personalised disease management. It is clear 
that much of the near future work in complex traits genetics will focus on the 
search for rare variants of larger effects, which may underlie many of the current 
associations with the common variants of modest effects. The already established 
collaborations within the common disease genetics community, and the constantly 
reducing costs of whole genome sequencing, promise to yield many exciting 
findings in near future. 
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